0001493152-23-029706.txt : 20230821 0001493152-23-029706.hdr.sgml : 20230821 20230821171604 ACCESSION NUMBER: 0001493152-23-029706 CONFORMED SUBMISSION TYPE: 10-Q PUBLIC DOCUMENT COUNT: 59 CONFORMED PERIOD OF REPORT: 20230630 FILED AS OF DATE: 20230821 DATE AS OF CHANGE: 20230821 FILER: COMPANY DATA: COMPANY CONFORMED NAME: ENDONOVO THERAPEUTICS, INC. CENTRAL INDEX KEY: 0001528172 STANDARD INDUSTRIAL CLASSIFICATION: ELECTROMEDICAL & ELECTROTHERAPEUTIC APPARATUS [3845] IRS NUMBER: 452552528 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 10-Q SEC ACT: 1934 Act SEC FILE NUMBER: 000-55453 FILM NUMBER: 231190012 BUSINESS ADDRESS: STREET 1: 6320 CANOGA AVENUE STREET 2: 15TH FLOOR CITY: WOODLAND HILLS STATE: CA ZIP: 91367 BUSINESS PHONE: (800) 489-4774 MAIL ADDRESS: STREET 1: 6320 CANOGA AVENUE STREET 2: 15TH FLOOR CITY: WOODLAND HILLS STATE: CA ZIP: 91367 FORMER COMPANY: FORMER CONFORMED NAME: Hanover Portfolio Acquisitions, Inc. DATE OF NAME CHANGE: 20110920 FORMER COMPANY: FORMER CONFORMED NAME: Hanover Portfoliio Acquisitions, Inc. DATE OF NAME CHANGE: 20110817 10-Q 1 form10-q.htm
0001528172 false --12-31 Q2 P3Y 0001528172 2023-01-01 2023-06-30 0001528172 2023-08-21 0001528172 2023-06-30 0001528172 2022-12-31 0001528172 us-gaap:NonrelatedPartyMember 2023-06-30 0001528172 us-gaap:NonrelatedPartyMember 2022-12-31 0001528172 us-gaap:RelatedPartyMember 2023-06-30 0001528172 us-gaap:RelatedPartyMember 2022-12-31 0001528172 ENDV:SuperAASuperVotingPreferredStockMember 2023-06-30 0001528172 ENDV:SuperAASuperVotingPreferredStockMember 2022-12-31 0001528172 ENDV:SeriesBConvertiblePreferredStockMember 2023-06-30 0001528172 ENDV:SeriesBConvertiblePreferredStockMember 2022-12-31 0001528172 ENDV:SeriesCConvertiblePreferredStockMember 2023-06-30 0001528172 ENDV:SeriesCConvertiblePreferredStockMember 2022-12-31 0001528172 ENDV:SeriesDConvertiblePreferredStockMember 2023-06-30 0001528172 ENDV:SeriesDConvertiblePreferredStockMember 2022-12-31 0001528172 2023-04-01 2023-06-30 0001528172 2022-04-01 2022-06-30 0001528172 2022-01-01 2022-06-30 0001528172 2021-12-31 0001528172 2022-06-30 0001528172 us-gaap:PreferredStockMember ENDV:SeriesAAPreferredStockMember 2022-12-31 0001528172 us-gaap:PreferredStockMember ENDV:SeriesBConvertiblePreferredStockMember 2022-12-31 0001528172 us-gaap:PreferredStockMember ENDV:SeriesCConvertiblePreferredStockMember 2022-12-31 0001528172 us-gaap:PreferredStockMember ENDV:SeriesDConvertiblePreferredStockMember 2022-12-31 0001528172 us-gaap:CommonStockMember 2022-12-31 0001528172 us-gaap:AdditionalPaidInCapitalMember 2022-12-31 0001528172 ENDV:SubscriptionReceivableMember 2022-12-31 0001528172 us-gaap:RetainedEarningsMember 2022-12-31 0001528172 us-gaap:PreferredStockMember ENDV:SeriesAAPreferredStockMember 2023-03-31 0001528172 us-gaap:PreferredStockMember ENDV:SeriesBConvertiblePreferredStockMember 2023-03-31 0001528172 us-gaap:PreferredStockMember ENDV:SeriesCConvertiblePreferredStockMember 2023-03-31 0001528172 us-gaap:PreferredStockMember ENDV:SeriesDConvertiblePreferredStockMember 2023-03-31 0001528172 us-gaap:CommonStockMember 2023-03-31 0001528172 us-gaap:AdditionalPaidInCapitalMember 2023-03-31 0001528172 ENDV:SubscriptionReceivableMember 2023-03-31 0001528172 us-gaap:RetainedEarningsMember 2023-03-31 0001528172 2023-03-31 0001528172 us-gaap:PreferredStockMember ENDV:SeriesAAPreferredStockMember 2021-12-31 0001528172 us-gaap:PreferredStockMember ENDV:SeriesBConvertiblePreferredStockMember 2021-12-31 0001528172 us-gaap:PreferredStockMember ENDV:SeriesCConvertiblePreferredStockMember 2021-12-31 0001528172 us-gaap:PreferredStockMember ENDV:SeriesDConvertiblePreferredStockMember 2021-12-31 0001528172 us-gaap:CommonStockMember 2021-12-31 0001528172 us-gaap:AdditionalPaidInCapitalMember 2021-12-31 0001528172 ENDV:SubscriptionReceivableMember 2021-12-31 0001528172 us-gaap:RetainedEarningsMember 2021-12-31 0001528172 us-gaap:PreferredStockMember ENDV:SeriesAAPreferredStockMember 2022-03-31 0001528172 us-gaap:PreferredStockMember ENDV:SeriesBConvertiblePreferredStockMember 2022-03-31 0001528172 us-gaap:PreferredStockMember ENDV:SeriesCConvertiblePreferredStockMember 2022-03-31 0001528172 us-gaap:PreferredStockMember ENDV:SeriesDConvertiblePreferredStockMember 2022-03-31 0001528172 us-gaap:CommonStockMember 2022-03-31 0001528172 us-gaap:AdditionalPaidInCapitalMember 2022-03-31 0001528172 ENDV:SubscriptionReceivableMember 2022-03-31 0001528172 us-gaap:RetainedEarningsMember 2022-03-31 0001528172 2022-03-31 0001528172 us-gaap:PreferredStockMember ENDV:SeriesAAPreferredStockMember 2023-01-01 2023-03-31 0001528172 us-gaap:PreferredStockMember ENDV:SeriesBConvertiblePreferredStockMember 2023-01-01 2023-03-31 0001528172 us-gaap:PreferredStockMember ENDV:SeriesCConvertiblePreferredStockMember 2023-01-01 2023-03-31 0001528172 us-gaap:PreferredStockMember ENDV:SeriesDConvertiblePreferredStockMember 2023-01-01 2023-03-31 0001528172 us-gaap:CommonStockMember 2023-01-01 2023-03-31 0001528172 us-gaap:AdditionalPaidInCapitalMember 2023-01-01 2023-03-31 0001528172 ENDV:SubscriptionReceivableMember 2023-01-01 2023-03-31 0001528172 us-gaap:RetainedEarningsMember 2023-01-01 2023-03-31 0001528172 2023-01-01 2023-03-31 0001528172 us-gaap:PreferredStockMember ENDV:SeriesAAPreferredStockMember 2023-04-01 2023-06-30 0001528172 us-gaap:PreferredStockMember ENDV:SeriesBConvertiblePreferredStockMember 2023-04-01 2023-06-30 0001528172 us-gaap:PreferredStockMember ENDV:SeriesCConvertiblePreferredStockMember 2023-04-01 2023-06-30 0001528172 us-gaap:PreferredStockMember ENDV:SeriesDConvertiblePreferredStockMember 2023-04-01 2023-06-30 0001528172 us-gaap:CommonStockMember 2023-04-01 2023-06-30 0001528172 us-gaap:AdditionalPaidInCapitalMember 2023-04-01 2023-06-30 0001528172 ENDV:SubscriptionReceivableMember 2023-04-01 2023-06-30 0001528172 us-gaap:RetainedEarningsMember 2023-04-01 2023-06-30 0001528172 us-gaap:PreferredStockMember ENDV:SeriesAAPreferredStockMember 2022-01-01 2022-03-31 0001528172 us-gaap:PreferredStockMember ENDV:SeriesBConvertiblePreferredStockMember 2022-01-01 2022-03-31 0001528172 us-gaap:PreferredStockMember ENDV:SeriesCConvertiblePreferredStockMember 2022-01-01 2022-03-31 0001528172 us-gaap:PreferredStockMember ENDV:SeriesDConvertiblePreferredStockMember 2022-01-01 2022-03-31 0001528172 us-gaap:CommonStockMember 2022-01-01 2022-03-31 0001528172 us-gaap:AdditionalPaidInCapitalMember 2022-01-01 2022-03-31 0001528172 ENDV:SubscriptionReceivableMember 2022-01-01 2022-03-31 0001528172 us-gaap:RetainedEarningsMember 2022-01-01 2022-03-31 0001528172 2022-01-01 2022-03-31 0001528172 us-gaap:PreferredStockMember ENDV:SeriesAAPreferredStockMember 2022-04-01 2022-06-30 0001528172 us-gaap:PreferredStockMember ENDV:SeriesBConvertiblePreferredStockMember 2022-04-01 2022-06-30 0001528172 us-gaap:PreferredStockMember ENDV:SeriesCConvertiblePreferredStockMember 2022-04-01 2022-06-30 0001528172 us-gaap:PreferredStockMember ENDV:SeriesDConvertiblePreferredStockMember 2022-04-01 2022-06-30 0001528172 us-gaap:CommonStockMember 2022-04-01 2022-06-30 0001528172 us-gaap:AdditionalPaidInCapitalMember 2022-04-01 2022-06-30 0001528172 ENDV:SubscriptionReceivableMember 2022-04-01 2022-06-30 0001528172 us-gaap:RetainedEarningsMember 2022-04-01 2022-06-30 0001528172 us-gaap:PreferredStockMember ENDV:SeriesAAPreferredStockMember 2023-06-30 0001528172 us-gaap:PreferredStockMember ENDV:SeriesBConvertiblePreferredStockMember 2023-06-30 0001528172 us-gaap:PreferredStockMember ENDV:SeriesCConvertiblePreferredStockMember 2023-06-30 0001528172 us-gaap:PreferredStockMember ENDV:SeriesDConvertiblePreferredStockMember 2023-06-30 0001528172 us-gaap:CommonStockMember 2023-06-30 0001528172 us-gaap:AdditionalPaidInCapitalMember 2023-06-30 0001528172 ENDV:SubscriptionReceivableMember 2023-06-30 0001528172 us-gaap:RetainedEarningsMember 2023-06-30 0001528172 us-gaap:PreferredStockMember ENDV:SeriesAAPreferredStockMember 2022-06-30 0001528172 us-gaap:PreferredStockMember ENDV:SeriesBConvertiblePreferredStockMember 2022-06-30 0001528172 us-gaap:PreferredStockMember ENDV:SeriesCConvertiblePreferredStockMember 2022-06-30 0001528172 us-gaap:PreferredStockMember ENDV:SeriesDConvertiblePreferredStockMember 2022-06-30 0001528172 us-gaap:CommonStockMember 2022-06-30 0001528172 us-gaap:AdditionalPaidInCapitalMember 2022-06-30 0001528172 ENDV:SubscriptionReceivableMember 2022-06-30 0001528172 us-gaap:RetainedEarningsMember 2022-06-30 0001528172 ENDV:AssetsPurchaseAgreementMember 2022-09-26 2022-09-26 0001528172 us-gaap:EmployeeStockOptionMember 2023-01-01 2023-06-30 0001528172 us-gaap:EmployeeStockOptionMember 2022-01-01 2022-06-30 0001528172 us-gaap:WarrantMember 2022-01-01 2022-06-30 0001528172 ENDV:RoyaltyAndLicensingNetMember 2023-04-01 2023-06-30 0001528172 ENDV:RoyaltyAndLicensingNetMember 2022-04-01 2022-06-30 0001528172 ENDV:RoyaltyAndLicensingNetMember 2023-01-01 2023-06-30 0001528172 ENDV:RoyaltyAndLicensingNetMember 2022-01-01 2022-06-30 0001528172 ENDV:DirectSalesMedicalCareProvidersGrossMember 2023-04-01 2023-06-30 0001528172 ENDV:DirectSalesMedicalCareProvidersGrossMember 2022-04-01 2022-06-30 0001528172 ENDV:DirectSalesMedicalCareProvidersGrossMember 2023-01-01 2023-06-30 0001528172 ENDV:DirectSalesMedicalCareProvidersGrossMember 2022-01-01 2022-06-30 0001528172 ENDV:SalesSupportServiceAgreementMember ENDV:PulseTherapeuticTechnologyMember 2023-01-25 0001528172 ENDV:RioGrandeNeurosciencesIncMember 2017-12-01 2017-12-31 0001528172 2022-01-01 2022-12-31 0001528172 ENDV:FormerRelatedPartyMember 2023-06-30 0001528172 ENDV:FormerRelatedPartyMember 2022-12-31 0001528172 srt:MinimumMember 2023-06-30 0001528172 srt:MaximumMember 2023-06-30 0001528172 srt:MinimumMember 2023-01-01 2023-06-30 0001528172 srt:MaximumMember 2023-01-01 2023-06-30 0001528172 ENDV:FixedRateNotesMember 2023-06-30 0001528172 ENDV:FixedRateNotesMember 2022-12-31 0001528172 ENDV:VariableRateNotesMember 2023-01-01 2023-06-30 0001528172 ENDV:FormerRelatedPartyMember srt:MinimumMember 2023-06-30 0001528172 ENDV:FormerRelatedPartyMember srt:MaximumMember 2023-06-30 0001528172 ENDV:FormerRelatedPartyMember 2023-01-01 2023-06-30 0001528172 ENDV:ThreeFixedRatedNotesMember 2022-06-30 0001528172 ENDV:ThreeFixedRatedNotesMember 2022-01-01 2022-06-30 0001528172 ENDV:SixteenFixedRatedNotesMember 2022-06-30 0001528172 ENDV:PastMaturityMember ENDV:SixteenFixedRatedNotesMember 2022-06-30 0001528172 us-gaap:PrivatePlacementMember 2015-08-31 0001528172 us-gaap:PrivatePlacementMember 2015-08-01 2015-08-31 0001528172 us-gaap:PrivatePlacementMember 2022-06-30 0001528172 us-gaap:PrivatePlacementMember 2021-12-31 0001528172 ENDV:VariableRateNotesMember 2022-06-30 0001528172 ENDV:PastMaturityMember ENDV:VariableRateNotesMember 2022-06-30 0001528172 ENDV:PreferredStockDesignatedMember 2023-06-30 0001528172 ENDV:SeriesAAPreferredStockMember 2013-02-22 0001528172 ENDV:SeriesAAPreferredStockMember 2013-02-21 2013-02-22 0001528172 ENDV:SeriesAAPreferredStockMember 2023-06-30 0001528172 ENDV:SeriesAAPreferredStockMember 2022-12-31 0001528172 us-gaap:SeriesBPreferredStockMember 2017-02-07 0001528172 us-gaap:SeriesBPreferredStockMember 2017-02-06 2017-02-07 0001528172 us-gaap:SeriesBPreferredStockMember 2023-06-30 0001528172 us-gaap:SeriesBPreferredStockMember 2022-12-31 0001528172 ENDV:SeriesCConvertibleRedeemablePreferredStockMember 2017-12-22 0001528172 ENDV:SeriesCConvertibleRedeemablePreferredStockMember 2017-12-21 2017-12-22 0001528172 ENDV:SeriesCConvertibleRedeemablePreferredStockMember 2020-01-28 2020-01-29 0001528172 ENDV:SeriesCConvertibleRedeemablePreferredStockMember 2023-06-30 0001528172 ENDV:SeriesCConvertibleRedeemablePreferredStockMember 2022-12-31 0001528172 ENDV:SeriesDConvertiblePreferredStockMember 2019-11-11 0001528172 ENDV:SeriesDConvertiblePreferredStockMember 2023-01-01 2023-06-30 0001528172 us-gaap:CommonStockMember 2023-01-01 2023-06-30 0001528172 ENDV:OneInvestorMember 2023-01-01 2023-06-30 0001528172 us-gaap:CommonStockMember us-gaap:SeriesDPreferredStockMember 2023-01-01 2023-06-30 0001528172 us-gaap:SeriesDPreferredStockMember 2023-01-01 2023-06-30 0001528172 us-gaap:PrivatePlacementMember 2023-01-01 2023-06-30 0001528172 ENDV:SecuritiesPurchaseAgreementsMember 2023-01-01 2023-06-30 0001528172 us-gaap:CommonStockMember 2022-01-01 2022-06-30 0001528172 ENDV:OneInvestorMember 2022-01-01 2022-06-30 0001528172 ENDV:PurchaseAgreementMember 2022-01-01 2022-06-30 0001528172 ENDV:SeriesAAMember 2023-06-30 0001528172 ENDV:PreferredSeriesBMember 2023-06-30 0001528172 ENDV:PreferredSeriesCMember 2023-06-30 0001528172 ENDV:PreferredSeriesDMember 2023-06-30 0001528172 ENDV:UndesignatedMember 2023-06-30 0001528172 ENDV:StockOptionsMember 2022-12-31 0001528172 ENDV:StockOptionsMember 2023-01-01 2023-06-30 0001528172 ENDV:StockOptionsMember 2023-06-30 0001528172 us-gaap:WarrantMember 2022-12-31 0001528172 us-gaap:WarrantMember 2023-01-01 2023-06-30 0001528172 us-gaap:WarrantMember 2023-06-30 0001528172 srt:ExecutiveOfficerMember 2023-06-30 0001528172 srt:ExecutiveOfficerMember 2023-01-01 2023-06-30 0001528172 ENDV:OneFormerExecutiveOfficerMember 2023-06-30 0001528172 srt:OfficerMember 2023-06-30 0001528172 ENDV:FormerPresidentMember 2023-06-30 0001528172 us-gaap:MeasurementInputExpectedTermMember 2023-01-01 2023-06-30 0001528172 us-gaap:MeasurementInputExpectedTermMember 2022-01-01 2022-06-30 0001528172 us-gaap:MeasurementInputExercisePriceMember srt:MinimumMember 2023-06-30 0001528172 us-gaap:MeasurementInputExercisePriceMember srt:MaximumMember 2023-06-30 0001528172 us-gaap:MeasurementInputExercisePriceMember srt:MinimumMember 2022-06-30 0001528172 us-gaap:MeasurementInputExercisePriceMember srt:MaximumMember 2022-06-30 0001528172 us-gaap:MeasurementInputPriceVolatilityMember srt:MinimumMember 2023-06-30 0001528172 us-gaap:MeasurementInputPriceVolatilityMember srt:MaximumMember 2023-06-30 0001528172 us-gaap:MeasurementInputPriceVolatilityMember srt:MinimumMember 2022-06-30 0001528172 us-gaap:MeasurementInputPriceVolatilityMember srt:MaximumMember 2022-06-30 0001528172 us-gaap:MeasurementInputExpectedDividendRateMember 2023-06-30 0001528172 us-gaap:MeasurementInputExpectedDividendRateMember 2022-06-30 0001528172 us-gaap:MeasurementInputRiskFreeInterestRateMember srt:MinimumMember 2023-06-30 0001528172 us-gaap:MeasurementInputRiskFreeInterestRateMember srt:MaximumMember 2023-06-30 0001528172 us-gaap:MeasurementInputRiskFreeInterestRateMember srt:MinimumMember 2022-06-30 0001528172 us-gaap:MeasurementInputRiskFreeInterestRateMember srt:MaximumMember 2022-06-30 0001528172 ENDV:ForfeituresMember 2023-06-30 0001528172 ENDV:ForfeituresMember 2022-06-30 0001528172 us-gaap:FairValueInputsLevel3Member 2022-12-31 0001528172 us-gaap:FairValueInputsLevel3Member 2023-01-01 2023-06-30 0001528172 us-gaap:FairValueInputsLevel3Member 2023-06-30 0001528172 us-gaap:FairValueInputsLevel1Member 2023-06-30 0001528172 us-gaap:FairValueInputsLevel2Member 2023-06-30 0001528172 us-gaap:SalesRevenueNetMember us-gaap:CustomerConcentrationRiskMember ENDV:OneSignificantCustomerMember 2023-01-01 2023-06-30 0001528172 us-gaap:SalesRevenueNetMember us-gaap:SupplierConcentrationRiskMember ENDV:SupplierMember 2023-01-01 2023-06-30 0001528172 ENDV:TwoNotesExtensionAgreementsMember us-gaap:SubsequentEventMember 2023-07-01 2023-08-14 0001528172 ENDV:SecuriyPurchaseAgreementMember us-gaap:SubsequentEventMember ENDV:OneInvestorMember 2023-07-01 2023-08-14 0001528172 ENDV:ProductionAgreementMember us-gaap:SubsequentEventMember 2023-07-01 2023-08-14 0001528172 us-gaap:ConvertibleDebtMember us-gaap:SubsequentEventMember 2023-08-14 0001528172 us-gaap:ConvertibleDebtMember us-gaap:SubsequentEventMember 2023-07-01 2023-08-14 0001528172 us-gaap:SubsequentEventMember ENDV:ConsultantAndChiefExecutiveOfficerMember 2023-07-01 2023-08-14 iso4217:USD xbrli:shares iso4217:USD xbrli:shares xbrli:pure ENDV:Integer

 

 

 

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

 

FORM 10-Q

 

(Mark One)

 

QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

 

For the quarterly period ended: June 30, 2023

 

TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

 

For the transition period from _______ to _______.

 

Commission File Number: 000-55453

 

ENDONOVO THERAPEUTICS, INC.

(Exact name of registrant as specified in its charter)

 

Delaware   45-2552528
(State or other jurisdiction of   (I.R.S. Employer
incorporation or organization)   Identification No.)

 

6320 Canoga Avenue, 15th Floor, Woodland Hills, CA 91367

(Address of principal executive offices, zip code)

 

(800) 489-4774

(Registrant’s telephone number, including area code)

 

Securities registered pursuant to Section 12(b) of the Securities Exchange Act: None

 

Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days.

Yes ☒ No ☐

 

Indicate by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T (§232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit such files). Yes ☒ No ☐

 

Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company, or an emerging growth company. See the definitions of “large accelerated filer,” “accelerated filer,” “smaller reporting company,” and “emerging growth company” in Rule 12b-2 of the Exchange Act.

 

Large accelerated filer ☐ Accelerated filer ☐
   
Non-accelerated filer Smaller reporting company
   
  Emerging growth company

 

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

 

Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act).

Yes ☐ No

 

As of August 21, 2023, there were 317,902,405 shares of common stock, $0.0001 par value issued and outstanding.

 

 

 

 

 

 

ENDONOVO THERAPEUTICS, INC.

TABLE OF CONTENTS

FORM 10-Q REPORT

June 30, 2023

 

   

Page

Number

PART I - FINANCIAL INFORMATION  
     
Item 1. Condensed Consolidated Financial Statements (unaudited) 3
Item 2. Management’s Discussion and Analysis of Financial Condition and Results of Operations 20
Item 3. Quantitative and Qualitative Disclosures About Market Risk 23
Item 4. Controls and Procedures 23
     
PART II - OTHER INFORMATION  
     
Item 1. Legal Proceedings 24
Item 1A. Risk Factors 24
Item 2. Unregistered Sales of Equity Securities and Use of Proceeds 24
Item 3. Defaults Upon Senior Securities. 25
Item 4. Mine Safety Disclosures 25
Item 5. Other Information. 25
Item 6. Exhibits. 25
     
SIGNATURES 26

 

2

 

 

PART I - FINANCIAL INFORMATION

 

Item 1. Financial Statements.

 

Endonovo Therapeutics, Inc.

Condensed Consolidated Balance Sheets

 

   June 30, 2023   December 31, 2022 
   (Unaudited)   (Audited) 
         
ASSETS          
Current assets:          
Cash  $32,602   $98 
Prepaid expenses and other current assets   40,231    15,724 
Total current assets   72,833    15,822 
           
Patents, net   941,988    1,265,444 
Total assets  $1,014,821   $1,281,266 
           
LIABILITIES AND SHAREHOLDERS’ DEFICIT          
Current liabilities          
Accounts payable and accrued liabilities  $1,166,997   $884,195 
Accounts payable and accrued liabilities – related party   282,000    - 
Accrued interest related to notes payable   4,134,397    3,542,650 
Deferred compensation   4,053,368    3,918,788 
Deferred compensation – related party   570,068    523,818 
Notes payable, net of discounts of $25,585 and $10,587 as of June 30, 2023 and December 31, 2022   6,922,497    7,041,145 
Notes payable – former related party   104,600    112,100 
Derivative liability   5,902,829    17,359,064 
           
Total current liabilities   23,136,756    33,381,760 
           
Acquisition payable   79,825    79,825 
Total liabilities   23,216,581    33,461,585 
COMMITMENTS AND CONTINGENCIES, note 9   -    - 
           
Shareholders’ deficit          
Super AA super voting preferred stock, $0.001 par value; 1,000,000 authorized and 25,000 issued and outstanding at June 30, 2023 and December 31, 2022   25    25 
Series B convertible preferred stock, $0.0001 par value; 50,000 shares authorized, 600 shares issued and outstanding at June 30, 2023 and December 31, 2022   1    1 
Series C convertible preferred stock, $0.0001 par value; 8,000 shares authorized, 738 shares issued and outstanding at June 30, 2023 and December 31, 2022   -    - 
Series D convertible preferred stock, $0.0001 par value; 20,000 shares authorized, 0 and 50 issued and outstanding at June 30, 2023 and December 31, 2022   -    - 
Common stock, $0.0001 par value; 2,500,000,000 shares authorized; 278,802,405 and 213,227,538 shares issued and outstanding as of June 30, 2023 and December 31, 2022   27,880    21,322 
Additional paid-in capital   43,636,323    42,919,086 
Stock subscriptions receivable   (1,570)   (1,570)
Accumulated deficit   (65,864,419)   (75,119,183)
Total shareholders’ deficit   (22,201,760)   (32,180,319)
Total liabilities and shareholders’ deficit  $1,014,821   $1,281,266 

 

See accompanying summary of accounting policies and notes to unaudited condensed consolidated financial statements.

 

3

 

 

Endonovo Therapeutics, Inc.

Condensed Consolidated Statements of Operations

(Unaudited)

 

   2023   2022   2023   2022 
   Three Months Ended   Six Months Ended 
   June 30,   June 30, 
   2023   2022   2023   2022 
                 
Revenue  $45,200   $650   $132,740   $2,932 
Cost of revenue   -    383    3,996    1,097 
Gross profit   45,200    267    128,744    1,835 
                     
Operating expenses   1,176,509    1,799,016    1,789,343    2,286,346 
Loss from operations   (1,131,309)   (1,798,749)   (1,660,599)   (2,284,511)
                     
Other income (expense)                    
Change in fair value of derivative liability   3,419,564    (316,606)   11,445,466    (1,846,964)
Gain (loss) on settlement of debt   103,602    104,760    156,062    43,813 
Other expense   (15,328)   (178,000)   (24,518)   (178,000)
Interest expense, net   (312,869)   (337,536)   (622,249)   (673,678)
Other income (expense)   3,194,969    (727,382)   10,954,761    (2,654,829)
                     
Income (Loss) before income taxes   2,063,660    (2,526,131)   9,294,162    (4,939,340)
                     
Provision for income taxes   -    -    -    - 
                     
Net Income (Loss)  $2,063,660   $(2,526,131)  $9,294,162   $(4,939,340)
                     
Basic Income (Loss) per share  $0.00   $(0.02)  $0.04   $(0.05)
Diluted Loss per share  $(0.01)  $(0.02)  $(0.00)  $(0.05)
Weighted average common share outstanding:                    
Basic   276,330,405    134,360,871    263,948,243    106,696,127 
Diluted   1,350,743,592    134,360,871    1,338,361,430    106,696,127 

 

See accompanying summary of accounting policies and notes to unaudited condensed consolidated financial statements.

 

4

 

 

Endonovo Therapeutics, Inc.

Condensed Consolidated Statements of Cash Flows

(Unaudited)

 

   2023   2022 
   Six Months ended June 30, 
   2023   2022 
Operating activities:          
Net Income (Loss)  $9,294,162   $(4,939,340)
Adjustments to reconcile net income (loss) to cash used in operating activities:          
Amortization expense   323,457    323,456 
Stock compensation expense   566,500    - 
Fair value of equity issued for services   107,468    1,281,900 
Loss (gain) on extinguishment of debt   (156,062)   (43,813)
Amortization of note discount and original issue discount   14,627    59,138 
Change in fair value of derivative liability   (11,445,466)   1,846,964 
Changes in assets and liabilities:          
Prepaid expenses and other current assets   11,974    2,975 
Account payable and accrued liabilities (related and unrelated parties)   74,827    205,844 
Accrued interest   600,747    614,540 
Deferred compensation   268,770    318,900 
Net cash used in operating activities   (338,996)   (329,436)
           
Financing activities:          
Proceeds from the issuance of notes payable not of costs   146,000    250,000 
Repayments on former related party of notes payable   (7,500)   (6,500)
Repayments of convertible debt in cash   (20,000)   - 
Proceeds from issuance of common stock and units, net   253,000    - 
Net cash provided by financing activities   371,500    243,500 
           
Net increase (decrease) in cash   32,504    (85,936)
Cash, beginning of year   98    85,936 
Cash, end of period  $32,602   $- 
           
Supplemental disclosure of cash flow information:          
Cash paid for interest  $-   $- 
Cash paid for income taxes  $-   $- 
           
Non-Cash Investing and Financing Activities:          
Conversion of notes payable and accrued interest to common stock  $109,000   $204,000 
Conversion of Preferred C Stock to common stock  $500   $- 
Issuance of common stock to settle debt  $45,000   $- 
Debt discount from issuance of debt  $29,625   $33,167 

Conversion of notes to common stock pursuant to settlement agreement

  $159,419   $- 

 

See accompanying summary of accounting policies and notes to unaudited condensed consolidated financial statements.

 

5

 

 

Endonovo Therapeutics, Inc.

Condensed Consolidated Statement of Shareholders’ Deficit

(Unaudited)

 

For three and six months ended June 30, 2023

 

   Shares   Amount   Shares   Amount   Shares   Amount   Shares   Amount   Shares   Amount   Capital   Re ceivable   Deficit   Deficit 
   Series AA Preferred Stock   Series B Convertible Preferred Stock   Series C Convertible Preferred Stock   Series D Convertible Preferred Stock   Common Stock  

Additional

Paid-in

   Subscription   Accumulated  

Total

Shareholder’s

 
   Shares   Amount   Shares   Amount   Shares   Amount   Shares   Amount   Shares   Amount   Capital   Receivable   Deficit   Deficit 
                                                         
Balance December 31, 2022   25,000   $   25    600   $1    738   $      -    50   $     -    213,227,538   $21,322   $42,919,086   $(1,570)  $(75,119,183)  $(32,180,319)
                                                                       
Shares issued for conversion of notes payable and accrued interest   -    -    -    -    -    -    -    -    10,900,000    1,090    107,910    -    -    109,000 
Shares issued pursuant to make good provision                                           1,507,277    151    24,719              24,870 
Shares issued for settlement of debt   -    -    -    -    -    -    -    -    4,300,590    430    66,659    -    -    67,089 
Issuance of common shares for services   -    -    -    -    -    -    -    -    12,850,000    1,285    171,665    -    -    172,950 
Common stock issued for cash, net of fees   -    -    -    -    -    -    -    -    22,500,000    2,250    204,750    -    -    207,000 
Shares issued for conversion of Preferred Series D to common shares   -    -    -    -    -    -    (50)   -    5,000,000    500    (500)   -    -    - 
Inducement loss related to conversion of preferred stock   -    -    -    -    -    -    -    -    -    -    39,398    -    (39,398)   - 
Net income   -    -    -    -    -    -    -    -    -    -    -     -    7,230,502    7,230,502 
Balance March 31, 2023   25,000   $25    600   $1    738   $-    -   $-    270,285,405   $27,028   $43,533,687   $(1,570)  $(67,928,079)  $(24,368,908)
Shares issued for conversion of deferred compensation   -    -    -    -    -    -    -    -    1,667,000    167    24,171    -    -    24,338 
Issuance of commitment shares in connection with promissory notes   -    -    -    -    -    -    -    -    850,000    85    11,040    -    -    11,125 
Stock-based compensation   -    -    -    -    -    -    -    -    -    -    6,025    -    -    6,025 
Common Shares issued for services   -    -    -    -    -    -    -    -    1,000,000    100    15,900    -    -    16,000 
Common stock issued for cash, net of fees   -    -    -    -    -    -    -    -    5,000,000    500    45,500    -    -    46,000 
Net Income   -    -    -    -    -    -    -    -    -    -    -    -    2,063,660    2,063,660 
Balance June 30, 2023   25,000   $25    600   $1    738   $-    -   $-    278,802,405   $27,880   $43,636,323   $(1,570)  $(65,864,419)  $(22,201,760)

 

6

 

 

For three and six months ended June 30, 2022

 

   Series AA Preferred Stock   Series B Convertible Preferred Stock   Series C Convertible Preferred Stock   Series D Convertible Preferred Stock   Common Stock  

Additional

Paid-in

   Subscription   Accumulated  

Total

Shareholder’s

 
   Shares   Amount   Shares   Amount   Shares   Amount   Shares   Amount   Shares   Amount   Capital   Receivable   Deficit   Deficit 
                                                         
Balance December 31, 2020   25,000   $25    600   $     1    738   $     -    305   $     -    74,498,760   $7,449   $40,663,187   $(1,570)  $(56,443,416)  $(15,774,324)
                                                                       
Shares issued for conversion of notes payable and accrued interest   -    -    -    -    -    -    -    -    3,700,000    370    88,430    -    -    88,800 
Common stock issued for settlement of debt                                           2,428,777    243    45,904              46,147 
Issuance of commitment shares in connection with promissory note   -    -    -    -    -    -    -    -    700,000    70    15,680    -    -    15,750 
Net loss for the quarter ended March 31, 2022   -    -    -    -    -    -    -    -    -    -         -    (2,413,209)   (2,413,209)
Balance March 31, 2022   25,000   $25    600   $1    738   $-    305   $-    81,327,538   $8,132   $40,813,201   $(1,570)  $(58,856,625)  $(18,036,836)
Shares issued for conversion of notes payable and accrued interest   -    -    -    -    -    -    -    -    6,500,000    650    114,550    -    -    115,200 
Issuance of commitment shares in connection with promissory note   -    -    -    -    -    -    -    -    350,000    35    5,698    -    -    5,733 
Common Shares issued for services   -    -    -    -    -    -    -    -    62,250,000    6,225    1,275,675    -    -    1,281,900 
Net loss   -    -    -    -    -    -    -    -    -    -    -    -    (2,526,131)   (2,526,131)
Balance June 30, 2022   25,000   $25    600   $1    738   $-    305   $-    150,427,538   $15,042   $42,209,124   $(1,570)  $61,382,756   $(19,160,134)

 

See accompanying summary of accounting policies and notes to unaudited condensed consolidated financial statements.

 

7

 

 

Endonovo Therapeutics, Inc.

Notes to Condensed Consolidated Financial Statements

 

Note 1 - Organization and Nature of Business

 

Endonovo Therapeutics, Inc. (Endonovo or the “Company”) is an innovative biotechnology company that has developed a bio-electronic approach to regenerative medicine. Endonovo is a growth stage company whose stock is publicly traded (OTCQB: ENDV).

 

The Company develops, manufactures, and distributes evolutionary medical devices focused on the rapid healing of wounds and reduction of pain, edema, and inflammation in the human body. The Company’s non-invasive bioelectric medical devices are designed to target inflammation, cardiovascular diseases, chronic kidney disease, and central nervous system disorders (“CNS” disorders).

 

The Company’s non-invasive Electroceutical® therapeutics device, SofPulse®, using pulsed short-wave radiofrequency at 27.12 MHz has been FDA-Cleared and CE Marked for the palliative treatment of soft tissue injuries and post-operative plain and edema, and has CMS National Coverage for the treatment of chronic wounds. The Company’s current portfolio of pre-clinical stage Electroceutical® therapeutics devices address chronic kidney disease, liver disease non-alcoholic steatohepatitis (NASH), cardiovascular and peripheral artery disease (PAD) and ischemic stroke.

 

Endonovo’s core mission is to transform the field of medicine by developing safe, wearable, non-invasive bioelectric medical devices that deliver the Company’s Electroceutical® Therapy. Endonovo’s bioelectric Electroceutical® devices harnesses bioelectricity to restore key electrochemical processes that initiate anti-inflammatory processes and growth factors in the body necessary for healing to rapidly occur.

 

The Company intends to be structured into two separate divisions:

 

A commercial stage developer primarily of non-invasive wearable Electroceuticals® therapeutic devices for pain relief, general wellness, and wound curatives with many of its products marketed under the SofPulse® brand name. This division will be controlled by Ira Weisberg, the Company’s President and Chief Commercial Officer.
M&A division with a strategy of purchasing profitable companies, which will be managed by the Company’s current Chief Executive Officer.

 

Note 2 – Summary of significant accounting policies.

 

Basis of Presentation and Principles of Consolidation

 

The accompanying unaudited interim condensed consolidated financial statements have been presented in accordance with accounting principles generally accepted in the United States of America (“GAAP”) for interim financial information and the instructions to Article 8 of Regulation S-X. Accordingly, the financial statements do not include all of the information and notes required by GAAP for complete financial statements. The accompanying consolidated condensed balance sheet as of June 30, 2023, the consolidated statements of operations for the three and six months ended June 30, 2023 and 2022, the consolidated statements of cash flows for the six months ended June 30, 2023 and 2022, and the consolidated statements of shareholders’ deficit for the three and six months ended June 30, 2023 and 2022 are unaudited; however, in the opinion of management such interim consolidated financial statements reflect all adjustments, consisting solely of normal recurring adjustments, necessary for a fair presentation of the results for the periods presented. The accompanying financial information should be read in conjunction with the financial statements and the notes thereto in the Company’s most recent Annual Report on Form 10-K, as filed with the Securities and Exchange Commission (the “SEC”) on April 17, 2023. The results of operations for the period presented are not necessarily indicative of the results that might be expected for future interim periods or for the full year.

 

Liquidity and Going Concern

 

The Company’s unaudited condensed consolidated financial statements are prepared using GAAP applicable to a going concern, which contemplates the realization of assets and liquidation of liabilities in the normal course of business. The Company has not yet established an ongoing source of revenues sufficient to cover its operating costs and to continue as a going concern. The ability of the Company to continue as a going concern is dependent on the Company’s ability to obtain adequate capital to fund operating losses until it becomes profitable.

 

As of June 30, 2023, the Company had cash of approximately $32,600 and a working capital deficiency of approximately $23.1 million. During the six months ended June 30, 2023, the Company used approximately $0.3 million of cash in its operation. The Company has incurred recurring losses resulting in an accumulated deficit of approximately $65.9 million as of June 30, 2023. These conditions raise substantial doubt as to its ability to continue as going concern within one year from issuance date of these unaudited consolidated financial statements.

 

8

 

 

Endonovo Therapeutics, Inc.

Notes to Condensed Consolidated Financial Statements (continued)

 

During the six months ended June 30, 2023, the Company has raised $0.4 million in equity and debt financings. The Company will continue to raise additional capital through either debt or equity financing to fund its operations. However, there is no assurance that the Company can raise enough funds or generate sufficient revenues to pay its obligations as they become due, which raises substantial doubt about our ability to continue as a going concern.

 

On September 26, 2022, the Company entered into an asset purchase agreement with a Company, which is engaged in the business of providing and laying of concrete primarily for residential tract developers, pursuant to which the Company will acquire all of the assets and liabilities for approximately $25.2 million. The Company intends to raise the consideration through debt and equity financing. Such a transaction has not yet closed at the report date.

 

No adjustments have been made to the carrying value of assets or liabilities as a result of this uncertainty. To reduce the risk of not being able to continue as a going concern, management is commercializing its FDA cleared and CE marked products and has commenced implementing its business plan to materialize revenues from potential future license agreements, and or diversifying its business activities with the potential acquisition of specialty construction company. The Company will continue to raise additional capital through the issuance of fixed-rate conversion feature promissory notes.

 

Use of Estimates

 

The preparation of financial statements in conformity with accounting principles generally accepted in the United States of America requires management to make estimates and assumptions that affect the amounts reported in the condensed consolidated financial statements and accompanying notes. Critical estimates include the assessment of impairment of finite lived intangibles, the valuation of the derivative liability, the valuation of warrants and stock options, and the valuation of deferred income tax assets. Management uses its historical records and knowledge of its business in making these estimates. Actual results could differ from these estimates.

 

Earnings (Loss) Per Share

 

The Company utilizes Financial Accounting Standards Board (“FASB”) Accounting Standards Codification (“ASC”) 260, “Earnings per Share.” Basic earnings (loss) per share is computed based on the earnings (loss) attributable to common shareholders divided by the weighted average number of shares outstanding for the period excluding any dilutive effects of options, warrants, unvested share awards and convertible securities. Diluted earnings (loss) per common share is calculated similar to basic earnings (loss) per share except that the denominator is increased to include additional common share equivalents available upon exercise of stock option, warrants, common shares issuable under convertible debt and restricted stock using the treasury stock method. Dilutive common share equivalents include the dilutive effect of in-the-money share equivalents, which are calculated based on the average share price for each period using the treasury stock method, excluding any common share equivalents if their effect would be anti-dilutive. In periods in which a net loss has been incurred, all potentially dilutive common shares are considered anti-dilutive and thus are excluded from the calculation. Securities that are excluded from the calculation of weighted average dilutive common shares because their inclusion would have been antidilutive for the six months ended June 30, 2023, include stock options, warrants, and notes payable.

 

The Company has 6,011,750 stock options to purchase an equivalent number of shares of common stock outstanding at June 30, 2023. The Company has 513,730 options and 2,000 warrants to purchase common stock outstanding at June 30, 2022.

 

The components of basic and diluted income (loss) per share for the six months ended June 30, 2023 and 2022 were as follows:

 

   2023   2022 
   Six months ended June 30, 
   2023   2022 
Numerator:          
Net income (loss) attributable to common shareholders  $9,294,162   $(4,939,340)
           
Effect of dilutive securities          
Convertible notes   (10,823,217)   - 
Net loss for diluted earnings per share  $(1,529,055)  $(4,939,340)
Denominator:          
Weighted-average number of common shares outstanding during the period   263,948,243    106,696,127 
Dilutive effect of convertible notes payable   1,074,413,187    - 
Common stock and common stock equivalents used for diluted loss per share   1,338,361,430    106,696,127 

 

The components of basic and diluted income (loss) per share for the three months ended June 30, 2023 and 2022 were as follows:

 

   2023   2022 
   Three months ended June 30, 
   2023   2022 
Numerator:          
Net income (loss) attributable to common shareholders  $2,063,660   $(2,526,131)
           
Effect of dilutive securities          
Convertible notes   (3,106,695)   - 
Net loss for diluted earnings per share  $(1,043,035)  $(2,526,131)
Denominator:          
Weighted-average number of common shares outstanding during the period   276,330,405    134,360,871 
Dilutive effect of convertible notes payable   1,074,413,187    - 
Common stock and common stock equivalents used for diluted loss per share   1,350,743,592    134,360,871 

 

Accounts Receivable

 

The Company uses the specific identification method for recording the provision for doubtful accounts, which was $0 as of June 30, 2023 and December 31, 2022. Account receivables are written off when all collection attempts have failed.

 

9

 

 

Endonovo Therapeutics, Inc.

Notes to Condensed Consolidated Financial Statements (continued)

 

Newly Adopted Accounting Principles

 

The Company has evaluated all the recent accounting pronouncements and determined that there are no other accounting pronouncements that will have a material effect on the Company’s consolidated financial statements.

 

Note 3 - Revenue Recognition

 

Contracts with Customers

 

The Company adopted ASC 606, Revenue from Contracts with Customers effective January 1, 2019, using the modified retrospective method applied to those contracts which were not substantially completed as of January 1, 2019. These standards provide guidance on recognizing revenue, including a five-step model to determine when revenue recognition is appropriate. The standard requires that an entity recognize revenue to depict the transfer of control of promised goods or services to customers in an amount that reflects the consideration to which the entity expects to be entitled in exchange for those goods or services.

 

The Company routinely plans on entering into contracts with customers that include general commercial terms and conditions, notification requirements for price increases, shipping terms and in most cases prices for the products and services that we offer. The Company’s performance obligations are established when a customer submits a purchase order notification (in writing, electronically or verbally) for goods and services, and we accept the order. The Company identified performance obligations as the delivery of the requested product or service in appropriate quantities and to the location specified in the customer’s contract and/or purchase order. The Company generally recognize revenue upon the satisfaction of these criteria when control of the product or service has been transferred to the customer at which time, the Company has an unconditional right to receive payment. The Company’s sales and sale prices are final, and our prices are not affected by contingent events that could impact the transaction price.

 

Revenues for our SofPulse® product is typically recognized at the time the product is shipped, at which time the title passes to the customer, and there are no further performance obligations. Royalty/licensing revenue is also recognized at one point in time, when the units are shipped.

 

In connection with offering products and services provided to the end user by third-party vendors, the Company reviews the relationship between us, the vendor, and the end user to assess whether revenue should be reported on a gross or net basis. In asserting whether revenue should be reported on a gross or net basis, the Company considers whether the Company acts as a principal in the transaction and control the goods and services used to fulfill the performance obligation(s) associated with the transaction.

 

10

 

 

Endonovo Therapeutics, Inc.

Notes to Condensed Consolidated Financial Statements (continued)

 

Sources of Revenue

 

The Company has identified the following revenues by revenue source:

 

1. Sales to plastic surgeons
2. Sales to wound care facilities
3. Sales to hospital
4. Sales to other physicians
5. Royalty fee from licensing, net

 

For the three and six months ended June 30, 2023 and 2022, the sources of revenue were as follows:

 

   2023   2022   2023   2022 
   Three Months Ended June 30,   Six Months Ended June 30, 
   2023   2022   2023   2022 
                 
Royalty/licensing, net  $45,200   $-   $126,520   $- 
Direct sales- medical care providers, gross   -    650    6,220    2,932 
Total sources of revenue  $45,200   $650   $132,740   $2,932 

 

The royalty/licensing revenue recognized in the six months ended June 30, 2023, resulted from specific transactions. No general patent rights were assigned to the distributor. The royalty / licensing revenue is recorded on a net basis as the Company was not considered the principal but an agent for accounting purposes. The royalty / licensing revenue, net includes an ongoing contract with a customer that has a total gross sales value of $300,000, for which the Company recognized net revenue of $126,520 based on 1,000 units delivered during the period ended June 30, 2023. The royalty/licensing revenue is recognized when Pulse Therapeutic Technology picks up the units from the Company’s vendor.

 

On January 25, 2023, the Company entered into a sales support services agreement with Pulse Therapeutic Technology (“PTT”), an entity controlled by a former related party, under which PTT has been selling Sofpulse® on a nonexclusive basis. Pursuant to such agreement, the deferred compensation owed to this former related party has been fully extinguished for a total amount of approximately $118,000.

 

Warranty

 

Our general product warranties do not extend beyond an assurance that the product delivered will be consistent with stated specifications and do not include separate performance obligations.

 

Significant Judgments in the Application of the Guidance in ASC 606

 

There are no significant judgments associated with the satisfaction of our performance obligations. We generally satisfy performance obligations upon shipment of the product to the customer. This is consistent with the time in which the customer obtains control of the products. Performance obligations are also generally settled quickly after the purchase order acceptance, therefore the value of unsatisfied performance obligations at the end of any reporting period is generally immaterial.

 

We consider variable consideration in establishing the transaction price. Forms of variable consideration applicable to our arrangements include sales returns, rebates, volume-based bonuses, and prompt pay discounts. We use historical information along with an analysis of the expected value to properly calculate and to consider the need to constrain estimates of variable consideration. Such amounts are included as a reduction to revenue from the sale of products in the periods in which the related revenue is recognized and adjusted in future periods as necessary.

 

Practical Expedients

 

Our payment terms for sales direct to distributors are substantially less than the one-year collection period that falls within the practical expedient in determination of whether a significant financing component exists.

 

11

 

 

Endonovo Therapeutics, Inc.

Notes to Condensed Consolidated Financial Statements (continued)

 

Note 4 – Patents.

 

In December 2017, we acquired from Rio Grande Neurosciences, Inc. (RGN) a patent portfolio for $4,500,000. The earliest patents expire in 2024. The following is a summary of patents less accumulated amortization at June 30, 2023 and December 31, 2022:

 

   June 30, 2023   December 31, 2022 
         
Patents  $4,500,000   $4,500,000 
           
Less accumulated amortization   3,558,012    3,234,556 
           
Patents, net  $941,988   $1,265,444 

 

Amortization expense associated with patents was $323,456 for the six months ended June 30, 2023 and 2022.

 

The estimated future amortization expense related to patents as of June 30, 2023, is as follows:

 

Twelve Months Ending June 30,  Amount 
     
2024  $646,910 
2025   295,078 
      
Total  $941,988 

 

Note 5- Notes Payable

 

As of June 30, 2023, and December 31, 2022, the notes payable activity was as follows:

 

   June 30, 2023   December 31, 2022 
         
Notes payable at beginning of period  $7,163,832   $7,256,930 
Notes payable issued   150,000    465,000 
Repayments of notes payable in cash   (27,500)   (14,000)
Settlement on note payable   (133,650)   (163,826)
Less amounts converted to stock   (100,000)   (380,272)
Notes payable at end of period   7,052,682    7,163,832 
Less debt discount   (25,585)   (10,587)
Note payable, net  $7,027,097   $7,153,245 
           
Notes payable issued to a former related party  $104,600   $112,100 
Notes payable issued to non-related parties  $6,922,497   $7,041,145 

 

The maturity dates on the notes-payable are as follows:

 

   Notes to     
12 months ending, 

Former

related party

  

Non-related

parties

   Total 
             
Past due  $104,600   $6,733,082   $6,837,682 
June 30, 2024   -    215,000    215,000 
   $104,600   $6,948,082   $7,052,682 

 

Activity for the six months ended June 30, 2023

 

Fixed rate notes

 

During the six months ended June 30, 2023, the Company converted $100,000 in principal and $9,000 in accrued interest into 10,900,000 shares of common stock.

 

During the six months ended June 30, 2023, the Company executed a second amendment to a fixed rate note to extend the maturity date in exchange for $20,000 payment to the current balance of the note as of June 30, 2023, and $2,500 in extension fee payable at the revised maturity date.

 

During the six months ended June 30, 2023, the Company issued three fixed-rate notes for an aggregate amount of $150,000, which carry interest between 10% and 15% and with maturity ranging between one to nine (1 to 9) months from issuance.

 

12

 

 

Endonovo Therapeutics, Inc.

Notes to Condensed Consolidated Financial Statements (continued)

 

As of June 30, 2023, the Company has a total of twenty-two (22) fixed-rate notes, of which sixteen (16) have a make good provision for a total principal of $1,395,000 and $338,403 in accrued interest. Balance of fixed-rate notes was $1,849,728 and $1,819,728 as of June 30, 2023, and December 31, 2022, respectively. Accrued interest on fixed-rate notes was approximately $429,500 and $310,960 as of June 30, 2023, and December 31, 2023, respectively.

 

Such provision will require the Company to issue additional shares to ensure that the investor can realize a profit of 15% or 18% reselling the conversion shares. The value of the make good provision was approximately $250,000 as of June 30, 2023 and is reported under Accounts payable and accrued liabilities in the condensed consolidated balance sheet as of June 30, 2023. In addition, certain fixed-rate notes include a prepayment provision, which entitles the holder to a 15% cash premium. The Company concluded that such provision was not deemed material and probable as of June 30, 2023.

 

Variable-rate notes

 

During the six months ended June 30, 2023, the Company executed a settlement agreement with one investor to extinguish the remaining principal balance of a promissory note into 4,300,590 shares of common stock, which resulted in a gain from debt extinguishment of approximately $77,000.

 

Fixed Rate note (former related party)

 

Notes payable to a former related party in the aggregate amount of $104,600 were outstanding at June 30, 2023, which are past maturity date. The notes bear interest between 10% and 12% per annum. During the six months ended June 30, 2023, the Company repaid $7,500 in principal amount to this former related party. Refer to Note 7- Related Party Transactions.

 

Activity for the six months ended June 30, 2022

 

Fixed rates Notes

 

During the six months ended June 30, 2022, the Company issued three (3) fixed rate promissory notes totaling $250,000 for funding of $250,000 with original terms of nine months and interest rates of 15%. The holder of the promissory note can convert the outstanding unpaid principal and accrued interest at a fixed conversion rate, subject to standard anti-dilution features, six months after issuance date.

 

As of June 30, 2022, the Company has sixteen (16) fixed-rate promissory notes with an outstanding balance of $1,891,204, of which $1,116,204 are past maturity.

 

In October 2013, July 2014, October 2014 and August 2015, the Company initiated a series of private placements for up to $500,000, each, of financing by the issuance of notes payable at a minimum of $25,000, one unit. The notes bear interest at 10% per annum and were due and payable with accrued interest one year from issuance. During the six months ended June 30, 2022, the Company did not issue notes in connection with these private placements and did not repay any of these notes. As of June 30, 2022, and December 31, 2021, notes payable outstanding under these private placements are $624,903, all of which are past maturity.

 

During the six months ended June 30, 2022, the Company converted $110,204 in accrued interest and $93,796 in principal balance into 10,200,000 shares of common stock.

 

As of June 30, 2022, the Company has a total of sixteen (16) fixed-rate notes, of which twelve (12) for total principal amount of $1,250,000 includes a make good shares provision. Such provision will require the Company to issue additional shares to ensure that the investor can realize a profit of 15% reselling the conversion shares. The Company accrued $178,000 related to the make-good provision as the amount is probable and can be reasonably estimated pursuant to ASC 450 Contingencies. Such amount was presented as other expense in the condensed consolidated statement of operations.

 

Certain fixed-rate notes include a prepayment provision, which entitles the holder to a 15% premium upon cash redemption by the Company. The prepayment penalty approximates $121,000 as of June 30, 2022, but the Company determined that such liability is not probable as of June 30, 2022, pursuant to ASC 450 Contingencies.

 

Variable-rate notes

 

The gross amount of all convertible notes with variable conversion rates outstanding as of June 30, 2022, is $4,770,926, of which $4,770,926 are past maturity. There has been no conversion of notes into the Company’s common stock during the three and six months ended June 30, 2022.

 

13

 

 

Endonovo Therapeutics, Inc.

Notes to Condensed Consolidated Financial Statements (continued)

 

Note 6 - Shareholders’ Deficit

 

Preferred Stock

 

The Company has authorized 5,000,000 shares of preferred stock which have been designated as follows:

 

   Number of Shares
Authorized
   Number of Shares
Outstanding at
June 30, 2023
   Par Value  

Liquidation

Value

 
Series AA   1,000,000    25,000   $0.0010   $- 
Preferred Series B   50,000    600   $0.0001   $100 
Preferred Series C   8,000    738   $0.0001   $1,000 
Preferred Series D   20,000    -   $0.0001   $1,000 
Undesignated   3,922,000    -    -    - 

 

Series AA Preferred Shares

 

On February 22, 2013, the Board of Directors of the Company authorized an amendment to the Company’s Articles of Incorporation, as amended (the “Articles of Incorporation”), in the form of a Certificate of Designation that authorized the issuance of up to one million (1,000,000) shares of a new series of preferred stock, par value $0.001 per share, designated “Series AA Super Voting Preferred Stock,” for which the board of director established the rights, preferences and limitations thereof.

 

Each holder of outstanding shares of Series AA Super Voting Preferred Stock shall be entitled to one hundred thousand (100,000) votes for each share of Series AA Super Voting Preferred Stock held on the record date for the determination of stockholders entitled to vote at each meeting of stockholders of the Company. The Series AA Super Voting Preferred Stockholders will receive no dividends nor any value on liquidation.

 

There was no activity during the six months ended June 30, 2023. There were 25,000 shares of Series AA Preferred stock outstanding as of June 30, 2023 and December 31, 2022.

 

Series B Convertible Preferred Stock

 

On February 7, 2017, the Company filed a certificate of designation for 50,000 shares of Series B Convertible Preferred Stock designated as Series B (“Series B”) which are authorized and convertible, at the option of the holder, commencing six months from the date of issuance into common shares and warrants. For each share of Series B, the holder, on conversion, shall receive the stated value divided by 75% of the market price on the date of purchase of Series B and a three-year warrant exercisable into up to a like amount of common shares with an exercise price of 150% of the market price as defined in the Certificate of Designation. Dividends shall be paid only if dividends on the Company’s issued and outstanding Common Stock are paid, and the amount paid to the Series B holder will be as though the conversion shares had been issued. Series B holders have no voting rights. Upon liquidation, the holder of Series B, shall be entitled to receive an amount equal to the stated value, $100 per share, plus any accrued and unpaid dividends thereon before any distribution is made to Series C Secured Redeemable Preferred Stock or common stockholders.

 

There was no activity during the six months ended June 30, 2023. There were 600 shares of Series B outstanding as of June 30, 2023 and December 31, 2022.

 

14

 

 

Endonovo Therapeutics, Inc.

Notes to Condensed Consolidated Financial Statements (continued)

 

Series C Convertible Redeemable Preferred Stock

 

On December 22, 2017, the Company filed a certificate of designation for 8,000 shares of Series C Secured Redeemable Preferred Stock (“Series C”). Each share of the C Preferred is entitled to receive a $20 quarterly dividend commencing March 31, 2018, and each quarter thereafter and is to be redeemed for the stated value, $1,000 per share, plus accrued dividends in cash (i) at the Company’s option, commencing one year from issuance and (ii) mandatorily as of December 31, 2019. Management determined that the Series C should be classified as liability per the guidance in ASC 480 Distinguishing Liabilities from Equity as of December 31, 2019. On January 29, 2020, the Company filed the amended and restated certificate of designation fort its Series C Secured Redeemable Preferred Stock. The amendment changed the rights of the Series C by (a) removing the requirement to redeem the Series C, (b) removing the obligation to pay dividends on the Series C, (c) Allowing the holders of shares of Series C to convert the stated value of their shares into common stock of the Company at 75% of the closing price of such common stock on the day prior to the conversion. The C Preferred does not have any rights to vote with the common stock.

 

Upon liquidation, the holder of Series C, shall be entitled to receive an amount equal to the stated value, $1,000 per share, plus any accrued and unpaid dividends thereon before any distribution is made to common stockholders but after distributions are made to holders of Series B.

 

There was no activity during the six months ended June 30, 2023. There were 738 shares of Series C outstanding, as of June 30, 2023 and December 31, 2022

 

Series D Convertible Preferred Stock

 

On November 11, 2019, the Company filed a certificate of designation for 20,000 shares of Series D Convertible Preferred Stock designated as Series D (“Series D”), which are authorized and convertible, at the option of the holder, at any time from the date of issuance, into shares of common shares. On or prior to August 1, 2020, for each share of Series D, the holder, on conversion, shall receive a number of common shares equal to 0.01% of the Company’s issued and outstanding shares on conversion date and for conversion on or after August 2, 2020, the holder shall receive conversion shares as though the conversion date was August 1, 2020, with no further adjustments for issuances by the Company of common stock after August 1, 2020, except for stock split or reverse stock splits of the common stock. Management classified the Series D in permanent equity as of June 30, 2023.

 

The Series D holders have no voting rights. Upon liquidation, the holder of Series D, shall be entitled to receive an amount equal to the stated value, $1,000 per share, plus any accrued and unpaid dividends thereon before any distribution is made to common stockholders.

 

During the six months ended June 30, 2023, the Company issued 5,000,000 shares of common stock upon conversion of the remaining 50 shares of Series D preferred stock. The Company is also committed to providing additional shares of common stock if the holders of Series D do not realize a 15% profit on the resale of the conversion shares. As of June 30, 2023, and December 31, 2022, there were 0 and 50 shares of Series D outstanding, respectively.

 

Common Stock

 

Activity during the six months ended June 30, 2023

 

During the six months ended June 30, 2023, the Company issued 10,900,000 shares of common stock for the conversion of $109,000 of principal accrued interest from one note holder.

 

During the six months ended June 30, 2023, the Company issued 1,507,277 shares of common stock pursuant to a make-good provision, which resulted in a loss on debt extinguishment of $24,870.

 

During the six months June 30, 2023, the Company issued 4,300,590 shares of common stock pursuant to a debt settlement of aggregate principal of $113,650, resulting in a gain on debt extinguishment of approximately $77,000.

 

During the six months June 30, 2023, the Company issued 1667,000 shares of common stock pursuant to a deferred compensation settlement with a fair value of $24,338.

 

During the six months ended June 30, 2023, the Company issued 5,967,590 shares of common stock pursuant to a debt settlement.

 

During the six months ended June 30, 2023, the Company issued 13,850,000 shares of common stock for services for a total fair value of $188,950.

 

During the six months ended June 30, 2023, the Company issued 5,000,000 shares of common stock in exchange for 50 shares of Series D Preferred, which resulted in an inducement loss of $39,398 recorded as a deemed dividend in the shareholders’ deficit as of June 30, 2023.

 

During the six months ended June 30, 2023, the Company issued 5 1/2 units or the equivalent of 27,500,000 shares of common stock pursuant to a private placement for total net cash receipt of $253,000.

 

During the six months ended June 30, 2023, the Company issued 850,000 commitment shares pursuant to executed securities purchase agreements with an estimated fair value of $11,125.

 

Activity during the six months ended June 30, 2022

 

During the six months ended June 30, 2022, the Company issued 10,200,000 shares of common stock for the conversion of $93,796 of principal notes and accrued interest in the amount of $110,204.

 

During the six months ended June 30, 2022, the Company issued 2,428,777 shares of common stock pursuant to a make-whole provision from an April 2021 debt settlement with one investor.

 

During the six months ended June 30, 2022, the Company issued 1,050,000 shares of common stock as commitment shares in connection with securities purchase agreements.

 

During the six months ended June 30, 2022, the Company issued 62,250,000 shares of common stock for services for total fair value of $1,281,900.

 

15

 

 

Endonovo Therapeutics, Inc.

Notes to Condensed Consolidated Financial Statements (continued)

 

Stock Options

 

The balance of all stock options outstanding as of June 30, 2023, is as follows:

 

       Weighted
Average
   Weighted
Average
Remaining
   Aggregate 
       Exercise Price   Contractual   Intrinsic 
   Options   Per Share   Term (years)   Value 
Outstanding at December 31, 2022   3,012,410   $0.22    3.40    31,200 
Granted   3,000,000   $0.01    -      
Cancelled   (660)  $11.60    -      
Exercised   -   $-    -      
Outstanding at June 30, 2023   6,011,750   $0.12    3.06   $- 
                     
Exercisable at June 30, 2023   1,011,750   $0.64    1.83   $- 

 

Share-based compensation expenses for the six months ended June 30, 2023 and 2022, totaled approximately $6,000 and $0, respectively. The remaining stock-based compensation to be recognized is approximately $36,000, which will be recognized over 2.5 years.

 

Warrants

 

The balance of all warrants outstanding as of June 30, 2023, is as follows:

 

   Outstanding Warrants     
       Weighted
Average
   Weighted Average Remaining 
       Exercise Price   Contractual 
   Shares   Per Share   Term (years) 
Outstanding at December 31, 2022   2,000   $50.0    0.22 
Granted   -   $-    - 
Cancelled   (2,000)  $50.0    - 
Exercised   -   $-      
Outstanding at June 30, 2023   -   $-    - 
                
Exercisable at June 30, 2023   -   $-    - 

 

16

 

 

Endonovo Therapeutics, Inc.

Notes to Condensed Consolidated Financial Statements (continued)

 

Note 7 – Related Party and former related parties Transactions.

 

One executive officer of the Company has agreed to defer a portion of his compensation until cash flow improves. As of June 30, 2023, the balance of the deferred compensation was $570,068, which reflects $150,000 accrual of deferred compensation and $103,750 of cash repayment of deferred compensation during the six months ended June 30, 2023.

 

As of June 30, 2023, the Company accrued for the issuance of 20,000,000 shares of the Company’s common stock with a fair value of $282,000. Such balance is reported under accounts payable and accrued liabilities related party in the condensed consolidated balance sheet as of June 30, 2022.

 

One former executive of the Company has agreed to defer a portion of his compensation until cash flow improves. As of June 30, 2023, the balance of his deferred compensation was $632,257. No activity occurred during the six months ended June 30, 2023.

 

From time-to-time officer of the Company advance monies to the Company to cover costs. The balance of short-term advances due to one officer of the Company at June 30, 2023, was $375 and is included in the Company’s accounts payable and accrued liabilities balance as of June 30, 2023. During the six months ended June 30, 2023, the Company’s executive officer advanced an aggregate amount of $250 for corporate expenses, and $2,500 was repaid back as of June 30, 2023.

 

As of June 30, 2023, notes payable remained outstanding to the former President of the Company, in the amount of $104,600. As of June 30, 2023, accrued interests on these notes payable totaled approximately $85,445, and are included in accrued expenses on the condensed consolidated balance sheets.

 

Note 8 – Fair Value Measurements

 

The Company issued Variable Debentures, which contained variable conversion rates based on unknown future prices of the Company’s common stock. This results in a conversion feature. The Company measures the conversion feature using the Black Scholes option pricing model using the following assumptions:

 

    Six months ended June 30, 
    2023    2022 
           
Expected term   1 month    1 month 
Exercise price  $0.0066-$0.0151   $

0.004 – $0.015

 
Expected volatility   154%-158%   152%-169%
Expected dividends   None    None 
Risk-free interest rate   4.64%-5.40%   1.63% to 2.80%
Forfeitures   None    None 

 

The assumptions used in determining fair value represent management’s best estimates, but these estimates involve inherent uncertainties and the application of management’s judgment. As a result, if factors change, including changes in the market value of the Company’s common stock, managements’ assessment, or significant fluctuations in the volatility of the trading market for the Company’s common stock, the Company’s fair value estimates could be materially different in the future.

 

The Company computes the fair value of the derivative liability at each reporting period and the change in the fair value is recorded as non-cash expense or income. The key component in the value of the derivative liability is the Company’s stock price, which is subject to significant fluctuation and is not under its control. The resulting effect on net income (loss) is therefore subject to significant fluctuation and will continue to be so until the Company’s variable debentures, which the convertible feature is associated with, are converted into common stock or paid in full in cash. Assuming all other fair value inputs remain constant, the Company will record non-cash expense when its stock price increases and non-cash income when its stock price decreases.

 

17

 

 

Endonovo Therapeutics, Inc.

Notes to Condensed Consolidated Financial Statements (continued)

 

The following table presents changes in the liabilities with significant unobservable inputs (level 3) for the three months ended June 30, 2023:

 

   Derivative 
   Liability 
Balance December 31, 2022  $17,359,064 
      
Settlement debt   (10,769)
Change in estimated fair value   (11,445,466)
      
Balance June 30, 2023  $5,902,829 

 

Accounting guidance on fair value measurements and disclosures defines fair value, establishes a framework for measuring the fair value of assets and liabilities using a hierarchy system, and defines required disclosures. It clarifies that fair value is the price that would be received to sell an asset or paid to transfer a liability in an orderly transaction between market participants in the market in which the reporting entity transacts business.

 

The Company’s balance sheet contains derivative liabilities that are recorded at fair value on a recurring basis. The three-level valuation hierarchy for disclosure of fair value is as follows:

 

Level 1: uses quoted market prices in active markets for identical assets or liabilities.

 

Level 2: uses observable market-based inputs or unobservable inputs that are corroborated by market data.

 

Level 3: uses unobservable inputs that are not corroborated by market data.

 

The fair value of the Company’s recorded derivative liability is determined based on unobservable inputs that are not corroborated by market data, which require a Level 3 classification. A Black Scholes option pricing model was used to determine the fair value. The Company records derivative liability on the condensed consolidated balance sheets at fair value with changes in fair value recorded in the condensed consolidated statements of operation.

 

The following table presents balances in the liabilities with significant unobservable inputs (Level 3) as of June 30, 2023:

 

   Fair Value Measurements Using 
   Quoted
Prices in
             
   Active
Markets for
   Significant Other   Significant     
   Identical
Assets
   Observable
Inputs
   Unobservable
Inputs
     
   (Level 1)   (Level 2)   (Level 3)   Total 
                 
As of June 30, 2023                    
Derivative liability  $    -   $    -   $5,902,829   $5,902,829 
Total  $-   $-   $5,902,829   $5,902,829 

 

18

 

 

Endonovo Therapeutics, Inc.

Notes to Condensed Consolidated Financial Statements (continued)

 

Note 9 – Commitments and Contingencies

 

Legal Matters

 

The Company is subject to certain legal proceedings, which it considers routine to its business activities. As of June 30, 2023, the Company believes, after consultation with legal counsel, that the ultimate outcome of such legal proceedings, whether individually or in the aggregate, is not likely to have a material adverse effect on the Company’s financial position, results of operations or liquidity.

 

Note 10 – Concentrations.

 

Sales

 

During the six months ended June 30, 2023, we had one significant customer, which accounted for approximately 100% of sales. In addition, the Company generated all of its royalty/licensing revenue from one former related party.

 

Supplier

 

We also have a single source for our bioelectric medical devices, which account for 100% of our sales. The interruption of products provided by this supplier would adversely affect our business and financial condition unless an alternative source of products could be found.

 

Note 11 – Subsequent Events

 

Management has evaluated events that have occurred subsequent to the date of these consolidated condensed financial statements and has determined that, other than those listed below, no such reportable subsequent events exist through the date the financial statements were issued in accordance with FASB ASC Topic 855, “Subsequent Events.”

 

Subsequent to June 30, 2023, the Company issued 500,000 shares of common stock pursuant to two notes extension agreements.

 

Subsequent to June 30, 2023, the Company issued 1,000,000 shares of common stock pursuant to a securities purchase agreement with one investor. Such a liability was accrued for and reported under accounts payable and accrued liabilities in the consolidated balance sheet as of June 30, 2023.

 

Subsequent to June 30, 2023, the Company issued 8,000,000 shares of common stock pursuant to a production agreement.

 

Subsequent to June 30, 2023, the Company issued a convertible note in the principal amount of $20,000 carrying a coupon of 10% and a three-month maturity date.

 

Subsequent to June 30, 2023, the Company issued an aggregate of 29,600,000 shares of common stock for additional consideration to consultants and to the Company’s Chief Executive Officer, previously granted in the first fiscal quarter. Such a liability was accrued for and reported under accounts payable and accrued liabilities in the consolidated balance sheet as of June 30, 2023.

 

19

 

 

Item 2. Management’s Discussion and Analysis of Financial Condition and Results of Operations

 

Cautionary Notice Regarding Forward Looking Statements

 

The information contained in Item 2 contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. Actual results may materially differ from those projected in the forward-looking statements as a result of certain risks and uncertainties set forth in this report. Although management believes that the assumptions made and expectations reflected in the forward-looking statements are reasonable, there is no assurance that the underlying assumptions will, in fact, prove to be correct or that actual results will not be different from expectations expressed in this report.

 

This filing contains a number of forward-looking statements which reflect management’s current views and expectations with respect to our business, strategies, products, future results and events, and financial performance. All statements made in this filing other than statements of historical fact, including statements addressing operating performance, events, or developments which management expects or anticipates will or may occur in the future, including statements related to distributor channels, volume growth, revenues, profitability, new products, adequacy of funds from operations, statements expressing general optimism about future operating results, and non-historical information, are forward looking statements. In particular, the words “believe,” “expect,” “intend,” “anticipate,” “estimate,” “may,” and variations of such words, and similar expressions identify forward-looking statements, but are not the exclusive means of identifying such statements, and their absence does not mean that the statement is not forward-looking. These forward-looking statements are subject to certain risks and uncertainties, including those discussed below. Our actual results, performance or achievements could differ materially from historical results as well as those expressed in, anticipated, or implied by these forward-looking statements. We do not undertake any obligation to revise these forward-looking statements to reflect any future events or circumstances.

 

Readers should not place undue reliance on these forward-looking statements, which are based on management’s current expectations and projections about future events, are not guarantees of future performance, are subject to risks, uncertainties and assumptions (including those described below), and apply only as of the date of this filing. Our actual results, performance or achievements could differ materially from the results expressed in, or implied by, these forward-looking statements. We undertake no obligation to publicly update or revise any forward-looking statements, whether as a result of new information, future events, or otherwise.

 

Overview

 

Endonovo Therapeutics, Inc. (Endonovo or the “Company”) is an innovative biotechnology company that has developed a bio-electronic approach to regenerative medicine. Endonovo is a growth stage company whose stock is publicly traded (OTCQB: ENDV).

 

The Company develops, manufactures and distributes evolutionary medical devices focused on the rapid healing of wounds and reduction of pain, edema and inflammation in the human body. The Company’s non-invasive bioelectric medical devices are designed to target inflammation, cardiovascular diseases, chronic kidney disease, and central nervous system disorders (“CNS” disorders).

 

The Company’s non-invasive Electroceutical® therapeutics device, SofPulse®, using pulsed short-wave radiofrequency at 27.12 MHz has been FDA-Cleared and CE Marked for the palliative treatment of soft tissue injuries and post-operative plain and edema, and has CMS National Coverage for the treatment of chronic wounds. The Company’s current portfolio of pre-clinical stage Electroceutical® therapeutics devices address chronic kidney disease, liver disease non-alcoholic steatohepatitis (NASH), cardiovascular and peripheral artery disease (PAD) and ischemic stroke.

 

Endonovo’s core mission is to transform the field of medicine by developing safe, wearable, non-invasive bioelectric medical devices that deliver the Company’s Electroceutical® Therapy. Endonovo’s bioelectric Electroceutical® devices harnesses bioelectricity to restore key electrochemical processes that initiate anti-inflammatory processes and growth factors in the body necessary for healing to rapidly occur.

 

Going Concern

 

Our independent registered auditors included an explanatory paragraph in their opinion on our consolidated financial statements as of and for the fiscal year ended December 31, 2022, that states that our ongoing losses and lack of resources cause reasonable doubt about our ability to continue as a going concern.

 

Critical Accounting Policies

 

A summary of our significant accounting policies is included in Note 1 of the “Notes to the Consolidated Financial Statements,” contained in our Form 10-K for the year ended December 31, 2022. Management believes that the consistent application of these policies enables us to provide users of the financial statements with useful and reliable information about our operating results and financial condition. The summary condensed consolidated financial statements are prepared in accordance with accounting principles generally accepted in the U.S., which require us to make estimates and assumptions. We did not experience any significant changes during the six months ended June 30, 2023, in any of our critical accounting policies from those contained in our Form 10-K for the year ended December 31, 2022.

 

20

 

 

New Accounting Pronouncements

 

See Note 1 of Notes to Condensed Consolidated Financial Statements for further discussion of new accounting standards that have been adopted or are being evaluated for future adoption.

 

Results of Operations

 

Six Months ended June 31, 2023, and 2022:

 

   Six Months Ended June 30,   Favorable     
   2023   2022   (Unfavorable)   % 
                 
Revenue  $132,740   $2,932   $129,808    4,427%
Cost of revenue   3,996    1,097    (2,899)   (264)%
Gross profit   128,744    1,835    126,909    6,916%
                     
Operating expenses   1,789,343    2,286,346    497,003    22%
                     
Loss from operations   (1,660,599)   (2,284,511)   623,912    27%
                     
Other income (expense)   10,954,761    (2,654,829)   13,609,590    513%
                     
Net loss  $9,294,162   $(4,939,340)  $14,233,502    288%

 

Revenue

 

Revenue of the Company’s SofPulse® product during the six months ended June 30, 2023, was $6,220, an increase of $3,288, or 112%, compared to $2,932 for the six months ended June 30, 2022.

 

We anticipate that revenue will increase in future periods as the roll out of the SofPulse® product continues. The Company is looking to partner with global participants in the medical device market to spur its expansion. The Company expects such investment alternatives to include partnerships, joint ventures, distribution, and licensing agreements for the PEMF medical technology. The Company is also looking to expand on current initiatives with the Department of Defense, the Department of Veterans Affairs, and other surgical and pain management markets.

 

During the six months ended June 30, 2023, the Company also recognized $126,520 in royalty/licensing revenue from a former related party.

 

Cost of Revenue

 

Cost of revenue during the six months ended June 30, 2023, was $3,996, an increase of $2,899 or 264% compared to $1,097 for the six months ended June 30, 2022. Cost of revenue is recognized on those sales recorded as gross for which we are the principal in the transaction as opposed to net sales which reflect no cost of revenue. It is anticipated that cost of revenue will increase in future quarters as the roll out of the SofPulse® product continues.

 

Operating Expenses

 

Operating expenses decreased by $497,003 or 27%, to $1,789,343 for the six months ended June 30, 2023, compared to $2,286,346 for the six months ended June 30, 2022. This change was due primarily due a decrease in stock-based compensation expense by approximately $607,600, offset by an increase in consulting fees by approximately $122,000.

 

Other Expense/Income

 

Other income for the six months ended June 30, 2023, was $10,954,761 compared to an expense of $2,654,829 for the six months ended June 30, 2022. This change was due primarily to a decrease in the fair value of the Company’s derivative liability which generated an income from the change of fair value of $11.4 million as opposed to an expense of $1.8 million in the comparable period in the previous year. In addition, the Company’s gain on debt extinguishment increased by $0.1 million compared to the prior year and other expenses decreased by $0.2 million in the current year compared to the prior period.

 

We anticipate continued large fluctuations in other income/expense as a result of quarterly re-evaluation of the Company’s derivative liabilities.

 

Three Months ended June 31, 2023, and 2022:

 

   Three Months Ended June 30,   Favorable     
   2023   2022   (Unfavorable)   % 
                 
Revenue  $45,200   $650   $44,550    6,853%
Cost of revenue   -    383    383    100%
Gross profit   45,200    267    44,933    16,828%
                     
Operating expenses   1,176,509    1,799,016    622,507    35%
                     
Loss from operations   (1,131,309)   (1,798,749)   667,440    37%
                     
Other income (expense)   3,194,969    (727,382)   3,922,351    539%
                     
Net gain/loss  $2,063,660   $(2,526,131)  $4,589,791    182%

 

21

 

 

Revenue

 

Revenue of the Company’s SofPulse® product during the three months ended June 30, 2023, was $0, a decrease of $650, or 100%, compared to $650 for the three months ended June 30, 2022.

 

We anticipate that revenue will increase in future periods as the roll out of the SofPulse® product continues. The Company is looking to partner with global participants in the medical device market to spur its expansion. The Company expects such investment alternatives to include partnerships, joint ventures, distribution, and licensing agreements for the PEMF medical technology. The Company is also looking to expand on current initiatives with the Department of Defense, the Department of Veterans Affairs, and other surgical and pain management markets.

 

During the three months ended June 30, 2023, the Company also recognized $45,200 in royalty/licensing revenue from a former related party.

 

Cost of Revenue

 

Cost of revenue during the three months ended June 30, 2023, was $0, a decrease of $383 or 100% compared to $383 for the three months ended June 30, 2022. Cost of revenue is recognized on those sales recorded as gross for which we are the principal in the transaction as opposed to net sales which reflect no cost of revenue. It is anticipated that cost of revenue will increase in future quarters as the roll out of the SofPulse® product continues.

 

Operating Expenses

 

Operating expenses decreased by $622,507 or 35%, to $1,176,509 for the three months ended June 30, 2023, compared to $1,799,016 for the three months ended June 30, 2022. This change was due primarily to a decrease in stock-based compensation by approximately $661,000, offset by an increase in consulting fees by approximately $69,000.

 

Other Income (Expense)

 

Other income for the three months ended June 30, 2023, was $3,194,969 compared to other expense of $727,382 for the three months ended June 30, 2022. This change was due primarily to a decrease in the valuation of our derivative liabilities, which resulted in a positive change in the fair value of our derivative of approximately $3.4 million as opposed to an expense of $0.3 million in the comparable period in prior year, and a reduction in other expenses by approximately $163,000. We anticipate continued large fluctuations in other income (expense) as a result of quarterly re-evaluation of derivative liabilities.

 

Liquidity and Capital Resources

 

   As of     
   June 30,
2023
   December 31,
2022
   Favorable
(Unfavorable)
 
Working Capital               
                
Current assets  $72,833   $15,822   $57,011 
Current liabilities   23,136,756    33,381,760    10,245,004 
Working capital deficit  $(23,063,923)  $(33,365,938)  $10,302,015 
                
Long-term debt  $79,825   $79,825   $- 
                
Shareholders’ deficit  $(22,201,760)  $(32,180,319)  $9,978,559 

 

   Six Months Ended June 30,   Favorable 
   2023   2022   (Unfavorable) 
Statements of Cash Flows Select Information               
                
Net cash provided (used) by:               
Operating activities  $(338,996)  $(329,436)  $(9,560)
Financing activities  $371,500   $243,500   $128,000 

 

   As of     
   June 30,
2023
   December 31, 2022   Favorable
(Unfavorable)
 
Balance Sheet Select Information               
                
Cash  $32,602   $98   $32,504 
                
Accounts payable and accrued expenses  $10,206,830   $8,869,451   $(1,337,379)

 

Since January 1, 2023, and through June 30, 2023, the Company has raised approximately $0.4 million in equity and debt transactions. These funds have been used to fund on-going corporate operations. Our accompanying condensed consolidated financial statements have been prepared assuming the Company will continue as a going concern, which contemplates realization of assets and the satisfaction of liabilities in the normal course of business for the twelve-month period following the date of these condensed consolidated financial statements. Our cash on hand at June 30, 2023 was approximately $32,600. The Company has incurred substantial losses since its inception. Its current liabilities exceed its current assets and available cash is not sufficient to fund expected future operations. The Company is contemplating raising additional capital through debt and equity in order to continue the funding of its operations and to acquire a profitable business. However, there is no assurance that the Company can raise sufficient funds or generate sufficient revenues to pay its obligations as they become due, which raises substantial doubt about our ability to continue as a going concern.

 

22

 

 

The Company is not aware of any recently issued accounting pronouncements that when adopted will have a material effect on the Company’s financial position or results of its operations.

 

Off-Balance Sheet Arrangements

 

We have no off-balance sheet arrangements.

 

Item 3. Quantitative and Qualitative Disclosures about Market Risk.

 

We are a Smaller Reporting Company and are not required to provide the information under this item.

 

Item 4. Controls and Procedures.

 

Disclosure of controls and procedures.

 

We maintain disclosure controls and procedures that are designed to ensure that information required to be disclosed in our reports, filed under the Securities Exchange Act of 1934, is recorded, processed, summarized and reported within the time periods specified in the SEC’s rules and forms, and that such information is accumulated and communicated to our management, including our chief executive officer and chief financial officer, as appropriate, to allow timely decisions regarding required disclosure. In designing and evaluating the disclosure controls and procedures, management recognized that any controls and procedures, no matter how well designed and operated, can provide only reasonable and not absolute assurance of achieving the desired control objectives. In reaching a reasonable level of assurance, management necessarily was required to apply its judgment in evaluating the cost-benefit relationship of possible controls and procedures. In addition, the design of any system of controls also is based in part upon certain assumptions about the likelihood of future events, and there can be no assurance that any design will succeed in achieving its stated goals under all potential future conditions. Over time, control may become inadequate because of changes in conditions or the degree of compliance with policies or procedures may deteriorate. Because of the inherent limitations in a cost-effective control system, misstatements due to error or fraud may occur and not be detected.

 

As required by the SEC Rule 13a-15(b), we carried out an evaluation under the supervision and with the participation of our management, including our principal executive officer and principal financial officer, of the effectiveness of the design and operation of our disclosure controls and procedures as of the end of the period covered by this report. Based on the foregoing, our principal executive officer and principal financial officer concluded that our disclosure controls and procedures were not effective at a reasonable assurance level due to the material weaknesses described below.

 

In light of the material weaknesses described below, we performed additional analysis and other post-closing procedures to ensure our financial statements were prepared in accordance with generally accepted accounting principles. Accordingly, we believe that the financial statements included in this report fairly present, in all material respects, our financial condition, results of operations and cash flows for the periods presented.

 

A material weakness is a control deficiency (within the meaning of the Public Company Accounting Oversight Board (PCAOB) Auditing Standard No. 2) or combination of control deficiencies that result in more than a remote likelihood that a material misstatement of the annual or interim financial statements will not be prevented or detected.

 

Management has identified the following two material weaknesses which have caused management to conclude that as of June 30, 2023, our disclosure controls and procedures were not effective at the reasonable assurance level:

 

1. We do not have written documentation of our internal control policies and procedures. Written documentation of key internal controls over financial reporting is a requirement of Section 404 of the Sarbanes-Oxley Act, which is applicable to us for the quarter ended June 30, 2023. Management evaluated the impact of our failure to have written documentation of our internal controls and procedures on our assessment of our disclosure controls and procedures and has concluded that the control deficiency that resulted represented a material weakness.

 

23

 

 

2. We do not have sufficient segregation of duties within accounting functions, which is a basic internal control. Due to our size and nature, segregation of all conflicting duties may not always be possible and may not be economically feasible. However, to the extent possible, the authorization of transactions, the custody of assets and the recording of transactions should be performed by separate individuals. The recording of transactions function is maintained by a third-party consulting firm whereas authorization and custody remains under the Company’s Chief Executive Officer’s responsibility. Management evaluated the impact of our failure to have segregation of duties on our assessment of our disclosure controls and procedures and has concluded that the control deficiency that resulted represented a material weakness.

 

To address these material weaknesses, management performed additional analyses and other procedures to ensure that the financial statements included herein fairly present, in all material respects, our financial position, results of operations and cash flows for the periods presented.

 

Changes in internal controls over financial reporting.

 

There has been no change in our internal control over financial reporting that occurred during the fiscal quarter covered by this Quarterly Report on Form 10-Q that has materially affected, or is reasonably likely to materially affect, our internal control over financial reporting.

 

PART II - OTHER INFORMATION

 

Item 1. Legal Proceedings.

 

The Company is subject to certain legal proceedings, which it considers routine to its business activities. As of June 30, 2023, the Company believes, after consultation with legal counsel, that the ultimate outcome of such legal proceedings, whether individually or in the aggregate, is not likely to have a material adverse effect on the Company’s financial position, results of operations or liquidity.

 

Item 1A. Risk Factors.

 

We are a smaller reporting company (as defined in Rule 12b-2 of the Exchange Act) and are not required to provide the information under this item.

 

Item 2. Unregistered Sales of Equity Securities and Use of Proceeds.

 

Number of        
Common Shares   Source of    
Issued   Payment  Amount 
         
10,900,000   Conversion of notes and accrued interest  $109,000 
4,300,590   Settlement of debt   67,089 
1,667,000   Settlement of deferred compensation   24,338 
5,000,000   Conversion preferred stock   - 
27,500,000   Cash   253,000 
1,507,277   Make good provision   24,870 
13,850,000   Shares for services   188,950 
850,000   Commitment shares   11,125 

 

The above issuances of securities during the six months ended June 30, 2023, were exempt from registration pursuant to Section 4(2), and/or Regulation D promulgated under the Securities Act. These securities qualified for exemption under Section 4(2) of the Securities Act since the issuance of these securities by us did not involve a public offering. The offering was not a “public offering” as defined in Section 4(2) due to the insubstantial number of persons involved in the deal, size of the offering, manner of the offering and number of securities offered. We did not undertake an offering in which we sold a high number of securities to a high number of investors. In addition, these stockholders had the necessary investment intent as required by Section 4(2) since they agreed to and received share certificates bearing a legend stating that such securities are restricted pursuant to Rule 144 of the Securities Act. This restriction ensures that these securities would not be immediately redistributed into the market and therefore not be part of a “public offering.” Based on an analysis of the above factors, we have met the requirements to qualify for exemption under Section 4(2) of the Securities Act for this transaction.

 

24

 

 

Item 3. Defaults upon Senior Securities.

 

None

 

Item 4. Mine Safety Disclosures.

 

Not applicable

 

Item 5. Other Information

 

None

 

Item 6. Exhibits

 

(a) Exhibits

 

Exhibit

Number

  Exhibit Title
     
31.1*   Certification of Principal Executive Officer and Principal Financial Officer, pursuant to 18 U.S.C. Section 1350 as adopted pursuant to Section 302 of the Sarbanes-Oxley Act of 2002.
     
32.1*   Certification of Principal Executive Officer and Principal Financial Officer, pursuant to 18 U.S.C. Section 1350 as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002.
     
101*   Inline XBRL Document set for the financial statements and accompanying notes in Part I, Item 1, of this Quarterly Report on Form 10-Q
     
104*   Inline XBRL for the cover page of this Quarterly Report on Form 10-Q, included in the Exhibit 101 Inline XBRL Document Set.
     
    Exhibits designated by the symbol * are filed or furnished with this Quarterly Report on Form 10-Q

 

25

 

 

SIGNATURES

 

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

 

Dated: August 21, 2023 Endonovo Therapeutics, Inc.
   
  By: /s/ Alan Collier
    Alan Collier
   

Chief Executive Officer

    (Duly Authorized Officer, Principal Executive Officer, and Principal Financial Officer)

 

26

 

EX-31.1 2 ex31-1.htm

 

Exhibit 31.1

 

Certification of Principal Executive Officer and Principal Financial Officer

Pursuant to 18 U.S.C. 1350

(Section 302 of the Sarbanes-Oxley Act of 2002)

 

I, Alan Collier, Chief Executive Officer, and Principal Financial Officer, certifies that:

 

1. I have reviewed this Quarterly Report on Form 10-Q of Endonovo Therapeutics, Inc. for the period ended June 30, 2023;
   
2. Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;
   
3. Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;
   
4. I am responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have:

 

  (a) Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;
     
  (b) Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;
     
  (c) Evaluated the effectiveness of the registrant’s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and
     
  (d) Disclosed in this report any change in the registrant’s internal control over financial reporting that occurred during the registrant’s most recent fiscal quarter (the registrant’s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant’s internal control over financial reporting; and

 

5. I have disclosed, based on our most recent evaluation, to the registrant’s auditors and the audit committee of registrant’s board of directors (or persons performing the equivalent functions):

 

  (a) All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant’s ability to record, process, summarize and report financial information; and
     
  (b) Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant’s internal controls.

 

Dated: August 21, 2023 /s/ Alan Collier
  Chief Executive Officer and Principal Financial Officer

 

 

 

EX-32.1 3 ex32-1.htm

 

Exhibit 32.1

 

CERTIFICATION PURSUANT TO

18 U.S.C. §1350,

AS ADOPTED PURSUANT TO

SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002

 

In connection with the Quarterly Report of Endonovo Therapeutics, Inc. (the “Company”) on Form 10-Q for the period ended June 30, 2023, as filed with the Securities and Exchange Commission on the date hereof (the “Report”), I, Alan Collier, Chief Executive Officer, and Principal Financial Officer of the Company, certifies, pursuant to 18 U.S.C. §1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, that:

 

1. The Report fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934; and

 

2. The information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company.

 

    /s/ Alan Collier
  Name: Alan Collier
  Title: Chief Executive Officer and Principal Financial Officer
  Date: August 21, 2023

 

This certification accompanies each Report pursuant to § 906 of the Sarbanes-Oxley Act of 2002 and shall not, except to the extent required by the Sarbanes-Oxley Act of 2002, be deemed filed by the Company for purposes of §18 of the Securities Exchange Act of 1934, as amended.

 

 

 

EX-101.SCH 4 endv-20230630.xsd XBRL SCHEMA FILE 00000001 - Document - Cover link:presentationLink link:calculationLink link:definitionLink 00000002 - Statement - Condensed Consolidated Balance Sheets link:presentationLink link:calculationLink link:definitionLink 00000003 - Statement - Condensed Consolidated Balance Sheets (Parenthetical) link:presentationLink link:calculationLink link:definitionLink 00000004 - Statement - Condensed Consolidated Statements of Operations (Unaudited) link:presentationLink link:calculationLink link:definitionLink 00000005 - Statement - Condensed Consolidated Statements of Cash Flows (Unaudited) link:presentationLink link:calculationLink link:definitionLink 00000006 - Statement - Condensed Consolidated Statement of Shareholders' Deficit (Unaudited) link:presentationLink link:calculationLink link:definitionLink 00000007 - Disclosure - Organization and Nature of Business link:presentationLink link:calculationLink link:definitionLink 00000008 - Disclosure - Summary of significant accounting policies link:presentationLink link:calculationLink link:definitionLink 00000009 - Disclosure - Revenue Recognition link:presentationLink link:calculationLink link:definitionLink 00000010 - Disclosure - Patents link:presentationLink link:calculationLink link:definitionLink 00000011 - Disclosure - Notes Payable link:presentationLink link:calculationLink link:definitionLink 00000012 - Disclosure - Shareholders’ Deficit link:presentationLink link:calculationLink link:definitionLink 00000013 - Disclosure - Related Party and former related parties Transactions link:presentationLink link:calculationLink link:definitionLink 00000014 - Disclosure - Fair Value Measurements link:presentationLink link:calculationLink link:definitionLink 00000015 - Disclosure - Commitments and Contingencies link:presentationLink link:calculationLink link:definitionLink 00000016 - Disclosure - Concentrations link:presentationLink link:calculationLink link:definitionLink 00000017 - Disclosure - Subsequent Events link:presentationLink link:calculationLink link:definitionLink 00000018 - Disclosure - Summary of significant accounting policies (Policies) link:presentationLink link:calculationLink link:definitionLink 00000019 - Disclosure - Summary of significant accounting policies (Tables) link:presentationLink link:calculationLink link:definitionLink 00000020 - Disclosure - Revenue Recognition (Tables) link:presentationLink link:calculationLink link:definitionLink 00000021 - Disclosure - Patents (Tables) link:presentationLink link:calculationLink link:definitionLink 00000022 - Disclosure - Notes Payable (Tables) link:presentationLink link:calculationLink link:definitionLink 00000023 - Disclosure - Shareholders’ Deficit (Tables) link:presentationLink link:calculationLink link:definitionLink 00000024 - Disclosure - Fair Value Measurements (Tables) link:presentationLink link:calculationLink link:definitionLink 00000025 - Disclosure - Schedule of Earnings Per Share Basic and Diluted (Details) link:presentationLink link:calculationLink link:definitionLink 00000026 - Disclosure - Summary of significant accounting policies (Details Narrative) link:presentationLink link:calculationLink link:definitionLink 00000027 - Disclosure - Schedule of Source of Revenue (Details) link:presentationLink link:calculationLink link:definitionLink 00000028 - Disclosure - Revenue Recognition (Details Narrative) link:presentationLink link:calculationLink link:definitionLink 00000029 - Disclosure - Schedule of Patents (Details) link:presentationLink link:calculationLink link:definitionLink 00000030 - Disclosure - Schedule of Estimated Future Amortization Expense (Details) link:presentationLink link:calculationLink link:definitionLink 00000031 - Disclosure - Patents (Details Narrative) link:presentationLink link:calculationLink link:definitionLink 00000032 - Disclosure - Schedule of Notes Payable (Details) link:presentationLink link:calculationLink link:definitionLink 00000033 - Disclosure - Schedule of Maturity Dates of Notes Payable (Details) link:presentationLink link:calculationLink link:definitionLink 00000034 - Disclosure - Notes Payable (Details Narrative) link:presentationLink link:calculationLink link:definitionLink 00000035 - Disclosure - Schedule of Preferred Stock (Details) link:presentationLink link:calculationLink link:definitionLink 00000036 - Disclosure - Schedule of Stock Options Outstanding (Details) link:presentationLink link:calculationLink link:definitionLink 00000037 - Disclosure - Schedule of Warrants Outstanding (Details) link:presentationLink link:calculationLink link:definitionLink 00000038 - Disclosure - Shareholders’ Deficit (Details Narrative) link:presentationLink link:calculationLink link:definitionLink 00000039 - Disclosure - Related Party and former related parties Transactions (Details Narrative) link:presentationLink link:calculationLink link:definitionLink 00000040 - Disclosure - Schedule of Conversion Feature Using Black Scholes Option Pricing Model (Details) link:presentationLink link:calculationLink link:definitionLink 00000041 - Disclosure - Schedule of Fair Value of Derivative Liability (Details) link:presentationLink link:calculationLink link:definitionLink 00000042 - Disclosure - Schedule of Liabilities Significant Unobservable Inputs (Details) link:presentationLink link:calculationLink link:definitionLink 00000043 - Disclosure - Concentrations (Details Narrative) link:presentationLink link:calculationLink link:definitionLink 00000044 - Disclosure - Subsequent Events (Details Narrative) link:presentationLink link:calculationLink link:definitionLink EX-101.CAL 5 endv-20230630_cal.xml XBRL CALCULATION FILE EX-101.DEF 6 endv-20230630_def.xml XBRL DEFINITION FILE EX-101.LAB 7 endv-20230630_lab.xml XBRL LABEL FILE Related Party, Type [Axis] Nonrelated Party [Member] Related Party [Member] Class of Stock [Axis] Super AA Super Voting Preferred Stock [Member] Series B Convertible Preferred Stock [Member] Series C Convertible Preferred Stock [Member] Series D Convertible Preferred Stock [Member] Equity Components [Axis] Preferred Stock [Member] Series AA Preferred Stock [Member] Common Stock [Member] Additional Paid-in Capital [Member] Subscription Receivable [Member] Retained Earnings [Member] Collaborative Arrangement and Arrangement Other than Collaborative [Axis] Assets Purchase Agreement [Member] Antidilutive Securities [Axis] Share-Based Payment Arrangement, Option [Member] Warrant [Member] Product and Service [Axis] Royalty/Licensing, Net [Member] Direct Sales Medical Care Providers Gross [Member] Sales Support Service Agreement [Member] Pulse Therapeutic Technology [Member] Legal Entity [Axis] Rio Grande Neurosciences, Inc. [Member] Former Related Party [Member] Statistical Measurement [Axis] Minimum [Member] Maximum [Member] Debt Instrument [Axis] Fixed Rate Notes [Member] Variable Rate Notes [Member] 3 Fixed Rated Notes [Member] 16 Fixed Rated Notes [Member] Scenario [Axis] Past Maturity [Member] Sale of Stock [Axis] Private Placement [Member] Preferred Stock Designated [Member] Series B Preferred Stock [Member] Series C Convertible Redeemable Preferred Stock [Member] Title of Individual [Axis] One Investor [Member] Series D Preferred Stock [Member] Securities Purchase Agreements [Member] Purchase Agreement [Member] Series AA [Member] Preferred Series B [Member] Preferred Series C [Member] Preferred Series D [Member] Undesignated [Member] Financial Instrument [Axis] Stock Options [Member] Executive Officer [Member] One Former Executive Officer [Member] Officer [Member] Former President [Member] Measurement Input Type [Axis] Measurement Input, Expected Term [Member] Measurement Input, Exercise Price [Member] Measurement Input, Price Volatility [Member] Measurement Input, Expected Dividend Rate [Member] Measurement Input, Risk Free Interest Rate [Member] Forfeitures [Member] Fair Value Hierarchy and NAV [Axis] Fair Value, Inputs, Level 3 [Member] Fair Value, Inputs, Level 1 [Member] Fair Value, Inputs, Level 2 [Member] Concentration Risk Benchmark [Axis] Revenue Benchmark [Member] Concentration Risk Type [Axis] Customer Concentration Risk [Member] Customer [Axis] One Significant Customer [Member] Supplier Concentration Risk [Member] Supplier [Member] Two Notes Extension Agreements [Member] Subsequent Event Type [Axis] Subsequent Event [Member] Securiy Purchase Agreement [Member] Production Agreement [Member] Short-Term Debt, Type [Axis] Convertible Debt [Member] Consultant and Chief Executive Officer [Member] Cover [Abstract] Document Type Amendment Flag Amendment Description Document Registration Statement Document Annual Report Document Quarterly Report Document Transition Report Document Shell Company Report Document Shell Company Event Date Document Period Start Date Document Period End Date Document Fiscal Period Focus Document Fiscal Year Focus Current Fiscal Year End Date Entity File Number Entity Registrant Name Entity Central Index Key Entity Primary SIC Number Entity Tax Identification Number Entity Incorporation, State or Country Code Entity Address, Address Line One Entity Address, Address Line Two Entity Address, Address Line Three Entity Address, City or Town Entity Address, State or Province Entity Address, Country Entity Address, Postal Zip Code Country Region City Area Code Local Phone Number Extension Written Communications Soliciting Material Pre-commencement Tender Offer Pre-commencement Issuer Tender Offer Title of 12(b) Security No Trading Symbol Flag Trading Symbol Security Exchange Name Title of 12(g) Security Security Reporting Obligation Annual Information Form Audited Annual Financial Statements Entity Well-known Seasoned Issuer Entity Voluntary Filers Entity Current Reporting Status Entity Interactive Data Current Entity Filer Category Entity Small Business Entity Emerging Growth Company Elected Not To Use the Extended Transition Period Document Accounting Standard Other Reporting Standard Item Number Entity Shell Company Entity Public Float Entity Bankruptcy Proceedings, Reporting Current Entity Common Stock, Shares Outstanding Documents Incorporated by Reference [Text Block] Statement [Table] Statement [Line Items] ASSETS Current assets: Cash Prepaid expenses and other current assets Total current assets Patents, net Total assets LIABILITIES AND SHAREHOLDERS’ DEFICIT Current liabilities Accounts payable and accrued liabilities Accrued interest related to notes payable Deferred compensation Notes payable Derivative liability Total current liabilities Acquisition payable Total liabilities COMMITMENTS AND CONTINGENCIES, note 9 Shareholders’ deficit Preferred stock value Common stock, $0.0001 par value; 2,500,000,000 shares authorized; 278,802,405 and 213,227,538 shares issued and outstanding as of June 30, 2023 and December 31, 2022 Additional paid-in capital Stock subscriptions receivable Accumulated deficit Total shareholders’ deficit Total liabilities and shareholders’ deficit Discounts on notes payable current Preferred stock, par value Preferred stock, shares authorized Preferred stock, shares issued Preferred stock, shares outstanding Common stock, par value Common stock, shares authorized Common stock, shares issued Common stock, shares outstanding Income Statement [Abstract] Revenue Cost of revenue Gross profit Operating expenses Loss from operations Other income (expense) Change in fair value of derivative liability Gain (loss) on settlement of debt Other expense Interest expense, net Other income (expense) Income (Loss) before income taxes Provision for income taxes Net Income (Loss) Basic Income (Loss) per share Diluted Loss per share Weighted average common share outstanding: Basic Diluted Statement of Cash Flows [Abstract] Operating activities: Net Income (Loss) Adjustments to reconcile net income (loss) to cash used in operating activities: Amortization expense Stock compensation expense Fair value of equity issued for services Loss (gain) on extinguishment of debt Amortization of note discount and original issue discount Change in fair value of derivative liability Changes in assets and liabilities: Prepaid expenses and other current assets Account payable and accrued liabilities (related and unrelated parties) Accrued interest Deferred compensation Net cash used in operating activities Financing activities: Proceeds from the issuance of notes payable not of costs Repayments on former related party of notes payable Repayments of convertible debt in cash Proceeds from issuance of common stock and units, net Net cash provided by financing activities Net increase (decrease) in cash Cash, beginning of year Cash, end of period Supplemental disclosure of cash flow information: Cash paid for interest Cash paid for income taxes Non-Cash Investing and Financing Activities: Conversion of notes payable and accrued interest to common stock Conversion of Preferred C Stock to common stock Issuance of common stock to settle debt Debt discount from issuance of debt Conversion of notes to common stock pursuant to settlement agreement Balance Balance, shares Shares issued for conversion of notes payable and accrued interest Shares issued for conversion of notes payable and accrued interest, shares Shares issued pursuant to make good provision Shares issued pursuant to make good provision, shares Common stock issued for settlement of debt Common stock issued for settlement of debt, shares Common Shares issued for services Common Shares issued for services, shares Common stock issued for cash, net of fees Common stock issued for cash, net of fees, shares Shares issued for conversion of Preferred Series D to common shares Shares issued for conversion of Preferred Series D to common shares, shares Inducement loss related to conversion of preferred stock Net Income (loss) Shares issued for conversion of deferred compensation Shares issued for conversion of deferred compensation, shares Issuance of commitment shares in connection with promissory note Issuance of commitment shares in connection with promissory notes, shares Stock-based compensation Balance Balance, shares Organization, Consolidation and Presentation of Financial Statements [Abstract] Organization and Nature of Business Accounting Policies [Abstract] Summary of significant accounting policies Revenue from Contract with Customer [Abstract] Revenue Recognition Goodwill and Intangible Assets Disclosure [Abstract] Patents Debt Disclosure [Abstract] Notes Payable Equity [Abstract] Shareholders’ Deficit Related Party Transactions [Abstract] Related Party and former related parties Transactions Fair Value Disclosures [Abstract] Fair Value Measurements Commitments and Contingencies Disclosure [Abstract] Commitments and Contingencies Risks and Uncertainties [Abstract] Concentrations Subsequent Events [Abstract] Subsequent Events Basis of Presentation and Principles of Consolidation Liquidity and Going Concern Use of Estimates Earnings (Loss) Per Share Accounts Receivable Newly Adopted Accounting Principles Schedule of Earnings Per Share Basic and Diluted Schedule of Source of Revenue Schedule of Patents Schedule of Estimated Future Amortization Expense Schedule of Notes Payable Schedule of Maturity Dates of Notes Payable Schedule of Preferred Stock Schedule of Stock Options Outstanding Schedule of Warrants Outstanding Schedule of Conversion Feature Using Black Scholes Option Pricing Model Schedule of Fair Value of Derivative Liability Schedule of Liabilities Significant Unobservable Inputs Net income (loss) attributable to common shareholders Convertible notes Net loss for diluted earnings per share Weighted-average number of common shares outstanding during the period Dilutive effect of convertible notes payable Common stock and common stock equivalents used for diluted loss per share Collaborative Arrangement and Arrangement Other than Collaborative [Table] Collaborative Arrangement and Arrangement Other than Collaborative [Line Items] Cash Working capital Net cash provided by (used in) operating activities Accumulated deficit Proceeds from equity financing Purchase of assets and Liabilities Anti dilutive shares Accounts receivable allowance for credit loss, current Disaggregation of Revenue [Table] Disaggregation of Revenue [Line Items] Total sources of revenue [custom:GrossSaleValueOfOngoingContract] Contract with Customer, Liability, Revenue Recognized Number of Reporting Units Patents Less accumulated amortization Patents, net 2024 2025 Acquisition of patents Patents expiration period Amortization expense Schedule of Defined Benefit Plans Disclosures [Table] Defined Benefit Plan Disclosure [Line Items] Notes payable at beginning of period Notes payable issued Repayments of notes payable in cash Settlement on note payable Less amounts converted to stock Notes payable at end of period Less debt discount Note payable, net Past due June 30, 2024 Total Schedule of Long-Term Debt Instruments [Table] Debt Instrument [Line Items] Debt conversion, stock issued value Debt instrument, accrued interest Debt conversion, stock issued shares Repayments of convertible debt in cash Extension fee payable Note payable issued Debt instrument, interest rate Maturity term Principal amount Accrued interest Notes payable Accrued interest Debt instrument description Value of good provision Description of percentage of cash premium Gain on debt extinguishment Note payable outstanding Principal payment of debt Promissory notes Proceeds from issuance of note payable Debt instrument description Prepayment penalty Convertible notes Accumulated Other Comprehensive Income (Loss) [Table] Accumulated Other Comprehensive Income (Loss) [Line Items] Number of Shares Authorized Number of Shares Outstanding Par Value Liquidation Value Debt Securities, Held-to-Maturity, Allowance for Credit Loss [Table] Debt Securities, Held-to-Maturity, Allowance for Credit Loss [Line Items] Stock Options Outstanding, Beginning Balance Weighted Average Exercise Price Per Share, Beginning Balance Weighted Average Remaining Contractual Term (years), Outstanding Beginning Aggregated Intrinsic Value, Outstanding Beginning Balance Stock Options Outstanding, Granted Weighted Average Exercise Price Per Share, Granted Stock Options Outstanding, Cancelled Weighted Average Exercise Price Per Share, Cancelled Stock Options Outstanding, Exercised Weighted Average Exercise Price Per Share, Exercised Stock Options Outstanding, Ending Balance Weighted Average Exercise Price Per Share, Ending Balance Weighted Average Remaining Contractual Term (years), Ending Aggregated Intrinsic Value, Ending Stock Options Outstanding, Exercisable Ending Balance Weighted Average Exercise Price Per Share, Exercisable Ending Balance Weighted Average Remaining Contractual Term (years), Exercisable Aggregated Intrinsic Value, Exercisable Ending Shares Outstanding, Beginning Balance Weighted Average Exercise Price Per Share, Outstanding Beginning Balance Weighted Average Remaining Contractual Term (years), Outstanding Beginning Shares, Granted Weighted Average Exercise Price Per Share, Granted Shares, Cancelled Weighted Average Exercise Price Per Share, Cancelled Shares, Exercised Weighted Average Exercise Price Per Share, Exercised Shares Outstanding, Ending Balance Weighted Average Exercise Price Per Share, Outstanding Ending Balance Shares Exercisable, Ending Balance Weighted Average Exercise Price Per Share, Exercisable Ending Balance Number of shares authorized Preferred stock voting rights Stated value dividend Warrants term Share exercise price Liquidation value of preferred stock, per share Preferred stock, dividend per share Change in rights due to amendment and restated certificate, description Conversion price Number of shares issued Shares issued for conversion of notes payable, shares Conversion of stock description Shares issued for conversion of notes payable Issuance of common stock Number of shares issued, share Fair value of defered compensation Shares issued for common stock for services, shares Shares issued for common stock for services, value Inducement loss Common stock new issuance, value Share-based compensation expenses Unrecognized stock-based compensation expense Remaining vesting period Schedule of Related Party Transactions, by Related Party [Table] Related Party Transaction [Line Items] Deferred compensation Accrual deferred compensation Cash repayments of deferred compensation Number of shares issued Number of shares issued, value Due to officer Advance from officer Repayment of debt Notes payable, related parties Interest payable Fair Value Measurement Inputs and Valuation Techniques [Table] Fair Value Measurement Inputs and Valuation Techniques [Line Items] Fair value assumptions, measurement input, term Fair value assumptions, measurement input, percentage Fair Value, Recurring and Nonrecurring [Table] Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items] Derivative Liability, beginning balance Settlement debt Change in estimated fair value Derivative Liability, ending balance Derivative liability Total Concentration Risk [Table] Concentration Risk [Line Items] Concentration risk, percentage Subsequent Event [Table] Subsequent Event [Line Items] Number of shares issued Coupon rate Maturity period Accrued interest related to notes payable. Super AA Super Voting Preferred Stock [Member] Series B Convertible Preferred Stock [Member] Series C Convertible Preferred Stock [Member] Series D Convertible Preferred Stock [Member] Fair value of commitment shares issued with debt Amortization of note discount and original issue discount. Amortization of discount on Series C Preferred stock liability. Issuance of common stock to settle debt Conversion Of Preferred C Stock To Common Stock Disclosure of accounting policy for liquidity and going concern. Accrual of deferred compensation. One Former Executive Officer [Member] Assets Purchase Agreement [Member] Former President [Member] Debt discount from issuance of debt. Fair value assumptions, measurement input, term. Forfeitures [Member] The average number of shares or units issued and outstanding gross that are used in calculating diluted EPS or earnings per unit (EPU), determined based on the timing of issuance of shares or units in the period. Common stock and common stock equivalents used for diluted income per share. Series AA Preferred Stock [Member] Subscription Receivable [Member] Supplier [Member] Schedule of Source of Revenue [Table Text Block] Royalty/Licensing, Net [Member] Rio Grande Neurosciences, Inc. [Member] Patents expiration period. Notes payable issued to non-related parties. Settlements on note payable. Former Related Party [Member] Repayments of deferred compensation. Long term debt past maturity. Stock issued during period value connection with promissory notes. Stock issued during period shares connection with promissory notes. Extension fee payable. Good provision value. Certain fixed percentage of cash premium Variable Rate Notes [Member] Commitment shares issuable pursuant to securities purchase agreement. Past Maturity [Member] One Significant Customer [Member] Prepayment Penalty Schedule of preferred stock [Table text block]. Preferred Stock Designated [Member] Series AA [Member] Preferred Series B [Member] Preferred Series C [Member] Preferred Series D [Member] Undesignated [Member] Warrant term. Share exercise percentage. Series C Convertible Redeemable Preferred Stock [Member] Change in rights due to amendmend and restated certificate, description. Conversion price percentage. One Investor [Member] Inducement loss related to conversion of preferred stock. Purchase Agreement [Member] Stock Options [Member] Weighted average remaining contractual term (years), beginning outstanding. Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Exercisable Term 2. Share based compensation arrangement by share based payment award non option equity exercisable. Share based compensation for outstanding weighted average exercise price. Share based compensation arrangement by share based paymet award non option grand in period weighted average exercise price. Share based compensation arrangement by share based paymet award non option forfeited or expired in period weighted average exercise price. Share based compensation arrangement by share based paymet award non option exercised in period weighted average exercise price. Share based compensation arrangement by share based paymet award non option weighted average exercisable. Weighted average remaining contractual term (years), beginning outstanding. Working capital deficiency. Gross sales value of ongoing contract. Shares issued for conversion of deferred compensation shares. Shares issued for conversion of deferred compensation value. Sixteen Fixed Rated Notes [Member] Three Fixed Rated Notes [Member] Direct Sales Medical Care Providers Gross [Member] Securities Purchase Agreements [Member] Sales Support Service Agreement [Member] Pulse Therapeutic Technology [Member] Fixed Rate Notes [Member] Two Notes Extension Agreements [Member] Securiy Purchase Agreement [Member] Production Agreement [Member] Consultant and Chief Executive Officer [Member] Debt instrument coupon rate. Assets, Current Assets Liabilities, Current Liabilities Stockholders' Equity Note, Subscriptions Receivable Equity, Attributable to Parent Liabilities and Equity Gross Profit Operating Income (Loss) Nonoperating Income (Expense) Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest Increase (Decrease) in Prepaid Expense and Other Assets Increase (Decrease) in Deferred Compensation Net Cash Provided by (Used in) Operating Activities Net Cash Provided by (Used in) Financing Activities Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents, Including Disposal Group and Discontinued Operations Shares, Outstanding Cash [Default Label] Finite-Lived Patents, Gross Amortization of Intangible Assets Notes Payable [Default Label] Repayments of Notes Payable Conversion of Stock, Amount Converted Debt Instrument, Unamortized Discount Notes and Loans Payable Interest Payable Debt Instrument, Interest Rate Terms Convertible Debt Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Number Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Weighted Average Exercise Price Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested and Expected to Vest, Outstanding, Aggregate Intrinsic Value Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Forfeitures in Period Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Number Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Weighted Average Exercise Price Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Intrinsic Value Share-Based Compensation Arrangement by Share-Based Payment Award, Non-Option Equity Instruments, Outstanding, Number ShareBasedCompensationArrangementByShareBasedPaymetAwardNonOptionOutstandingWeightedAverageExercisePrice SharebasedCompensationArrangementBySharebasedPaymentAwardNonOptionsOutstandingWeightedAverageRemainingContractualTerm1 Term loan Share-Based Compensation Arrangement by Share-Based Payment Award, Non-Option Equity Instruments, Forfeitures ShareBasedCompensationArrangementByShareBasedPaymetAwardNonOptionForfeitedOrExpiredInPeriodWeightedAverageExercisePrice ShareBasedCompensationArrangementByShareBasedPaymetAwardNonOptionExercisedInPeriodWeightedAverageExercisePrice Series B preferred stock dividend payable in common stock ShareBasedCompensationArrangementByShareBasedPaymetAwardNonOptionWeightedAverageExercisable Deferred Compensation Equity Fair Value, Net Derivative Asset (Liability) Measured on Recurring Basis with Unobservable Inputs Derivative Liability Financial Liabilities Fair Value Disclosure EX-101.PRE 8 endv-20230630_pre.xml XBRL PRESENTATION FILE XML 9 R1.htm IDEA: XBRL DOCUMENT v3.23.2
Cover - shares
6 Months Ended
Jun. 30, 2023
Aug. 21, 2023
Cover [Abstract]    
Document Type 10-Q  
Amendment Flag false  
Document Quarterly Report true  
Document Transition Report false  
Document Period End Date Jun. 30, 2023  
Document Fiscal Period Focus Q2  
Document Fiscal Year Focus 2023  
Current Fiscal Year End Date --12-31  
Entity File Number 000-55453  
Entity Registrant Name ENDONOVO THERAPEUTICS, INC.  
Entity Central Index Key 0001528172  
Entity Tax Identification Number 45-2552528  
Entity Incorporation, State or Country Code DE  
Entity Address, Address Line One 6320 Canoga Avenue  
Entity Address, Address Line Two 15th Floor  
Entity Address, City or Town Woodland Hills  
Entity Address, State or Province CA  
Entity Address, Postal Zip Code 91367  
City Area Code (800)  
Local Phone Number 489-4774  
Entity Current Reporting Status Yes  
Entity Interactive Data Current Yes  
Entity Filer Category Non-accelerated Filer  
Entity Small Business true  
Entity Emerging Growth Company false  
Entity Shell Company false  
Entity Common Stock, Shares Outstanding   317,902,405
XML 10 R2.htm IDEA: XBRL DOCUMENT v3.23.2
Condensed Consolidated Balance Sheets - USD ($)
Jun. 30, 2023
Dec. 31, 2022
Current assets:    
Cash $ 32,602 $ 98
Prepaid expenses and other current assets 40,231 15,724
Total current assets 72,833 15,822
Patents, net 941,988 1,265,444
Total assets 1,014,821 1,281,266
Current liabilities    
Accrued interest related to notes payable 4,134,397 3,542,650
Derivative liability 5,902,829 17,359,064
Total current liabilities 23,136,756 33,381,760
Acquisition payable 79,825 79,825
Total liabilities 23,216,581 33,461,585
COMMITMENTS AND CONTINGENCIES, note 9
Shareholders’ deficit    
Common stock, $0.0001 par value; 2,500,000,000 shares authorized; 278,802,405 and 213,227,538 shares issued and outstanding as of June 30, 2023 and December 31, 2022 27,880 21,322
Additional paid-in capital 43,636,323 42,919,086
Stock subscriptions receivable (1,570) (1,570)
Accumulated deficit (65,864,419) (75,119,183)
Total shareholders’ deficit (22,201,760) (32,180,319)
Total liabilities and shareholders’ deficit 1,014,821 1,281,266
Super AA Super Voting Preferred Stock [Member]    
Shareholders’ deficit    
Preferred stock value 25 25
Series B Convertible Preferred Stock [Member]    
Shareholders’ deficit    
Preferred stock value 1 1
Series C Convertible Preferred Stock [Member]    
Shareholders’ deficit    
Preferred stock value
Series D Convertible Preferred Stock [Member]    
Shareholders’ deficit    
Preferred stock value
Nonrelated Party [Member]    
Current liabilities    
Accounts payable and accrued liabilities 1,166,997 884,195
Deferred compensation 4,053,368 3,918,788
Notes payable 6,922,497 7,041,145
Related Party [Member]    
Current liabilities    
Accounts payable and accrued liabilities 282,000
Deferred compensation 570,068 523,818
Notes payable $ 104,600 $ 112,100
XML 11 R3.htm IDEA: XBRL DOCUMENT v3.23.2
Condensed Consolidated Balance Sheets (Parenthetical) - USD ($)
Jun. 30, 2023
Dec. 31, 2022
Discounts on notes payable current $ 25,585 $ 10,587
Common stock, par value $ 0.0001 $ 0.0001
Common stock, shares authorized 2,500,000,000 2,500,000,000
Common stock, shares issued 278,802,405 213,227,538
Common stock, shares outstanding 278,802,405 213,227,538
Super AA Super Voting Preferred Stock [Member]    
Preferred stock, par value $ 0.001 $ 0.001
Preferred stock, shares authorized 1,000,000 1,000,000
Preferred stock, shares issued 25,000 25,000
Preferred stock, shares outstanding 25,000 25,000
Series B Convertible Preferred Stock [Member]    
Preferred stock, par value $ 0.0001 $ 0.0001
Preferred stock, shares authorized 50,000 50,000
Preferred stock, shares issued 600 600
Preferred stock, shares outstanding 600 600
Series C Convertible Preferred Stock [Member]    
Preferred stock, par value $ 0.0001 $ 0.0001
Preferred stock, shares authorized 8,000 8,000
Preferred stock, shares issued 738 738
Preferred stock, shares outstanding 738 738
Series D Convertible Preferred Stock [Member]    
Preferred stock, par value $ 0.0001 $ 0.0001
Preferred stock, shares authorized 20,000 20,000
Preferred stock, shares issued 0 50
Preferred stock, shares outstanding 0 50
XML 12 R4.htm IDEA: XBRL DOCUMENT v3.23.2
Condensed Consolidated Statements of Operations (Unaudited) - USD ($)
3 Months Ended 6 Months Ended
Jun. 30, 2023
Jun. 30, 2022
Jun. 30, 2023
Jun. 30, 2022
Income Statement [Abstract]        
Revenue $ 45,200 $ 650 $ 132,740 $ 2,932
Cost of revenue 383 3,996 1,097
Gross profit 45,200 267 128,744 1,835
Operating expenses 1,176,509 1,799,016 1,789,343 2,286,346
Loss from operations (1,131,309) (1,798,749) (1,660,599) (2,284,511)
Other income (expense)        
Change in fair value of derivative liability 3,419,564 (316,606) 11,445,466 (1,846,964)
Gain (loss) on settlement of debt 103,602 104,760 156,062 43,813
Other expense (15,328) (178,000) (24,518) (178,000)
Interest expense, net (312,869) (337,536) (622,249) (673,678)
Other income (expense) 3,194,969 (727,382) 10,954,761 (2,654,829)
Income (Loss) before income taxes 2,063,660 (2,526,131) 9,294,162 (4,939,340)
Provision for income taxes
Net Income (Loss) $ 2,063,660 $ (2,526,131) $ 9,294,162 $ (4,939,340)
Basic Income (Loss) per share $ 0.00 $ (0.02) $ 0.04 $ (0.05)
Diluted Loss per share $ (0.01) $ (0.02) $ (0.00) $ (0.05)
Weighted average common share outstanding:        
Basic 276,330,405 134,360,871 263,948,243 106,696,127
Diluted 1,350,743,592 134,360,871 1,338,361,430 106,696,127
XML 13 R5.htm IDEA: XBRL DOCUMENT v3.23.2
Condensed Consolidated Statements of Cash Flows (Unaudited) - USD ($)
6 Months Ended
Jun. 30, 2023
Jun. 30, 2022
Operating activities:    
Net Income (Loss) $ 9,294,162 $ (4,939,340)
Adjustments to reconcile net income (loss) to cash used in operating activities:    
Amortization expense 323,457 323,456
Stock compensation expense 566,500
Fair value of equity issued for services 107,468 1,281,900
Loss (gain) on extinguishment of debt (156,062) (43,813)
Amortization of note discount and original issue discount 14,627 59,138
Change in fair value of derivative liability (11,445,466) 1,846,964
Changes in assets and liabilities:    
Prepaid expenses and other current assets 11,974 2,975
Account payable and accrued liabilities (related and unrelated parties) 74,827 205,844
Accrued interest 600,747 614,540
Deferred compensation 268,770 318,900
Net cash used in operating activities (338,996) (329,436)
Financing activities:    
Proceeds from the issuance of notes payable not of costs 146,000 250,000
Repayments on former related party of notes payable (7,500) (6,500)
Repayments of convertible debt in cash (20,000)
Proceeds from issuance of common stock and units, net 253,000
Net cash provided by financing activities 371,500 243,500
Net increase (decrease) in cash 32,504 (85,936)
Cash, beginning of year 98 85,936
Cash, end of period 32,602
Supplemental disclosure of cash flow information:    
Cash paid for interest
Cash paid for income taxes
Non-Cash Investing and Financing Activities:    
Conversion of notes payable and accrued interest to common stock 109,000 204,000
Conversion of Preferred C Stock to common stock 500
Issuance of common stock to settle debt 45,000
Debt discount from issuance of debt 29,625 33,167
Conversion of notes to common stock pursuant to settlement agreement $ 159,419
XML 14 R6.htm IDEA: XBRL DOCUMENT v3.23.2
Condensed Consolidated Statement of Shareholders' Deficit (Unaudited) - USD ($)
Preferred Stock [Member]
Series AA Preferred Stock [Member]
Preferred Stock [Member]
Series B Convertible Preferred Stock [Member]
Preferred Stock [Member]
Series C Convertible Preferred Stock [Member]
Preferred Stock [Member]
Series D Convertible Preferred Stock [Member]
Common Stock [Member]
Additional Paid-in Capital [Member]
Subscription Receivable [Member]
Retained Earnings [Member]
Total
Balance at Dec. 31, 2021 $ 25 $ 1 $ 7,449 $ 40,663,187 $ (1,570) $ (56,443,416) $ (15,774,324)
Balance, shares at Dec. 31, 2021 25,000 600 738 305 74,498,760        
Shares issued for conversion of notes payable and accrued interest $ 370 88,430 88,800
Shares issued for conversion of notes payable and accrued interest, shares         3,700,000        
Common stock issued for settlement of debt         $ 243 45,904     46,147
Common stock issued for settlement of debt, shares         2,428,777        
Net Income (loss)   (2,413,209) (2,413,209)
Issuance of commitment shares in connection with promissory note $ 70 15,680 15,750
Issuance of commitment shares in connection with promissory notes, shares         700,000        
Balance at Mar. 31, 2022 $ 25 $ 1 $ 8,132 40,813,201 (1,570) (58,856,625) (18,036,836)
Balance, shares at Mar. 31, 2022 25,000 600 738 305 81,327,538        
Balance at Dec. 31, 2021 $ 25 $ 1 $ 7,449 40,663,187 (1,570) (56,443,416) $ (15,774,324)
Balance, shares at Dec. 31, 2021 25,000 600 738 305 74,498,760        
Shares issued for conversion of notes payable and accrued interest, shares                 10,200,000
Common Shares issued for services                 $ 1,281,900
Common Shares issued for services, shares                 62,250,000
Net Income (loss)                 $ (4,939,340)
Balance at Jun. 30, 2022 $ 25 $ 1 $ 15,042 42,209,124 (1,570) 61,382,756 (19,160,134)
Balance, shares at Jun. 30, 2022 25,000 600 738 305 150,427,538        
Balance at Mar. 31, 2022 $ 25 $ 1 $ 8,132 40,813,201 (1,570) (58,856,625) (18,036,836)
Balance, shares at Mar. 31, 2022 25,000 600 738 305 81,327,538        
Shares issued for conversion of notes payable and accrued interest $ 650 114,550 115,200
Shares issued for conversion of notes payable and accrued interest, shares         6,500,000        
Common Shares issued for services $ 6,225 1,275,675 1,281,900
Common Shares issued for services, shares         62,250,000        
Net Income (loss) (2,526,131) (2,526,131)
Issuance of commitment shares in connection with promissory note $ 35 5,698 5,733
Issuance of commitment shares in connection with promissory notes, shares         350,000        
Balance at Jun. 30, 2022 $ 25 $ 1 $ 15,042 42,209,124 (1,570) 61,382,756 (19,160,134)
Balance, shares at Jun. 30, 2022 25,000 600 738 305 150,427,538        
Balance at Dec. 31, 2022 $ 25 $ 1 $ 21,322 42,919,086 (1,570) (75,119,183) (32,180,319)
Balance, shares at Dec. 31, 2022 25,000 600 738 50 213,227,538        
Shares issued for conversion of notes payable and accrued interest $ 1,090 107,910 109,000
Shares issued for conversion of notes payable and accrued interest, shares         10,900,000        
Shares issued pursuant to make good provision         $ 151 24,719     24,870
Shares issued pursuant to make good provision, shares         1,507,277        
Common stock issued for settlement of debt $ 430 66,659 67,089
Common stock issued for settlement of debt, shares         4,300,590        
Common Shares issued for services $ 1,285 171,665 172,950
Common Shares issued for services, shares         12,850,000        
Common stock issued for cash, net of fees $ 2,250 204,750 207,000
Common stock issued for cash, net of fees, shares         22,500,000        
Shares issued for conversion of Preferred Series D to common shares $ 500 (500)
Shares issued for conversion of Preferred Series D to common shares, shares       (50) 5,000,000        
Inducement loss related to conversion of preferred stock 39,398 (39,398)
Net Income (loss) 7,230,502 7,230,502
Balance at Mar. 31, 2023 $ 25 $ 1 $ 27,028 43,533,687 (1,570) (67,928,079) (24,368,908)
Balance, shares at Mar. 31, 2023 25,000 600 738 270,285,405        
Balance at Dec. 31, 2022 $ 25 $ 1 $ 21,322 42,919,086 (1,570) (75,119,183) $ (32,180,319)
Balance, shares at Dec. 31, 2022 25,000 600 738 50 213,227,538        
Shares issued for conversion of notes payable and accrued interest, shares         4,300,590       10,900,000
Shares issued pursuant to make good provision         $ 282,000        
Shares issued pursuant to make good provision, shares         20,000,000        
Common Shares issued for services                 $ 188,950
Common Shares issued for services, shares                 13,850,000
Common stock issued for cash, net of fees, shares         5,967,590        
Net Income (loss)                 $ 9,294,162
Shares issued for conversion of deferred compensation         $ 24,338        
Shares issued for conversion of deferred compensation, shares         1,667,000        
Balance at Jun. 30, 2023 $ 25 $ 1 $ 27,880 43,636,323 (1,570) (65,864,419) (22,201,760)
Balance, shares at Jun. 30, 2023 25,000 600 738 278,802,405        
Balance at Mar. 31, 2023 $ 25 $ 1 $ 27,028 43,533,687 (1,570) (67,928,079) (24,368,908)
Balance, shares at Mar. 31, 2023 25,000 600 738 270,285,405        
Common Shares issued for services $ 100 15,900 16,000
Common Shares issued for services, shares         1,000,000        
Common stock issued for cash, net of fees $ 500 45,500 46,000
Common stock issued for cash, net of fees, shares         5,000,000        
Net Income (loss) 2,063,660 2,063,660
Shares issued for conversion of deferred compensation $ 167 24,171 24,338
Shares issued for conversion of deferred compensation, shares         1,667,000        
Issuance of commitment shares in connection with promissory note $ 85 11,040 11,125
Issuance of commitment shares in connection with promissory notes, shares         850,000        
Stock-based compensation 6,025 6,025
Balance at Jun. 30, 2023 $ 25 $ 1 $ 27,880 $ 43,636,323 $ (1,570) $ (65,864,419) $ (22,201,760)
Balance, shares at Jun. 30, 2023 25,000 600 738 278,802,405        
XML 15 R7.htm IDEA: XBRL DOCUMENT v3.23.2
Organization and Nature of Business
6 Months Ended
Jun. 30, 2023
Organization, Consolidation and Presentation of Financial Statements [Abstract]  
Organization and Nature of Business

Note 1 - Organization and Nature of Business

 

Endonovo Therapeutics, Inc. (Endonovo or the “Company”) is an innovative biotechnology company that has developed a bio-electronic approach to regenerative medicine. Endonovo is a growth stage company whose stock is publicly traded (OTCQB: ENDV).

 

The Company develops, manufactures, and distributes evolutionary medical devices focused on the rapid healing of wounds and reduction of pain, edema, and inflammation in the human body. The Company’s non-invasive bioelectric medical devices are designed to target inflammation, cardiovascular diseases, chronic kidney disease, and central nervous system disorders (“CNS” disorders).

 

The Company’s non-invasive Electroceutical® therapeutics device, SofPulse®, using pulsed short-wave radiofrequency at 27.12 MHz has been FDA-Cleared and CE Marked for the palliative treatment of soft tissue injuries and post-operative plain and edema, and has CMS National Coverage for the treatment of chronic wounds. The Company’s current portfolio of pre-clinical stage Electroceutical® therapeutics devices address chronic kidney disease, liver disease non-alcoholic steatohepatitis (NASH), cardiovascular and peripheral artery disease (PAD) and ischemic stroke.

 

Endonovo’s core mission is to transform the field of medicine by developing safe, wearable, non-invasive bioelectric medical devices that deliver the Company’s Electroceutical® Therapy. Endonovo’s bioelectric Electroceutical® devices harnesses bioelectricity to restore key electrochemical processes that initiate anti-inflammatory processes and growth factors in the body necessary for healing to rapidly occur.

 

The Company intends to be structured into two separate divisions:

 

A commercial stage developer primarily of non-invasive wearable Electroceuticals® therapeutic devices for pain relief, general wellness, and wound curatives with many of its products marketed under the SofPulse® brand name. This division will be controlled by Ira Weisberg, the Company’s President and Chief Commercial Officer.
M&A division with a strategy of purchasing profitable companies, which will be managed by the Company’s current Chief Executive Officer.

 

XML 16 R8.htm IDEA: XBRL DOCUMENT v3.23.2
Summary of significant accounting policies
6 Months Ended
Jun. 30, 2023
Accounting Policies [Abstract]  
Summary of significant accounting policies

Note 2 – Summary of significant accounting policies.

 

Basis of Presentation and Principles of Consolidation

 

The accompanying unaudited interim condensed consolidated financial statements have been presented in accordance with accounting principles generally accepted in the United States of America (“GAAP”) for interim financial information and the instructions to Article 8 of Regulation S-X. Accordingly, the financial statements do not include all of the information and notes required by GAAP for complete financial statements. The accompanying consolidated condensed balance sheet as of June 30, 2023, the consolidated statements of operations for the three and six months ended June 30, 2023 and 2022, the consolidated statements of cash flows for the six months ended June 30, 2023 and 2022, and the consolidated statements of shareholders’ deficit for the three and six months ended June 30, 2023 and 2022 are unaudited; however, in the opinion of management such interim consolidated financial statements reflect all adjustments, consisting solely of normal recurring adjustments, necessary for a fair presentation of the results for the periods presented. The accompanying financial information should be read in conjunction with the financial statements and the notes thereto in the Company’s most recent Annual Report on Form 10-K, as filed with the Securities and Exchange Commission (the “SEC”) on April 17, 2023. The results of operations for the period presented are not necessarily indicative of the results that might be expected for future interim periods or for the full year.

 

Liquidity and Going Concern

 

The Company’s unaudited condensed consolidated financial statements are prepared using GAAP applicable to a going concern, which contemplates the realization of assets and liquidation of liabilities in the normal course of business. The Company has not yet established an ongoing source of revenues sufficient to cover its operating costs and to continue as a going concern. The ability of the Company to continue as a going concern is dependent on the Company’s ability to obtain adequate capital to fund operating losses until it becomes profitable.

 

As of June 30, 2023, the Company had cash of approximately $32,600 and a working capital deficiency of approximately $23.1 million. During the six months ended June 30, 2023, the Company used approximately $0.3 million of cash in its operation. The Company has incurred recurring losses resulting in an accumulated deficit of approximately $65.9 million as of June 30, 2023. These conditions raise substantial doubt as to its ability to continue as going concern within one year from issuance date of these unaudited consolidated financial statements.

 

 

Endonovo Therapeutics, Inc.

Notes to Condensed Consolidated Financial Statements (continued)

 

During the six months ended June 30, 2023, the Company has raised $0.4 million in equity and debt financings. The Company will continue to raise additional capital through either debt or equity financing to fund its operations. However, there is no assurance that the Company can raise enough funds or generate sufficient revenues to pay its obligations as they become due, which raises substantial doubt about our ability to continue as a going concern.

 

On September 26, 2022, the Company entered into an asset purchase agreement with a Company, which is engaged in the business of providing and laying of concrete primarily for residential tract developers, pursuant to which the Company will acquire all of the assets and liabilities for approximately $25.2 million. The Company intends to raise the consideration through debt and equity financing. Such a transaction has not yet closed at the report date.

 

No adjustments have been made to the carrying value of assets or liabilities as a result of this uncertainty. To reduce the risk of not being able to continue as a going concern, management is commercializing its FDA cleared and CE marked products and has commenced implementing its business plan to materialize revenues from potential future license agreements, and or diversifying its business activities with the potential acquisition of specialty construction company. The Company will continue to raise additional capital through the issuance of fixed-rate conversion feature promissory notes.

 

Use of Estimates

 

The preparation of financial statements in conformity with accounting principles generally accepted in the United States of America requires management to make estimates and assumptions that affect the amounts reported in the condensed consolidated financial statements and accompanying notes. Critical estimates include the assessment of impairment of finite lived intangibles, the valuation of the derivative liability, the valuation of warrants and stock options, and the valuation of deferred income tax assets. Management uses its historical records and knowledge of its business in making these estimates. Actual results could differ from these estimates.

 

Earnings (Loss) Per Share

 

The Company utilizes Financial Accounting Standards Board (“FASB”) Accounting Standards Codification (“ASC”) 260, “Earnings per Share.” Basic earnings (loss) per share is computed based on the earnings (loss) attributable to common shareholders divided by the weighted average number of shares outstanding for the period excluding any dilutive effects of options, warrants, unvested share awards and convertible securities. Diluted earnings (loss) per common share is calculated similar to basic earnings (loss) per share except that the denominator is increased to include additional common share equivalents available upon exercise of stock option, warrants, common shares issuable under convertible debt and restricted stock using the treasury stock method. Dilutive common share equivalents include the dilutive effect of in-the-money share equivalents, which are calculated based on the average share price for each period using the treasury stock method, excluding any common share equivalents if their effect would be anti-dilutive. In periods in which a net loss has been incurred, all potentially dilutive common shares are considered anti-dilutive and thus are excluded from the calculation. Securities that are excluded from the calculation of weighted average dilutive common shares because their inclusion would have been antidilutive for the six months ended June 30, 2023, include stock options, warrants, and notes payable.

 

The Company has 6,011,750 stock options to purchase an equivalent number of shares of common stock outstanding at June 30, 2023. The Company has 513,730 options and 2,000 warrants to purchase common stock outstanding at June 30, 2022.

 

The components of basic and diluted income (loss) per share for the six months ended June 30, 2023 and 2022 were as follows:

 

   2023   2022 
   Six months ended June 30, 
   2023   2022 
Numerator:          
Net income (loss) attributable to common shareholders  $9,294,162   $(4,939,340)
           
Effect of dilutive securities          
Convertible notes   (10,823,217)   - 
Net loss for diluted earnings per share  $(1,529,055)  $(4,939,340)
Denominator:          
Weighted-average number of common shares outstanding during the period   263,948,243    106,696,127 
Dilutive effect of convertible notes payable   1,074,413,187    - 
Common stock and common stock equivalents used for diluted loss per share   1,338,361,430    106,696,127 

 

The components of basic and diluted income (loss) per share for the three months ended June 30, 2023 and 2022 were as follows:

 

   2023   2022 
   Three months ended June 30, 
   2023   2022 
Numerator:          
Net income (loss) attributable to common shareholders  $2,063,660   $(2,526,131)
           
Effect of dilutive securities          
Convertible notes   (3,106,695)   - 
Net loss for diluted earnings per share  $(1,043,035)  $(2,526,131)
Denominator:          
Weighted-average number of common shares outstanding during the period   276,330,405    134,360,871 
Dilutive effect of convertible notes payable   1,074,413,187    - 
Common stock and common stock equivalents used for diluted loss per share   1,350,743,592    134,360,871 

 

Accounts Receivable

 

The Company uses the specific identification method for recording the provision for doubtful accounts, which was $0 as of June 30, 2023 and December 31, 2022. Account receivables are written off when all collection attempts have failed.

 

 

Endonovo Therapeutics, Inc.

Notes to Condensed Consolidated Financial Statements (continued)

 

Newly Adopted Accounting Principles

 

The Company has evaluated all the recent accounting pronouncements and determined that there are no other accounting pronouncements that will have a material effect on the Company’s consolidated financial statements.

 

XML 17 R9.htm IDEA: XBRL DOCUMENT v3.23.2
Revenue Recognition
6 Months Ended
Jun. 30, 2023
Revenue from Contract with Customer [Abstract]  
Revenue Recognition

Note 3 - Revenue Recognition

 

Contracts with Customers

 

The Company adopted ASC 606, Revenue from Contracts with Customers effective January 1, 2019, using the modified retrospective method applied to those contracts which were not substantially completed as of January 1, 2019. These standards provide guidance on recognizing revenue, including a five-step model to determine when revenue recognition is appropriate. The standard requires that an entity recognize revenue to depict the transfer of control of promised goods or services to customers in an amount that reflects the consideration to which the entity expects to be entitled in exchange for those goods or services.

 

The Company routinely plans on entering into contracts with customers that include general commercial terms and conditions, notification requirements for price increases, shipping terms and in most cases prices for the products and services that we offer. The Company’s performance obligations are established when a customer submits a purchase order notification (in writing, electronically or verbally) for goods and services, and we accept the order. The Company identified performance obligations as the delivery of the requested product or service in appropriate quantities and to the location specified in the customer’s contract and/or purchase order. The Company generally recognize revenue upon the satisfaction of these criteria when control of the product or service has been transferred to the customer at which time, the Company has an unconditional right to receive payment. The Company’s sales and sale prices are final, and our prices are not affected by contingent events that could impact the transaction price.

 

Revenues for our SofPulse® product is typically recognized at the time the product is shipped, at which time the title passes to the customer, and there are no further performance obligations. Royalty/licensing revenue is also recognized at one point in time, when the units are shipped.

 

In connection with offering products and services provided to the end user by third-party vendors, the Company reviews the relationship between us, the vendor, and the end user to assess whether revenue should be reported on a gross or net basis. In asserting whether revenue should be reported on a gross or net basis, the Company considers whether the Company acts as a principal in the transaction and control the goods and services used to fulfill the performance obligation(s) associated with the transaction.

 

 

Endonovo Therapeutics, Inc.

Notes to Condensed Consolidated Financial Statements (continued)

 

Sources of Revenue

 

The Company has identified the following revenues by revenue source:

 

1. Sales to plastic surgeons
2. Sales to wound care facilities
3. Sales to hospital
4. Sales to other physicians
5. Royalty fee from licensing, net

 

For the three and six months ended June 30, 2023 and 2022, the sources of revenue were as follows:

 

   2023   2022   2023   2022 
   Three Months Ended June 30,   Six Months Ended June 30, 
   2023   2022   2023   2022 
                 
Royalty/licensing, net  $45,200   $-   $126,520   $- 
Direct sales- medical care providers, gross   -    650    6,220    2,932 
Total sources of revenue  $45,200   $650   $132,740   $2,932 

 

The royalty/licensing revenue recognized in the six months ended June 30, 2023, resulted from specific transactions. No general patent rights were assigned to the distributor. The royalty / licensing revenue is recorded on a net basis as the Company was not considered the principal but an agent for accounting purposes. The royalty / licensing revenue, net includes an ongoing contract with a customer that has a total gross sales value of $300,000, for which the Company recognized net revenue of $126,520 based on 1,000 units delivered during the period ended June 30, 2023. The royalty/licensing revenue is recognized when Pulse Therapeutic Technology picks up the units from the Company’s vendor.

 

On January 25, 2023, the Company entered into a sales support services agreement with Pulse Therapeutic Technology (“PTT”), an entity controlled by a former related party, under which PTT has been selling Sofpulse® on a nonexclusive basis. Pursuant to such agreement, the deferred compensation owed to this former related party has been fully extinguished for a total amount of approximately $118,000.

 

Warranty

 

Our general product warranties do not extend beyond an assurance that the product delivered will be consistent with stated specifications and do not include separate performance obligations.

 

Significant Judgments in the Application of the Guidance in ASC 606

 

There are no significant judgments associated with the satisfaction of our performance obligations. We generally satisfy performance obligations upon shipment of the product to the customer. This is consistent with the time in which the customer obtains control of the products. Performance obligations are also generally settled quickly after the purchase order acceptance, therefore the value of unsatisfied performance obligations at the end of any reporting period is generally immaterial.

 

We consider variable consideration in establishing the transaction price. Forms of variable consideration applicable to our arrangements include sales returns, rebates, volume-based bonuses, and prompt pay discounts. We use historical information along with an analysis of the expected value to properly calculate and to consider the need to constrain estimates of variable consideration. Such amounts are included as a reduction to revenue from the sale of products in the periods in which the related revenue is recognized and adjusted in future periods as necessary.

 

Practical Expedients

 

Our payment terms for sales direct to distributors are substantially less than the one-year collection period that falls within the practical expedient in determination of whether a significant financing component exists.

 

 

Endonovo Therapeutics, Inc.

Notes to Condensed Consolidated Financial Statements (continued)

 

XML 18 R10.htm IDEA: XBRL DOCUMENT v3.23.2
Patents
6 Months Ended
Jun. 30, 2023
Goodwill and Intangible Assets Disclosure [Abstract]  
Patents

Note 4 – Patents.

 

In December 2017, we acquired from Rio Grande Neurosciences, Inc. (RGN) a patent portfolio for $4,500,000. The earliest patents expire in 2024. The following is a summary of patents less accumulated amortization at June 30, 2023 and December 31, 2022:

 

   June 30, 2023   December 31, 2022 
         
Patents  $4,500,000   $4,500,000 
           
Less accumulated amortization   3,558,012    3,234,556 
           
Patents, net  $941,988   $1,265,444 

 

Amortization expense associated with patents was $323,456 for the six months ended June 30, 2023 and 2022.

 

The estimated future amortization expense related to patents as of June 30, 2023, is as follows:

 

Twelve Months Ending June 30,  Amount 
     
2024  $646,910 
2025   295,078 
      
Total  $941,988 

 

XML 19 R11.htm IDEA: XBRL DOCUMENT v3.23.2
Notes Payable
6 Months Ended
Jun. 30, 2023
Debt Disclosure [Abstract]  
Notes Payable

Note 5- Notes Payable

 

As of June 30, 2023, and December 31, 2022, the notes payable activity was as follows:

 

   June 30, 2023   December 31, 2022 
         
Notes payable at beginning of period  $7,163,832   $7,256,930 
Notes payable issued   150,000    465,000 
Repayments of notes payable in cash   (27,500)   (14,000)
Settlement on note payable   (133,650)   (163,826)
Less amounts converted to stock   (100,000)   (380,272)
Notes payable at end of period   7,052,682    7,163,832 
Less debt discount   (25,585)   (10,587)
Note payable, net  $7,027,097   $7,153,245 
           
Notes payable issued to a former related party  $104,600   $112,100 
Notes payable issued to non-related parties  $6,922,497   $7,041,145 

 

The maturity dates on the notes-payable are as follows:

 

   Notes to     
12 months ending, 

Former

related party

  

Non-related

parties

   Total 
             
Past due  $104,600   $6,733,082   $6,837,682 
June 30, 2024   -    215,000    215,000 
   $104,600   $6,948,082   $7,052,682 

 

Activity for the six months ended June 30, 2023

 

Fixed rate notes

 

During the six months ended June 30, 2023, the Company converted $100,000 in principal and $9,000 in accrued interest into 10,900,000 shares of common stock.

 

During the six months ended June 30, 2023, the Company executed a second amendment to a fixed rate note to extend the maturity date in exchange for $20,000 payment to the current balance of the note as of June 30, 2023, and $2,500 in extension fee payable at the revised maturity date.

 

During the six months ended June 30, 2023, the Company issued three fixed-rate notes for an aggregate amount of $150,000, which carry interest between 10% and 15% and with maturity ranging between one to nine (1 to 9) months from issuance.

 

 

Endonovo Therapeutics, Inc.

Notes to Condensed Consolidated Financial Statements (continued)

 

As of June 30, 2023, the Company has a total of twenty-two (22) fixed-rate notes, of which sixteen (16) have a make good provision for a total principal of $1,395,000 and $338,403 in accrued interest. Balance of fixed-rate notes was $1,849,728 and $1,819,728 as of June 30, 2023, and December 31, 2022, respectively. Accrued interest on fixed-rate notes was approximately $429,500 and $310,960 as of June 30, 2023, and December 31, 2023, respectively.

 

Such provision will require the Company to issue additional shares to ensure that the investor can realize a profit of 15% or 18% reselling the conversion shares. The value of the make good provision was approximately $250,000 as of June 30, 2023 and is reported under Accounts payable and accrued liabilities in the condensed consolidated balance sheet as of June 30, 2023. In addition, certain fixed-rate notes include a prepayment provision, which entitles the holder to a 15% cash premium. The Company concluded that such provision was not deemed material and probable as of June 30, 2023.

 

Variable-rate notes

 

During the six months ended June 30, 2023, the Company executed a settlement agreement with one investor to extinguish the remaining principal balance of a promissory note into 4,300,590 shares of common stock, which resulted in a gain from debt extinguishment of approximately $77,000.

 

Fixed Rate note (former related party)

 

Notes payable to a former related party in the aggregate amount of $104,600 were outstanding at June 30, 2023, which are past maturity date. The notes bear interest between 10% and 12% per annum. During the six months ended June 30, 2023, the Company repaid $7,500 in principal amount to this former related party. Refer to Note 7- Related Party Transactions.

 

Activity for the six months ended June 30, 2022

 

Fixed rates Notes

 

During the six months ended June 30, 2022, the Company issued three (3) fixed rate promissory notes totaling $250,000 for funding of $250,000 with original terms of nine months and interest rates of 15%. The holder of the promissory note can convert the outstanding unpaid principal and accrued interest at a fixed conversion rate, subject to standard anti-dilution features, six months after issuance date.

 

As of June 30, 2022, the Company has sixteen (16) fixed-rate promissory notes with an outstanding balance of $1,891,204, of which $1,116,204 are past maturity.

 

In October 2013, July 2014, October 2014 and August 2015, the Company initiated a series of private placements for up to $500,000, each, of financing by the issuance of notes payable at a minimum of $25,000, one unit. The notes bear interest at 10% per annum and were due and payable with accrued interest one year from issuance. During the six months ended June 30, 2022, the Company did not issue notes in connection with these private placements and did not repay any of these notes. As of June 30, 2022, and December 31, 2021, notes payable outstanding under these private placements are $624,903, all of which are past maturity.

 

During the six months ended June 30, 2022, the Company converted $110,204 in accrued interest and $93,796 in principal balance into 10,200,000 shares of common stock.

 

As of June 30, 2022, the Company has a total of sixteen (16) fixed-rate notes, of which twelve (12) for total principal amount of $1,250,000 includes a make good shares provision. Such provision will require the Company to issue additional shares to ensure that the investor can realize a profit of 15% reselling the conversion shares. The Company accrued $178,000 related to the make-good provision as the amount is probable and can be reasonably estimated pursuant to ASC 450 Contingencies. Such amount was presented as other expense in the condensed consolidated statement of operations.

 

Certain fixed-rate notes include a prepayment provision, which entitles the holder to a 15% premium upon cash redemption by the Company. The prepayment penalty approximates $121,000 as of June 30, 2022, but the Company determined that such liability is not probable as of June 30, 2022, pursuant to ASC 450 Contingencies.

 

Variable-rate notes

 

The gross amount of all convertible notes with variable conversion rates outstanding as of June 30, 2022, is $4,770,926, of which $4,770,926 are past maturity. There has been no conversion of notes into the Company’s common stock during the three and six months ended June 30, 2022.

 

 

Endonovo Therapeutics, Inc.

Notes to Condensed Consolidated Financial Statements (continued)

 

XML 20 R12.htm IDEA: XBRL DOCUMENT v3.23.2
Shareholders’ Deficit
6 Months Ended
Jun. 30, 2023
Equity [Abstract]  
Shareholders’ Deficit

Note 6 - Shareholders’ Deficit

 

Preferred Stock

 

The Company has authorized 5,000,000 shares of preferred stock which have been designated as follows:

 

   Number of Shares
Authorized
   Number of Shares
Outstanding at
June 30, 2023
   Par Value  

Liquidation

Value

 
Series AA   1,000,000    25,000   $0.0010   $- 
Preferred Series B   50,000    600   $0.0001   $100 
Preferred Series C   8,000    738   $0.0001   $1,000 
Preferred Series D   20,000    -   $0.0001   $1,000 
Undesignated   3,922,000    -    -    - 

 

Series AA Preferred Shares

 

On February 22, 2013, the Board of Directors of the Company authorized an amendment to the Company’s Articles of Incorporation, as amended (the “Articles of Incorporation”), in the form of a Certificate of Designation that authorized the issuance of up to one million (1,000,000) shares of a new series of preferred stock, par value $0.001 per share, designated “Series AA Super Voting Preferred Stock,” for which the board of director established the rights, preferences and limitations thereof.

 

Each holder of outstanding shares of Series AA Super Voting Preferred Stock shall be entitled to one hundred thousand (100,000) votes for each share of Series AA Super Voting Preferred Stock held on the record date for the determination of stockholders entitled to vote at each meeting of stockholders of the Company. The Series AA Super Voting Preferred Stockholders will receive no dividends nor any value on liquidation.

 

There was no activity during the six months ended June 30, 2023. There were 25,000 shares of Series AA Preferred stock outstanding as of June 30, 2023 and December 31, 2022.

 

Series B Convertible Preferred Stock

 

On February 7, 2017, the Company filed a certificate of designation for 50,000 shares of Series B Convertible Preferred Stock designated as Series B (“Series B”) which are authorized and convertible, at the option of the holder, commencing six months from the date of issuance into common shares and warrants. For each share of Series B, the holder, on conversion, shall receive the stated value divided by 75% of the market price on the date of purchase of Series B and a three-year warrant exercisable into up to a like amount of common shares with an exercise price of 150% of the market price as defined in the Certificate of Designation. Dividends shall be paid only if dividends on the Company’s issued and outstanding Common Stock are paid, and the amount paid to the Series B holder will be as though the conversion shares had been issued. Series B holders have no voting rights. Upon liquidation, the holder of Series B, shall be entitled to receive an amount equal to the stated value, $100 per share, plus any accrued and unpaid dividends thereon before any distribution is made to Series C Secured Redeemable Preferred Stock or common stockholders.

 

There was no activity during the six months ended June 30, 2023. There were 600 shares of Series B outstanding as of June 30, 2023 and December 31, 2022.

 

 

Endonovo Therapeutics, Inc.

Notes to Condensed Consolidated Financial Statements (continued)

 

Series C Convertible Redeemable Preferred Stock

 

On December 22, 2017, the Company filed a certificate of designation for 8,000 shares of Series C Secured Redeemable Preferred Stock (“Series C”). Each share of the C Preferred is entitled to receive a $20 quarterly dividend commencing March 31, 2018, and each quarter thereafter and is to be redeemed for the stated value, $1,000 per share, plus accrued dividends in cash (i) at the Company’s option, commencing one year from issuance and (ii) mandatorily as of December 31, 2019. Management determined that the Series C should be classified as liability per the guidance in ASC 480 Distinguishing Liabilities from Equity as of December 31, 2019. On January 29, 2020, the Company filed the amended and restated certificate of designation fort its Series C Secured Redeemable Preferred Stock. The amendment changed the rights of the Series C by (a) removing the requirement to redeem the Series C, (b) removing the obligation to pay dividends on the Series C, (c) Allowing the holders of shares of Series C to convert the stated value of their shares into common stock of the Company at 75% of the closing price of such common stock on the day prior to the conversion. The C Preferred does not have any rights to vote with the common stock.

 

Upon liquidation, the holder of Series C, shall be entitled to receive an amount equal to the stated value, $1,000 per share, plus any accrued and unpaid dividends thereon before any distribution is made to common stockholders but after distributions are made to holders of Series B.

 

There was no activity during the six months ended June 30, 2023. There were 738 shares of Series C outstanding, as of June 30, 2023 and December 31, 2022

 

Series D Convertible Preferred Stock

 

On November 11, 2019, the Company filed a certificate of designation for 20,000 shares of Series D Convertible Preferred Stock designated as Series D (“Series D”), which are authorized and convertible, at the option of the holder, at any time from the date of issuance, into shares of common shares. On or prior to August 1, 2020, for each share of Series D, the holder, on conversion, shall receive a number of common shares equal to 0.01% of the Company’s issued and outstanding shares on conversion date and for conversion on or after August 2, 2020, the holder shall receive conversion shares as though the conversion date was August 1, 2020, with no further adjustments for issuances by the Company of common stock after August 1, 2020, except for stock split or reverse stock splits of the common stock. Management classified the Series D in permanent equity as of June 30, 2023.

 

The Series D holders have no voting rights. Upon liquidation, the holder of Series D, shall be entitled to receive an amount equal to the stated value, $1,000 per share, plus any accrued and unpaid dividends thereon before any distribution is made to common stockholders.

 

During the six months ended June 30, 2023, the Company issued 5,000,000 shares of common stock upon conversion of the remaining 50 shares of Series D preferred stock. The Company is also committed to providing additional shares of common stock if the holders of Series D do not realize a 15% profit on the resale of the conversion shares. As of June 30, 2023, and December 31, 2022, there were 0 and 50 shares of Series D outstanding, respectively.

 

Common Stock

 

Activity during the six months ended June 30, 2023

 

During the six months ended June 30, 2023, the Company issued 10,900,000 shares of common stock for the conversion of $109,000 of principal accrued interest from one note holder.

 

During the six months ended June 30, 2023, the Company issued 1,507,277 shares of common stock pursuant to a make-good provision, which resulted in a loss on debt extinguishment of $24,870.

 

During the six months June 30, 2023, the Company issued 4,300,590 shares of common stock pursuant to a debt settlement of aggregate principal of $113,650, resulting in a gain on debt extinguishment of approximately $77,000.

 

During the six months June 30, 2023, the Company issued 1667,000 shares of common stock pursuant to a deferred compensation settlement with a fair value of $24,338.

 

During the six months ended June 30, 2023, the Company issued 5,967,590 shares of common stock pursuant to a debt settlement.

 

During the six months ended June 30, 2023, the Company issued 13,850,000 shares of common stock for services for a total fair value of $188,950.

 

During the six months ended June 30, 2023, the Company issued 5,000,000 shares of common stock in exchange for 50 shares of Series D Preferred, which resulted in an inducement loss of $39,398 recorded as a deemed dividend in the shareholders’ deficit as of June 30, 2023.

 

During the six months ended June 30, 2023, the Company issued 5 1/2 units or the equivalent of 27,500,000 shares of common stock pursuant to a private placement for total net cash receipt of $253,000.

 

During the six months ended June 30, 2023, the Company issued 850,000 commitment shares pursuant to executed securities purchase agreements with an estimated fair value of $11,125.

 

Activity during the six months ended June 30, 2022

 

During the six months ended June 30, 2022, the Company issued 10,200,000 shares of common stock for the conversion of $93,796 of principal notes and accrued interest in the amount of $110,204.

 

During the six months ended June 30, 2022, the Company issued 2,428,777 shares of common stock pursuant to a make-whole provision from an April 2021 debt settlement with one investor.

 

During the six months ended June 30, 2022, the Company issued 1,050,000 shares of common stock as commitment shares in connection with securities purchase agreements.

 

During the six months ended June 30, 2022, the Company issued 62,250,000 shares of common stock for services for total fair value of $1,281,900.

 

 

Endonovo Therapeutics, Inc.

Notes to Condensed Consolidated Financial Statements (continued)

 

Stock Options

 

The balance of all stock options outstanding as of June 30, 2023, is as follows:

 

       Weighted
Average
   Weighted
Average
Remaining
   Aggregate 
       Exercise Price   Contractual   Intrinsic 
   Options   Per Share   Term (years)   Value 
Outstanding at December 31, 2022   3,012,410   $0.22    3.40    31,200 
Granted   3,000,000   $0.01    -      
Cancelled   (660)  $11.60    -      
Exercised   -   $-    -      
Outstanding at June 30, 2023   6,011,750   $0.12    3.06   $- 
                     
Exercisable at June 30, 2023   1,011,750   $0.64    1.83   $- 

 

Share-based compensation expenses for the six months ended June 30, 2023 and 2022, totaled approximately $6,000 and $0, respectively. The remaining stock-based compensation to be recognized is approximately $36,000, which will be recognized over 2.5 years.

 

Warrants

 

The balance of all warrants outstanding as of June 30, 2023, is as follows:

 

   Outstanding Warrants     
       Weighted
Average
   Weighted Average Remaining 
       Exercise Price   Contractual 
   Shares   Per Share   Term (years) 
Outstanding at December 31, 2022   2,000   $50.0    0.22 
Granted   -   $-    - 
Cancelled   (2,000)  $50.0    - 
Exercised   -   $-      
Outstanding at June 30, 2023   -   $-    - 
                
Exercisable at June 30, 2023   -   $-    - 

 

 

Endonovo Therapeutics, Inc.

Notes to Condensed Consolidated Financial Statements (continued)

 

XML 21 R13.htm IDEA: XBRL DOCUMENT v3.23.2
Related Party and former related parties Transactions
6 Months Ended
Jun. 30, 2023
Related Party Transactions [Abstract]  
Related Party and former related parties Transactions

Note 7 – Related Party and former related parties Transactions.

 

One executive officer of the Company has agreed to defer a portion of his compensation until cash flow improves. As of June 30, 2023, the balance of the deferred compensation was $570,068, which reflects $150,000 accrual of deferred compensation and $103,750 of cash repayment of deferred compensation during the six months ended June 30, 2023.

 

As of June 30, 2023, the Company accrued for the issuance of 20,000,000 shares of the Company’s common stock with a fair value of $282,000. Such balance is reported under accounts payable and accrued liabilities related party in the condensed consolidated balance sheet as of June 30, 2022.

 

One former executive of the Company has agreed to defer a portion of his compensation until cash flow improves. As of June 30, 2023, the balance of his deferred compensation was $632,257. No activity occurred during the six months ended June 30, 2023.

 

From time-to-time officer of the Company advance monies to the Company to cover costs. The balance of short-term advances due to one officer of the Company at June 30, 2023, was $375 and is included in the Company’s accounts payable and accrued liabilities balance as of June 30, 2023. During the six months ended June 30, 2023, the Company’s executive officer advanced an aggregate amount of $250 for corporate expenses, and $2,500 was repaid back as of June 30, 2023.

 

As of June 30, 2023, notes payable remained outstanding to the former President of the Company, in the amount of $104,600. As of June 30, 2023, accrued interests on these notes payable totaled approximately $85,445, and are included in accrued expenses on the condensed consolidated balance sheets.

 

XML 22 R14.htm IDEA: XBRL DOCUMENT v3.23.2
Fair Value Measurements
6 Months Ended
Jun. 30, 2023
Fair Value Disclosures [Abstract]  
Fair Value Measurements

Note 8 – Fair Value Measurements

 

The Company issued Variable Debentures, which contained variable conversion rates based on unknown future prices of the Company’s common stock. This results in a conversion feature. The Company measures the conversion feature using the Black Scholes option pricing model using the following assumptions:

 

    Six months ended June 30, 
    2023    2022 
           
Expected term   1 month    1 month 
Exercise price  $0.0066-$0.0151   $

0.004 – $0.015

 
Expected volatility   154%-158%   152%-169%
Expected dividends   None    None 
Risk-free interest rate   4.64%-5.40%   1.63% to 2.80%
Forfeitures   None    None 

 

The assumptions used in determining fair value represent management’s best estimates, but these estimates involve inherent uncertainties and the application of management’s judgment. As a result, if factors change, including changes in the market value of the Company’s common stock, managements’ assessment, or significant fluctuations in the volatility of the trading market for the Company’s common stock, the Company’s fair value estimates could be materially different in the future.

 

The Company computes the fair value of the derivative liability at each reporting period and the change in the fair value is recorded as non-cash expense or income. The key component in the value of the derivative liability is the Company’s stock price, which is subject to significant fluctuation and is not under its control. The resulting effect on net income (loss) is therefore subject to significant fluctuation and will continue to be so until the Company’s variable debentures, which the convertible feature is associated with, are converted into common stock or paid in full in cash. Assuming all other fair value inputs remain constant, the Company will record non-cash expense when its stock price increases and non-cash income when its stock price decreases.

 

 

Endonovo Therapeutics, Inc.

Notes to Condensed Consolidated Financial Statements (continued)

 

The following table presents changes in the liabilities with significant unobservable inputs (level 3) for the three months ended June 30, 2023:

 

   Derivative 
   Liability 
Balance December 31, 2022  $17,359,064 
      
Settlement debt   (10,769)
Change in estimated fair value   (11,445,466)
      
Balance June 30, 2023  $5,902,829 

 

Accounting guidance on fair value measurements and disclosures defines fair value, establishes a framework for measuring the fair value of assets and liabilities using a hierarchy system, and defines required disclosures. It clarifies that fair value is the price that would be received to sell an asset or paid to transfer a liability in an orderly transaction between market participants in the market in which the reporting entity transacts business.

 

The Company’s balance sheet contains derivative liabilities that are recorded at fair value on a recurring basis. The three-level valuation hierarchy for disclosure of fair value is as follows:

 

Level 1: uses quoted market prices in active markets for identical assets or liabilities.

 

Level 2: uses observable market-based inputs or unobservable inputs that are corroborated by market data.

 

Level 3: uses unobservable inputs that are not corroborated by market data.

 

The fair value of the Company’s recorded derivative liability is determined based on unobservable inputs that are not corroborated by market data, which require a Level 3 classification. A Black Scholes option pricing model was used to determine the fair value. The Company records derivative liability on the condensed consolidated balance sheets at fair value with changes in fair value recorded in the condensed consolidated statements of operation.

 

The following table presents balances in the liabilities with significant unobservable inputs (Level 3) as of June 30, 2023:

 

   Fair Value Measurements Using 
   Quoted
Prices in
             
   Active
Markets for
   Significant Other   Significant     
   Identical
Assets
   Observable
Inputs
   Unobservable
Inputs
     
   (Level 1)   (Level 2)   (Level 3)   Total 
                 
As of June 30, 2023                    
Derivative liability  $    -   $    -   $5,902,829   $5,902,829 
Total  $-   $-   $5,902,829   $5,902,829 

 

 

Endonovo Therapeutics, Inc.

Notes to Condensed Consolidated Financial Statements (continued)

 

XML 23 R15.htm IDEA: XBRL DOCUMENT v3.23.2
Commitments and Contingencies
6 Months Ended
Jun. 30, 2023
Commitments and Contingencies Disclosure [Abstract]  
Commitments and Contingencies

Note 9 – Commitments and Contingencies

 

Legal Matters

 

The Company is subject to certain legal proceedings, which it considers routine to its business activities. As of June 30, 2023, the Company believes, after consultation with legal counsel, that the ultimate outcome of such legal proceedings, whether individually or in the aggregate, is not likely to have a material adverse effect on the Company’s financial position, results of operations or liquidity.

 

XML 24 R16.htm IDEA: XBRL DOCUMENT v3.23.2
Concentrations
6 Months Ended
Jun. 30, 2023
Risks and Uncertainties [Abstract]  
Concentrations

Note 10 – Concentrations.

 

Sales

 

During the six months ended June 30, 2023, we had one significant customer, which accounted for approximately 100% of sales. In addition, the Company generated all of its royalty/licensing revenue from one former related party.

 

Supplier

 

We also have a single source for our bioelectric medical devices, which account for 100% of our sales. The interruption of products provided by this supplier would adversely affect our business and financial condition unless an alternative source of products could be found.

 

XML 25 R17.htm IDEA: XBRL DOCUMENT v3.23.2
Subsequent Events
6 Months Ended
Jun. 30, 2023
Subsequent Events [Abstract]  
Subsequent Events

Note 11 – Subsequent Events

 

Management has evaluated events that have occurred subsequent to the date of these consolidated condensed financial statements and has determined that, other than those listed below, no such reportable subsequent events exist through the date the financial statements were issued in accordance with FASB ASC Topic 855, “Subsequent Events.”

 

Subsequent to June 30, 2023, the Company issued 500,000 shares of common stock pursuant to two notes extension agreements.

 

Subsequent to June 30, 2023, the Company issued 1,000,000 shares of common stock pursuant to a securities purchase agreement with one investor. Such a liability was accrued for and reported under accounts payable and accrued liabilities in the consolidated balance sheet as of June 30, 2023.

 

Subsequent to June 30, 2023, the Company issued 8,000,000 shares of common stock pursuant to a production agreement.

 

Subsequent to June 30, 2023, the Company issued a convertible note in the principal amount of $20,000 carrying a coupon of 10% and a three-month maturity date.

 

Subsequent to June 30, 2023, the Company issued an aggregate of 29,600,000 shares of common stock for additional consideration to consultants and to the Company’s Chief Executive Officer, previously granted in the first fiscal quarter. Such a liability was accrued for and reported under accounts payable and accrued liabilities in the consolidated balance sheet as of June 30, 2023.

XML 26 R18.htm IDEA: XBRL DOCUMENT v3.23.2
Summary of significant accounting policies (Policies)
6 Months Ended
Jun. 30, 2023
Accounting Policies [Abstract]  
Basis of Presentation and Principles of Consolidation

Basis of Presentation and Principles of Consolidation

 

The accompanying unaudited interim condensed consolidated financial statements have been presented in accordance with accounting principles generally accepted in the United States of America (“GAAP”) for interim financial information and the instructions to Article 8 of Regulation S-X. Accordingly, the financial statements do not include all of the information and notes required by GAAP for complete financial statements. The accompanying consolidated condensed balance sheet as of June 30, 2023, the consolidated statements of operations for the three and six months ended June 30, 2023 and 2022, the consolidated statements of cash flows for the six months ended June 30, 2023 and 2022, and the consolidated statements of shareholders’ deficit for the three and six months ended June 30, 2023 and 2022 are unaudited; however, in the opinion of management such interim consolidated financial statements reflect all adjustments, consisting solely of normal recurring adjustments, necessary for a fair presentation of the results for the periods presented. The accompanying financial information should be read in conjunction with the financial statements and the notes thereto in the Company’s most recent Annual Report on Form 10-K, as filed with the Securities and Exchange Commission (the “SEC”) on April 17, 2023. The results of operations for the period presented are not necessarily indicative of the results that might be expected for future interim periods or for the full year.

 

Liquidity and Going Concern

Liquidity and Going Concern

 

The Company’s unaudited condensed consolidated financial statements are prepared using GAAP applicable to a going concern, which contemplates the realization of assets and liquidation of liabilities in the normal course of business. The Company has not yet established an ongoing source of revenues sufficient to cover its operating costs and to continue as a going concern. The ability of the Company to continue as a going concern is dependent on the Company’s ability to obtain adequate capital to fund operating losses until it becomes profitable.

 

As of June 30, 2023, the Company had cash of approximately $32,600 and a working capital deficiency of approximately $23.1 million. During the six months ended June 30, 2023, the Company used approximately $0.3 million of cash in its operation. The Company has incurred recurring losses resulting in an accumulated deficit of approximately $65.9 million as of June 30, 2023. These conditions raise substantial doubt as to its ability to continue as going concern within one year from issuance date of these unaudited consolidated financial statements.

 

 

Endonovo Therapeutics, Inc.

Notes to Condensed Consolidated Financial Statements (continued)

 

During the six months ended June 30, 2023, the Company has raised $0.4 million in equity and debt financings. The Company will continue to raise additional capital through either debt or equity financing to fund its operations. However, there is no assurance that the Company can raise enough funds or generate sufficient revenues to pay its obligations as they become due, which raises substantial doubt about our ability to continue as a going concern.

 

On September 26, 2022, the Company entered into an asset purchase agreement with a Company, which is engaged in the business of providing and laying of concrete primarily for residential tract developers, pursuant to which the Company will acquire all of the assets and liabilities for approximately $25.2 million. The Company intends to raise the consideration through debt and equity financing. Such a transaction has not yet closed at the report date.

 

No adjustments have been made to the carrying value of assets or liabilities as a result of this uncertainty. To reduce the risk of not being able to continue as a going concern, management is commercializing its FDA cleared and CE marked products and has commenced implementing its business plan to materialize revenues from potential future license agreements, and or diversifying its business activities with the potential acquisition of specialty construction company. The Company will continue to raise additional capital through the issuance of fixed-rate conversion feature promissory notes.

 

Use of Estimates

Use of Estimates

 

The preparation of financial statements in conformity with accounting principles generally accepted in the United States of America requires management to make estimates and assumptions that affect the amounts reported in the condensed consolidated financial statements and accompanying notes. Critical estimates include the assessment of impairment of finite lived intangibles, the valuation of the derivative liability, the valuation of warrants and stock options, and the valuation of deferred income tax assets. Management uses its historical records and knowledge of its business in making these estimates. Actual results could differ from these estimates.

 

Earnings (Loss) Per Share

Earnings (Loss) Per Share

 

The Company utilizes Financial Accounting Standards Board (“FASB”) Accounting Standards Codification (“ASC”) 260, “Earnings per Share.” Basic earnings (loss) per share is computed based on the earnings (loss) attributable to common shareholders divided by the weighted average number of shares outstanding for the period excluding any dilutive effects of options, warrants, unvested share awards and convertible securities. Diluted earnings (loss) per common share is calculated similar to basic earnings (loss) per share except that the denominator is increased to include additional common share equivalents available upon exercise of stock option, warrants, common shares issuable under convertible debt and restricted stock using the treasury stock method. Dilutive common share equivalents include the dilutive effect of in-the-money share equivalents, which are calculated based on the average share price for each period using the treasury stock method, excluding any common share equivalents if their effect would be anti-dilutive. In periods in which a net loss has been incurred, all potentially dilutive common shares are considered anti-dilutive and thus are excluded from the calculation. Securities that are excluded from the calculation of weighted average dilutive common shares because their inclusion would have been antidilutive for the six months ended June 30, 2023, include stock options, warrants, and notes payable.

 

The Company has 6,011,750 stock options to purchase an equivalent number of shares of common stock outstanding at June 30, 2023. The Company has 513,730 options and 2,000 warrants to purchase common stock outstanding at June 30, 2022.

 

The components of basic and diluted income (loss) per share for the six months ended June 30, 2023 and 2022 were as follows:

 

   2023   2022 
   Six months ended June 30, 
   2023   2022 
Numerator:          
Net income (loss) attributable to common shareholders  $9,294,162   $(4,939,340)
           
Effect of dilutive securities          
Convertible notes   (10,823,217)   - 
Net loss for diluted earnings per share  $(1,529,055)  $(4,939,340)
Denominator:          
Weighted-average number of common shares outstanding during the period   263,948,243    106,696,127 
Dilutive effect of convertible notes payable   1,074,413,187    - 
Common stock and common stock equivalents used for diluted loss per share   1,338,361,430    106,696,127 

 

The components of basic and diluted income (loss) per share for the three months ended June 30, 2023 and 2022 were as follows:

 

   2023   2022 
   Three months ended June 30, 
   2023   2022 
Numerator:          
Net income (loss) attributable to common shareholders  $2,063,660   $(2,526,131)
           
Effect of dilutive securities          
Convertible notes   (3,106,695)   - 
Net loss for diluted earnings per share  $(1,043,035)  $(2,526,131)
Denominator:          
Weighted-average number of common shares outstanding during the period   276,330,405    134,360,871 
Dilutive effect of convertible notes payable   1,074,413,187    - 
Common stock and common stock equivalents used for diluted loss per share   1,350,743,592    134,360,871 

 

Accounts Receivable

Accounts Receivable

 

The Company uses the specific identification method for recording the provision for doubtful accounts, which was $0 as of June 30, 2023 and December 31, 2022. Account receivables are written off when all collection attempts have failed.

 

 

Endonovo Therapeutics, Inc.

Notes to Condensed Consolidated Financial Statements (continued)

 

Newly Adopted Accounting Principles

Newly Adopted Accounting Principles

 

The Company has evaluated all the recent accounting pronouncements and determined that there are no other accounting pronouncements that will have a material effect on the Company’s consolidated financial statements.

XML 27 R19.htm IDEA: XBRL DOCUMENT v3.23.2
Summary of significant accounting policies (Tables)
6 Months Ended
Jun. 30, 2023
Accounting Policies [Abstract]  
Schedule of Earnings Per Share Basic and Diluted

The components of basic and diluted income (loss) per share for the six months ended June 30, 2023 and 2022 were as follows:

 

   2023   2022 
   Six months ended June 30, 
   2023   2022 
Numerator:          
Net income (loss) attributable to common shareholders  $9,294,162   $(4,939,340)
           
Effect of dilutive securities          
Convertible notes   (10,823,217)   - 
Net loss for diluted earnings per share  $(1,529,055)  $(4,939,340)
Denominator:          
Weighted-average number of common shares outstanding during the period   263,948,243    106,696,127 
Dilutive effect of convertible notes payable   1,074,413,187    - 
Common stock and common stock equivalents used for diluted loss per share   1,338,361,430    106,696,127 

 

The components of basic and diluted income (loss) per share for the three months ended June 30, 2023 and 2022 were as follows:

 

   2023   2022 
   Three months ended June 30, 
   2023   2022 
Numerator:          
Net income (loss) attributable to common shareholders  $2,063,660   $(2,526,131)
           
Effect of dilutive securities          
Convertible notes   (3,106,695)   - 
Net loss for diluted earnings per share  $(1,043,035)  $(2,526,131)
Denominator:          
Weighted-average number of common shares outstanding during the period   276,330,405    134,360,871 
Dilutive effect of convertible notes payable   1,074,413,187    - 
Common stock and common stock equivalents used for diluted loss per share   1,350,743,592    134,360,871 
XML 28 R20.htm IDEA: XBRL DOCUMENT v3.23.2
Revenue Recognition (Tables)
6 Months Ended
Jun. 30, 2023
Revenue from Contract with Customer [Abstract]  
Schedule of Source of Revenue

For the three and six months ended June 30, 2023 and 2022, the sources of revenue were as follows:

 

   2023   2022   2023   2022 
   Three Months Ended June 30,   Six Months Ended June 30, 
   2023   2022   2023   2022 
                 
Royalty/licensing, net  $45,200   $-   $126,520   $- 
Direct sales- medical care providers, gross   -    650    6,220    2,932 
Total sources of revenue  $45,200   $650   $132,740   $2,932 
XML 29 R21.htm IDEA: XBRL DOCUMENT v3.23.2
Patents (Tables)
6 Months Ended
Jun. 30, 2023
Goodwill and Intangible Assets Disclosure [Abstract]  
Schedule of Patents

 

   June 30, 2023   December 31, 2022 
         
Patents  $4,500,000   $4,500,000 
           
Less accumulated amortization   3,558,012    3,234,556 
           
Patents, net  $941,988   $1,265,444 
Schedule of Estimated Future Amortization Expense

The estimated future amortization expense related to patents as of June 30, 2023, is as follows:

 

Twelve Months Ending June 30,  Amount 
     
2024  $646,910 
2025   295,078 
      
Total  $941,988 
XML 30 R22.htm IDEA: XBRL DOCUMENT v3.23.2
Notes Payable (Tables)
6 Months Ended
Jun. 30, 2023
Debt Disclosure [Abstract]  
Schedule of Notes Payable

As of June 30, 2023, and December 31, 2022, the notes payable activity was as follows:

 

   June 30, 2023   December 31, 2022 
         
Notes payable at beginning of period  $7,163,832   $7,256,930 
Notes payable issued   150,000    465,000 
Repayments of notes payable in cash   (27,500)   (14,000)
Settlement on note payable   (133,650)   (163,826)
Less amounts converted to stock   (100,000)   (380,272)
Notes payable at end of period   7,052,682    7,163,832 
Less debt discount   (25,585)   (10,587)
Note payable, net  $7,027,097   $7,153,245 
           
Notes payable issued to a former related party  $104,600   $112,100 
Notes payable issued to non-related parties  $6,922,497   $7,041,145 
Schedule of Maturity Dates of Notes Payable

The maturity dates on the notes-payable are as follows:

 

   Notes to     
12 months ending, 

Former

related party

  

Non-related

parties

   Total 
             
Past due  $104,600   $6,733,082   $6,837,682 
June 30, 2024   -    215,000    215,000 
   $104,600   $6,948,082   $7,052,682 
XML 31 R23.htm IDEA: XBRL DOCUMENT v3.23.2
Shareholders’ Deficit (Tables)
6 Months Ended
Jun. 30, 2023
Equity [Abstract]  
Schedule of Preferred Stock

The Company has authorized 5,000,000 shares of preferred stock which have been designated as follows:

 

   Number of Shares
Authorized
   Number of Shares
Outstanding at
June 30, 2023
   Par Value  

Liquidation

Value

 
Series AA   1,000,000    25,000   $0.0010   $- 
Preferred Series B   50,000    600   $0.0001   $100 
Preferred Series C   8,000    738   $0.0001   $1,000 
Preferred Series D   20,000    -   $0.0001   $1,000 
Undesignated   3,922,000    -    -    - 
Schedule of Stock Options Outstanding

The balance of all stock options outstanding as of June 30, 2023, is as follows:

 

       Weighted
Average
   Weighted
Average
Remaining
   Aggregate 
       Exercise Price   Contractual   Intrinsic 
   Options   Per Share   Term (years)   Value 
Outstanding at December 31, 2022   3,012,410   $0.22    3.40    31,200 
Granted   3,000,000   $0.01    -      
Cancelled   (660)  $11.60    -      
Exercised   -   $-    -      
Outstanding at June 30, 2023   6,011,750   $0.12    3.06   $- 
                     
Exercisable at June 30, 2023   1,011,750   $0.64    1.83   $- 
Schedule of Warrants Outstanding

The balance of all warrants outstanding as of June 30, 2023, is as follows:

 

   Outstanding Warrants     
       Weighted
Average
   Weighted Average Remaining 
       Exercise Price   Contractual 
   Shares   Per Share   Term (years) 
Outstanding at December 31, 2022   2,000   $50.0    0.22 
Granted   -   $-    - 
Cancelled   (2,000)  $50.0    - 
Exercised   -   $-      
Outstanding at June 30, 2023   -   $-    - 
                
Exercisable at June 30, 2023   -   $-    - 
XML 32 R24.htm IDEA: XBRL DOCUMENT v3.23.2
Fair Value Measurements (Tables)
6 Months Ended
Jun. 30, 2023
Fair Value Disclosures [Abstract]  
Schedule of Conversion Feature Using Black Scholes Option Pricing Model

 

    Six months ended June 30, 
    2023    2022 
           
Expected term   1 month    1 month 
Exercise price  $0.0066-$0.0151   $

0.004 – $0.015

 
Expected volatility   154%-158%   152%-169%
Expected dividends   None    None 
Risk-free interest rate   4.64%-5.40%   1.63% to 2.80%
Forfeitures   None    None 
Schedule of Fair Value of Derivative Liability

The following table presents changes in the liabilities with significant unobservable inputs (level 3) for the three months ended June 30, 2023:

 

   Derivative 
   Liability 
Balance December 31, 2022  $17,359,064 
      
Settlement debt   (10,769)
Change in estimated fair value   (11,445,466)
      
Balance June 30, 2023  $5,902,829 
Schedule of Liabilities Significant Unobservable Inputs

The following table presents balances in the liabilities with significant unobservable inputs (Level 3) as of June 30, 2023:

 

   Fair Value Measurements Using 
   Quoted
Prices in
             
   Active
Markets for
   Significant Other   Significant     
   Identical
Assets
   Observable
Inputs
   Unobservable
Inputs
     
   (Level 1)   (Level 2)   (Level 3)   Total 
                 
As of June 30, 2023                    
Derivative liability  $    -   $    -   $5,902,829   $5,902,829 
Total  $-   $-   $5,902,829   $5,902,829 
XML 33 R25.htm IDEA: XBRL DOCUMENT v3.23.2
Schedule of Earnings Per Share Basic and Diluted (Details) - USD ($)
3 Months Ended 6 Months Ended
Jun. 30, 2023
Jun. 30, 2022
Jun. 30, 2023
Jun. 30, 2022
Accounting Policies [Abstract]        
Net income (loss) attributable to common shareholders $ 2,063,660 $ (2,526,131) $ 9,294,162 $ (4,939,340)
Convertible notes (3,106,695) (10,823,217)
Net loss for diluted earnings per share $ (1,043,035) $ (2,526,131) $ (1,529,055) $ (4,939,340)
Weighted-average number of common shares outstanding during the period 276,330,405 134,360,871 263,948,243 106,696,127
Dilutive effect of convertible notes payable 1,074,413,187 1,074,413,187
Common stock and common stock equivalents used for diluted loss per share 1,350,743,592 134,360,871 1,338,361,430 106,696,127
XML 34 R26.htm IDEA: XBRL DOCUMENT v3.23.2
Summary of significant accounting policies (Details Narrative) - USD ($)
3 Months Ended 6 Months Ended
Sep. 26, 2022
Jun. 30, 2023
Jun. 30, 2022
Jun. 30, 2023
Jun. 30, 2022
Dec. 31, 2022
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]            
Cash   $ 32,600   $ 32,600    
Working capital   23,100,000   23,100,000    
Net cash provided by (used in) operating activities       338,996 $ 329,436  
Accumulated deficit   $ 65,864,419   65,864,419   $ 75,119,183
Proceeds from equity financing       $ 400,000    
Anti dilutive shares   1,074,413,187 1,074,413,187  
Accounts receivable allowance for credit loss, current   $ 0   $ 0   $ 0
Share-Based Payment Arrangement, Option [Member]            
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]            
Anti dilutive shares       6,011,750 513,730  
Warrant [Member]            
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]            
Anti dilutive shares         2,000  
Assets Purchase Agreement [Member]            
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]            
Purchase of assets and Liabilities $ 25,200,000          
XML 35 R27.htm IDEA: XBRL DOCUMENT v3.23.2
Schedule of Source of Revenue (Details) - USD ($)
3 Months Ended 6 Months Ended
Jun. 30, 2023
Jun. 30, 2022
Jun. 30, 2023
Jun. 30, 2022
Disaggregation of Revenue [Line Items]        
Total sources of revenue $ 45,200 $ 650 $ 132,740 $ 2,932
Royalty/Licensing, Net [Member]        
Disaggregation of Revenue [Line Items]        
Total sources of revenue 45,200 126,520
Direct Sales Medical Care Providers Gross [Member]        
Disaggregation of Revenue [Line Items]        
Total sources of revenue $ 650 $ 6,220 $ 2,932
XML 36 R28.htm IDEA: XBRL DOCUMENT v3.23.2
Revenue Recognition (Details Narrative)
6 Months Ended
Jun. 30, 2023
USD ($)
Integer
Jan. 25, 2023
USD ($)
Sales Support Service Agreement [Member] | Pulse Therapeutic Technology [Member]    
Disaggregation of Revenue [Line Items]    
Deferred compensation   $ 118,000
Royalty/Licensing, Net [Member]    
Disaggregation of Revenue [Line Items]    
[custom:GrossSaleValueOfOngoingContract] $ 300,000  
Contract with Customer, Liability, Revenue Recognized $ 126,520  
Number of Reporting Units | Integer 1,000  
XML 37 R29.htm IDEA: XBRL DOCUMENT v3.23.2
Schedule of Patents (Details) - USD ($)
Jun. 30, 2023
Dec. 31, 2022
Goodwill and Intangible Assets Disclosure [Abstract]    
Patents $ 4,500,000 $ 4,500,000
Less accumulated amortization 3,558,012 3,234,556
Patents, net $ 941,988 $ 1,265,444
XML 38 R30.htm IDEA: XBRL DOCUMENT v3.23.2
Schedule of Estimated Future Amortization Expense (Details) - USD ($)
Jun. 30, 2023
Dec. 31, 2022
Goodwill and Intangible Assets Disclosure [Abstract]    
2024 $ 646,910  
2025 295,078  
Patents, net $ 941,988 $ 1,265,444
XML 39 R31.htm IDEA: XBRL DOCUMENT v3.23.2
Patents (Details Narrative) - USD ($)
1 Months Ended 6 Months Ended
Dec. 31, 2017
Jun. 30, 2023
Jun. 30, 2022
Amortization expense   $ 323,456 $ 323,456
Rio Grande Neurosciences, Inc. [Member]      
Acquisition of patents $ 4,500,000    
Patents expiration period 2024    
XML 40 R32.htm IDEA: XBRL DOCUMENT v3.23.2
Schedule of Notes Payable (Details) - USD ($)
6 Months Ended 12 Months Ended
Jun. 30, 2023
Dec. 31, 2022
Defined Benefit Plan Disclosure [Line Items]    
Notes payable at beginning of period $ 7,163,832 $ 7,256,930
Notes payable issued 150,000 465,000
Repayments of notes payable in cash (27,500) (14,000)
Settlement on note payable (133,650) (163,826)
Less amounts converted to stock (100,000) (380,272)
Notes payable at end of period 7,052,682 7,163,832
Less debt discount (25,585) (10,587)
Note payable, net 7,027,097 7,153,245
Former Related Party [Member]    
Defined Benefit Plan Disclosure [Line Items]    
Notes payable 104,600 112,100
Nonrelated Party [Member]    
Defined Benefit Plan Disclosure [Line Items]    
Notes payable $ 6,922,497 $ 7,041,145
XML 41 R33.htm IDEA: XBRL DOCUMENT v3.23.2
Schedule of Maturity Dates of Notes Payable (Details)
Jun. 30, 2023
USD ($)
Defined Benefit Plan Disclosure [Line Items]  
Past due $ 6,837,682
June 30, 2024 215,000
Total 7,052,682
Former Related Party [Member]  
Defined Benefit Plan Disclosure [Line Items]  
Past due 104,600
June 30, 2024
Total 104,600
Nonrelated Party [Member]  
Defined Benefit Plan Disclosure [Line Items]  
Past due 6,733,082
June 30, 2024 215,000
Total $ 6,948,082
XML 42 R34.htm IDEA: XBRL DOCUMENT v3.23.2
Notes Payable (Details Narrative) - USD ($)
1 Months Ended 3 Months Ended 6 Months Ended 12 Months Ended
Aug. 31, 2015
Jun. 30, 2023
Jun. 30, 2022
Jun. 30, 2023
Jun. 30, 2022
Dec. 31, 2022
Dec. 31, 2021
Debt Instrument [Line Items]              
Debt conversion, stock issued value       $ 100,000 $ 93,796    
Debt instrument, accrued interest       $ 9,000      
Debt conversion, stock issued shares       10,900,000 10,200,000    
Repayments of convertible debt in cash       $ 20,000    
Extension fee payable       2,500      
Note payable issued       150,000   $ 465,000  
Principal amount   $ 1,395,000 $ 1,250,000 1,395,000 1,250,000    
Accrued interest   338,403 110,204 338,403 110,204    
Notes payable   7,052,682   $ 7,052,682   7,163,832 $ 7,256,930
Debt instrument description       the Company to issue additional shares to ensure that the investor can realize a profit of 15% or 18% reselling the conversion shares      
Value of good provision   250,000 178,000 $ 250,000 $ 178,000    
Description of percentage of cash premium       certain fixed-rate notes include a prepayment provision, which entitles the holder to a 15% cash premium Certain fixed-rate notes include a prepayment provision, which entitles the holder to a 15% premium upon cash redemption by the Company    
Gain on debt extinguishment   103,602 104,760 $ 156,062 $ 43,813    
Proceeds from issuance of note payable       146,000 $ 250,000    
Debt instrument description         Such provision will require the Company to issue additional shares to ensure that the investor can realize a profit of 15% reselling the conversion shares    
Prepayment penalty     121,000   $ 121,000    
Private Placement [Member]              
Debt Instrument [Line Items]              
Debt instrument, interest rate 10.00%            
Principal amount $ 500,000            
Note payable outstanding     624,903   624,903   $ 624,903
Proceeds from issuance of note payable $ 25,000            
Former Related Party [Member]              
Debt Instrument [Line Items]              
Note payable outstanding   104,600   104,600   112,100  
Principal payment of debt       7,500      
Fixed Rate Notes [Member]              
Debt Instrument [Line Items]              
Notes payable   1,849,728   1,849,728   1,819,728  
Accrued interest   $ 429,500   $ 429,500   $ 310,960  
Variable Rate Notes [Member]              
Debt Instrument [Line Items]              
Debt conversion, stock issued shares       4,300,590      
Gain on debt extinguishment       $ 77,000      
Convertible notes     4,770,926   4,770,926    
Variable Rate Notes [Member] | Past Maturity [Member]              
Debt Instrument [Line Items]              
Convertible notes     $ 4,770,926   $ 4,770,926    
3 Fixed Rated Notes [Member]              
Debt Instrument [Line Items]              
Debt instrument, interest rate     15.00%   15.00%    
Promissory notes     $ 250,000   $ 250,000    
Proceeds from issuance of note payable         250,000    
16 Fixed Rated Notes [Member]              
Debt Instrument [Line Items]              
Notes payable     1,891,204   1,891,204    
16 Fixed Rated Notes [Member] | Past Maturity [Member]              
Debt Instrument [Line Items]              
Notes payable     $ 1,116,204   $ 1,116,204    
Minimum [Member]              
Debt Instrument [Line Items]              
Debt instrument, interest rate   10.00%   10.00%      
Maturity term       1 month      
Minimum [Member] | Former Related Party [Member]              
Debt Instrument [Line Items]              
Debt instrument, interest rate   10.00%   10.00%      
Maximum [Member]              
Debt Instrument [Line Items]              
Debt instrument, interest rate   15.00%   15.00%      
Maturity term       9 months      
Maximum [Member] | Former Related Party [Member]              
Debt Instrument [Line Items]              
Debt instrument, interest rate   12.00%   12.00%      
XML 43 R35.htm IDEA: XBRL DOCUMENT v3.23.2
Schedule of Preferred Stock (Details)
Jun. 30, 2023
USD ($)
$ / shares
shares
Series AA [Member]  
Accumulated Other Comprehensive Income (Loss) [Line Items]  
Number of Shares Authorized 1,000,000
Number of Shares Outstanding 25,000
Par Value | $ / shares $ 0.0010
Liquidation Value | $
Preferred Series B [Member]  
Accumulated Other Comprehensive Income (Loss) [Line Items]  
Number of Shares Authorized 50,000
Number of Shares Outstanding 600
Par Value | $ / shares $ 0.0001
Liquidation Value | $ $ 100
Preferred Series C [Member]  
Accumulated Other Comprehensive Income (Loss) [Line Items]  
Number of Shares Authorized 8,000
Number of Shares Outstanding 738
Par Value | $ / shares $ 0.0001
Liquidation Value | $ $ 1,000
Preferred Series D [Member]  
Accumulated Other Comprehensive Income (Loss) [Line Items]  
Number of Shares Authorized 20,000
Number of Shares Outstanding
Par Value | $ / shares $ 0.0001
Liquidation Value | $ $ 1,000
Undesignated [Member]  
Accumulated Other Comprehensive Income (Loss) [Line Items]  
Number of Shares Authorized 3,922,000
Number of Shares Outstanding
Par Value | $ / shares
Liquidation Value | $
XML 44 R36.htm IDEA: XBRL DOCUMENT v3.23.2
Schedule of Stock Options Outstanding (Details) - Stock Options [Member]
6 Months Ended
Jun. 30, 2023
USD ($)
$ / shares
shares
Debt Securities, Held-to-Maturity, Allowance for Credit Loss [Line Items]  
Stock Options Outstanding, Beginning Balance | shares 3,012,410
Weighted Average Exercise Price Per Share, Beginning Balance | $ / shares $ 0.22
Weighted Average Remaining Contractual Term (years), Outstanding Beginning 3 years 4 months 24 days
Aggregated Intrinsic Value, Outstanding Beginning Balance | $ $ 31,200
Stock Options Outstanding, Granted | shares 3,000,000
Weighted Average Exercise Price Per Share, Granted | $ / shares $ 0.01
Stock Options Outstanding, Cancelled | shares (660)
Weighted Average Exercise Price Per Share, Cancelled | $ / shares $ 11.60
Stock Options Outstanding, Exercised | shares
Weighted Average Exercise Price Per Share, Exercised | $ / shares
Stock Options Outstanding, Ending Balance | shares 6,011,750
Weighted Average Exercise Price Per Share, Ending Balance | $ / shares $ 0.12
Weighted Average Remaining Contractual Term (years), Ending 3 years 21 days
Aggregated Intrinsic Value, Ending | $
Stock Options Outstanding, Exercisable Ending Balance | shares 1,011,750
Weighted Average Exercise Price Per Share, Exercisable Ending Balance | $ / shares $ 0.64
Weighted Average Remaining Contractual Term (years), Exercisable 1 year 9 months 29 days
Aggregated Intrinsic Value, Exercisable Ending | $
XML 45 R37.htm IDEA: XBRL DOCUMENT v3.23.2
Schedule of Warrants Outstanding (Details) - Warrant [Member]
6 Months Ended
Jun. 30, 2023
$ / shares
shares
Accumulated Other Comprehensive Income (Loss) [Line Items]  
Shares Outstanding, Beginning Balance | shares 2,000
Weighted Average Exercise Price Per Share, Outstanding Beginning Balance | $ / shares $ 50.0
Weighted Average Remaining Contractual Term (years), Outstanding Beginning 2 months 19 days
Shares, Granted | shares
Weighted Average Exercise Price Per Share, Granted | $ / shares
Shares, Cancelled | shares (2,000)
Weighted Average Exercise Price Per Share, Cancelled | $ / shares $ 50.0
Shares, Exercised | shares
Weighted Average Exercise Price Per Share, Exercised | $ / shares
Shares Outstanding, Ending Balance | shares
Weighted Average Exercise Price Per Share, Outstanding Ending Balance | $ / shares
Shares Exercisable, Ending Balance | shares
Weighted Average Exercise Price Per Share, Exercisable Ending Balance | $ / shares
XML 46 R38.htm IDEA: XBRL DOCUMENT v3.23.2
Shareholders’ Deficit (Details Narrative) - USD ($)
3 Months Ended 6 Months Ended
Jan. 29, 2020
Dec. 22, 2017
Feb. 07, 2017
Feb. 22, 2013
Jun. 30, 2023
Mar. 31, 2023
Jun. 30, 2022
Mar. 31, 2022
Jun. 30, 2023
Jun. 30, 2022
Dec. 31, 2022
Nov. 11, 2019
Aug. 31, 2015
Accumulated Other Comprehensive Income (Loss) [Line Items]                          
Gain on debt extinguishment         $ 103,602   $ 104,760   $ 156,062 $ 43,813      
Debt conversion, stock issued shares                 10,900,000 10,200,000      
Principal amount         1,395,000   1,250,000   $ 1,395,000 $ 1,250,000      
Fair value of defered compensation         24,338                
Shares issued for common stock for services, shares                 13,850,000 62,250,000      
Shares issued for common stock for services, value         16,000 $ 172,950 1,281,900   $ 188,950 $ 1,281,900      
Common stock new issuance, value         46,000 $ 207,000              
Accrued interest         338,403   $ 110,204   338,403 110,204      
Share-based compensation expenses                 6,000 $ 0      
Unrecognized stock-based compensation expense         $ 36,000       $ 36,000        
Remaining vesting period                 2 years 6 months        
Securities Purchase Agreements [Member]                          
Accumulated Other Comprehensive Income (Loss) [Line Items]                          
Issuance of common stock                 850,000        
Shares issued for common stock for services, value                 $ 11,125        
Purchase Agreement [Member]                          
Accumulated Other Comprehensive Income (Loss) [Line Items]                          
Issuance of common stock                   1,050,000      
Private Placement [Member]                          
Accumulated Other Comprehensive Income (Loss) [Line Items]                          
Issuance of common stock                 27,500,000        
Principal amount                         $ 500,000
Common stock new issuance, value                 $ 253,000        
One Investor [Member]                          
Accumulated Other Comprehensive Income (Loss) [Line Items]                          
Issuance of common stock                 1,507,277 2,428,777      
Gain on debt extinguishment                 $ 24,870        
Series AA Preferred Stock [Member]                          
Accumulated Other Comprehensive Income (Loss) [Line Items]                          
Number of shares authorized       1,000,000                  
Preferred stock, par value       $ 0.001                  
Preferred stock voting rights       Each holder of outstanding shares of Series AA Super Voting Preferred Stock shall be entitled to one hundred thousand (100,000) votes for each share of Series AA Super Voting Preferred Stock held on the record date for the determination of stockholders entitled to vote at each meeting of stockholders of the Company                  
Preferred stock, shares outstanding         25,000       25,000   25,000    
Series B Preferred Stock [Member]                          
Accumulated Other Comprehensive Income (Loss) [Line Items]                          
Number of shares authorized     50,000                    
Preferred stock, shares outstanding         600       600   600    
Stated value dividend     75.00%                    
Warrants term     three-year                    
Share exercise price     150.00%                    
Liquidation value of preferred stock, per share     $ 100                    
Series C Convertible Redeemable Preferred Stock [Member]                          
Accumulated Other Comprehensive Income (Loss) [Line Items]                          
Number of shares authorized   8,000                      
Preferred stock, shares outstanding         738       738   738    
Liquidation value of preferred stock, per share   $ 1,000     $ 1,000       $ 1,000        
Preferred stock, dividend per share   $ 20                      
Change in rights due to amendment and restated certificate, description the Company filed the amended and restated certificate of designation fort its Series C Secured Redeemable Preferred Stock. The amendment changed the rights of the Series C by (a) removing the requirement to redeem the Series C, (b) removing the obligation to pay dividends on the Series C, (c) Allowing the holders of shares of Series C to convert the stated value of their shares into common stock of the Company at 75% of the closing price of such common stock on the day prior to the conversion. The C Preferred does not have any rights to vote with the common stock                        
Series D Convertible Preferred Stock [Member]                          
Accumulated Other Comprehensive Income (Loss) [Line Items]                          
Number of shares authorized         20,000       20,000   20,000 20,000  
Preferred stock, par value         $ 0.0001       $ 0.0001   $ 0.0001    
Preferred stock, shares outstanding         0       0   50    
Liquidation value of preferred stock, per share         $ 1,000       $ 1,000        
Conversion price                       0.01%  
Number of shares issued         5,000,000       5,000,000        
Shares issued for conversion of notes payable, shares                 50        
Conversion of stock description                 The Company is also committed to providing additional shares of common stock if the holders of Series D do not realize a 15% profit on the resale of the conversion shares        
Series D Preferred Stock [Member]                          
Accumulated Other Comprehensive Income (Loss) [Line Items]                          
Inducement loss                 $ 39,398        
Preferred Stock Designated [Member]                          
Accumulated Other Comprehensive Income (Loss) [Line Items]                          
Number of shares authorized         5,000,000       5,000,000        
Common Stock [Member]                          
Accumulated Other Comprehensive Income (Loss) [Line Items]                          
Number of shares issued         5,000,000       5,000,000        
Shares issued for conversion of notes payable, shares                 10,900,000 10,200,000      
Shares issued for conversion of notes payable                 $ 109,000 $ 93,796      
Issuance of common stock         5,000,000 22,500,000     5,967,590        
Gain on debt extinguishment                 $ 77,000        
Debt conversion, stock issued shares           10,900,000 6,500,000 3,700,000 4,300,590        
Principal amount         $ 113,650       $ 113,650        
Number of shares issued, share         1,667,000       1,667,000        
Fair value of defered compensation         $ 167       $ 24,338        
Shares issued for common stock for services, shares         1,000,000 12,850,000 62,250,000            
Shares issued for common stock for services, value         $ 100 $ 1,285 $ 6,225            
Common stock new issuance, value         $ 500 $ 2,250              
Accrued interest             $ 110,204     $ 110,204      
Common Stock [Member] | Series D Preferred Stock [Member]                          
Accumulated Other Comprehensive Income (Loss) [Line Items]                          
Shares issued for conversion of notes payable, shares                 50        
XML 47 R39.htm IDEA: XBRL DOCUMENT v3.23.2
Related Party and former related parties Transactions (Details Narrative) - USD ($)
3 Months Ended 6 Months Ended
Mar. 31, 2023
Jun. 30, 2023
Jun. 30, 2022
Related Party Transaction [Line Items]      
Number of shares issued, value $ 24,870    
Repayment of debt   $ 7,500 $ 6,500
Officer [Member]      
Related Party Transaction [Line Items]      
Due to officer   $ 375  
Common Stock [Member]      
Related Party Transaction [Line Items]      
Number of shares issued 1,507,277 20,000,000  
Number of shares issued, value $ 151 $ 282,000  
Executive Officer [Member]      
Related Party Transaction [Line Items]      
Deferred compensation   570,068  
Accrual deferred compensation   150,000  
Cash repayments of deferred compensation   103,750  
Advance from officer   250  
Repayment of debt   2,500  
One Former Executive Officer [Member]      
Related Party Transaction [Line Items]      
Deferred compensation   632,257  
Former President [Member]      
Related Party Transaction [Line Items]      
Notes payable, related parties   104,600  
Interest payable   $ 85,445  
XML 48 R40.htm IDEA: XBRL DOCUMENT v3.23.2
Schedule of Conversion Feature Using Black Scholes Option Pricing Model (Details)
6 Months Ended
Jun. 30, 2023
$ / shares
Jun. 30, 2022
$ / shares
Measurement Input, Expected Term [Member]    
Fair Value Measurement Inputs and Valuation Techniques [Line Items]    
Fair value assumptions, measurement input, term 1 month 1 month
Measurement Input, Exercise Price [Member] | Minimum [Member]    
Fair Value Measurement Inputs and Valuation Techniques [Line Items]    
Fair value assumptions, measurement input, percentage 0.0066 0.004
Measurement Input, Exercise Price [Member] | Maximum [Member]    
Fair Value Measurement Inputs and Valuation Techniques [Line Items]    
Fair value assumptions, measurement input, percentage 0.0151 0.015
Measurement Input, Price Volatility [Member] | Minimum [Member]    
Fair Value Measurement Inputs and Valuation Techniques [Line Items]    
Fair value assumptions, measurement input, percentage 154 152
Measurement Input, Price Volatility [Member] | Maximum [Member]    
Fair Value Measurement Inputs and Valuation Techniques [Line Items]    
Fair value assumptions, measurement input, percentage 158 169
Measurement Input, Expected Dividend Rate [Member]    
Fair Value Measurement Inputs and Valuation Techniques [Line Items]    
Fair value assumptions, measurement input, percentage 0 0
Measurement Input, Risk Free Interest Rate [Member] | Minimum [Member]    
Fair Value Measurement Inputs and Valuation Techniques [Line Items]    
Fair value assumptions, measurement input, percentage 4.64 1.63
Measurement Input, Risk Free Interest Rate [Member] | Maximum [Member]    
Fair Value Measurement Inputs and Valuation Techniques [Line Items]    
Fair value assumptions, measurement input, percentage 5.40 2.80
Forfeitures [Member]    
Fair Value Measurement Inputs and Valuation Techniques [Line Items]    
Fair value assumptions, measurement input, percentage 0 0
XML 49 R41.htm IDEA: XBRL DOCUMENT v3.23.2
Schedule of Fair Value of Derivative Liability (Details) - Fair Value, Inputs, Level 3 [Member]
6 Months Ended
Jun. 30, 2023
USD ($)
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]  
Derivative Liability, beginning balance $ 17,359,064
Settlement debt (10,769)
Change in estimated fair value (11,445,466)
Derivative Liability, ending balance $ 5,902,829
XML 50 R42.htm IDEA: XBRL DOCUMENT v3.23.2
Schedule of Liabilities Significant Unobservable Inputs (Details)
Jun. 30, 2023
USD ($)
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]  
Derivative liability $ 5,902,829
Total 5,902,829
Fair Value, Inputs, Level 1 [Member]  
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]  
Derivative liability
Total
Fair Value, Inputs, Level 2 [Member]  
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]  
Derivative liability
Total
Fair Value, Inputs, Level 3 [Member]  
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]  
Derivative liability 5,902,829
Total $ 5,902,829
XML 51 R43.htm IDEA: XBRL DOCUMENT v3.23.2
Concentrations (Details Narrative) - Revenue Benchmark [Member]
6 Months Ended
Jun. 30, 2023
Customer Concentration Risk [Member] | One Significant Customer [Member]  
Concentration Risk [Line Items]  
Concentration risk, percentage 100.00%
Supplier Concentration Risk [Member] | Supplier [Member]  
Concentration Risk [Line Items]  
Concentration risk, percentage 100.00%
XML 52 R44.htm IDEA: XBRL DOCUMENT v3.23.2
Subsequent Events (Details Narrative) - USD ($)
1 Months Ended 6 Months Ended
Aug. 14, 2023
Jun. 30, 2023
Jun. 30, 2022
Subsequent Event [Line Items]      
Principal amount   $ 1,395,000 $ 1,250,000
One Investor [Member]      
Subsequent Event [Line Items]      
Number of shares issued   1,507,277 2,428,777
Subsequent Event [Member] | Convertible Debt [Member]      
Subsequent Event [Line Items]      
Principal amount $ 20,000    
Coupon rate 10.00%    
Maturity period P3Y    
Subsequent Event [Member] | Consultant and Chief Executive Officer [Member]      
Subsequent Event [Line Items]      
Number of shares issued 29,600,000    
Two Notes Extension Agreements [Member] | Subsequent Event [Member]      
Subsequent Event [Line Items]      
Number of shares issued 500,000    
Securiy Purchase Agreement [Member] | Subsequent Event [Member] | One Investor [Member]      
Subsequent Event [Line Items]      
Number of shares issued 1,000,000    
Production Agreement [Member] | Subsequent Event [Member]      
Subsequent Event [Line Items]      
Number of shares issued 8,000,000    
XML 53 form10-q_htm.xml IDEA: XBRL DOCUMENT 0001528172 2023-01-01 2023-06-30 0001528172 2023-08-21 0001528172 2023-06-30 0001528172 2022-12-31 0001528172 us-gaap:NonrelatedPartyMember 2023-06-30 0001528172 us-gaap:NonrelatedPartyMember 2022-12-31 0001528172 us-gaap:RelatedPartyMember 2023-06-30 0001528172 us-gaap:RelatedPartyMember 2022-12-31 0001528172 ENDV:SuperAASuperVotingPreferredStockMember 2023-06-30 0001528172 ENDV:SuperAASuperVotingPreferredStockMember 2022-12-31 0001528172 ENDV:SeriesBConvertiblePreferredStockMember 2023-06-30 0001528172 ENDV:SeriesBConvertiblePreferredStockMember 2022-12-31 0001528172 ENDV:SeriesCConvertiblePreferredStockMember 2023-06-30 0001528172 ENDV:SeriesCConvertiblePreferredStockMember 2022-12-31 0001528172 ENDV:SeriesDConvertiblePreferredStockMember 2023-06-30 0001528172 ENDV:SeriesDConvertiblePreferredStockMember 2022-12-31 0001528172 2023-04-01 2023-06-30 0001528172 2022-04-01 2022-06-30 0001528172 2022-01-01 2022-06-30 0001528172 2021-12-31 0001528172 2022-06-30 0001528172 ENDV:SeriesAAPreferredStockMember us-gaap:PreferredStockMember 2022-12-31 0001528172 ENDV:SeriesBConvertiblePreferredStockMember us-gaap:PreferredStockMember 2022-12-31 0001528172 ENDV:SeriesCConvertiblePreferredStockMember us-gaap:PreferredStockMember 2022-12-31 0001528172 ENDV:SeriesDConvertiblePreferredStockMember us-gaap:PreferredStockMember 2022-12-31 0001528172 us-gaap:CommonStockMember 2022-12-31 0001528172 us-gaap:AdditionalPaidInCapitalMember 2022-12-31 0001528172 ENDV:SubscriptionReceivableMember 2022-12-31 0001528172 us-gaap:RetainedEarningsMember 2022-12-31 0001528172 ENDV:SeriesAAPreferredStockMember us-gaap:PreferredStockMember 2023-03-31 0001528172 ENDV:SeriesBConvertiblePreferredStockMember us-gaap:PreferredStockMember 2023-03-31 0001528172 ENDV:SeriesCConvertiblePreferredStockMember us-gaap:PreferredStockMember 2023-03-31 0001528172 ENDV:SeriesDConvertiblePreferredStockMember us-gaap:PreferredStockMember 2023-03-31 0001528172 us-gaap:CommonStockMember 2023-03-31 0001528172 us-gaap:AdditionalPaidInCapitalMember 2023-03-31 0001528172 ENDV:SubscriptionReceivableMember 2023-03-31 0001528172 us-gaap:RetainedEarningsMember 2023-03-31 0001528172 2023-03-31 0001528172 ENDV:SeriesAAPreferredStockMember us-gaap:PreferredStockMember 2021-12-31 0001528172 ENDV:SeriesBConvertiblePreferredStockMember us-gaap:PreferredStockMember 2021-12-31 0001528172 ENDV:SeriesCConvertiblePreferredStockMember us-gaap:PreferredStockMember 2021-12-31 0001528172 ENDV:SeriesDConvertiblePreferredStockMember us-gaap:PreferredStockMember 2021-12-31 0001528172 us-gaap:CommonStockMember 2021-12-31 0001528172 us-gaap:AdditionalPaidInCapitalMember 2021-12-31 0001528172 ENDV:SubscriptionReceivableMember 2021-12-31 0001528172 us-gaap:RetainedEarningsMember 2021-12-31 0001528172 ENDV:SeriesAAPreferredStockMember us-gaap:PreferredStockMember 2022-03-31 0001528172 ENDV:SeriesBConvertiblePreferredStockMember us-gaap:PreferredStockMember 2022-03-31 0001528172 ENDV:SeriesCConvertiblePreferredStockMember us-gaap:PreferredStockMember 2022-03-31 0001528172 ENDV:SeriesDConvertiblePreferredStockMember us-gaap:PreferredStockMember 2022-03-31 0001528172 us-gaap:CommonStockMember 2022-03-31 0001528172 us-gaap:AdditionalPaidInCapitalMember 2022-03-31 0001528172 ENDV:SubscriptionReceivableMember 2022-03-31 0001528172 us-gaap:RetainedEarningsMember 2022-03-31 0001528172 2022-03-31 0001528172 ENDV:SeriesAAPreferredStockMember us-gaap:PreferredStockMember 2023-01-01 2023-03-31 0001528172 ENDV:SeriesBConvertiblePreferredStockMember us-gaap:PreferredStockMember 2023-01-01 2023-03-31 0001528172 ENDV:SeriesCConvertiblePreferredStockMember us-gaap:PreferredStockMember 2023-01-01 2023-03-31 0001528172 ENDV:SeriesDConvertiblePreferredStockMember us-gaap:PreferredStockMember 2023-01-01 2023-03-31 0001528172 us-gaap:CommonStockMember 2023-01-01 2023-03-31 0001528172 us-gaap:AdditionalPaidInCapitalMember 2023-01-01 2023-03-31 0001528172 ENDV:SubscriptionReceivableMember 2023-01-01 2023-03-31 0001528172 us-gaap:RetainedEarningsMember 2023-01-01 2023-03-31 0001528172 2023-01-01 2023-03-31 0001528172 ENDV:SeriesAAPreferredStockMember us-gaap:PreferredStockMember 2023-04-01 2023-06-30 0001528172 ENDV:SeriesBConvertiblePreferredStockMember us-gaap:PreferredStockMember 2023-04-01 2023-06-30 0001528172 ENDV:SeriesCConvertiblePreferredStockMember us-gaap:PreferredStockMember 2023-04-01 2023-06-30 0001528172 ENDV:SeriesDConvertiblePreferredStockMember us-gaap:PreferredStockMember 2023-04-01 2023-06-30 0001528172 us-gaap:CommonStockMember 2023-04-01 2023-06-30 0001528172 us-gaap:AdditionalPaidInCapitalMember 2023-04-01 2023-06-30 0001528172 ENDV:SubscriptionReceivableMember 2023-04-01 2023-06-30 0001528172 us-gaap:RetainedEarningsMember 2023-04-01 2023-06-30 0001528172 ENDV:SeriesAAPreferredStockMember us-gaap:PreferredStockMember 2022-01-01 2022-03-31 0001528172 ENDV:SeriesBConvertiblePreferredStockMember us-gaap:PreferredStockMember 2022-01-01 2022-03-31 0001528172 ENDV:SeriesCConvertiblePreferredStockMember us-gaap:PreferredStockMember 2022-01-01 2022-03-31 0001528172 ENDV:SeriesDConvertiblePreferredStockMember us-gaap:PreferredStockMember 2022-01-01 2022-03-31 0001528172 us-gaap:CommonStockMember 2022-01-01 2022-03-31 0001528172 us-gaap:AdditionalPaidInCapitalMember 2022-01-01 2022-03-31 0001528172 ENDV:SubscriptionReceivableMember 2022-01-01 2022-03-31 0001528172 us-gaap:RetainedEarningsMember 2022-01-01 2022-03-31 0001528172 2022-01-01 2022-03-31 0001528172 ENDV:SeriesAAPreferredStockMember us-gaap:PreferredStockMember 2022-04-01 2022-06-30 0001528172 ENDV:SeriesBConvertiblePreferredStockMember us-gaap:PreferredStockMember 2022-04-01 2022-06-30 0001528172 ENDV:SeriesCConvertiblePreferredStockMember us-gaap:PreferredStockMember 2022-04-01 2022-06-30 0001528172 ENDV:SeriesDConvertiblePreferredStockMember us-gaap:PreferredStockMember 2022-04-01 2022-06-30 0001528172 us-gaap:CommonStockMember 2022-04-01 2022-06-30 0001528172 us-gaap:AdditionalPaidInCapitalMember 2022-04-01 2022-06-30 0001528172 ENDV:SubscriptionReceivableMember 2022-04-01 2022-06-30 0001528172 us-gaap:RetainedEarningsMember 2022-04-01 2022-06-30 0001528172 ENDV:SeriesAAPreferredStockMember us-gaap:PreferredStockMember 2023-06-30 0001528172 ENDV:SeriesBConvertiblePreferredStockMember us-gaap:PreferredStockMember 2023-06-30 0001528172 ENDV:SeriesCConvertiblePreferredStockMember us-gaap:PreferredStockMember 2023-06-30 0001528172 ENDV:SeriesDConvertiblePreferredStockMember us-gaap:PreferredStockMember 2023-06-30 0001528172 us-gaap:CommonStockMember 2023-06-30 0001528172 us-gaap:AdditionalPaidInCapitalMember 2023-06-30 0001528172 ENDV:SubscriptionReceivableMember 2023-06-30 0001528172 us-gaap:RetainedEarningsMember 2023-06-30 0001528172 ENDV:SeriesAAPreferredStockMember us-gaap:PreferredStockMember 2022-06-30 0001528172 ENDV:SeriesBConvertiblePreferredStockMember us-gaap:PreferredStockMember 2022-06-30 0001528172 ENDV:SeriesCConvertiblePreferredStockMember us-gaap:PreferredStockMember 2022-06-30 0001528172 ENDV:SeriesDConvertiblePreferredStockMember us-gaap:PreferredStockMember 2022-06-30 0001528172 us-gaap:CommonStockMember 2022-06-30 0001528172 us-gaap:AdditionalPaidInCapitalMember 2022-06-30 0001528172 ENDV:SubscriptionReceivableMember 2022-06-30 0001528172 us-gaap:RetainedEarningsMember 2022-06-30 0001528172 ENDV:AssetsPurchaseAgreementMember 2022-09-26 2022-09-26 0001528172 us-gaap:EmployeeStockOptionMember 2023-01-01 2023-06-30 0001528172 us-gaap:EmployeeStockOptionMember 2022-01-01 2022-06-30 0001528172 us-gaap:WarrantMember 2022-01-01 2022-06-30 0001528172 ENDV:RoyaltyAndLicensingNetMember 2023-04-01 2023-06-30 0001528172 ENDV:RoyaltyAndLicensingNetMember 2022-04-01 2022-06-30 0001528172 ENDV:RoyaltyAndLicensingNetMember 2023-01-01 2023-06-30 0001528172 ENDV:RoyaltyAndLicensingNetMember 2022-01-01 2022-06-30 0001528172 ENDV:DirectSalesMedicalCareProvidersGrossMember 2023-04-01 2023-06-30 0001528172 ENDV:DirectSalesMedicalCareProvidersGrossMember 2022-04-01 2022-06-30 0001528172 ENDV:DirectSalesMedicalCareProvidersGrossMember 2023-01-01 2023-06-30 0001528172 ENDV:DirectSalesMedicalCareProvidersGrossMember 2022-01-01 2022-06-30 0001528172 ENDV:PulseTherapeuticTechnologyMember ENDV:SalesSupportServiceAgreementMember 2023-01-25 0001528172 ENDV:RioGrandeNeurosciencesIncMember 2017-12-01 2017-12-31 0001528172 2022-01-01 2022-12-31 0001528172 ENDV:FormerRelatedPartyMember 2023-06-30 0001528172 ENDV:FormerRelatedPartyMember 2022-12-31 0001528172 srt:MinimumMember 2023-06-30 0001528172 srt:MaximumMember 2023-06-30 0001528172 srt:MinimumMember 2023-01-01 2023-06-30 0001528172 srt:MaximumMember 2023-01-01 2023-06-30 0001528172 ENDV:FixedRateNotesMember 2023-06-30 0001528172 ENDV:FixedRateNotesMember 2022-12-31 0001528172 ENDV:VariableRateNotesMember 2023-01-01 2023-06-30 0001528172 srt:MinimumMember ENDV:FormerRelatedPartyMember 2023-06-30 0001528172 srt:MaximumMember ENDV:FormerRelatedPartyMember 2023-06-30 0001528172 ENDV:FormerRelatedPartyMember 2023-01-01 2023-06-30 0001528172 ENDV:ThreeFixedRatedNotesMember 2022-06-30 0001528172 ENDV:ThreeFixedRatedNotesMember 2022-01-01 2022-06-30 0001528172 ENDV:SixteenFixedRatedNotesMember 2022-06-30 0001528172 ENDV:PastMaturityMember ENDV:SixteenFixedRatedNotesMember 2022-06-30 0001528172 us-gaap:PrivatePlacementMember 2015-08-31 0001528172 us-gaap:PrivatePlacementMember 2015-08-01 2015-08-31 0001528172 us-gaap:PrivatePlacementMember 2022-06-30 0001528172 us-gaap:PrivatePlacementMember 2021-12-31 0001528172 ENDV:VariableRateNotesMember 2022-06-30 0001528172 ENDV:PastMaturityMember ENDV:VariableRateNotesMember 2022-06-30 0001528172 ENDV:PreferredStockDesignatedMember 2023-06-30 0001528172 ENDV:SeriesAAPreferredStockMember 2013-02-22 0001528172 ENDV:SeriesAAPreferredStockMember 2013-02-21 2013-02-22 0001528172 ENDV:SeriesAAPreferredStockMember 2023-06-30 0001528172 ENDV:SeriesAAPreferredStockMember 2022-12-31 0001528172 us-gaap:SeriesBPreferredStockMember 2017-02-07 0001528172 us-gaap:SeriesBPreferredStockMember 2017-02-06 2017-02-07 0001528172 us-gaap:SeriesBPreferredStockMember 2023-06-30 0001528172 us-gaap:SeriesBPreferredStockMember 2022-12-31 0001528172 ENDV:SeriesCConvertibleRedeemablePreferredStockMember 2017-12-22 0001528172 ENDV:SeriesCConvertibleRedeemablePreferredStockMember 2017-12-21 2017-12-22 0001528172 ENDV:SeriesCConvertibleRedeemablePreferredStockMember 2020-01-28 2020-01-29 0001528172 ENDV:SeriesCConvertibleRedeemablePreferredStockMember 2023-06-30 0001528172 ENDV:SeriesCConvertibleRedeemablePreferredStockMember 2022-12-31 0001528172 ENDV:SeriesDConvertiblePreferredStockMember 2019-11-11 0001528172 ENDV:SeriesDConvertiblePreferredStockMember 2023-01-01 2023-06-30 0001528172 us-gaap:CommonStockMember 2023-01-01 2023-06-30 0001528172 ENDV:OneInvestorMember 2023-01-01 2023-06-30 0001528172 us-gaap:SeriesDPreferredStockMember us-gaap:CommonStockMember 2023-01-01 2023-06-30 0001528172 us-gaap:SeriesDPreferredStockMember 2023-01-01 2023-06-30 0001528172 us-gaap:PrivatePlacementMember 2023-01-01 2023-06-30 0001528172 ENDV:SecuritiesPurchaseAgreementsMember 2023-01-01 2023-06-30 0001528172 us-gaap:CommonStockMember 2022-01-01 2022-06-30 0001528172 ENDV:OneInvestorMember 2022-01-01 2022-06-30 0001528172 ENDV:PurchaseAgreementMember 2022-01-01 2022-06-30 0001528172 ENDV:SeriesAAMember 2023-06-30 0001528172 ENDV:PreferredSeriesBMember 2023-06-30 0001528172 ENDV:PreferredSeriesCMember 2023-06-30 0001528172 ENDV:PreferredSeriesDMember 2023-06-30 0001528172 ENDV:UndesignatedMember 2023-06-30 0001528172 ENDV:StockOptionsMember 2022-12-31 0001528172 ENDV:StockOptionsMember 2023-01-01 2023-06-30 0001528172 ENDV:StockOptionsMember 2023-06-30 0001528172 us-gaap:WarrantMember 2022-12-31 0001528172 us-gaap:WarrantMember 2023-01-01 2023-06-30 0001528172 us-gaap:WarrantMember 2023-06-30 0001528172 srt:ExecutiveOfficerMember 2023-06-30 0001528172 srt:ExecutiveOfficerMember 2023-01-01 2023-06-30 0001528172 ENDV:OneFormerExecutiveOfficerMember 2023-06-30 0001528172 srt:OfficerMember 2023-06-30 0001528172 ENDV:FormerPresidentMember 2023-06-30 0001528172 us-gaap:MeasurementInputExpectedTermMember 2023-01-01 2023-06-30 0001528172 us-gaap:MeasurementInputExpectedTermMember 2022-01-01 2022-06-30 0001528172 srt:MinimumMember us-gaap:MeasurementInputExercisePriceMember 2023-06-30 0001528172 srt:MaximumMember us-gaap:MeasurementInputExercisePriceMember 2023-06-30 0001528172 srt:MinimumMember us-gaap:MeasurementInputExercisePriceMember 2022-06-30 0001528172 srt:MaximumMember us-gaap:MeasurementInputExercisePriceMember 2022-06-30 0001528172 srt:MinimumMember us-gaap:MeasurementInputPriceVolatilityMember 2023-06-30 0001528172 srt:MaximumMember us-gaap:MeasurementInputPriceVolatilityMember 2023-06-30 0001528172 srt:MinimumMember us-gaap:MeasurementInputPriceVolatilityMember 2022-06-30 0001528172 srt:MaximumMember us-gaap:MeasurementInputPriceVolatilityMember 2022-06-30 0001528172 us-gaap:MeasurementInputExpectedDividendRateMember 2023-06-30 0001528172 us-gaap:MeasurementInputExpectedDividendRateMember 2022-06-30 0001528172 srt:MinimumMember us-gaap:MeasurementInputRiskFreeInterestRateMember 2023-06-30 0001528172 srt:MaximumMember us-gaap:MeasurementInputRiskFreeInterestRateMember 2023-06-30 0001528172 srt:MinimumMember us-gaap:MeasurementInputRiskFreeInterestRateMember 2022-06-30 0001528172 srt:MaximumMember us-gaap:MeasurementInputRiskFreeInterestRateMember 2022-06-30 0001528172 ENDV:ForfeituresMember 2023-06-30 0001528172 ENDV:ForfeituresMember 2022-06-30 0001528172 us-gaap:FairValueInputsLevel3Member 2022-12-31 0001528172 us-gaap:FairValueInputsLevel3Member 2023-01-01 2023-06-30 0001528172 us-gaap:FairValueInputsLevel3Member 2023-06-30 0001528172 us-gaap:FairValueInputsLevel1Member 2023-06-30 0001528172 us-gaap:FairValueInputsLevel2Member 2023-06-30 0001528172 ENDV:OneSignificantCustomerMember us-gaap:SalesRevenueNetMember us-gaap:CustomerConcentrationRiskMember 2023-01-01 2023-06-30 0001528172 ENDV:SupplierMember us-gaap:SalesRevenueNetMember us-gaap:SupplierConcentrationRiskMember 2023-01-01 2023-06-30 0001528172 us-gaap:SubsequentEventMember ENDV:TwoNotesExtensionAgreementsMember 2023-07-01 2023-08-14 0001528172 ENDV:OneInvestorMember us-gaap:SubsequentEventMember ENDV:SecuriyPurchaseAgreementMember 2023-07-01 2023-08-14 0001528172 us-gaap:SubsequentEventMember ENDV:ProductionAgreementMember 2023-07-01 2023-08-14 0001528172 us-gaap:ConvertibleDebtMember us-gaap:SubsequentEventMember 2023-08-14 0001528172 us-gaap:ConvertibleDebtMember us-gaap:SubsequentEventMember 2023-07-01 2023-08-14 0001528172 ENDV:ConsultantAndChiefExecutiveOfficerMember us-gaap:SubsequentEventMember 2023-07-01 2023-08-14 iso4217:USD shares iso4217:USD shares pure ENDV:Integer 0001528172 false --12-31 Q2 P3Y 10-Q true 2023-06-30 2023 false 000-55453 ENDONOVO THERAPEUTICS, INC. DE 45-2552528 6320 Canoga Avenue 15th Floor Woodland Hills CA 91367 (800) 489-4774 Yes Yes Non-accelerated Filer true false false 317902405 32602 98 40231 15724 72833 15822 941988 1265444 1014821 1281266 1166997 884195 282000 282000 4134397 3542650 4053368 3918788 570068 523818 570068 523818 25585 10587 6922497 7041145 104600 112100 104600 112100 5902829 17359064 23136756 33381760 79825 79825 23216581 33461585 0.001 0.001 1000000 1000000 25000 25000 25000 25000 25 25 0.0001 0.0001 50000 50000 600 600 600 600 1 1 0.0001 0.0001 8000 8000 738 738 738 738 0.0001 0.0001 20000 20000 0 0 50 50 0.0001 0.0001 2500000000 2500000000 278802405 278802405 213227538 213227538 27880 21322 43636323 42919086 1570 1570 -65864419 -75119183 -22201760 -32180319 1014821 1281266 45200 650 132740 2932 383 3996 1097 45200 267 128744 1835 1176509 1799016 1789343 2286346 -1131309 -1798749 -1660599 -2284511 3419564 -316606 11445466 -1846964 103602 104760 156062 43813 -15328 -178000 -24518 -178000 -312869 -337536 -622249 -673678 3194969 -727382 10954761 -2654829 2063660 -2526131 9294162 -4939340 2063660 -2526131 9294162 -4939340 0.00 -0.02 0.04 -0.05 -0.01 -0.02 -0.00 -0.05 276330405 134360871 263948243 106696127 1350743592 134360871 1338361430 106696127 9294162 -4939340 323457 323456 566500 107468 1281900 156062 43813 14627 59138 11445466 -1846964 -11974 -2975 74827 205844 600747 614540 268770 318900 -338996 -329436 146000 250000 7500 6500 20000 253000 371500 243500 32504 -85936 98 85936 32602 109000 204000 500 45000 29625 33167 159419 25000 25 600 1 738 50 213227538 21322 42919086 -1570 -75119183 -32180319 10900000 1090 107910 109000 1507277 151 24719 24870 4300590 430 66659 67089 12850000 1285 171665 172950 22500000 2250 204750 207000 -50 5000000 500 -500 39398 -39398 7230502 7230502 25000 25 600 1 738 270285405 27028 43533687 -1570 -67928079 -24368908 1667000 167 24171 24338 850000 85 11040 11125 6025 6025 1000000 100 15900 16000 5000000 500 45500 46000 2063660 2063660 25000 25 600 1 738 278802405 27880 43636323 -1570 -65864419 -22201760 25000 25 600 1 738 305 74498760 7449 40663187 -1570 -56443416 -15774324 3700000 370 88430 88800 2428777 243 45904 46147 700000 70 15680 15750 -2413209 -2413209 25000 25 600 1 738 305 81327538 8132 40813201 -1570 -58856625 -18036836 25000 25 600 1 738 305 81327538 8132 40813201 -1570 -58856625 -18036836 6500000 650 114550 115200 350000 35 5698 5733 62250000 6225 1275675 1281900 -2526131 -2526131 -2526131 -2526131 25000 25 600 1 738 305 150427538 15042 42209124 -1570 61382756 -19160134 25000 25 600 1 738 305 150427538 15042 42209124 -1570 61382756 -19160134 <p id="xdx_80F_eus-gaap--OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock_zfeQqczTgF8d" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Note 1 - <span id="xdx_82A_znfN9DJB0j6b">Organization and Nature of Business</span></b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Endonovo Therapeutics, Inc. (Endonovo or the “Company”) is an innovative biotechnology company that has developed a bio-electronic approach to regenerative medicine. Endonovo is a growth stage company whose stock is publicly traded (OTCQB: ENDV).</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The Company develops, manufactures, and distributes evolutionary medical devices focused on the rapid healing of wounds and reduction of pain, edema, and inflammation in the human body. The Company’s non-invasive bioelectric medical devices are designed to target inflammation, cardiovascular diseases, chronic kidney disease, and central nervous system disorders (“CNS” disorders).</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The Company’s non-invasive Electroceutical® therapeutics device, SofPulse®, using pulsed short-wave radiofrequency at 27.12 MHz has been FDA-Cleared and CE Marked for the palliative treatment of soft tissue injuries and post-operative plain and edema, and has CMS National Coverage for the treatment of chronic wounds. The Company’s current portfolio of pre-clinical stage Electroceutical® therapeutics devices address chronic kidney disease, liver disease non-alcoholic steatohepatitis (NASH), cardiovascular and peripheral artery disease (PAD) and ischemic stroke.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Endonovo’s core mission is to transform the field of medicine by developing safe, wearable, non-invasive bioelectric medical devices that deliver the Company’s Electroceutical<sup>®</sup> Therapy. Endonovo’s bioelectric Electroceutical<sup>®</sup> devices harnesses <i>bioelectricity</i> to restore key electrochemical processes that initiate anti-inflammatory processes and growth factors in the body necessary for healing to rapidly occur.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The Company intends to be structured into two separate divisions:</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"><tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; width: 0.25in"></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">■</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">A commercial stage developer primarily of non-invasive wearable Electroceuticals® therapeutic devices for pain relief, general wellness, and wound curatives with many of its products marketed under the SofPulse® brand name. This division will be controlled by Ira Weisberg, the Company’s President and Chief Commercial Officer.</span></td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; width: 0.25in"></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; width: 0.25in">■</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">M&amp;A division with a strategy of purchasing profitable companies, which will be managed by the Company’s current Chief Executive Officer.</span></td></tr></table> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p id="xdx_808_eus-gaap--SignificantAccountingPoliciesTextBlock_zBEEDpPeo1z1" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Note 2 – <span id="xdx_821_zGPZgvol76X5">Summary of significant accounting policies</span>.</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p id="xdx_84A_eus-gaap--BasisOfAccountingPolicyPolicyTextBlock_zce5goYRCPB5" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i><span id="xdx_86A_z7OtEmHCQdfe">Basis of Presentation and Principles of Consolidation</span></i></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The accompanying unaudited interim condensed consolidated financial statements have been presented in accordance with accounting principles generally accepted in the United States of America (“GAAP”) for interim financial information and the instructions to Article 8 of Regulation S-X. Accordingly, the financial statements do not include all of the information and notes required by GAAP for complete financial statements. The accompanying consolidated condensed balance sheet as of June 30, 2023, the consolidated statements of operations for the three and six months ended June 30, 2023 and 2022, the consolidated statements of cash flows for the six months ended June 30, 2023 and 2022, and the consolidated statements of shareholders’ deficit for the three and six months ended June 30, 2023 and 2022 are unaudited; however, in the opinion of management such interim consolidated financial statements reflect all adjustments, consisting solely of normal recurring adjustments, necessary for a fair presentation of the results for the periods presented. The accompanying financial information should be read in conjunction with the financial statements and the notes thereto in the Company’s most recent Annual Report on Form 10-K, as filed with the Securities and Exchange Commission (the “SEC”) on April 17, 2023. The results of operations for the period presented are not necessarily indicative of the results that might be expected for future interim periods or for the full year.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p id="xdx_84C_ecustom--LiquidityAndGoingConcernPolicyTextTextBlock_zenjEzwmt9r8" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i><span id="xdx_86B_zlWtI6r10FF4">Liquidity and Going Concern</span></i></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The Company’s unaudited condensed consolidated financial statements are prepared using GAAP applicable to a going concern, which contemplates the realization of assets and liquidation of liabilities in the normal course of business. The Company has not yet established an ongoing source of revenues sufficient to cover its operating costs and to continue as a going concern. The ability of the Company to continue as a going concern is dependent on the Company’s ability to obtain adequate capital to fund operating losses until it becomes profitable.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">As of June 30, 2023, the Company had cash of approximately $<span id="xdx_90A_eus-gaap--Cash_iI_c20230630_zqEZvGoHytr4">32,600</span> and a working capital deficiency of approximately $<span id="xdx_904_ecustom--WorkingCapitalDeficiency_iI_pn5n6_c20230630_zGChJU5n5k2i" title="Working capital">23.1</span> million. During the six months ended June 30, 2023, the Company used approximately $<span id="xdx_901_eus-gaap--NetCashProvidedByUsedInOperatingActivities_iN_pn5n6_di_c20230101__20230630_zFF0aVzou4V2" title="Net cash provided by (used in) operating activities">0.3</span> million of cash in its operation. The Company has incurred recurring losses resulting in an accumulated deficit of approximately $<span id="xdx_90B_eus-gaap--RetainedEarningsAccumulatedDeficit_iNI_pn5n6_di_c20230630_zsmjQMyGidxg" title="Accumulated deficit">65.9</span> million as of June 30, 2023. These conditions raise substantial doubt as to its ability to continue as going concern within one year from issuance date of these unaudited consolidated financial statements.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Endonovo Therapeutics, Inc.</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Notes to Condensed Consolidated Financial Statements (continued)</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">During the six months ended June 30, 2023, the Company has raised $<span id="xdx_908_eus-gaap--ProceedsFromIssuanceOrSaleOfEquity_pn5n6_c20230101__20230630_zDzDORm0BKXe" title="Proceeds from equity financing">0.4</span> million in equity and debt financings. The Company will continue to raise additional capital through either debt or equity financing to fund its operations. However, there is no assurance that the Company can raise enough funds or generate sufficient revenues to pay its obligations as they become due, which raises substantial doubt about our ability to continue as a going concern.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On September 26, 2022, the Company entered into an asset purchase agreement with a Company, which is engaged in the business of providing and laying of concrete primarily for residential tract developers, pursuant to which the Company will acquire all of the assets and liabilities for approximately $<span id="xdx_909_eus-gaap--StockIssuedDuringPeriodValuePurchaseOfAssets_pn5n6_c20220926__20220926__us-gaap--TypeOfArrangementAxis__custom--AssetsPurchaseAgreementMember_zBHsZ2rBn9r8" title="Purchase of assets and Liabilities">25.2</span> million. The Company intends to raise the consideration through debt and equity financing. Such a transaction has not yet closed at the report date.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">No adjustments have been made to the carrying value of assets or liabilities as a result of this uncertainty. To reduce the risk of not being able to continue as a going concern, management is commercializing its FDA cleared and CE marked products and has commenced implementing its business plan to materialize revenues from potential future license agreements, and or diversifying its business activities with the potential acquisition of specialty construction company. The Company will continue to raise additional capital through the issuance of fixed-rate conversion feature promissory notes.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p id="xdx_841_eus-gaap--UseOfEstimates_zJ0AGF4OLVgj" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i><span id="xdx_86D_zUdyyLaQtW0f">Use of Estimates</span></i></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The preparation of financial statements in conformity with accounting principles generally accepted in the United States of America requires management to make estimates and assumptions that affect the amounts reported in the condensed consolidated financial statements and accompanying notes. Critical estimates include the assessment of impairment of finite lived intangibles, the valuation of the derivative liability, the valuation of warrants and stock options, and the valuation of deferred income tax assets. Management uses its historical records and knowledge of its business in making these estimates. Actual results could differ from these estimates.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p id="xdx_840_eus-gaap--EarningsPerSharePolicyTextBlock_zE2g1vOwcFx6" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i><span id="xdx_86B_zDgwfCZcgH77">Earnings (Loss) Per Share</span></i></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The Company utilizes Financial Accounting Standards Board (“FASB”) Accounting Standards Codification (“ASC”) 260, “Earnings per Share.” Basic earnings (loss) per share is computed based on the earnings (loss) attributable to common shareholders divided by the weighted average number of shares outstanding for the period excluding any dilutive effects of options, warrants, unvested share awards and convertible securities. Diluted earnings (loss) per common share is calculated similar to basic earnings (loss) per share except that the denominator is increased to include additional common share equivalents available upon exercise of stock option, warrants, common shares issuable under convertible debt and restricted stock using the treasury stock method. Dilutive common share equivalents include the dilutive effect of in-the-money share equivalents, which are calculated based on the average share price for each period using the treasury stock method, excluding any common share equivalents if their effect would be anti-dilutive. In periods in which a net loss has been incurred, all potentially dilutive common shares are considered anti-dilutive and thus are excluded from the calculation. Securities that are excluded from the calculation of weighted average dilutive common shares because their inclusion would have been antidilutive for the six months ended June 30, 2023, include stock options, warrants, and notes payable.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: left; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The Company has <span id="xdx_902_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_c20230101__20230630__us-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__us-gaap--EmployeeStockOptionMember_zCtG8DI1S05l" title="Anti dilutive shares">6,011,750</span> stock options to purchase an equivalent number of shares of common stock outstanding at June 30, 2023. The Company has <span id="xdx_902_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_c20220101__20220630__us-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__us-gaap--EmployeeStockOptionMember_z3OXExfjgaLd" title="Anti dilutive shares">513,730</span> options and <span id="xdx_909_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_c20220101__20220630__us-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__us-gaap--WarrantMember_zLttmogtxtcl" title="Anti dilutive shares">2,000</span> warrants to purchase common stock outstanding at June 30, 2022.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0pt; margin-bottom: 0pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p id="xdx_896_eus-gaap--ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock_zTNn1NMQ5CYb" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The components of basic and diluted income (loss) per share for the six months ended June 30, 2023 and 2022 were as follows:</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0pt; margin-bottom: 0pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span><span id="xdx_8B2_zagQGh1Rgbq8" style="display: none">Schedule of Earnings Per Share Basic and Diluted</span></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"> <tr style="display: none; vertical-align: bottom"> <td> </td><td style="padding-bottom: 1.5pt"> </td> <td colspan="2" id="xdx_49A_20230101__20230630_zJvGPSvHjWPc" style="border-bottom: Black 1.5pt solid; text-align: center">2023</td><td style="padding-bottom: 1.5pt"> </td><td style="padding-bottom: 1.5pt"> </td> <td colspan="2" id="xdx_49F_20220101__20220630_zU0JecEf1sP4" style="border-bottom: Black 1.5pt solid; text-align: center">2022</td><td style="padding-bottom: 1.5pt"> </td></tr> <tr style="vertical-align: bottom"> <td> </td><td style="padding-bottom: 1.5pt"> </td> <td colspan="6" style="border-bottom: Black 1.5pt solid; text-align: center">Six months ended June 30,</td><td style="padding-bottom: 1.5pt"> </td></tr> <tr style="vertical-align: bottom"> <td> </td><td style="padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center">2023</td><td style="padding-bottom: 1.5pt"> </td><td style="padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center">2022</td><td style="padding-bottom: 1.5pt"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td>Numerator:</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr id="xdx_40E_eus-gaap--NetIncomeLossAvailableToCommonStockholdersBasic_zHhOHy4gWFb2" style="vertical-align: bottom; background-color: White"> <td style="width: 60%; text-align: left">Net income (loss) attributable to common shareholders</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 16%; text-align: right">9,294,162</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 16%; text-align: right">(4,939,340</td><td style="width: 1%; text-align: left">)</td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="font-weight: bold; font-style: italic; text-align: left">Effect of dilutive securities</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr id="xdx_404_eus-gaap--DilutiveSecuritiesEffectOnBasicEarningsPerShareOther_zCUrsufziRIc" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left">Convertible notes</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">(10,823,217</td><td style="text-align: left">)</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0882">-</span></td><td style="text-align: left"> </td></tr> <tr id="xdx_406_eus-gaap--NetIncomeLossAttributableToParentDiluted_zJidruJAYJfc" style="vertical-align: bottom; background-color: White"> <td style="text-align: left; padding-bottom: 2.5pt">Net loss for diluted earnings per share</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">(1,529,055</td><td style="padding-bottom: 2.5pt; text-align: left">)</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">(4,939,340</td><td style="padding-bottom: 2.5pt; text-align: left">)</td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td>Denominator:</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr id="xdx_407_ecustom--WeightedAverageNumberOfDilutedSharesOutstandingGross_zvNlTlDKMq9i" style="vertical-align: bottom; background-color: White"> <td style="text-align: left">Weighted-average number of common shares outstanding during the period</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">263,948,243</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">106,696,127</td><td style="text-align: left"> </td></tr> <tr id="xdx_40B_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_zBPNvi17I0ra" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left; padding-bottom: 1.5pt">Dilutive effect of convertible notes payable</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">1,074,413,187</td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0891">-</span></td><td style="padding-bottom: 1.5pt; text-align: left"> </td></tr> <tr id="xdx_40E_ecustom--CommonStockAndCommonStockEquivalentsUsedForDilutedIncomePerShare_zUfGeR1r8Ccf" style="vertical-align: bottom; background-color: White"> <td style="text-align: justify; padding-bottom: 2.5pt">Common stock and common stock equivalents used for diluted loss per share</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left"> </td><td style="border-bottom: Black 2.5pt double; text-align: right">1,338,361,430</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left"> </td><td style="border-bottom: Black 2.5pt double; text-align: right">106,696,127</td><td style="padding-bottom: 2.5pt; text-align: left"> </td></tr> </table> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0pt; margin-bottom: 0pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The components of basic and diluted income (loss) per share for the three months ended June 30, 2023 and 2022 were as follows:</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0pt; margin-bottom: 0pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"> <tr style="display: none; vertical-align: bottom"> <td> </td><td style="padding-bottom: 1.5pt"> </td> <td colspan="2" id="xdx_492_20230401__20230630_zFlRg4S5DHn8" style="border-bottom: Black 1.5pt solid; text-align: center">2023</td><td style="padding-bottom: 1.5pt"> </td><td style="padding-bottom: 1.5pt"> </td> <td colspan="2" id="xdx_49D_20220401__20220630_zMnKSSDMldf2" style="border-bottom: Black 1.5pt solid; text-align: center">2022</td><td style="padding-bottom: 1.5pt"> </td></tr> <tr style="vertical-align: bottom"> <td> </td><td style="padding-bottom: 1.5pt"> </td> <td colspan="6" style="border-bottom: Black 1.5pt solid; text-align: center">Three months ended June 30,</td><td style="padding-bottom: 1.5pt"> </td></tr> <tr style="vertical-align: bottom"> <td> </td><td style="padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center">2023</td><td style="padding-bottom: 1.5pt"> </td><td style="padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center">2022</td><td style="padding-bottom: 1.5pt"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td>Numerator:</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr id="xdx_40E_eus-gaap--NetIncomeLossAvailableToCommonStockholdersBasic_zbpaEYbl1CD9" style="vertical-align: bottom; background-color: White"> <td style="width: 60%; text-align: left">Net income (loss) attributable to common shareholders</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 16%; text-align: right">2,063,660</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 16%; text-align: right">(2,526,131</td><td style="width: 1%; text-align: left">)</td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="font-weight: bold; font-style: italic; text-align: left">Effect of dilutive securities</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr id="xdx_404_eus-gaap--DilutiveSecuritiesEffectOnBasicEarningsPerShareOther_zUS92wCTkylc" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left">Convertible notes</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">(3,106,695</td><td style="text-align: left">)</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0900">-</span></td><td style="text-align: left"> </td></tr> <tr id="xdx_406_eus-gaap--NetIncomeLossAttributableToParentDiluted_zjmCMI9y4CCd" style="vertical-align: bottom; background-color: White"> <td style="text-align: left; padding-bottom: 2.5pt">Net loss for diluted earnings per share</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">(1,043,035</td><td style="padding-bottom: 2.5pt; text-align: left">)</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">(2,526,131</td><td style="padding-bottom: 2.5pt; text-align: left">)</td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td>Denominator:</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr id="xdx_407_ecustom--WeightedAverageNumberOfDilutedSharesOutstandingGross_zb5YX4swH1Fd" style="vertical-align: bottom; background-color: White"> <td style="text-align: left">Weighted-average number of common shares outstanding during the period</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">276,330,405</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">134,360,871</td><td style="text-align: left"> </td></tr> <tr id="xdx_40B_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_zePJAmW7coJc" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left; padding-bottom: 1.5pt">Dilutive effect of convertible notes payable</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">1,074,413,187</td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0909">-</span></td><td style="padding-bottom: 1.5pt; text-align: left"> </td></tr> <tr id="xdx_40E_ecustom--CommonStockAndCommonStockEquivalentsUsedForDilutedIncomePerShare_zqs9GoLuAPh6" style="vertical-align: bottom; background-color: White"> <td style="text-align: justify; padding-bottom: 2.5pt">Common stock and common stock equivalents used for diluted loss per share</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left"> </td><td style="border-bottom: Black 2.5pt double; text-align: right">1,350,743,592</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left"> </td><td style="border-bottom: Black 2.5pt double; text-align: right">134,360,871</td><td style="padding-bottom: 2.5pt; text-align: left"> </td></tr> </table> <p id="xdx_8A5_zihF75jshad6" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i> </i></span></p> <p id="xdx_847_eus-gaap--TradeAndOtherAccountsReceivablePolicy_z5mQnDIetxv4" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i><span id="xdx_86D_zDTTe0MEAIxg">Accounts Receivable</span></i></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The Company uses the specific identification method for recording the provision for doubtful accounts, which was $<span id="xdx_907_eus-gaap--AllowanceForDoubtfulAccountsReceivableCurrent_iI_c20230630_zjUgJpKmf0R9" title="Accounts receivable allowance for credit loss, current"><span id="xdx_905_eus-gaap--AllowanceForDoubtfulAccountsReceivableCurrent_iI_c20221231_zayvnsdfCj1b" title="Accounts receivable allowance for credit loss, current">0</span></span> as of June 30, 2023 and December 31, 2022. Account receivables are written off when all collection attempts have failed.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Endonovo Therapeutics, Inc.</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Notes to Condensed Consolidated Financial Statements (continued)</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p id="xdx_84C_eus-gaap--NewAccountingPronouncementsPolicyPolicyTextBlock_z4cBuU87KoMg" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i><span style="text-decoration: underline"><span id="xdx_86F_zDNtZNbNh231">Newly Adopted Accounting Principles</span></span></i></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The Company has evaluated all the recent accounting pronouncements and determined that there are no other accounting pronouncements that will have a material effect on the Company’s consolidated financial statements.</span></p> <p id="xdx_856_zfaefLrC0q1i" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p id="xdx_84A_eus-gaap--BasisOfAccountingPolicyPolicyTextBlock_zce5goYRCPB5" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i><span id="xdx_86A_z7OtEmHCQdfe">Basis of Presentation and Principles of Consolidation</span></i></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The accompanying unaudited interim condensed consolidated financial statements have been presented in accordance with accounting principles generally accepted in the United States of America (“GAAP”) for interim financial information and the instructions to Article 8 of Regulation S-X. Accordingly, the financial statements do not include all of the information and notes required by GAAP for complete financial statements. The accompanying consolidated condensed balance sheet as of June 30, 2023, the consolidated statements of operations for the three and six months ended June 30, 2023 and 2022, the consolidated statements of cash flows for the six months ended June 30, 2023 and 2022, and the consolidated statements of shareholders’ deficit for the three and six months ended June 30, 2023 and 2022 are unaudited; however, in the opinion of management such interim consolidated financial statements reflect all adjustments, consisting solely of normal recurring adjustments, necessary for a fair presentation of the results for the periods presented. The accompanying financial information should be read in conjunction with the financial statements and the notes thereto in the Company’s most recent Annual Report on Form 10-K, as filed with the Securities and Exchange Commission (the “SEC”) on April 17, 2023. The results of operations for the period presented are not necessarily indicative of the results that might be expected for future interim periods or for the full year.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p id="xdx_84C_ecustom--LiquidityAndGoingConcernPolicyTextTextBlock_zenjEzwmt9r8" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i><span id="xdx_86B_zlWtI6r10FF4">Liquidity and Going Concern</span></i></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The Company’s unaudited condensed consolidated financial statements are prepared using GAAP applicable to a going concern, which contemplates the realization of assets and liquidation of liabilities in the normal course of business. The Company has not yet established an ongoing source of revenues sufficient to cover its operating costs and to continue as a going concern. The ability of the Company to continue as a going concern is dependent on the Company’s ability to obtain adequate capital to fund operating losses until it becomes profitable.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">As of June 30, 2023, the Company had cash of approximately $<span id="xdx_90A_eus-gaap--Cash_iI_c20230630_zqEZvGoHytr4">32,600</span> and a working capital deficiency of approximately $<span id="xdx_904_ecustom--WorkingCapitalDeficiency_iI_pn5n6_c20230630_zGChJU5n5k2i" title="Working capital">23.1</span> million. During the six months ended June 30, 2023, the Company used approximately $<span id="xdx_901_eus-gaap--NetCashProvidedByUsedInOperatingActivities_iN_pn5n6_di_c20230101__20230630_zFF0aVzou4V2" title="Net cash provided by (used in) operating activities">0.3</span> million of cash in its operation. The Company has incurred recurring losses resulting in an accumulated deficit of approximately $<span id="xdx_90B_eus-gaap--RetainedEarningsAccumulatedDeficit_iNI_pn5n6_di_c20230630_zsmjQMyGidxg" title="Accumulated deficit">65.9</span> million as of June 30, 2023. These conditions raise substantial doubt as to its ability to continue as going concern within one year from issuance date of these unaudited consolidated financial statements.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Endonovo Therapeutics, Inc.</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Notes to Condensed Consolidated Financial Statements (continued)</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">During the six months ended June 30, 2023, the Company has raised $<span id="xdx_908_eus-gaap--ProceedsFromIssuanceOrSaleOfEquity_pn5n6_c20230101__20230630_zDzDORm0BKXe" title="Proceeds from equity financing">0.4</span> million in equity and debt financings. The Company will continue to raise additional capital through either debt or equity financing to fund its operations. However, there is no assurance that the Company can raise enough funds or generate sufficient revenues to pay its obligations as they become due, which raises substantial doubt about our ability to continue as a going concern.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On September 26, 2022, the Company entered into an asset purchase agreement with a Company, which is engaged in the business of providing and laying of concrete primarily for residential tract developers, pursuant to which the Company will acquire all of the assets and liabilities for approximately $<span id="xdx_909_eus-gaap--StockIssuedDuringPeriodValuePurchaseOfAssets_pn5n6_c20220926__20220926__us-gaap--TypeOfArrangementAxis__custom--AssetsPurchaseAgreementMember_zBHsZ2rBn9r8" title="Purchase of assets and Liabilities">25.2</span> million. The Company intends to raise the consideration through debt and equity financing. Such a transaction has not yet closed at the report date.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">No adjustments have been made to the carrying value of assets or liabilities as a result of this uncertainty. To reduce the risk of not being able to continue as a going concern, management is commercializing its FDA cleared and CE marked products and has commenced implementing its business plan to materialize revenues from potential future license agreements, and or diversifying its business activities with the potential acquisition of specialty construction company. The Company will continue to raise additional capital through the issuance of fixed-rate conversion feature promissory notes.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> 32600 23100000 -300000 -65900000 400000 25200000 <p id="xdx_841_eus-gaap--UseOfEstimates_zJ0AGF4OLVgj" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i><span id="xdx_86D_zUdyyLaQtW0f">Use of Estimates</span></i></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The preparation of financial statements in conformity with accounting principles generally accepted in the United States of America requires management to make estimates and assumptions that affect the amounts reported in the condensed consolidated financial statements and accompanying notes. Critical estimates include the assessment of impairment of finite lived intangibles, the valuation of the derivative liability, the valuation of warrants and stock options, and the valuation of deferred income tax assets. Management uses its historical records and knowledge of its business in making these estimates. Actual results could differ from these estimates.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p id="xdx_840_eus-gaap--EarningsPerSharePolicyTextBlock_zE2g1vOwcFx6" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i><span id="xdx_86B_zDgwfCZcgH77">Earnings (Loss) Per Share</span></i></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The Company utilizes Financial Accounting Standards Board (“FASB”) Accounting Standards Codification (“ASC”) 260, “Earnings per Share.” Basic earnings (loss) per share is computed based on the earnings (loss) attributable to common shareholders divided by the weighted average number of shares outstanding for the period excluding any dilutive effects of options, warrants, unvested share awards and convertible securities. Diluted earnings (loss) per common share is calculated similar to basic earnings (loss) per share except that the denominator is increased to include additional common share equivalents available upon exercise of stock option, warrants, common shares issuable under convertible debt and restricted stock using the treasury stock method. Dilutive common share equivalents include the dilutive effect of in-the-money share equivalents, which are calculated based on the average share price for each period using the treasury stock method, excluding any common share equivalents if their effect would be anti-dilutive. In periods in which a net loss has been incurred, all potentially dilutive common shares are considered anti-dilutive and thus are excluded from the calculation. Securities that are excluded from the calculation of weighted average dilutive common shares because their inclusion would have been antidilutive for the six months ended June 30, 2023, include stock options, warrants, and notes payable.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: left; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The Company has <span id="xdx_902_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_c20230101__20230630__us-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__us-gaap--EmployeeStockOptionMember_zCtG8DI1S05l" title="Anti dilutive shares">6,011,750</span> stock options to purchase an equivalent number of shares of common stock outstanding at June 30, 2023. The Company has <span id="xdx_902_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_c20220101__20220630__us-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__us-gaap--EmployeeStockOptionMember_z3OXExfjgaLd" title="Anti dilutive shares">513,730</span> options and <span id="xdx_909_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_c20220101__20220630__us-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__us-gaap--WarrantMember_zLttmogtxtcl" title="Anti dilutive shares">2,000</span> warrants to purchase common stock outstanding at June 30, 2022.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0pt; margin-bottom: 0pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p id="xdx_896_eus-gaap--ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock_zTNn1NMQ5CYb" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The components of basic and diluted income (loss) per share for the six months ended June 30, 2023 and 2022 were as follows:</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0pt; margin-bottom: 0pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span><span id="xdx_8B2_zagQGh1Rgbq8" style="display: none">Schedule of Earnings Per Share Basic and Diluted</span></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"> <tr style="display: none; vertical-align: bottom"> <td> </td><td style="padding-bottom: 1.5pt"> </td> <td colspan="2" id="xdx_49A_20230101__20230630_zJvGPSvHjWPc" style="border-bottom: Black 1.5pt solid; text-align: center">2023</td><td style="padding-bottom: 1.5pt"> </td><td style="padding-bottom: 1.5pt"> </td> <td colspan="2" id="xdx_49F_20220101__20220630_zU0JecEf1sP4" style="border-bottom: Black 1.5pt solid; text-align: center">2022</td><td style="padding-bottom: 1.5pt"> </td></tr> <tr style="vertical-align: bottom"> <td> </td><td style="padding-bottom: 1.5pt"> </td> <td colspan="6" style="border-bottom: Black 1.5pt solid; text-align: center">Six months ended June 30,</td><td style="padding-bottom: 1.5pt"> </td></tr> <tr style="vertical-align: bottom"> <td> </td><td style="padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center">2023</td><td style="padding-bottom: 1.5pt"> </td><td style="padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center">2022</td><td style="padding-bottom: 1.5pt"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td>Numerator:</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr id="xdx_40E_eus-gaap--NetIncomeLossAvailableToCommonStockholdersBasic_zHhOHy4gWFb2" style="vertical-align: bottom; background-color: White"> <td style="width: 60%; text-align: left">Net income (loss) attributable to common shareholders</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 16%; text-align: right">9,294,162</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 16%; text-align: right">(4,939,340</td><td style="width: 1%; text-align: left">)</td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="font-weight: bold; font-style: italic; text-align: left">Effect of dilutive securities</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr id="xdx_404_eus-gaap--DilutiveSecuritiesEffectOnBasicEarningsPerShareOther_zCUrsufziRIc" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left">Convertible notes</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">(10,823,217</td><td style="text-align: left">)</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0882">-</span></td><td style="text-align: left"> </td></tr> <tr id="xdx_406_eus-gaap--NetIncomeLossAttributableToParentDiluted_zJidruJAYJfc" style="vertical-align: bottom; background-color: White"> <td style="text-align: left; padding-bottom: 2.5pt">Net loss for diluted earnings per share</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">(1,529,055</td><td style="padding-bottom: 2.5pt; text-align: left">)</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">(4,939,340</td><td style="padding-bottom: 2.5pt; text-align: left">)</td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td>Denominator:</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr id="xdx_407_ecustom--WeightedAverageNumberOfDilutedSharesOutstandingGross_zvNlTlDKMq9i" style="vertical-align: bottom; background-color: White"> <td style="text-align: left">Weighted-average number of common shares outstanding during the period</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">263,948,243</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">106,696,127</td><td style="text-align: left"> </td></tr> <tr id="xdx_40B_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_zBPNvi17I0ra" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left; padding-bottom: 1.5pt">Dilutive effect of convertible notes payable</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">1,074,413,187</td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0891">-</span></td><td style="padding-bottom: 1.5pt; text-align: left"> </td></tr> <tr id="xdx_40E_ecustom--CommonStockAndCommonStockEquivalentsUsedForDilutedIncomePerShare_zUfGeR1r8Ccf" style="vertical-align: bottom; background-color: White"> <td style="text-align: justify; padding-bottom: 2.5pt">Common stock and common stock equivalents used for diluted loss per share</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left"> </td><td style="border-bottom: Black 2.5pt double; text-align: right">1,338,361,430</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left"> </td><td style="border-bottom: Black 2.5pt double; text-align: right">106,696,127</td><td style="padding-bottom: 2.5pt; text-align: left"> </td></tr> </table> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0pt; margin-bottom: 0pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The components of basic and diluted income (loss) per share for the three months ended June 30, 2023 and 2022 were as follows:</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0pt; margin-bottom: 0pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"> <tr style="display: none; vertical-align: bottom"> <td> </td><td style="padding-bottom: 1.5pt"> </td> <td colspan="2" id="xdx_492_20230401__20230630_zFlRg4S5DHn8" style="border-bottom: Black 1.5pt solid; text-align: center">2023</td><td style="padding-bottom: 1.5pt"> </td><td style="padding-bottom: 1.5pt"> </td> <td colspan="2" id="xdx_49D_20220401__20220630_zMnKSSDMldf2" style="border-bottom: Black 1.5pt solid; text-align: center">2022</td><td style="padding-bottom: 1.5pt"> </td></tr> <tr style="vertical-align: bottom"> <td> </td><td style="padding-bottom: 1.5pt"> </td> <td colspan="6" style="border-bottom: Black 1.5pt solid; text-align: center">Three months ended June 30,</td><td style="padding-bottom: 1.5pt"> </td></tr> <tr style="vertical-align: bottom"> <td> </td><td style="padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center">2023</td><td style="padding-bottom: 1.5pt"> </td><td style="padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center">2022</td><td style="padding-bottom: 1.5pt"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td>Numerator:</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr id="xdx_40E_eus-gaap--NetIncomeLossAvailableToCommonStockholdersBasic_zbpaEYbl1CD9" style="vertical-align: bottom; background-color: White"> <td style="width: 60%; text-align: left">Net income (loss) attributable to common shareholders</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 16%; text-align: right">2,063,660</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 16%; text-align: right">(2,526,131</td><td style="width: 1%; text-align: left">)</td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="font-weight: bold; font-style: italic; text-align: left">Effect of dilutive securities</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr id="xdx_404_eus-gaap--DilutiveSecuritiesEffectOnBasicEarningsPerShareOther_zUS92wCTkylc" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left">Convertible notes</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">(3,106,695</td><td style="text-align: left">)</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0900">-</span></td><td style="text-align: left"> </td></tr> <tr id="xdx_406_eus-gaap--NetIncomeLossAttributableToParentDiluted_zjmCMI9y4CCd" style="vertical-align: bottom; background-color: White"> <td style="text-align: left; padding-bottom: 2.5pt">Net loss for diluted earnings per share</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">(1,043,035</td><td style="padding-bottom: 2.5pt; text-align: left">)</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">(2,526,131</td><td style="padding-bottom: 2.5pt; text-align: left">)</td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td>Denominator:</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr id="xdx_407_ecustom--WeightedAverageNumberOfDilutedSharesOutstandingGross_zb5YX4swH1Fd" style="vertical-align: bottom; background-color: White"> <td style="text-align: left">Weighted-average number of common shares outstanding during the period</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">276,330,405</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">134,360,871</td><td style="text-align: left"> </td></tr> <tr id="xdx_40B_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_zePJAmW7coJc" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left; padding-bottom: 1.5pt">Dilutive effect of convertible notes payable</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">1,074,413,187</td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0909">-</span></td><td style="padding-bottom: 1.5pt; text-align: left"> </td></tr> <tr id="xdx_40E_ecustom--CommonStockAndCommonStockEquivalentsUsedForDilutedIncomePerShare_zqs9GoLuAPh6" style="vertical-align: bottom; background-color: White"> <td style="text-align: justify; padding-bottom: 2.5pt">Common stock and common stock equivalents used for diluted loss per share</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left"> </td><td style="border-bottom: Black 2.5pt double; text-align: right">1,350,743,592</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left"> </td><td style="border-bottom: Black 2.5pt double; text-align: right">134,360,871</td><td style="padding-bottom: 2.5pt; text-align: left"> </td></tr> </table> <p id="xdx_8A5_zihF75jshad6" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i> </i></span></p> 6011750 513730 2000 <p id="xdx_896_eus-gaap--ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock_zTNn1NMQ5CYb" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The components of basic and diluted income (loss) per share for the six months ended June 30, 2023 and 2022 were as follows:</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0pt; margin-bottom: 0pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span><span id="xdx_8B2_zagQGh1Rgbq8" style="display: none">Schedule of Earnings Per Share Basic and Diluted</span></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"> <tr style="display: none; vertical-align: bottom"> <td> </td><td style="padding-bottom: 1.5pt"> </td> <td colspan="2" id="xdx_49A_20230101__20230630_zJvGPSvHjWPc" style="border-bottom: Black 1.5pt solid; text-align: center">2023</td><td style="padding-bottom: 1.5pt"> </td><td style="padding-bottom: 1.5pt"> </td> <td colspan="2" id="xdx_49F_20220101__20220630_zU0JecEf1sP4" style="border-bottom: Black 1.5pt solid; text-align: center">2022</td><td style="padding-bottom: 1.5pt"> </td></tr> <tr style="vertical-align: bottom"> <td> </td><td style="padding-bottom: 1.5pt"> </td> <td colspan="6" style="border-bottom: Black 1.5pt solid; text-align: center">Six months ended June 30,</td><td style="padding-bottom: 1.5pt"> </td></tr> <tr style="vertical-align: bottom"> <td> </td><td style="padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center">2023</td><td style="padding-bottom: 1.5pt"> </td><td style="padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center">2022</td><td style="padding-bottom: 1.5pt"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td>Numerator:</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr id="xdx_40E_eus-gaap--NetIncomeLossAvailableToCommonStockholdersBasic_zHhOHy4gWFb2" style="vertical-align: bottom; background-color: White"> <td style="width: 60%; text-align: left">Net income (loss) attributable to common shareholders</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 16%; text-align: right">9,294,162</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 16%; text-align: right">(4,939,340</td><td style="width: 1%; text-align: left">)</td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="font-weight: bold; font-style: italic; text-align: left">Effect of dilutive securities</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr id="xdx_404_eus-gaap--DilutiveSecuritiesEffectOnBasicEarningsPerShareOther_zCUrsufziRIc" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left">Convertible notes</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">(10,823,217</td><td style="text-align: left">)</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0882">-</span></td><td style="text-align: left"> </td></tr> <tr id="xdx_406_eus-gaap--NetIncomeLossAttributableToParentDiluted_zJidruJAYJfc" style="vertical-align: bottom; background-color: White"> <td style="text-align: left; padding-bottom: 2.5pt">Net loss for diluted earnings per share</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">(1,529,055</td><td style="padding-bottom: 2.5pt; text-align: left">)</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">(4,939,340</td><td style="padding-bottom: 2.5pt; text-align: left">)</td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td>Denominator:</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr id="xdx_407_ecustom--WeightedAverageNumberOfDilutedSharesOutstandingGross_zvNlTlDKMq9i" style="vertical-align: bottom; background-color: White"> <td style="text-align: left">Weighted-average number of common shares outstanding during the period</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">263,948,243</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">106,696,127</td><td style="text-align: left"> </td></tr> <tr id="xdx_40B_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_zBPNvi17I0ra" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left; padding-bottom: 1.5pt">Dilutive effect of convertible notes payable</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">1,074,413,187</td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0891">-</span></td><td style="padding-bottom: 1.5pt; text-align: left"> </td></tr> <tr id="xdx_40E_ecustom--CommonStockAndCommonStockEquivalentsUsedForDilutedIncomePerShare_zUfGeR1r8Ccf" style="vertical-align: bottom; background-color: White"> <td style="text-align: justify; padding-bottom: 2.5pt">Common stock and common stock equivalents used for diluted loss per share</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left"> </td><td style="border-bottom: Black 2.5pt double; text-align: right">1,338,361,430</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left"> </td><td style="border-bottom: Black 2.5pt double; text-align: right">106,696,127</td><td style="padding-bottom: 2.5pt; text-align: left"> </td></tr> </table> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0pt; margin-bottom: 0pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The components of basic and diluted income (loss) per share for the three months ended June 30, 2023 and 2022 were as follows:</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0pt; margin-bottom: 0pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"> <tr style="display: none; vertical-align: bottom"> <td> </td><td style="padding-bottom: 1.5pt"> </td> <td colspan="2" id="xdx_492_20230401__20230630_zFlRg4S5DHn8" style="border-bottom: Black 1.5pt solid; text-align: center">2023</td><td style="padding-bottom: 1.5pt"> </td><td style="padding-bottom: 1.5pt"> </td> <td colspan="2" id="xdx_49D_20220401__20220630_zMnKSSDMldf2" style="border-bottom: Black 1.5pt solid; text-align: center">2022</td><td style="padding-bottom: 1.5pt"> </td></tr> <tr style="vertical-align: bottom"> <td> </td><td style="padding-bottom: 1.5pt"> </td> <td colspan="6" style="border-bottom: Black 1.5pt solid; text-align: center">Three months ended June 30,</td><td style="padding-bottom: 1.5pt"> </td></tr> <tr style="vertical-align: bottom"> <td> </td><td style="padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center">2023</td><td style="padding-bottom: 1.5pt"> </td><td style="padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center">2022</td><td style="padding-bottom: 1.5pt"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td>Numerator:</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr id="xdx_40E_eus-gaap--NetIncomeLossAvailableToCommonStockholdersBasic_zbpaEYbl1CD9" style="vertical-align: bottom; background-color: White"> <td style="width: 60%; text-align: left">Net income (loss) attributable to common shareholders</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 16%; text-align: right">2,063,660</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 16%; text-align: right">(2,526,131</td><td style="width: 1%; text-align: left">)</td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="font-weight: bold; font-style: italic; text-align: left">Effect of dilutive securities</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr id="xdx_404_eus-gaap--DilutiveSecuritiesEffectOnBasicEarningsPerShareOther_zUS92wCTkylc" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left">Convertible notes</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">(3,106,695</td><td style="text-align: left">)</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0900">-</span></td><td style="text-align: left"> </td></tr> <tr id="xdx_406_eus-gaap--NetIncomeLossAttributableToParentDiluted_zjmCMI9y4CCd" style="vertical-align: bottom; background-color: White"> <td style="text-align: left; padding-bottom: 2.5pt">Net loss for diluted earnings per share</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">(1,043,035</td><td style="padding-bottom: 2.5pt; text-align: left">)</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">(2,526,131</td><td style="padding-bottom: 2.5pt; text-align: left">)</td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td>Denominator:</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr id="xdx_407_ecustom--WeightedAverageNumberOfDilutedSharesOutstandingGross_zb5YX4swH1Fd" style="vertical-align: bottom; background-color: White"> <td style="text-align: left">Weighted-average number of common shares outstanding during the period</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">276,330,405</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">134,360,871</td><td style="text-align: left"> </td></tr> <tr id="xdx_40B_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_zePJAmW7coJc" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left; padding-bottom: 1.5pt">Dilutive effect of convertible notes payable</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">1,074,413,187</td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0909">-</span></td><td style="padding-bottom: 1.5pt; text-align: left"> </td></tr> <tr id="xdx_40E_ecustom--CommonStockAndCommonStockEquivalentsUsedForDilutedIncomePerShare_zqs9GoLuAPh6" style="vertical-align: bottom; background-color: White"> <td style="text-align: justify; padding-bottom: 2.5pt">Common stock and common stock equivalents used for diluted loss per share</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left"> </td><td style="border-bottom: Black 2.5pt double; text-align: right">1,350,743,592</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left"> </td><td style="border-bottom: Black 2.5pt double; text-align: right">134,360,871</td><td style="padding-bottom: 2.5pt; text-align: left"> </td></tr> </table> 9294162 -4939340 -10823217 -1529055 -4939340 263948243 106696127 1074413187 1338361430 106696127 2063660 -2526131 -3106695 -1043035 -2526131 276330405 134360871 1074413187 1350743592 134360871 <p id="xdx_847_eus-gaap--TradeAndOtherAccountsReceivablePolicy_z5mQnDIetxv4" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i><span id="xdx_86D_zDTTe0MEAIxg">Accounts Receivable</span></i></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The Company uses the specific identification method for recording the provision for doubtful accounts, which was $<span id="xdx_907_eus-gaap--AllowanceForDoubtfulAccountsReceivableCurrent_iI_c20230630_zjUgJpKmf0R9" title="Accounts receivable allowance for credit loss, current"><span id="xdx_905_eus-gaap--AllowanceForDoubtfulAccountsReceivableCurrent_iI_c20221231_zayvnsdfCj1b" title="Accounts receivable allowance for credit loss, current">0</span></span> as of June 30, 2023 and December 31, 2022. Account receivables are written off when all collection attempts have failed.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Endonovo Therapeutics, Inc.</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Notes to Condensed Consolidated Financial Statements (continued)</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> 0 0 <p id="xdx_84C_eus-gaap--NewAccountingPronouncementsPolicyPolicyTextBlock_z4cBuU87KoMg" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i><span style="text-decoration: underline"><span id="xdx_86F_zDNtZNbNh231">Newly Adopted Accounting Principles</span></span></i></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The Company has evaluated all the recent accounting pronouncements and determined that there are no other accounting pronouncements that will have a material effect on the Company’s consolidated financial statements.</span></p> <p id="xdx_80A_eus-gaap--RevenueFromContractWithCustomerTextBlock_zwZY5nUGdagf" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Note 3 - <span id="xdx_826_zZr47zpI2a8g">Revenue Recognition</span></b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Contracts with Customers</i></b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.25in; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.25in; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The Company adopted ASC 606, <i>Revenue from Contracts with Customers</i> effective January 1, 2019, using the modified retrospective method applied to those contracts which were not substantially completed as of January 1, 2019<i>.</i> These standards provide guidance on recognizing revenue, including a five-step model to determine when revenue recognition is appropriate. The standard requires that an entity recognize revenue to depict the transfer of control of promised goods or services to customers in an amount that reflects the consideration to which the entity expects to be entitled in exchange for those goods or services.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.25in; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.25in; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The Company routinely plans on entering into contracts with customers that include general commercial terms and conditions, notification requirements for price increases, shipping terms and in most cases prices for the products and services that we offer. The Company’s performance obligations are established when a customer submits a purchase order notification (in writing, electronically or verbally) for goods and services, and we accept the order. The Company identified performance obligations as the delivery of the requested product or service in appropriate quantities and to the location specified in the customer’s contract and/or purchase order. The Company generally recognize revenue upon the satisfaction of these criteria when control of the product or service has been transferred to the customer at which time, the Company has an unconditional right to receive payment. The Company’s sales and sale prices are final, and our prices are not affected by contingent events that could impact the transaction price.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.25in; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.25in; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Revenues for our SofPulse® product is typically recognized at the time the product is shipped, at which time the title passes to the customer, and there are no further performance obligations. Royalty/licensing revenue is also recognized at one point in time, when the units are shipped.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.25in; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In connection with offering products and services provided to the end user by third-party vendors, the Company reviews the relationship between us, the vendor, and the end user to assess whether revenue should be reported on a gross or net basis. In asserting whether revenue should be reported on a gross or net basis, the Company considers whether the Company acts as a principal in the transaction and control the goods and services used to fulfill the performance obligation(s) associated with the transaction.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Endonovo Therapeutics, Inc.</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Notes to Condensed Consolidated Financial Statements (continued)</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Sources of Revenue</i></b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.25in; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.25in; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The Company has identified the following revenues by revenue source:</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.25in; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"> <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">1.</span></td> <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Sales to plastic surgeons</span></td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"> <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">2.</span></td> <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Sales to wound care facilities</span></td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"> <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">3.</span></td> <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Sales to hospital</span></td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"> <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">4.</span></td> <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Sales to other physicians</span></td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"> <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">5.</span></td> <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Royalty fee from licensing, net</span></td></tr> </table> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.25in; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p id="xdx_898_ecustom--ScheduleOfSourceOfRevenueTableTextBlock_z3okIlu50nJj" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">For the three and six months ended June 30, 2023 and 2022, the sources of revenue were as follows:</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span><span id="xdx_8B4_z2iicV0ywwzf" style="display: none">Schedule of Source of Revenue</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"> <tr style="display: none; vertical-align: bottom"> <td style="text-align: center"> </td><td style="padding-bottom: 1.5pt"> </td> <td colspan="2" id="xdx_49B_20230401__20230630_zHTkGtqyGbO4" style="border-bottom: Black 1.5pt solid; text-align: center">2023</td><td style="padding-bottom: 1.5pt"> </td><td style="padding-bottom: 1.5pt"> </td> <td colspan="2" id="xdx_493_20220401__20220630_zVoBEgR6z2te" style="border-bottom: Black 1.5pt solid; text-align: center">2022</td><td style="padding-bottom: 1.5pt"> </td><td style="padding-bottom: 1.5pt"> </td> <td colspan="2" id="xdx_498_20230101__20230630_zRCnbOWSFnq5" style="border-bottom: Black 1.5pt solid; text-align: center">2023</td><td style="padding-bottom: 1.5pt"> </td><td style="padding-bottom: 1.5pt"> </td> <td colspan="2" id="xdx_493_20220101__20220630_ztU9hOcI2pX1" style="border-bottom: Black 1.5pt solid; text-align: center">2022</td><td style="padding-bottom: 1.5pt"> </td></tr> <tr style="vertical-align: bottom"> <td style="text-align: center"> </td><td style="padding-bottom: 1.5pt"> </td> <td colspan="6" style="border-bottom: Black 1.5pt solid; text-align: center">Three Months Ended June 30,</td><td style="padding-bottom: 1.5pt"> </td><td style="padding-bottom: 1.5pt"> </td> <td colspan="6" style="border-bottom: Black 1.5pt solid; text-align: center">Six Months Ended June 30,</td><td style="padding-bottom: 1.5pt"> </td></tr> <tr style="vertical-align: bottom"> <td style="text-align: center"> </td><td style="padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center">2023</td><td style="padding-bottom: 1.5pt"> </td><td style="padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center">2022</td><td style="padding-bottom: 1.5pt"> </td><td style="padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center">2023</td><td style="padding-bottom: 1.5pt"> </td><td style="padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center">2022</td><td style="padding-bottom: 1.5pt"> </td></tr> <tr style="vertical-align: bottom"> <td> </td><td> </td> <td colspan="2"> </td><td> </td><td> </td> <td colspan="2"> </td><td> </td><td> </td> <td colspan="2"> </td><td> </td><td> </td> <td colspan="2"> </td><td> </td></tr> <tr id="xdx_402_eus-gaap--RevenueFromContractWithCustomerExcludingAssessedTax_hsrt--ProductOrServiceAxis__custom--RoyaltyAndLicensingNetMember_zsEIIQvQQiSh" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 40%; text-align: left">Royalty/licensing, net</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 11%; text-align: right">45,200</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 11%; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0927">-</span></td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 11%; text-align: right">126,520</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 11%; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0929">-</span></td><td style="width: 1%; text-align: left"> </td></tr> <tr id="xdx_40E_eus-gaap--RevenueFromContractWithCustomerExcludingAssessedTax_hsrt--ProductOrServiceAxis__custom--DirectSalesMedicalCareProvidersGrossMember_zuOG96LNkmm9" style="vertical-align: bottom; background-color: White"> <td style="text-align: left; padding-bottom: 1.5pt">Direct sales- medical care providers, gross</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0931">-</span></td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">650</td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">6,220</td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">2,932</td><td style="padding-bottom: 1.5pt; text-align: left"> </td></tr> <tr id="xdx_406_eus-gaap--RevenueFromContractWithCustomerExcludingAssessedTax_zJcfSjnIk7Lb" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left">Total sources of revenue</td><td> </td> <td style="text-align: left">$</td><td style="text-align: right">45,200</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left">$</td><td style="text-align: right">650</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left">$</td><td style="text-align: right">132,740</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left">$</td><td style="text-align: right">2,932</td><td style="text-align: left"> </td></tr> </table> <p id="xdx_8A0_zyUfpJYvfuo2" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The royalty/licensing revenue recognized in the six months ended June 30, 2023, resulted from specific transactions. No general patent rights were assigned to the distributor. The royalty / licensing revenue is recorded on a net basis as the Company was not considered the principal but an agent for accounting purposes. The royalty / licensing revenue, net includes an ongoing contract with a customer that has a total gross sales value of $<span id="xdx_90F_ecustom--GrossSaleValueOfOngoingContract_c20230101__20230630__srt--ProductOrServiceAxis__custom--RoyaltyAndLicensingNetMember_z55KNbv9LAi1">300,000</span></span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">, for which the Company recognized net revenue of $<span id="xdx_907_eus-gaap--ContractWithCustomerLiabilityRevenueRecognized_c20230101__20230630__srt--ProductOrServiceAxis__custom--RoyaltyAndLicensingNetMember_zvaNMjv0vKT5">126,520 </span></span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">based on <span id="xdx_90E_eus-gaap--NumberOfReportingUnits_uInteger_c20230101__20230630__srt--ProductOrServiceAxis__custom--RoyaltyAndLicensingNetMember_ze55RvrqUuc7">1,000 </span></span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">units delivered during the period ended June 30, 2023. </span>The royalty/licensing revenue is recognized when Pulse Therapeutic Technology picks up the units from the Company’s vendor.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0">On January 25, 2023, the Company entered into a sales support services agreement with Pulse Therapeutic Technology (“PTT”), an entity controlled by a former related party, under which PTT has been selling Sofpulse® on a nonexclusive basis. Pursuant to such agreement, the deferred compensation owed to this former related party has been fully extinguished for a total amount of approximately $<span id="xdx_901_eus-gaap--DeferredCompensationLiabilityCurrent_iI_c20230125__us-gaap--TypeOfArrangementAxis__custom--SalesSupportServiceAgreementMember__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--PulseTherapeuticTechnologyMember_zja2pI9tgvy7" title="Deferred compensation">118,000</span>.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Warranty</i></b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.25in; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.25in; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our general product warranties do not extend beyond an assurance that the product delivered will be consistent with stated specifications and do not include separate performance obligations.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.25in; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Significant Judgments in the Application of the Guidance in ASC 606</i></b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.25in; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.25in; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">There are no significant judgments associated with the satisfaction of our performance obligations. We generally satisfy performance obligations upon shipment of the product to the customer. This is consistent with the time in which the customer obtains control of the products. Performance obligations are also generally settled quickly after the purchase order acceptance, therefore the value of unsatisfied performance obligations at the end of any reporting period is generally immaterial.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.25in; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.25in; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We consider variable consideration in establishing the transaction price. Forms of variable consideration applicable to our arrangements include sales returns, rebates, volume-based bonuses, and prompt pay discounts. We use historical information along with an analysis of the expected value to properly calculate and to consider the need to constrain estimates of variable consideration. Such amounts are included as a reduction to revenue from the sale of products in the periods in which the related revenue is recognized and adjusted in future periods as necessary.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.25in; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Practical Expedients</i></b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.25in; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our payment terms for sales direct to distributors are substantially less than the one-year collection period that falls within the practical expedient in determination of whether a significant financing component exists.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.25in; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b> </b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Endonovo Therapeutics, Inc.</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Notes to Condensed Consolidated Financial Statements (continued)</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p id="xdx_898_ecustom--ScheduleOfSourceOfRevenueTableTextBlock_z3okIlu50nJj" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">For the three and six months ended June 30, 2023 and 2022, the sources of revenue were as follows:</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span><span id="xdx_8B4_z2iicV0ywwzf" style="display: none">Schedule of Source of Revenue</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"> <tr style="display: none; vertical-align: bottom"> <td style="text-align: center"> </td><td style="padding-bottom: 1.5pt"> </td> <td colspan="2" id="xdx_49B_20230401__20230630_zHTkGtqyGbO4" style="border-bottom: Black 1.5pt solid; text-align: center">2023</td><td style="padding-bottom: 1.5pt"> </td><td style="padding-bottom: 1.5pt"> </td> <td colspan="2" id="xdx_493_20220401__20220630_zVoBEgR6z2te" style="border-bottom: Black 1.5pt solid; text-align: center">2022</td><td style="padding-bottom: 1.5pt"> </td><td style="padding-bottom: 1.5pt"> </td> <td colspan="2" id="xdx_498_20230101__20230630_zRCnbOWSFnq5" style="border-bottom: Black 1.5pt solid; text-align: center">2023</td><td style="padding-bottom: 1.5pt"> </td><td style="padding-bottom: 1.5pt"> </td> <td colspan="2" id="xdx_493_20220101__20220630_ztU9hOcI2pX1" style="border-bottom: Black 1.5pt solid; text-align: center">2022</td><td style="padding-bottom: 1.5pt"> </td></tr> <tr style="vertical-align: bottom"> <td style="text-align: center"> </td><td style="padding-bottom: 1.5pt"> </td> <td colspan="6" style="border-bottom: Black 1.5pt solid; text-align: center">Three Months Ended June 30,</td><td style="padding-bottom: 1.5pt"> </td><td style="padding-bottom: 1.5pt"> </td> <td colspan="6" style="border-bottom: Black 1.5pt solid; text-align: center">Six Months Ended June 30,</td><td style="padding-bottom: 1.5pt"> </td></tr> <tr style="vertical-align: bottom"> <td style="text-align: center"> </td><td style="padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center">2023</td><td style="padding-bottom: 1.5pt"> </td><td style="padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center">2022</td><td style="padding-bottom: 1.5pt"> </td><td style="padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center">2023</td><td style="padding-bottom: 1.5pt"> </td><td style="padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center">2022</td><td style="padding-bottom: 1.5pt"> </td></tr> <tr style="vertical-align: bottom"> <td> </td><td> </td> <td colspan="2"> </td><td> </td><td> </td> <td colspan="2"> </td><td> </td><td> </td> <td colspan="2"> </td><td> </td><td> </td> <td colspan="2"> </td><td> </td></tr> <tr id="xdx_402_eus-gaap--RevenueFromContractWithCustomerExcludingAssessedTax_hsrt--ProductOrServiceAxis__custom--RoyaltyAndLicensingNetMember_zsEIIQvQQiSh" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 40%; text-align: left">Royalty/licensing, net</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 11%; text-align: right">45,200</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 11%; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0927">-</span></td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 11%; text-align: right">126,520</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 11%; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0929">-</span></td><td style="width: 1%; text-align: left"> </td></tr> <tr id="xdx_40E_eus-gaap--RevenueFromContractWithCustomerExcludingAssessedTax_hsrt--ProductOrServiceAxis__custom--DirectSalesMedicalCareProvidersGrossMember_zuOG96LNkmm9" style="vertical-align: bottom; background-color: White"> <td style="text-align: left; padding-bottom: 1.5pt">Direct sales- medical care providers, gross</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0931">-</span></td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">650</td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">6,220</td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">2,932</td><td style="padding-bottom: 1.5pt; text-align: left"> </td></tr> <tr id="xdx_406_eus-gaap--RevenueFromContractWithCustomerExcludingAssessedTax_zJcfSjnIk7Lb" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left">Total sources of revenue</td><td> </td> <td style="text-align: left">$</td><td style="text-align: right">45,200</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left">$</td><td style="text-align: right">650</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left">$</td><td style="text-align: right">132,740</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left">$</td><td style="text-align: right">2,932</td><td style="text-align: left"> </td></tr> </table> 45200 126520 650 6220 2932 45200 650 132740 2932 300000 126520 1000 118000 <p id="xdx_80C_eus-gaap--IntangibleAssetsDisclosureTextBlock_zqnjmi8vtbdg" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Note 4 – <span id="xdx_822_zpWWIA7pIwdi">Patents</span>.</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In December 2017, we acquired from Rio Grande Neurosciences, Inc. (RGN) a patent portfolio for $<span id="xdx_90D_eus-gaap--PaymentsToAcquireIntangibleAssets_c20171201__20171231__dei--LegalEntityAxis__custom--RioGrandeNeurosciencesIncMember_zE3RjjhkfmJg" title="Acquisition of patents">4,500,000</span>. The earliest patents expire in <span id="xdx_900_ecustom--PatentsExpirationPeriod_c20171201__20171231__dei--LegalEntityAxis__custom--RioGrandeNeurosciencesIncMember_zIGf32PcWxAj" title="Patents expiration period">2024</span>. The following is a summary of patents less accumulated amortization at June 30, 2023 and December 31, 2022:</span></p> <p id="xdx_89F_eus-gaap--ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock_zANA7nPil6Nl" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0pt; margin-bottom: 0pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span><span id="xdx_8B6_z7XJcB1OIsW7" style="display: none">Schedule of Patents</span></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-left: auto; border-collapse: collapse; width: 80%; margin-right: auto"> <tr style="vertical-align: bottom"> <td> </td><td style="padding-bottom: 1.5pt"> </td> <td colspan="2" id="xdx_495_20230630_zFeNy3IPlPxg" style="border-bottom: Black 1.5pt solid; text-align: center">June 30, 2023</td><td style="padding-bottom: 1.5pt"> </td><td style="padding-bottom: 1.5pt"> </td> <td colspan="2" id="xdx_499_20221231_z6THVQMhkWqi" style="border-bottom: Black 1.5pt solid; text-align: center">December 31, 2022</td><td style="padding-bottom: 1.5pt"> </td></tr> <tr style="vertical-align: bottom"> <td> </td><td> </td> <td colspan="2"> </td><td> </td><td> </td> <td colspan="2"> </td><td> </td></tr> <tr id="xdx_40A_eus-gaap--FiniteLivedPatentsGross_iI_maFLIANzX8N_zdAEpKEJAQ06" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 56%">Patents</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 18%; text-align: right">4,500,000</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 18%; text-align: right">4,500,000</td><td style="width: 1%; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr id="xdx_407_eus-gaap--FiniteLivedIntangibleAssetsAccumulatedAmortization_iI_msFLIANzX8N_ztcwWZ5XV7xd" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left; padding-bottom: 1.5pt">Less accumulated amortization</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">3,558,012</td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">3,234,556</td><td style="padding-bottom: 1.5pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr id="xdx_408_eus-gaap--FiniteLivedIntangibleAssetsNet_iTI_mtFLIANzX8N_zrVnEX5uJXNa" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left; padding-bottom: 1.5pt">Patents, net</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left">$</td><td style="border-bottom: Black 1.5pt solid; text-align: right">941,988</td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left">$</td><td style="border-bottom: Black 1.5pt solid; text-align: right">1,265,444</td><td style="padding-bottom: 1.5pt; text-align: left"> </td></tr> </table> <p id="xdx_8A5_zGt7RIm8B3s2" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0pt; margin-bottom: 0pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Amortization expense associated with patents was $<span id="xdx_906_eus-gaap--AmortizationOfIntangibleAssets_c20230101__20230630_zJyO0GY7pjC6" title="Amortization expense"><span id="xdx_90F_eus-gaap--AmortizationOfIntangibleAssets_c20220101__20220630_zMvTJwazd9vd" title="Amortization expense">323,456</span></span> for the six months ended June 30, 2023 and 2022.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0pt; margin-bottom: 0pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p id="xdx_899_eus-gaap--FiniteLivedIntangibleAssetsAmortizationExpenseTableTextBlock_zDApKrI7ZKo7" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The estimated future amortization expense related to patents as of June 30, 2023, is as follows:</span></p> <p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-right: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span><span id="xdx_8B5_zpdonXls8md" style="display: none">Schedule of Estimated Future Amortization Expense</span></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-left: auto; border-collapse: collapse; width: 80%; margin-right: auto"> <tr style="vertical-align: bottom"> <td style="border-bottom: Black 1.5pt solid; text-align: left">Twelve Months Ending June 30,</td><td style="padding-bottom: 1.5pt"> </td> <td colspan="2" id="xdx_49B_20230630_zpEHb2hskk6h" style="border-bottom: Black 1.5pt solid; text-align: center">Amount</td><td style="padding-bottom: 1.5pt"> </td></tr> <tr style="vertical-align: bottom"> <td style="text-align: left"> </td><td> </td> <td colspan="2"> </td><td> </td></tr> <tr id="xdx_403_eus-gaap--FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths_iI_maFLIANzbYA_z33FLv9DtC1d" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 80%; text-align: left">2024</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 16%; text-align: right">646,910</td><td style="width: 1%; text-align: left"> </td></tr> <tr id="xdx_405_eus-gaap--FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo_iI_maFLIANzbYA_z8RNGyFXBz68" style="vertical-align: bottom; background-color: White"> <td style="text-align: left; padding-bottom: 1.5pt">2025</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">295,078</td><td style="padding-bottom: 1.5pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr id="xdx_402_eus-gaap--FiniteLivedIntangibleAssetsNet_iTI_mtFLIANzbYA_zyOsYFvmPs39" style="vertical-align: bottom; background-color: White"> <td style="text-align: left; padding-bottom: 2.5pt">Total</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">941,988</td><td style="padding-bottom: 2.5pt; text-align: left"> </td></tr> </table> <p id="xdx_8A5_zQxSIgtRzYnc" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> 4500000 2024 <p id="xdx_89F_eus-gaap--ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock_zANA7nPil6Nl" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0pt; margin-bottom: 0pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span><span id="xdx_8B6_z7XJcB1OIsW7" style="display: none">Schedule of Patents</span></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-left: auto; border-collapse: collapse; width: 80%; margin-right: auto"> <tr style="vertical-align: bottom"> <td> </td><td style="padding-bottom: 1.5pt"> </td> <td colspan="2" id="xdx_495_20230630_zFeNy3IPlPxg" style="border-bottom: Black 1.5pt solid; text-align: center">June 30, 2023</td><td style="padding-bottom: 1.5pt"> </td><td style="padding-bottom: 1.5pt"> </td> <td colspan="2" id="xdx_499_20221231_z6THVQMhkWqi" style="border-bottom: Black 1.5pt solid; text-align: center">December 31, 2022</td><td style="padding-bottom: 1.5pt"> </td></tr> <tr style="vertical-align: bottom"> <td> </td><td> </td> <td colspan="2"> </td><td> </td><td> </td> <td colspan="2"> </td><td> </td></tr> <tr id="xdx_40A_eus-gaap--FiniteLivedPatentsGross_iI_maFLIANzX8N_zdAEpKEJAQ06" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 56%">Patents</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 18%; text-align: right">4,500,000</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 18%; text-align: right">4,500,000</td><td style="width: 1%; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr id="xdx_407_eus-gaap--FiniteLivedIntangibleAssetsAccumulatedAmortization_iI_msFLIANzX8N_ztcwWZ5XV7xd" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left; padding-bottom: 1.5pt">Less accumulated amortization</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">3,558,012</td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">3,234,556</td><td style="padding-bottom: 1.5pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr id="xdx_408_eus-gaap--FiniteLivedIntangibleAssetsNet_iTI_mtFLIANzX8N_zrVnEX5uJXNa" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left; padding-bottom: 1.5pt">Patents, net</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left">$</td><td style="border-bottom: Black 1.5pt solid; text-align: right">941,988</td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left">$</td><td style="border-bottom: Black 1.5pt solid; text-align: right">1,265,444</td><td style="padding-bottom: 1.5pt; text-align: left"> </td></tr> </table> 4500000 4500000 3558012 3234556 941988 1265444 323456 323456 <p id="xdx_899_eus-gaap--FiniteLivedIntangibleAssetsAmortizationExpenseTableTextBlock_zDApKrI7ZKo7" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The estimated future amortization expense related to patents as of June 30, 2023, is as follows:</span></p> <p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-right: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span><span id="xdx_8B5_zpdonXls8md" style="display: none">Schedule of Estimated Future Amortization Expense</span></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-left: auto; border-collapse: collapse; width: 80%; margin-right: auto"> <tr style="vertical-align: bottom"> <td style="border-bottom: Black 1.5pt solid; text-align: left">Twelve Months Ending June 30,</td><td style="padding-bottom: 1.5pt"> </td> <td colspan="2" id="xdx_49B_20230630_zpEHb2hskk6h" style="border-bottom: Black 1.5pt solid; text-align: center">Amount</td><td style="padding-bottom: 1.5pt"> </td></tr> <tr style="vertical-align: bottom"> <td style="text-align: left"> </td><td> </td> <td colspan="2"> </td><td> </td></tr> <tr id="xdx_403_eus-gaap--FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths_iI_maFLIANzbYA_z33FLv9DtC1d" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 80%; text-align: left">2024</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 16%; text-align: right">646,910</td><td style="width: 1%; text-align: left"> </td></tr> <tr id="xdx_405_eus-gaap--FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo_iI_maFLIANzbYA_z8RNGyFXBz68" style="vertical-align: bottom; background-color: White"> <td style="text-align: left; padding-bottom: 1.5pt">2025</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">295,078</td><td style="padding-bottom: 1.5pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr id="xdx_402_eus-gaap--FiniteLivedIntangibleAssetsNet_iTI_mtFLIANzbYA_zyOsYFvmPs39" style="vertical-align: bottom; background-color: White"> <td style="text-align: left; padding-bottom: 2.5pt">Total</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">941,988</td><td style="padding-bottom: 2.5pt; text-align: left"> </td></tr> </table> 646910 295078 941988 <p id="xdx_80D_eus-gaap--DebtDisclosureTextBlock_zfpP1SlcTTI2" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Note 5- <span id="xdx_825_zLco4BIjTrl3">Notes Payable</span></b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p id="xdx_892_eus-gaap--ScheduleOfDebtTableTextBlock_zPzhMAxBDlb2" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">As of June 30, 2023, and December 31, 2022, the notes payable activity was as follows:</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0pt; margin-bottom: 0pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span><span id="xdx_8B9_zXT6QmjRwck6" style="display: none">Schedule of Notes Payable</span></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-left: auto; border-collapse: collapse; width: 80%; margin-right: auto"> <tr style="vertical-align: bottom"> <td> </td><td style="padding-bottom: 1.5pt"> </td> <td colspan="2" id="xdx_490_20230101__20230630_zYAv4qMpJFTj" style="border-bottom: Black 1.5pt solid; text-align: center">June 30, 2023</td><td style="padding-bottom: 1.5pt"> </td><td style="padding-bottom: 1.5pt"> </td> <td colspan="2" id="xdx_492_20220101__20221231_zW0cJj3q6bUk" style="border-bottom: Black 1.5pt solid; text-align: center">December 31, 2022</td><td style="padding-bottom: 1.5pt"> </td></tr> <tr style="vertical-align: bottom"> <td> </td><td> </td> <td colspan="2"> </td><td> </td><td> </td> <td colspan="2"> </td><td> </td></tr> <tr id="xdx_404_eus-gaap--NotesPayable_iS_pp0p0_zeJXVsP4y1Zh" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 56%; text-align: left">Notes payable at beginning of period</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 18%; text-align: right">7,163,832</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 18%; text-align: right">7,256,930</td><td style="width: 1%; text-align: left"> </td></tr> <tr id="xdx_40D_ecustom--NotesPayableIssued_i_pp0p0" style="vertical-align: bottom; background-color: White"> <td style="text-align: left">Notes payable issued</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">150,000</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">465,000</td><td style="text-align: left"> </td></tr> <tr id="xdx_40B_eus-gaap--RepaymentsOfNotesPayable_iN_pp0p0_di_z5hpOswWRz2k" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left">Repayments of notes payable in cash</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">(27,500</td><td style="text-align: left">)</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">(14,000</td><td style="text-align: left">)</td></tr> <tr id="xdx_401_ecustom--SettlementsOnNotePayable_i_pp0p0" style="vertical-align: bottom; background-color: White"> <td style="text-align: left">Settlement on note payable</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">(133,650</td><td style="text-align: left">)</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">(163,826</td><td style="text-align: left">)</td></tr> <tr id="xdx_40C_eus-gaap--ConversionOfStockAmountConverted1_iN_pp0p0_di_zL0zKkppm3v7" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left; padding-bottom: 1.5pt">Less amounts converted to stock</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">(100,000</td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">(380,272</td><td style="padding-bottom: 1.5pt; text-align: left">)</td></tr> <tr id="xdx_40D_eus-gaap--NotesPayable_iE_pp0p0_zd94nmZ4KoJa" style="vertical-align: bottom; background-color: White"> <td style="text-align: left">Notes payable at end of period</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">7,052,682</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">7,163,832</td><td style="text-align: left"> </td></tr> <tr id="xdx_40F_eus-gaap--DebtInstrumentUnamortizedDiscount_iNE_pp0p0_di_zowhpfDFtnEi" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left; padding-bottom: 1.5pt">Less debt discount</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">(25,585</td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">(10,587</td><td style="padding-bottom: 1.5pt; text-align: left">)</td></tr> <tr id="xdx_403_eus-gaap--NotesAndLoansPayable_iE_pp0p0_zihjLrhtjlu5" style="vertical-align: bottom; background-color: White"> <td style="padding-bottom: 2.5pt"><span style="display: none; font-family: Times New Roman, Times, Serif; font-size: 10pt">Note payable, net</span></td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">7,027,097</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">7,153,245</td><td style="padding-bottom: 2.5pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left; padding-bottom: 2.5pt">Notes payable issued to a former related party</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_981_eus-gaap--NotesPayableCurrent_iI_c20230630__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--FormerRelatedPartyMember_z9utrYIU13x8" style="border-bottom: Black 2.5pt double; text-align: right" title="Notes payable">104,600</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_983_eus-gaap--NotesPayableCurrent_iI_c20221231__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--FormerRelatedPartyMember_zIXZp95BM1F9" style="border-bottom: Black 2.5pt double; text-align: right" title="Notes payable">112,100</td><td style="padding-bottom: 2.5pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left; padding-bottom: 2.5pt">Notes payable issued to non-related parties</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_984_eus-gaap--NotesPayableCurrent_iI_c20230630__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__us-gaap--NonrelatedPartyMember_z6hvY5qFPhS9" style="border-bottom: Black 2.5pt double; text-align: right" title="Notes payable">6,922,497</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_982_eus-gaap--NotesPayableCurrent_iI_c20221231__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__us-gaap--NonrelatedPartyMember_zvnqXjgKMto" style="border-bottom: Black 2.5pt double; text-align: right" title="Notes payable">7,041,145</td><td style="padding-bottom: 2.5pt; text-align: left"> </td></tr> </table> <p id="xdx_8A5_zzmyur5LVRp8" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0pt; margin-bottom: 0pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p id="xdx_89F_eus-gaap--ScheduleOfMaturitiesOfLongTermDebtTableTextBlock_z1uWcxmF0wzj" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The maturity dates on the notes-payable are as follows:</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span><span id="xdx_8B9_zV5oeq1Omto7" style="display: none">Schedule of Maturity Dates of Notes Payable</span></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-left: auto; border-collapse: collapse; width: 80%; margin-right: auto"> <tr style="vertical-align: bottom"> <td> </td><td style="padding-bottom: 1.5pt"> </td> <td colspan="6" style="border-bottom: Black 1.5pt solid; text-align: center">Notes to</td><td style="padding-bottom: 1.5pt"> </td><td style="padding-bottom: 1.5pt"> </td> <td colspan="2"> </td><td style="padding-bottom: 1.5pt"> </td></tr> <tr style="vertical-align: bottom"> <td style="border-bottom: Black 1.5pt solid">12 months ending,</td><td style="padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center"><p style="margin-top: 0; margin-bottom: 0">Former</p> <p style="margin-top: 0; margin-bottom: 0">related party</p></td><td style="padding-bottom: 1.5pt"> </td><td style="padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center"><p style="margin-top: 0; margin-bottom: 0">Non-related</p> <p style="margin-top: 0; margin-bottom: 0">parties</p></td><td style="padding-bottom: 1.5pt"> </td><td style="padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center">Total</td><td style="padding-bottom: 1.5pt"> </td></tr> <tr style="vertical-align: bottom"> <td> </td><td> </td> <td colspan="2" style="text-align: right"> </td><td> </td><td> </td> <td colspan="2" style="text-align: right"> </td><td> </td><td> </td> <td colspan="2" style="text-align: right"> </td><td> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 46%; text-align: left">Past due</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td id="xdx_986_ecustom--LongTermDebtPastMaturity_iI_c20230630__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--FormerRelatedPartyMember_zhEgfMbLKeff" style="width: 14%; text-align: right" title="Past due">104,600</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td id="xdx_982_ecustom--LongTermDebtPastMaturity_iI_c20230630__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__us-gaap--NonrelatedPartyMember_zm3U6B8SucG8" style="width: 14%; text-align: right" title="Past due">6,733,082</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td id="xdx_989_ecustom--LongTermDebtPastMaturity_iI_c20230630_zMJET5iml1e3" style="width: 14%; text-align: right" title="Past due">6,837,682</td><td style="width: 1%; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="padding-bottom: 1.5pt">June 30, 2024</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td id="xdx_982_eus-gaap--LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths_iI_c20230630__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--FormerRelatedPartyMember_zA11uIPVJpX8" style="border-bottom: Black 1.5pt solid; text-align: right" title="June 30, 2024"><span style="-sec-ix-hidden: xdx2ixbrl1019">-</span></td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td id="xdx_98D_eus-gaap--LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths_iI_c20230630__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__us-gaap--NonrelatedPartyMember_zfbYW3CiGoVf" style="border-bottom: Black 1.5pt solid; text-align: right" title="June 30, 2024">215,000</td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td id="xdx_988_eus-gaap--LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths_iI_c20230630_zuQeOa1KuGo4" style="border-bottom: Black 1.5pt solid; text-align: right" title="June 30, 2024">215,000</td><td style="padding-bottom: 1.5pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-bottom: 2.5pt"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_983_eus-gaap--LongTermDebt_iI_c20230630__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--FormerRelatedPartyMember_zcUdb4YrcNee" style="border-bottom: Black 2.5pt double; text-align: right" title="Total">104,600</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_98C_eus-gaap--LongTermDebt_iI_c20230630__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__us-gaap--NonrelatedPartyMember_z0x1dHsGm5Jj" style="border-bottom: Black 2.5pt double; text-align: right" title="Total">6,948,082</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_984_eus-gaap--LongTermDebt_iI_c20230630_zrrKSKvh22S6" style="border-bottom: Black 2.5pt double; text-align: right" title="Total">7,052,682</td><td style="padding-bottom: 2.5pt; text-align: left"> </td></tr> </table> <p id="xdx_8A6_z3ynXyipoHdk" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Activity for the six months ended June 30, 2023</i></b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Fixed rate notes</i></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">During the six months ended June 30, 2023, the Company converted $<span id="xdx_902_eus-gaap--DebtConversionOriginalDebtAmount1_c20230101__20230630_zbG2TPUEWkv3" title="Debt conversion, stock issued value">100,000</span> in principal and $<span id="xdx_903_eus-gaap--DebtInstrumentIncreaseAccruedInterest_c20230101__20230630_zX7xQcvwu9z1" title="Debt instrument, accrued interest">9,000</span> in accrued interest into <span id="xdx_90A_eus-gaap--DebtConversionConvertedInstrumentSharesIssued1_c20230101__20230630_ziejYk8jMpLa" title="Debt conversion, stock issued shares">10,900,000</span> shares of common stock.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">During the six months ended June 30, 2023, the Company executed a second amendment to a fixed rate note to extend the maturity date in exchange for $<span id="xdx_907_eus-gaap--RepaymentsOfConvertibleDebt_pp0p0_c20230101__20230630_zCzUD5mSDc54" title="Repayments of convertible debt in cash">20,000</span> payment to the current balance of the note as of June 30, 2023, and $<span id="xdx_904_ecustom--ExtensionFeePayable_c20230101__20230630_znjPl31fcdS4" title="Extension fee payable">2,500</span> in extension fee payable at the revised maturity date.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">During the six months ended June 30, 2023, the Company issued three fixed-rate notes for an aggregate amount of $<span id="xdx_90F_ecustom--NotesPayableIssued_c20230101__20230630_zv8L5JE9TDmh" title="Note payable issued">150,000</span>, which carry interest between <span id="xdx_90F_eus-gaap--DebtInstrumentInterestRateStatedPercentage_iI_pid_dp_uPure_c20230630__srt--RangeAxis__srt--MinimumMember_zSBKzDBcrVQb" title="Debt instrument, interest rate">10</span>% and <span id="xdx_902_eus-gaap--DebtInstrumentInterestRateStatedPercentage_iI_pid_dp_uPure_c20230630__srt--RangeAxis__srt--MaximumMember_z9Jbf36eg6q5" title="Debt instrument, interest rate">15</span>% and with maturity ranging between one to nine (<span id="xdx_90A_eus-gaap--DebtInstrumentTerm_dtM_c20230101__20230630__srt--RangeAxis__srt--MinimumMember_zqcerHiGIt6c" title="Maturity term">1</span> to <span id="xdx_90B_eus-gaap--DebtInstrumentTerm_dtM_c20230101__20230630__srt--RangeAxis__srt--MaximumMember_zv3noVlf6ZV5" title="Maturity term">9</span>) months from issuance.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b> </b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Endonovo Therapeutics, Inc.</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Notes to Condensed Consolidated Financial Statements (continued)</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">As of June 30, 2023, the Company has a total of twenty-two (22) fixed-rate notes, of which sixteen (16) have a make good provision for a total principal of $<span id="xdx_90D_eus-gaap--DebtInstrumentFaceAmount_iI_c20230630_ziWXIWD7oEj9" title="Principal amount">1,395,000</span> and $<span id="xdx_905_eus-gaap--InterestPayableCurrentAndNoncurrent_iI_c20230630_zGaThxaKxTVj" title="Accrued interest">338,403</span> in accrued interest. Balance of fixed-rate notes was $<span id="xdx_901_eus-gaap--NotesPayable_iI_c20230630__us-gaap--DebtInstrumentAxis__custom--FixedRateNotesMember_zxqTxAOHakJ5" title="Notes payable">1,849,728</span> and $<span id="xdx_905_eus-gaap--NotesPayable_iI_c20221231__us-gaap--DebtInstrumentAxis__custom--FixedRateNotesMember_z3gkCtKH3ajl" title="Notes payable">1,819,728</span> as of June 30, 2023, and December 31, 2022, respectively. Accrued interest on fixed-rate notes was approximately $<span id="xdx_90D_eus-gaap--InterestPayableCurrent_iI_c20230630__us-gaap--DebtInstrumentAxis__custom--FixedRateNotesMember_zTOPWo1viZn8" title="Accrued interest">429,500</span> and $<span id="xdx_902_eus-gaap--InterestPayableCurrent_iI_c20221231__us-gaap--DebtInstrumentAxis__custom--FixedRateNotesMember_zUqXJg6K0Qfh" title="Accrued interest">310,960</span> as of June 30, 2023, and December 31, 2023, respectively.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Such provision will require <span id="xdx_902_eus-gaap--DebtInstrumentDescription_c20230101__20230630_zjPVfUiCeco3" title="Debt instrument description">the Company to issue additional shares to ensure that the investor can realize a profit of 15% or 18% reselling the conversion shares</span>. The value of the make good provision was approximately $<span id="xdx_908_ecustom--GoodProvisionValue_iI_c20230630_zRUbGitzHcN9" title="Value of good provision">250,000</span> as of June 30, 2023 and is reported under Accounts payable and accrued liabilities in the condensed consolidated balance sheet as of June 30, 2023. In addition, <span id="xdx_902_ecustom--CertainFixedPercentageOfCashPremium_c20230101__20230630_z4UsHQAddMG2" title="Percentage of cash premium">certain fixed-rate notes include a prepayment provision, which entitles the holder to a 15% cash premium</span>. The Company concluded that such provision was not deemed material and probable as of June 30, 2023.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Variable-rate notes</i></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">During the six months ended June 30, 2023, the Company executed a settlement agreement with one investor to extinguish the remaining principal balance of a promissory note into <span id="xdx_900_eus-gaap--DebtConversionConvertedInstrumentSharesIssued1_c20230101__20230630__us-gaap--DebtInstrumentAxis__custom--VariableRateNotesMember_zkGgWzPeJ628" title="Debt conversion, stock issued shares">4,300,590</span> shares of common stock, which resulted in a gain from debt extinguishment of approximately $<span id="xdx_907_eus-gaap--GainsLossesOnExtinguishmentOfDebt_c20230101__20230630__us-gaap--DebtInstrumentAxis__custom--VariableRateNotesMember_zjKgTWdpbBL6" title="Gain on debt extinguishment">77,000</span>.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Fixed Rate note (former related party)</i></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Notes payable to a former related party in the aggregate amount of $<span id="xdx_902_eus-gaap--NotesPayableCurrent_iI_c20230630__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--FormerRelatedPartyMember_zp0EkC5k2081" title="Note payable">104,600</span> were outstanding at June 30, 2023, which are past maturity date. The notes bear interest between <span id="xdx_908_eus-gaap--DebtInstrumentInterestRateStatedPercentage_iI_pid_dp_uPure_c20230630__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--FormerRelatedPartyMember__srt--RangeAxis__srt--MinimumMember_z1hdr8A7AGod" title="Debt instrument, interest rate">10</span>% and <span id="xdx_90F_eus-gaap--DebtInstrumentInterestRateStatedPercentage_iI_pid_dp_uPure_c20230630__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--FormerRelatedPartyMember__srt--RangeAxis__srt--MaximumMember_z9of66Xzv9qi" title="Debt instrument, interest rate">12</span>% per annum. During the six months ended June 30, 2023, the Company repaid $<span id="xdx_908_eus-gaap--RepaymentsOfDebt_c20230101__20230630__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--FormerRelatedPartyMember_zRslcwCaXB3j" title="Principal payment of debt">7,500</span> in principal amount to this former related party. Refer to Note 7- Related Party Transactions.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Activity for the six months ended June 30, 2022</i></b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Fixed rates Notes</i></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">During the six months ended June 30, 2022, the Company issued three (3) fixed rate promissory notes totaling $<span id="xdx_90E_eus-gaap--OtherNotesPayable_iI_c20220630__us-gaap--DebtInstrumentAxis__custom--ThreeFixedRatedNotesMember_zaNdshjwnk3d" title="Promissory notes">250,000</span> for funding of $<span id="xdx_908_eus-gaap--ProceedsFromNotesPayable_c20220101__20220630__us-gaap--DebtInstrumentAxis__custom--ThreeFixedRatedNotesMember_zRxLmFl0N2t7" title="Proceeds from notes payable">250,000</span> with original terms of nine months and interest rates of <span id="xdx_90F_eus-gaap--DebtInstrumentInterestRateStatedPercentage_iI_pid_dp_uPure_c20220630__us-gaap--DebtInstrumentAxis__custom--ThreeFixedRatedNotesMember_zXyfbPx8tGAd" title="Debt instrument, interest rate">15</span>%. The holder of the promissory note can convert the outstanding unpaid principal and accrued interest at a fixed conversion rate, subject to standard anti-dilution features, six months after issuance date.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">As of June 30, 2022, the Company has sixteen (16) fixed-rate promissory notes with an outstanding balance of $<span id="xdx_90E_eus-gaap--NotesPayable_iI_c20220630__us-gaap--DebtInstrumentAxis__custom--SixteenFixedRatedNotesMember_zBIjZuscnhwb" title="Notes payable">1,891,204</span>, of which $<span id="xdx_907_eus-gaap--NotesPayable_iI_c20220630__srt--StatementScenarioAxis__custom--PastMaturityMember__us-gaap--DebtInstrumentAxis__custom--SixteenFixedRatedNotesMember_z7wxBDx83QId" title="Notes payable">1,116,204</span> are past maturity.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In October 2013, July 2014, October 2014 and August 2015, the Company initiated a series of private placements for up to $<span id="xdx_90F_eus-gaap--DebtInstrumentFaceAmount_iI_pp0p0_c20150831__us-gaap--SubsidiarySaleOfStockAxis__us-gaap--PrivatePlacementMember_zApcJdsLx3rl" title="Debt instrument face amount">500,000</span>, each, of financing by the issuance of notes payable at a minimum of $<span id="xdx_902_eus-gaap--ProceedsFromNotesPayable_pp0p0_c20150801__20150831__us-gaap--SubsidiarySaleOfStockAxis__us-gaap--PrivatePlacementMember_zP2lBCaNqSLc" title="Proceeds from issuance of note payable">25,000</span>, one unit. The notes bear interest at <span id="xdx_901_eus-gaap--DebtInstrumentInterestRateStatedPercentage_iI_pid_dp_uPure_c20150831__us-gaap--SubsidiarySaleOfStockAxis__us-gaap--PrivatePlacementMember_z7O2UszYjKUl" title="Debt instrument, interest rate">10</span>% per annum and were due and payable with accrued interest one year from issuance. During the six months ended June 30, 2022, the Company did not issue notes in connection with these private placements and did not repay any of these notes. As of June 30, 2022, and December 31, 2021, notes payable outstanding under these private placements are $<span id="xdx_907_eus-gaap--NotesPayableCurrent_iI_c20220630__us-gaap--SubsidiarySaleOfStockAxis__us-gaap--PrivatePlacementMember_zq03ABEmJAuf" title="Note payable outstanding"><span id="xdx_903_eus-gaap--NotesPayableCurrent_iI_c20211231__us-gaap--SubsidiarySaleOfStockAxis__us-gaap--PrivatePlacementMember_zA2mD2jVoETj" title="Note payable outstanding">624,903</span></span>, all of which are past maturity.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">During the six months ended June 30, 2022, the Company converted $<span id="xdx_90A_eus-gaap--InterestPayableCurrentAndNoncurrent_iI_pp0p0_c20220630_zJNxIxtsLRW" title="Accrued interest">110,204</span> in accrued interest and $<span id="xdx_90B_eus-gaap--DebtConversionOriginalDebtAmount1_pp0p0_c20220101__20220630_z6d743d8Pcal" title="Debt conversion, stock issued value">93,796</span> in principal balance into <span id="xdx_90B_eus-gaap--DebtConversionConvertedInstrumentSharesIssued1_c20220101__20220630_zBl66Yb29Dxf" title="Debt conversion, stock issued shares">10,200,000</span> shares of common stock.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">As of June 30, 2022, the Company has a total of sixteen (16) fixed-rate notes, of which twelve (12) for total principal amount of $<span id="xdx_90C_eus-gaap--DebtInstrumentFaceAmount_iI_c20220630_z0oYcWQ25yDc" title="Principal amount">1,250,000</span> includes a make good shares provision. <span id="xdx_901_eus-gaap--DebtInstrumentInterestRateTerms_c20220101__20220630_ziKb3z7kX7mk" title="Debt instrument description">Such provision will require the Company to issue additional shares to ensure that the investor can realize a profit of 15% reselling the conversion shares</span>. The Company accrued $<span id="xdx_904_ecustom--GoodProvisionValue_iI_c20220630_zBiSMI70obhf" title="Value of good provision">178,000</span> related to the make-good provision as the amount is probable and can be reasonably estimated pursuant to ASC 450 Contingencies. Such amount was presented as other expense in the condensed consolidated statement of operations.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_904_ecustom--CertainFixedPercentageOfCashPremium_c20220101__20220630_zqdll9pymo58" title="Description of percentage of cash premium">Certain fixed-rate notes include a prepayment provision, which entitles the holder to a 15% premium upon cash redemption by the Company</span>. The prepayment penalty approximates $<span id="xdx_900_ecustom--PrepaymentPenalty_iI_c20220630_zTRhNPSzcRb1" title="Prepayment penalty">121,000</span> as of June 30, 2022, but the Company determined that such liability is not probable as of June 30, 2022, pursuant to ASC 450 Contingencies.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Variable-rate notes</i></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The gross amount of all convertible notes with variable conversion rates outstanding as of June 30, 2022, is $<span id="xdx_90E_eus-gaap--ConvertibleDebt_iI_c20220630__us-gaap--DebtInstrumentAxis__custom--VariableRateNotesMember_zaR0zqjLtZxj" title="Convertible notes">4,770,926</span>, of which $<span id="xdx_901_eus-gaap--ConvertibleDebt_iI_c20220630__srt--StatementScenarioAxis__custom--PastMaturityMember__us-gaap--DebtInstrumentAxis__custom--VariableRateNotesMember_zp08X1nRNlnf" title="Convertible notes">4,770,926</span> are past maturity. There has been no conversion of notes into the Company’s common stock during the three and six months ended June 30, 2022.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i> </i></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b> </b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Endonovo Therapeutics, Inc.</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Notes to Condensed Consolidated Financial Statements (continued)</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p id="xdx_892_eus-gaap--ScheduleOfDebtTableTextBlock_zPzhMAxBDlb2" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">As of June 30, 2023, and December 31, 2022, the notes payable activity was as follows:</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0pt; margin-bottom: 0pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span><span id="xdx_8B9_zXT6QmjRwck6" style="display: none">Schedule of Notes Payable</span></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-left: auto; border-collapse: collapse; width: 80%; margin-right: auto"> <tr style="vertical-align: bottom"> <td> </td><td style="padding-bottom: 1.5pt"> </td> <td colspan="2" id="xdx_490_20230101__20230630_zYAv4qMpJFTj" style="border-bottom: Black 1.5pt solid; text-align: center">June 30, 2023</td><td style="padding-bottom: 1.5pt"> </td><td style="padding-bottom: 1.5pt"> </td> <td colspan="2" id="xdx_492_20220101__20221231_zW0cJj3q6bUk" style="border-bottom: Black 1.5pt solid; text-align: center">December 31, 2022</td><td style="padding-bottom: 1.5pt"> </td></tr> <tr style="vertical-align: bottom"> <td> </td><td> </td> <td colspan="2"> </td><td> </td><td> </td> <td colspan="2"> </td><td> </td></tr> <tr id="xdx_404_eus-gaap--NotesPayable_iS_pp0p0_zeJXVsP4y1Zh" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 56%; text-align: left">Notes payable at beginning of period</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 18%; text-align: right">7,163,832</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 18%; text-align: right">7,256,930</td><td style="width: 1%; text-align: left"> </td></tr> <tr id="xdx_40D_ecustom--NotesPayableIssued_i_pp0p0" style="vertical-align: bottom; background-color: White"> <td style="text-align: left">Notes payable issued</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">150,000</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">465,000</td><td style="text-align: left"> </td></tr> <tr id="xdx_40B_eus-gaap--RepaymentsOfNotesPayable_iN_pp0p0_di_z5hpOswWRz2k" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left">Repayments of notes payable in cash</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">(27,500</td><td style="text-align: left">)</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">(14,000</td><td style="text-align: left">)</td></tr> <tr id="xdx_401_ecustom--SettlementsOnNotePayable_i_pp0p0" style="vertical-align: bottom; background-color: White"> <td style="text-align: left">Settlement on note payable</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">(133,650</td><td style="text-align: left">)</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">(163,826</td><td style="text-align: left">)</td></tr> <tr id="xdx_40C_eus-gaap--ConversionOfStockAmountConverted1_iN_pp0p0_di_zL0zKkppm3v7" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left; padding-bottom: 1.5pt">Less amounts converted to stock</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">(100,000</td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">(380,272</td><td style="padding-bottom: 1.5pt; text-align: left">)</td></tr> <tr id="xdx_40D_eus-gaap--NotesPayable_iE_pp0p0_zd94nmZ4KoJa" style="vertical-align: bottom; background-color: White"> <td style="text-align: left">Notes payable at end of period</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">7,052,682</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">7,163,832</td><td style="text-align: left"> </td></tr> <tr id="xdx_40F_eus-gaap--DebtInstrumentUnamortizedDiscount_iNE_pp0p0_di_zowhpfDFtnEi" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left; padding-bottom: 1.5pt">Less debt discount</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">(25,585</td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">(10,587</td><td style="padding-bottom: 1.5pt; text-align: left">)</td></tr> <tr id="xdx_403_eus-gaap--NotesAndLoansPayable_iE_pp0p0_zihjLrhtjlu5" style="vertical-align: bottom; background-color: White"> <td style="padding-bottom: 2.5pt"><span style="display: none; font-family: Times New Roman, Times, Serif; font-size: 10pt">Note payable, net</span></td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">7,027,097</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">7,153,245</td><td style="padding-bottom: 2.5pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left; padding-bottom: 2.5pt">Notes payable issued to a former related party</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_981_eus-gaap--NotesPayableCurrent_iI_c20230630__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--FormerRelatedPartyMember_z9utrYIU13x8" style="border-bottom: Black 2.5pt double; text-align: right" title="Notes payable">104,600</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_983_eus-gaap--NotesPayableCurrent_iI_c20221231__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--FormerRelatedPartyMember_zIXZp95BM1F9" style="border-bottom: Black 2.5pt double; text-align: right" title="Notes payable">112,100</td><td style="padding-bottom: 2.5pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left; padding-bottom: 2.5pt">Notes payable issued to non-related parties</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_984_eus-gaap--NotesPayableCurrent_iI_c20230630__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__us-gaap--NonrelatedPartyMember_z6hvY5qFPhS9" style="border-bottom: Black 2.5pt double; text-align: right" title="Notes payable">6,922,497</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_982_eus-gaap--NotesPayableCurrent_iI_c20221231__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__us-gaap--NonrelatedPartyMember_zvnqXjgKMto" style="border-bottom: Black 2.5pt double; text-align: right" title="Notes payable">7,041,145</td><td style="padding-bottom: 2.5pt; text-align: left"> </td></tr> </table> 7163832 7256930 150000 465000 27500 14000 -133650 -163826 100000 380272 7052682 7163832 25585 10587 7027097 7153245 104600 112100 6922497 7041145 <p id="xdx_89F_eus-gaap--ScheduleOfMaturitiesOfLongTermDebtTableTextBlock_z1uWcxmF0wzj" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The maturity dates on the notes-payable are as follows:</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span><span id="xdx_8B9_zV5oeq1Omto7" style="display: none">Schedule of Maturity Dates of Notes Payable</span></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-left: auto; border-collapse: collapse; width: 80%; margin-right: auto"> <tr style="vertical-align: bottom"> <td> </td><td style="padding-bottom: 1.5pt"> </td> <td colspan="6" style="border-bottom: Black 1.5pt solid; text-align: center">Notes to</td><td style="padding-bottom: 1.5pt"> </td><td style="padding-bottom: 1.5pt"> </td> <td colspan="2"> </td><td style="padding-bottom: 1.5pt"> </td></tr> <tr style="vertical-align: bottom"> <td style="border-bottom: Black 1.5pt solid">12 months ending,</td><td style="padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center"><p style="margin-top: 0; margin-bottom: 0">Former</p> <p style="margin-top: 0; margin-bottom: 0">related party</p></td><td style="padding-bottom: 1.5pt"> </td><td style="padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center"><p style="margin-top: 0; margin-bottom: 0">Non-related</p> <p style="margin-top: 0; margin-bottom: 0">parties</p></td><td style="padding-bottom: 1.5pt"> </td><td style="padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center">Total</td><td style="padding-bottom: 1.5pt"> </td></tr> <tr style="vertical-align: bottom"> <td> </td><td> </td> <td colspan="2" style="text-align: right"> </td><td> </td><td> </td> <td colspan="2" style="text-align: right"> </td><td> </td><td> </td> <td colspan="2" style="text-align: right"> </td><td> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 46%; text-align: left">Past due</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td id="xdx_986_ecustom--LongTermDebtPastMaturity_iI_c20230630__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--FormerRelatedPartyMember_zhEgfMbLKeff" style="width: 14%; text-align: right" title="Past due">104,600</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td id="xdx_982_ecustom--LongTermDebtPastMaturity_iI_c20230630__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__us-gaap--NonrelatedPartyMember_zm3U6B8SucG8" style="width: 14%; text-align: right" title="Past due">6,733,082</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td id="xdx_989_ecustom--LongTermDebtPastMaturity_iI_c20230630_zMJET5iml1e3" style="width: 14%; text-align: right" title="Past due">6,837,682</td><td style="width: 1%; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="padding-bottom: 1.5pt">June 30, 2024</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td id="xdx_982_eus-gaap--LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths_iI_c20230630__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--FormerRelatedPartyMember_zA11uIPVJpX8" style="border-bottom: Black 1.5pt solid; text-align: right" title="June 30, 2024"><span style="-sec-ix-hidden: xdx2ixbrl1019">-</span></td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td id="xdx_98D_eus-gaap--LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths_iI_c20230630__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__us-gaap--NonrelatedPartyMember_zfbYW3CiGoVf" style="border-bottom: Black 1.5pt solid; text-align: right" title="June 30, 2024">215,000</td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td id="xdx_988_eus-gaap--LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths_iI_c20230630_zuQeOa1KuGo4" style="border-bottom: Black 1.5pt solid; text-align: right" title="June 30, 2024">215,000</td><td style="padding-bottom: 1.5pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-bottom: 2.5pt"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_983_eus-gaap--LongTermDebt_iI_c20230630__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--FormerRelatedPartyMember_zcUdb4YrcNee" style="border-bottom: Black 2.5pt double; text-align: right" title="Total">104,600</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_98C_eus-gaap--LongTermDebt_iI_c20230630__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__us-gaap--NonrelatedPartyMember_z0x1dHsGm5Jj" style="border-bottom: Black 2.5pt double; text-align: right" title="Total">6,948,082</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_984_eus-gaap--LongTermDebt_iI_c20230630_zrrKSKvh22S6" style="border-bottom: Black 2.5pt double; text-align: right" title="Total">7,052,682</td><td style="padding-bottom: 2.5pt; text-align: left"> </td></tr> </table> 104600 6733082 6837682 215000 215000 104600 6948082 7052682 100000 9000 10900000 20000 2500 150000 0.10 0.15 P1M P9M 1395000 338403 1849728 1819728 429500 310960 the Company to issue additional shares to ensure that the investor can realize a profit of 15% or 18% reselling the conversion shares 250000 certain fixed-rate notes include a prepayment provision, which entitles the holder to a 15% cash premium 4300590 77000 104600 0.10 0.12 7500 250000 250000 0.15 1891204 1116204 500000 25000 0.10 624903 624903 110204 93796 10200000 1250000 Such provision will require the Company to issue additional shares to ensure that the investor can realize a profit of 15% reselling the conversion shares 178000 Certain fixed-rate notes include a prepayment provision, which entitles the holder to a 15% premium upon cash redemption by the Company 121000 4770926 4770926 <p id="xdx_809_eus-gaap--StockholdersEquityNoteDisclosureTextBlock_z0hJlP9xhRM3" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Note 6 - <span id="xdx_829_zgrDwIZZ7q4i">Shareholders’ Deficit</span></b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Preferred Stock</i></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p id="xdx_89E_ecustom--ScheduleOfPreferredStockTableTextBlock_zH2GqsA9Yr9" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The Company has authorized <span class="xdx_phnt_RGlzY2xvc3VyZSAtIFNoYXJlaG9sZGVyc5IgRGVmaWNpdCAoRGV0YWlscyBOYXJyYXRpdmUpAA__" id="xdx_905_eus-gaap--PreferredStockSharesAuthorized_iI_pid_c20230630__us-gaap--StatementEquityComponentsAxis__custom--PreferredStockDesignatedMember_zOPL3nWiYbcg" title="Preferred stock, shares authorized">5,000,000</span> shares of preferred stock which have been designated as follows:</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0pt; margin-bottom: 0pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span><span id="xdx_8B4_ztcspczIZUwc" style="display: none">Schedule of Preferred Stock</span></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"> <tr style="vertical-align: bottom"> <td> </td><td style="padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center">Number of Shares <br/>Authorized</td><td style="padding-bottom: 1.5pt"> </td><td style="padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center">Number of Shares <br/>Outstanding at <br/>June 30, 2023</td><td style="padding-bottom: 1.5pt"> </td><td style="padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center">Par Value</td><td style="padding-bottom: 1.5pt"> </td><td style="padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center"><p style="margin-top: 0; margin-bottom: 0">Liquidation</p> <p style="margin-top: 0; margin-bottom: 0">Value</p></td><td style="padding-bottom: 1.5pt"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 40%; text-align: left">Series AA</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left"> </td><td id="xdx_98A_eus-gaap--PreferredStockSharesAuthorized_iI_pid_c20230630__us-gaap--StatementEquityComponentsAxis__custom--SeriesAAMember_z0YniJvTn68c" style="width: 11%; text-align: right" title="Number of Shares Authorized">1,000,000</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left"> </td><td id="xdx_982_eus-gaap--PreferredStockSharesOutstanding_iI_pid_c20230630__us-gaap--StatementEquityComponentsAxis__custom--SeriesAAMember_ziWp0zUN46ef" style="width: 11%; text-align: right" title="Number of Shares Outstanding">25,000</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td id="xdx_985_eus-gaap--PreferredStockParOrStatedValuePerShare_iI_pid_c20230630__us-gaap--StatementEquityComponentsAxis__custom--SeriesAAMember_zPKTy5re23Da" style="width: 11%; text-align: right" title="Par Value">0.0010</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td id="xdx_98A_eus-gaap--PreferredStockLiquidationPreferenceValue_iI_pp0p0_c20230630__us-gaap--StatementEquityComponentsAxis__custom--SeriesAAMember_zJuGfOsEIshg" style="width: 11%; text-align: right" title="Liquidation Value"><span style="-sec-ix-hidden: xdx2ixbrl1133">-</span></td><td style="width: 1%; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left">Preferred Series B</td><td> </td> <td style="text-align: left"> </td><td id="xdx_985_eus-gaap--PreferredStockSharesAuthorized_iI_pid_c20230630__us-gaap--StatementEquityComponentsAxis__custom--PreferredSeriesBMember_zwATapP1sd5d" style="text-align: right" title="Number of Shares Authorized">50,000</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_986_eus-gaap--PreferredStockSharesOutstanding_iI_pid_c20230630__us-gaap--StatementEquityComponentsAxis__custom--PreferredSeriesBMember_zJ8ZgHgOqHrh" style="text-align: right" title="Number of Shares Outstanding">600</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left">$</td><td id="xdx_98B_eus-gaap--PreferredStockParOrStatedValuePerShare_iI_pid_c20230630__us-gaap--StatementEquityComponentsAxis__custom--PreferredSeriesBMember_z5vyALhnBFBj" style="text-align: right" title="Par Value">0.0001</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left">$</td><td id="xdx_989_eus-gaap--PreferredStockLiquidationPreferenceValue_iI_pp0p0_c20230630__us-gaap--StatementEquityComponentsAxis__custom--PreferredSeriesBMember_zXfq6ZaOjPGd" style="text-align: right" title="Liquidation Value">100</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left">Preferred Series C</td><td> </td> <td style="text-align: left"> </td><td id="xdx_987_eus-gaap--PreferredStockSharesAuthorized_iI_pid_c20230630__us-gaap--StatementEquityComponentsAxis__custom--PreferredSeriesCMember_ziV0LxB9BSRj" style="text-align: right" title="Number of Shares Authorized">8,000</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_989_eus-gaap--PreferredStockSharesOutstanding_iI_pid_c20230630__us-gaap--StatementEquityComponentsAxis__custom--PreferredSeriesCMember_z1CKKJQh2004" style="text-align: right" title="Number of Shares Outstanding">738</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left">$</td><td id="xdx_985_eus-gaap--PreferredStockParOrStatedValuePerShare_iI_pid_c20230630__us-gaap--StatementEquityComponentsAxis__custom--PreferredSeriesCMember_zYJW59e06BP" style="text-align: right" title="Par Value">0.0001</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left">$</td><td id="xdx_98E_eus-gaap--PreferredStockLiquidationPreferenceValue_iI_pp0p0_c20230630__us-gaap--StatementEquityComponentsAxis__custom--PreferredSeriesCMember_zaphCbljEJgl" style="text-align: right" title="Liquidation Value">1,000</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left">Preferred Series D</td><td> </td> <td style="text-align: left"> </td><td id="xdx_986_eus-gaap--PreferredStockSharesAuthorized_iI_pid_c20230630__us-gaap--StatementEquityComponentsAxis__custom--PreferredSeriesDMember_zrTXBENnbjnl" style="text-align: right" title="Number of Shares Authorized">20,000</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_989_eus-gaap--PreferredStockSharesOutstanding_iI_pid_c20230630__us-gaap--StatementEquityComponentsAxis__custom--PreferredSeriesDMember_ztwcgFRaCwEa" style="text-align: right" title="Number of Shares Outstanding"><span style="-sec-ix-hidden: xdx2ixbrl1153">-</span></td><td style="text-align: left"> </td><td> </td> <td style="text-align: left">$</td><td id="xdx_982_eus-gaap--PreferredStockParOrStatedValuePerShare_iI_pid_c20230630__us-gaap--StatementEquityComponentsAxis__custom--PreferredSeriesDMember_z0POSIHRNKFd" style="text-align: right" title="Par Value">0.0001</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left">$</td><td id="xdx_988_eus-gaap--PreferredStockLiquidationPreferenceValue_iI_pp0p0_c20230630__us-gaap--StatementEquityComponentsAxis__custom--PreferredSeriesDMember_zVVF2AbZ26fi" style="text-align: right" title="Liquidation Value">1,000</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td>Undesignated</td><td> </td> <td style="text-align: left"> </td><td id="xdx_985_eus-gaap--PreferredStockSharesAuthorized_iI_pid_c20230630__us-gaap--StatementEquityComponentsAxis__custom--UndesignatedMember_ztJ1Lcw9mjob" style="text-align: right" title="Number of Shares Authorized">3,922,000</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_98E_eus-gaap--PreferredStockSharesOutstanding_iI_c20230630__us-gaap--StatementEquityComponentsAxis__custom--UndesignatedMember_zja5RKJV8Bq" style="text-align: right" title="Number of Shares Outstanding"><span style="-sec-ix-hidden: xdx2ixbrl1161">-</span></td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_98C_eus-gaap--PreferredStockParOrStatedValuePerShare_iI_c20230630__us-gaap--StatementEquityComponentsAxis__custom--UndesignatedMember_zPWh94fQhDIc" style="text-align: right" title="Par Value"><span style="-sec-ix-hidden: xdx2ixbrl1163">-</span></td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_980_eus-gaap--PreferredStockLiquidationPreferenceValue_iI_pp0p0_c20230630__us-gaap--StatementEquityComponentsAxis__custom--UndesignatedMember_zqW4ghILwRBi" style="text-align: right" title="Liquidation Value"><span style="-sec-ix-hidden: xdx2ixbrl1165">-</span></td><td style="text-align: left"> </td></tr> </table> <p id="xdx_8A4_zZgQ45Mic9z3" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Series AA Preferred Shares</i></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On February 22, 2013, the Board of Directors of the Company authorized an amendment to the Company’s Articles of Incorporation, as amended (the “Articles of Incorporation”), in the form of a Certificate of Designation that authorized the issuance of up to one million (<span id="xdx_90C_eus-gaap--PreferredStockSharesAuthorized_iI_c20130222__us-gaap--StatementClassOfStockAxis__custom--SeriesAAPreferredStockMember_z9KSIdJiVde8" title="Number of shares authorized">1,000,000</span>) shares of a new series of preferred stock, par value $<span id="xdx_90F_eus-gaap--PreferredStockParOrStatedValuePerShare_iI_c20130222__us-gaap--StatementClassOfStockAxis__custom--SeriesAAPreferredStockMember_zfIPF0FZvxKf" title="Preferred stock, par value">0.001</span> per share, designated “Series AA Super Voting Preferred Stock,” for which the board of director established the rights, preferences and limitations thereof.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_904_eus-gaap--PreferredStockVotingRights_c20130221__20130222__us-gaap--StatementClassOfStockAxis__custom--SeriesAAPreferredStockMember_zzpADtFJqHOb" title="Preferred stock voting rights">Each holder of outstanding shares of Series AA Super Voting Preferred Stock shall be entitled to one hundred thousand (100,000) votes for each share of Series AA Super Voting Preferred Stock held on the record date for the determination of stockholders entitled to vote at each meeting of stockholders of the Company</span>. The Series AA Super Voting Preferred Stockholders will receive no dividends nor any value on liquidation.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">There was no activity during the six months ended June 30, 2023. There were <span id="xdx_902_eus-gaap--PreferredStockSharesOutstanding_iI_c20230630__us-gaap--StatementClassOfStockAxis__custom--SeriesAAPreferredStockMember_zWkdCom7rf46" title="Preferred stock, shares outstanding"><span id="xdx_900_eus-gaap--PreferredStockSharesOutstanding_iI_c20221231__us-gaap--StatementClassOfStockAxis__custom--SeriesAAPreferredStockMember_z7KDBkMPYOvf" title="Preferred stock, shares outstanding">25,000</span></span> shares of Series AA Preferred stock outstanding as of June 30, 2023 and December 31, 2022.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Series B Convertible Preferred Stock</i></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On February 7, 2017, the Company filed a certificate of designation for <span id="xdx_90E_eus-gaap--PreferredStockSharesAuthorized_iI_c20170207__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesBPreferredStockMember_zwTME7zRvvjb" title="Number of shares authorized">50,000</span> shares of Series B Convertible Preferred Stock designated as Series B (“Series B”) which are authorized and convertible, at the option of the holder, commencing six months from the date of issuance into common shares and warrants. For each share of Series B, the holder, on conversion, shall receive the stated value divided by <span id="xdx_90B_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_pid_dp_uPure_c20170206__20170207__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesBPreferredStockMember_zVqJH6n0Jwx1" title="Stated value dividend">75</span>% of the market price on the date of purchase of Series B and a <span id="xdx_902_ecustom--WarrantTerm_c20170206__20170207__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesBPreferredStockMember_zXlDzirAIPB5" title="Warrants term">three-year</span> warrant exercisable into up to a like amount of common shares with an exercise price of <span id="xdx_90A_ecustom--ShareExercisePercentage_pid_dp_uPure_c20170206__20170207__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesBPreferredStockMember_z9YMoYqhn9z6" title="Share exercise price">150</span>% of the market price as defined in the Certificate of Designation. Dividends shall be paid only if dividends on the Company’s issued and outstanding Common Stock are paid, and the amount paid to the Series B holder will be as though the conversion shares had been issued. Series B holders have no voting rights. Upon liquidation, the holder of Series B, shall be entitled to receive an amount equal to the stated value, $<span id="xdx_90D_eus-gaap--PreferredStockLiquidationPreference_iI_c20170207__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesBPreferredStockMember_zTYUEUYruefk" title="Liquidation value of preferred stock, per share">100</span> per share, plus any accrued and unpaid dividends thereon before any distribution is made to Series C Secured Redeemable Preferred Stock or common stockholders.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">There was no activity during the six months ended June 30, 2023. There were <span id="xdx_90F_eus-gaap--PreferredStockSharesOutstanding_iI_c20230630__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesBPreferredStockMember_zBljZ5Frw4h1" title="Preferred stock, shares outstanding"><span id="xdx_901_eus-gaap--PreferredStockSharesOutstanding_iI_c20221231__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesBPreferredStockMember_zImf91nTZPq3" title="Preferred stock, shares outstanding">600</span></span> shares of Series B outstanding as of June 30, 2023 and December 31, 2022.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Endonovo Therapeutics, Inc.</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Notes to Condensed Consolidated Financial Statements (continued)</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Series C Convertible Redeemable Preferred Stock</i></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On December 22, 2017, the Company filed a certificate of designation for <span id="xdx_903_eus-gaap--PreferredStockSharesAuthorized_iI_c20171222__us-gaap--StatementClassOfStockAxis__custom--SeriesCConvertibleRedeemablePreferredStockMember_zgZml8JpdBJc" title="Number of shares authorized">8,000</span> shares of Series C Secured Redeemable Preferred Stock (“Series C”). Each share of the C Preferred is entitled to receive a $<span id="xdx_902_eus-gaap--PreferredStockDividendsPerShareCashPaid_c20171221__20171222__us-gaap--StatementClassOfStockAxis__custom--SeriesCConvertibleRedeemablePreferredStockMember_zfstXhHwCR54" title="Preferred stock, dividend per share">20</span> quarterly dividend commencing March 31, 2018, and each quarter thereafter and is to be redeemed for the stated value, $<span id="xdx_903_eus-gaap--PreferredStockLiquidationPreference_iI_c20171222__us-gaap--StatementClassOfStockAxis__custom--SeriesCConvertibleRedeemablePreferredStockMember_zTAy2fAUl4vl" title="Liquidation value of preferred stock, per share">1,000</span> per share, plus accrued dividends in cash (i) at the Company’s option, commencing one year from issuance and (ii) mandatorily as of December 31, 2019. Management determined that the Series C should be classified as liability per the guidance in ASC 480 Distinguishing Liabilities from Equity as of December 31, 2019. On January 29, 2020, <span id="xdx_906_ecustom--ChangeInRightsDueToAmendmendAndRestatedCertificateDescription_c20200128__20200129__us-gaap--StatementClassOfStockAxis__custom--SeriesCConvertibleRedeemablePreferredStockMember_zuqr774mQfu5" title="Change in rights due to amendment and restated certificate, description">the Company filed the amended and restated certificate of designation fort its Series C Secured Redeemable Preferred Stock. The amendment changed the rights of the Series C by (a) removing the requirement to redeem the Series C, (b) removing the obligation to pay dividends on the Series C, (c) Allowing the holders of shares of Series C to convert the stated value of their shares into common stock of the Company at 75% of the closing price of such common stock on the day prior to the conversion. The C Preferred does not have any rights to vote with the common stock</span>.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Upon liquidation, the holder of Series C, shall be entitled to receive an amount equal to the stated value, $<span id="xdx_909_eus-gaap--PreferredStockLiquidationPreference_iI_c20230630__us-gaap--StatementClassOfStockAxis__custom--SeriesCConvertibleRedeemablePreferredStockMember_zguOBQMwcQGl" title="Liquidation value of preferred stock, per share">1,000</span> per share, plus any accrued and unpaid dividends thereon before any distribution is made to common stockholders but after distributions are made to holders of Series B.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">There was no activity during the six months ended June 30, 2023. There were <span id="xdx_900_eus-gaap--PreferredStockSharesOutstanding_iI_c20230630__us-gaap--StatementClassOfStockAxis__custom--SeriesCConvertibleRedeemablePreferredStockMember_zKw4nY53Unsg" title="Convertible preferred stock, shares outstanding"><span id="xdx_907_eus-gaap--PreferredStockSharesOutstanding_iI_c20221231__us-gaap--StatementClassOfStockAxis__custom--SeriesCConvertibleRedeemablePreferredStockMember_zrFYmM3JoF5l" title="Convertible preferred stock, shares outstanding">738</span></span> shares of Series C outstanding, as of June 30, 2023 and December 31, 2022</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Series D Convertible Preferred Stock</i></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On November 11, 2019, the Company filed a certificate of designation for <span id="xdx_903_eus-gaap--PreferredStockSharesAuthorized_iI_c20191111__us-gaap--StatementClassOfStockAxis__custom--SeriesDConvertiblePreferredStockMember_zYeH6zwpKIvi" title="Number of shares authorized">20,000</span> shares of Series D Convertible Preferred Stock designated as Series D (“Series D”), which are authorized and convertible, at the option of the holder, at any time from the date of issuance, into shares of common shares. On or prior to August 1, 2020, for each share of Series D, the holder, on conversion, shall receive a number of common shares equal to <span id="xdx_907_ecustom--ConversionPricePercentage_iI_pid_dp_uPure_c20191111__us-gaap--StatementClassOfStockAxis__custom--SeriesDConvertiblePreferredStockMember_zw6OJFjB1LY5" title="Conversion price">0.01</span>% of the Company’s issued and outstanding shares on conversion date and for conversion on or after August 2, 2020, the holder shall receive conversion shares as though the conversion date was August 1, 2020, with no further adjustments for issuances by the Company of common stock after August 1, 2020, except for stock split or reverse stock splits of the common stock. Management classified the Series D in permanent equity as of June 30, 2023.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The Series D holders have no voting rights. Upon liquidation, the holder of Series D, shall be entitled to receive an amount equal to the stated value, $<span id="xdx_90B_eus-gaap--PreferredStockLiquidationPreference_iI_c20230630__us-gaap--StatementClassOfStockAxis__custom--SeriesDConvertiblePreferredStockMember_zA4owlfcz6V1" title="Liquidation value of preferred stock, per share">1,000</span> per share, plus any accrued and unpaid dividends thereon before any distribution is made to common stockholders.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">During the six months ended June 30, 2023, the Company issued <span id="xdx_90D_eus-gaap--SharesIssued_iI_c20230630__us-gaap--StatementClassOfStockAxis__custom--SeriesDConvertiblePreferredStockMember_zRNwnPr0eITk" title="Number of shares issued">5,000,000</span> shares of common stock upon conversion of the remaining <span id="xdx_905_eus-gaap--ConversionOfStockSharesIssued1_c20230101__20230630__us-gaap--StatementClassOfStockAxis__custom--SeriesDConvertiblePreferredStockMember_zyiG4ZV94am4" title="Conversion of stock issued, shares">50</span> shares of Series D preferred stock. <span id="xdx_904_eus-gaap--ConversionOfStockDescription_c20230101__20230630__us-gaap--StatementClassOfStockAxis__custom--SeriesDConvertiblePreferredStockMember_zyY580Sgxfib" title="Conversion of stock description">The Company is also committed to providing additional shares of common stock if the holders of Series D do not realize a 15% profit on the resale of the conversion shares</span>. As of June 30, 2023, and December 31, 2022, there were <span id="xdx_906_eus-gaap--PreferredStockSharesOutstanding_iI_c20230630__us-gaap--StatementClassOfStockAxis__custom--SeriesDConvertiblePreferredStockMember_zxD51p1njNrh" title="Preferred stock, shares outstanding">0</span> and <span id="xdx_90D_eus-gaap--PreferredStockSharesOutstanding_c20221231__us-gaap--StatementClassOfStockAxis__custom--SeriesDConvertiblePreferredStockMember_pdd" title="Preferred stock, shares outstanding">50</span> shares of Series D outstanding, respectively.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Common Stock</i></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Activity during the six months ended June 30, 2023</i></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">During the six months ended June 30, 2023, the Company issued <span id="xdx_903_eus-gaap--ConversionOfStockSharesIssued1_pid_c20230101__20230630__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zQfmqugRKIsh" title="Shares issued for conversion of notes payable, shares">10,900,000</span> shares of common stock for the conversion of $<span id="xdx_90C_eus-gaap--ConversionOfStockAmountIssued1_c20230101__20230630__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zvwGTJpD8Fag" title="Shares issued for conversion of notes payable">109,000</span> of principal accrued interest from one note holder.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">During the six months ended June 30, 2023, the Company issued <span id="xdx_90D_eus-gaap--StockIssuedDuringPeriodSharesNewIssues_c20230101__20230630__srt--TitleOfIndividualAxis__custom--OneInvestorMember_zpSlrMNYz7gb" title="Issuance of common stock">1,507,277</span> shares of common stock pursuant to a make-good provision, which resulted in a loss on debt extinguishment of $<span id="xdx_909_eus-gaap--GainsLossesOnExtinguishmentOfDebt_c20230101__20230630__srt--TitleOfIndividualAxis__custom--OneInvestorMember_zcW14LEOQCqf" title="Loss on debt extinguishment">24,870</span>.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">During the six months June 30, 2023, the Company issued <span id="xdx_90A_eus-gaap--DebtConversionConvertedInstrumentSharesIssued1_c20230101__20230630__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zwVXd9bUui24" title="Debt conversion, stock issued shares">4,300,590</span> shares of common stock pursuant to a debt settlement of aggregate principal of $<span id="xdx_905_eus-gaap--DebtInstrumentFaceAmount_iI_c20230630__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_z4a5DT4Yv16b" title="Principal amount">113,650</span>, resulting in a gain on debt extinguishment of approximately $<span id="xdx_908_eus-gaap--GainsLossesOnExtinguishmentOfDebt_c20230101__20230630__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zcOkAeKJDQHk" title="Gain on debt extinguishment">77,000</span>.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">During the six months June 30, 2023, the Company issued <span id="xdx_908_ecustom--SharesIssuedForConversionOfDeferredCompensationShares_c20230101__20230630__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zZohz7MSHR63" title="Number of shares issued, share">1667,000</span> shares of common stock pursuant to a deferred compensation settlement with a fair value of $<span id="xdx_90D_ecustom--SharesIssuedForConversionOfDeferredCompensationValue_c20230101__20230630__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zoFIlDkjqvFg" title="Fair value of defered compensation">24,338</span>.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">During the six months ended June 30, 2023, the Company issued <span id="xdx_902_eus-gaap--StockIssuedDuringPeriodSharesNewIssues_c20230101__20230630__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zT2VqVnCTqFh" title="Issuance of common stock">5,967,590</span> shares of common stock pursuant to a debt settlement.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">During the six months ended June 30, 2023, the Company issued <span id="xdx_901_eus-gaap--StockIssuedDuringPeriodSharesIssuedForServices_c20230101__20230630_zCcdG2tzo9Ni" title="Shares issued for common stock for services, shares">13,850,000</span> shares of common stock for services for a total fair value of $<span id="xdx_904_eus-gaap--StockIssuedDuringPeriodValueIssuedForServices_c20230101__20230630_zrqhhjyxaW5l" title="Shares issued for common stock for services, value">188,950</span>.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">During the six months ended June 30, 2023, the Company issued <span id="xdx_901_eus-gaap--SharesIssued_iI_c20230630__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zIG07CrFpsF" title="Number of shares issued">5,000,000</span> shares of common stock in exchange for <span id="xdx_90A_eus-gaap--ConversionOfStockSharesIssued1_c20230101__20230630__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesDPreferredStockMember_zOdQ34O8gLGa" title="Conversion of stock issued, shares">50</span> shares of Series D Preferred, which resulted in an inducement loss of $<span id="xdx_90D_ecustom--InducementLossRelatedToConversionOfPreferredStock_c20230101__20230630__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesDPreferredStockMember_zQ5KzbkY0lnk" title="Inducement loss">39,398</span> recorded as a deemed dividend in the shareholders’ deficit as of June 30, 2023.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">During the six months ended June 30, 2023, the Company issued 5 1/2 units or the equivalent of <span id="xdx_90F_eus-gaap--StockIssuedDuringPeriodSharesNewIssues_c20230101__20230630__us-gaap--SubsidiarySaleOfStockAxis__us-gaap--PrivatePlacementMember_z8BeVz8rbF5d" title="Common stock new issunace, shares">27,500,000</span> shares of common stock pursuant to a private placement for total net cash receipt of $<span id="xdx_901_eus-gaap--StockIssuedDuringPeriodValueNewIssues_c20230101__20230630__us-gaap--SubsidiarySaleOfStockAxis__us-gaap--PrivatePlacementMember_zo1eTKuibxtf" title="Common stock new issuance, value">253,000</span>.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">During the six months ended June 30, 2023, the Company issued <span id="xdx_90E_eus-gaap--StockIssuedDuringPeriodSharesNewIssues_c20230101__20230630__us-gaap--TypeOfArrangementAxis__custom--SecuritiesPurchaseAgreementsMember_zuuYU96pQMch" title="Issuance of common stock">850,000</span> commitment shares pursuant to executed securities purchase agreements with an estimated fair value of $<span id="xdx_904_eus-gaap--StockIssuedDuringPeriodValueIssuedForServices_c20230101__20230630__us-gaap--TypeOfArrangementAxis__custom--SecuritiesPurchaseAgreementsMember_z4uGOwtBOdyf" title="Shares issued for common stock for services, value">11,125</span>.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Activity during the six months ended June 30, 2022</i></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">During the six months ended June 30, 2022, the Company issued <span id="xdx_90D_eus-gaap--ConversionOfStockSharesIssued1_pid_c20220101__20220630__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zxFceioHcyVe" title="Shares issued for conversion of notes payable, shares">10,200,000</span> shares of common stock for the conversion of $<span id="xdx_908_eus-gaap--ConversionOfStockAmountIssued1_c20220101__20220630__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_z3dV13G3qIFi" title="Shares issued for conversion of notes payable">93,796</span> of principal notes and accrued interest in the amount of $<span id="xdx_907_eus-gaap--InterestPayableCurrentAndNoncurrent_iI_c20220630__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_z753lzNmE70e" title="Accrued interest">110,204</span>.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">During the six months ended June 30, 2022, the Company issued <span id="xdx_90C_eus-gaap--StockIssuedDuringPeriodSharesNewIssues_c20220101__20220630__srt--TitleOfIndividualAxis__custom--OneInvestorMember_zmqBjQmhHlKh" title="Issuance of common stock">2,428,777</span> shares of common stock pursuant to a make-whole provision from an April 2021 debt settlement with one investor.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">During the six months ended June 30, 2022, the Company issued <span id="xdx_902_eus-gaap--StockIssuedDuringPeriodSharesNewIssues_c20220101__20220630__us-gaap--TypeOfArrangementAxis__custom--PurchaseAgreementMember_z4M83NEPV0J6" title="Issuance of common stock">1,050,000</span> shares of common stock as commitment shares in connection with securities purchase agreements.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">During the six months ended June 30, 2022, the Company issued <span id="xdx_902_eus-gaap--StockIssuedDuringPeriodSharesIssuedForServices_c20220101__20220630_zb6xQANNfqWc" title="Shares issued for common stock for services, shares">62,250,000</span> shares of common stock for services for total fair value of $<span id="xdx_90A_eus-gaap--StockIssuedDuringPeriodValueIssuedForServices_c20220101__20220630_zk9PEOUeEwd7" title="Shares issued for common stock for services, value">1,281,900</span>.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Endonovo Therapeutics, Inc.</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Notes to Condensed Consolidated Financial Statements (continued)</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Stock Options</i></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p id="xdx_89F_eus-gaap--ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_ze1T2iORuKpc" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The balance of all stock options outstanding as of June 30, 2023, is as follows:</span></p> <p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-right: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span><span id="xdx_8BC_zDc6QnIuD5I7" style="display: none">Schedule of Stock Options Outstanding</span></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"> <tr style="vertical-align: bottom"> <td> </td><td> </td> <td colspan="2"> </td><td> </td><td> </td> <td colspan="2" style="text-align: center">Weighted <br/>Average</td><td> </td><td> </td> <td colspan="2" style="text-align: center">Weighted <br/>Average <br/>Remaining</td><td> </td><td> </td> <td colspan="2" style="text-align: center">Aggregate</td><td> </td></tr> <tr style="vertical-align: bottom"> <td> </td><td> </td> <td colspan="2"> </td><td> </td><td> </td> <td colspan="2" style="text-align: center">Exercise Price</td><td> </td><td> </td> <td colspan="2" style="text-align: center">Contractual</td><td> </td><td> </td> <td colspan="2" style="text-align: center">Intrinsic</td><td> </td></tr> <tr style="vertical-align: bottom"> <td> </td><td style="padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center">Options</td><td style="padding-bottom: 1.5pt"> </td><td style="padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center">Per Share</td><td style="padding-bottom: 1.5pt"> </td><td style="padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center">Term (years)</td><td style="padding-bottom: 1.5pt"> </td><td style="padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center">Value</td><td style="padding-bottom: 1.5pt"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 40%">Outstanding at December 31, 2022</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left"> </td><td id="xdx_986_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iS_c20230101__20230630__us-gaap--FinancialInstrumentAxis__custom--StockOptionsMember_zsOiyCT5vbk6" style="width: 11%; text-align: right" title="Stock Options Outstanding, Beginning Balance">3,012,410</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td id="xdx_989_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_iS_c20230101__20230630__us-gaap--FinancialInstrumentAxis__custom--StockOptionsMember_z00EkPecMAbl" style="width: 11%; text-align: right" title="Weighted Average Exercise Price Per Share, Beginning Balance">0.22</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left"> </td><td style="width: 11%; text-align: right"><span id="xdx_901_ecustom--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm1_dtY_c20230101__20230630__us-gaap--FinancialInstrumentAxis__custom--StockOptionsMember_zHJHlLT6kSXk" title="Weighted Average Remaining Contractual Term (years), Outstanding Beginning">3.40</span></td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left"> </td><td id="xdx_98D_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue_iS_c20230101__20230630__us-gaap--FinancialInstrumentAxis__custom--StockOptionsMember_ztOIJEhr6sv7" style="width: 11%; text-align: right" title="Aggregated Intrinsic Value, Outstanding Beginning Balance">31,200</td><td style="width: 1%; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="padding-left: 10pt">Granted</td><td> </td> <td style="text-align: left"> </td><td id="xdx_987_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_c20230101__20230630__us-gaap--FinancialInstrumentAxis__custom--StockOptionsMember_zBjfcWNHToM7" style="text-align: right" title="Stock Options Outstanding, Granted">3,000,000</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left">$</td><td id="xdx_981_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_c20230101__20230630__us-gaap--FinancialInstrumentAxis__custom--StockOptionsMember_zKD3Tc0ARdoh" style="text-align: right" title="Weighted Average Exercise Price Per Share, Granted">0.01</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">-</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-left: 10pt">Cancelled</td><td> </td> <td style="text-align: left"> </td><td id="xdx_98E_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_iN_di_c20230101__20230630__us-gaap--FinancialInstrumentAxis__custom--StockOptionsMember_zEfJsew9TY37" style="text-align: right" title="Stock Options Outstanding, Cancelled">(660</td><td style="text-align: left">)</td><td> </td> <td style="text-align: left">$</td><td id="xdx_988_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_c20230101__20230630__us-gaap--FinancialInstrumentAxis__custom--StockOptionsMember_zu6jGThdPm3a" style="text-align: right" title="Weighted Average Exercise Price Per Share, Cancelled">11.60</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">-</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="padding-left: 10pt; padding-bottom: 1.5pt">Exercised</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td id="xdx_98F_eus-gaap--StockIssuedDuringPeriodSharesStockOptionsExercised_c20230101__20230630__us-gaap--FinancialInstrumentAxis__custom--StockOptionsMember_zpROFQovvs8b" style="border-bottom: Black 1.5pt solid; text-align: right" title="Stock Options Outstanding, Exercised"><span style="-sec-ix-hidden: xdx2ixbrl1291">-</span></td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="padding-bottom: 1.5pt; text-align: left">$</td><td id="xdx_98F_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_c20230101__20230630__us-gaap--FinancialInstrumentAxis__custom--StockOptionsMember_z3K3yyoyWshk" style="padding-bottom: 1.5pt; text-align: right" title="Weighted Average Exercise Price Per Share, Exercised"><span style="-sec-ix-hidden: xdx2ixbrl1293">-</span></td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt; text-align: right">-</td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt; text-align: right"> </td><td style="padding-bottom: 1.5pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-bottom: 2.5pt">Outstanding at June 30, 2023</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left"> </td><td id="xdx_985_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iE_c20230101__20230630__us-gaap--FinancialInstrumentAxis__custom--StockOptionsMember_zwfMd6MBjOb5" style="border-bottom: Black 2.5pt double; text-align: right" title="Stock Options Outstanding, Ending Balance">6,011,750</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="padding-bottom: 2.5pt; text-align: left">$</td><td id="xdx_987_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_iE_c20230101__20230630__us-gaap--FinancialInstrumentAxis__custom--StockOptionsMember_zBZzskFLFcBg" style="padding-bottom: 2.5pt; text-align: right" title="Weighted Average Exercise Price Per Share, Ending Balance">0.12</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt; text-align: right"><span id="xdx_905_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_dtY_c20230101__20230630__us-gaap--FinancialInstrumentAxis__custom--StockOptionsMember_z8lQ8a35FRG2" title="Weighted Average Remaining Contractual Term (years), Ending">3.06</span></td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="padding-bottom: 2.5pt; text-align: left">$</td><td id="xdx_983_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue_iE_c20230101__20230630__us-gaap--FinancialInstrumentAxis__custom--StockOptionsMember_zQtwEqkvKbl3" style="padding-bottom: 2.5pt; text-align: right" title="Aggregated Intrinsic Value, Ending"><span style="-sec-ix-hidden: xdx2ixbrl1301">-</span></td><td style="padding-bottom: 2.5pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-bottom: 2.5pt">Exercisable at June 30, 2023</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left"> </td><td id="xdx_988_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_iE_c20230101__20230630__us-gaap--FinancialInstrumentAxis__custom--StockOptionsMember_z806iY9kPj62" style="border-bottom: Black 2.5pt double; text-align: right" title="Stock Options Outstanding, Exercisable Ending Balance">1,011,750</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="padding-bottom: 2.5pt; text-align: left">$</td><td id="xdx_982_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_iE_c20230101__20230630__us-gaap--FinancialInstrumentAxis__custom--StockOptionsMember_zNz8Argm2sUl" style="padding-bottom: 2.5pt; text-align: right" title="Weighted Average Exercise Price Per Share, Exercisable Ending Balance">0.64</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt; text-align: right"><span id="xdx_905_ecustom--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualExercisableTerm2_dtY_c20230101__20230630__us-gaap--FinancialInstrumentAxis__custom--StockOptionsMember_zQsdG8tS0vmi" title="Weighted Average Remaining Contractual Term (years), Exercisable">1.83</span></td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="padding-bottom: 2.5pt; text-align: left">$</td><td id="xdx_98E_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_iE_c20230101__20230630__us-gaap--FinancialInstrumentAxis__custom--StockOptionsMember_zfnl7DjGnl3j" style="padding-bottom: 2.5pt; text-align: right" title="Aggregated Intrinsic Value, Exercisable Ending"><span style="-sec-ix-hidden: xdx2ixbrl1309">-</span></td><td style="padding-bottom: 2.5pt; text-align: left"> </td></tr> </table> <p id="xdx_8AF_zG2FDiTBslN5" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Share-based compensation expenses for the six months ended June 30, 2023 and 2022, totaled approximately $<span id="xdx_909_eus-gaap--ShareBasedCompensation_c20230101__20230630_zEPLRsVXAbrc" title="Share-based compensation expenses">6,000</span> and $<span id="xdx_901_eus-gaap--ShareBasedCompensation_c20220101__20220630_zt3U95ackHra" title="Share-based compensation expenses">0</span>, respectively. The remaining stock-based compensation to be recognized is approximately $<span id="xdx_902_eus-gaap--EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized_iI_c20230630_zGMSV7SCCyUa" title="Unrecognized stock-based compensation expense">36,000</span>, which will be recognized over <span id="xdx_90D_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_dtY_c20230101__20230630_z0ZP32PG8Dfc" title="Remaining vesting period">2.5</span> years.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Warrants</i></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0pt; margin-bottom: 0pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p id="xdx_896_eus-gaap--ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock_zLN38eiL6Mda" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The balance of all warrants outstanding as of June 30, 2023, is as follows:</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span><span id="xdx_8BC_zm4hQ9Yj1xbj" style="display: none">Schedule of Warrants Outstanding</span></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-left: auto; border-collapse: collapse; width: 90%; margin-right: auto"> <tr style="vertical-align: bottom"> <td style="text-align: center"> </td><td style="padding-bottom: 1.5pt"> </td> <td colspan="6" style="border-bottom: Black 1.5pt solid; text-align: center">Outstanding Warrants</td><td style="padding-bottom: 1.5pt"> </td><td style="padding-bottom: 1.5pt"> </td> <td colspan="2" style="text-align: center"> </td><td style="padding-bottom: 1.5pt"> </td></tr> <tr style="vertical-align: bottom"> <td style="text-align: center"> </td><td> </td> <td colspan="2" style="text-align: center"> </td><td> </td><td> </td> <td colspan="2" style="text-align: center">Weighted <br/>Average</td><td> </td><td> </td> <td colspan="2" style="text-align: center">Weighted Average Remaining</td><td> </td></tr> <tr style="vertical-align: bottom"> <td style="text-align: center"> </td><td> </td> <td colspan="2" style="text-align: center"> </td><td> </td><td> </td> <td colspan="2" style="text-align: center">Exercise Price</td><td> </td><td> </td> <td colspan="2" style="text-align: center">Contractual</td><td> </td></tr> <tr style="vertical-align: bottom"> <td style="text-align: center"> </td><td style="padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center">Shares</td><td style="padding-bottom: 1.5pt"> </td><td style="padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center">Per Share</td><td style="padding-bottom: 1.5pt"> </td><td style="padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center">Term (years)</td><td style="padding-bottom: 1.5pt"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 46%">Outstanding at December 31, 2022</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left"> </td><td id="xdx_983_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber_iS_c20230101__20230630__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zrJyiUiyoCwl" style="width: 14%; text-align: right" title="Shares Outstanding, Beginning Balance">2,000</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td id="xdx_98E_ecustom--ShareBasedCompensationArrangementByShareBasedPaymetAwardNonOptionOutstandingWeightedAverageExercisePrice_iS_c20230101__20230630__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_z2NasDGsedM2" style="width: 14%; text-align: right" title="Weighted Average Exercise Price Per Share, Outstanding Beginning Balance">50.0</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left"> </td><td style="width: 14%; text-align: right"><span id="xdx_903_ecustom--SharebasedCompensationArrangementBySharebasedPaymentAwardNonOptionsOutstandingWeightedAverageRemainingContractualTerm1_dtY_c20230101__20230630__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zigaLo9ixDIi" title="Weighted Average Remaining Contractual Term (years), Outstanding Beginning">0.22</span></td><td style="width: 1%; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="padding-left: 10pt">Granted</td><td> </td> <td style="text-align: left"> </td><td id="xdx_98B_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted_c20230101__20230630__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zfN8n6JJlxA" style="text-align: right" title="Shares, Granted"><span style="-sec-ix-hidden: xdx2ixbrl1327">-</span></td><td style="text-align: left"> </td><td> </td> <td style="text-align: left">$</td><td id="xdx_986_ecustom--ShareBasedCompensationArrangementByShareBasedPaymetAwardNonOptionGrandInPeriodWeightedAverageExercisePrice_c20230101__20230630__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zPrkc6YTjJYa" style="text-align: right" title="Weighted Average Exercise Price Per Share, Granted"><span style="-sec-ix-hidden: xdx2ixbrl1329">-</span></td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">-</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-left: 10pt">Cancelled</td><td> </td> <td style="text-align: left"> </td><td id="xdx_985_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsForfeitures_iN_di_c20230101__20230630__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_z965mKva35B1" style="text-align: right" title="Shares, Cancelled">(2,000</td><td style="text-align: left">)</td><td> </td> <td style="text-align: left">$</td><td id="xdx_983_ecustom--ShareBasedCompensationArrangementByShareBasedPaymetAwardNonOptionForfeitedOrExpiredInPeriodWeightedAverageExercisePrice_c20230101__20230630__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zapq05LR8qq1" style="text-align: right" title="Weighted Average Exercise Price Per Share, Cancelled">50.0</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">-</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="padding-left: 10pt; padding-bottom: 1.5pt">Exercised</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td id="xdx_989_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised_c20230101__20230630__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zlxHQwh5za09" style="border-bottom: Black 1.5pt solid; text-align: right" title="Shares, Exercised"><span style="-sec-ix-hidden: xdx2ixbrl1335">-</span></td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="padding-bottom: 1.5pt; text-align: left">$</td><td id="xdx_984_ecustom--ShareBasedCompensationArrangementByShareBasedPaymetAwardNonOptionExercisedInPeriodWeightedAverageExercisePrice_c20230101__20230630__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zhqqdFo0Yzlj" style="padding-bottom: 1.5pt; text-align: right" title="Weighted Average Exercise Price Per Share, Exercised"><span style="-sec-ix-hidden: xdx2ixbrl1337">-</span></td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt; text-align: right"> </td><td style="padding-bottom: 1.5pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-bottom: 2.5pt">Outstanding at June 30, 2023</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left"> </td><td id="xdx_98E_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber_iE_c20230101__20230630__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zIAX3g9154W5" style="border-bottom: Black 2.5pt double; text-align: right" title="Shares Outstanding, Ending Balance"><span style="-sec-ix-hidden: xdx2ixbrl1339">-</span></td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="padding-bottom: 2.5pt; text-align: left">$</td><td id="xdx_988_ecustom--ShareBasedCompensationArrangementByShareBasedPaymetAwardNonOptionOutstandingWeightedAverageExercisePrice_iE_c20230101__20230630__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_z39UOseD77H2" style="padding-bottom: 2.5pt; text-align: right" title="Weighted Average Exercise Price Per Share, Outstanding Ending Balance"><span style="-sec-ix-hidden: xdx2ixbrl1341">-</span></td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt; text-align: right">-</td><td style="padding-bottom: 2.5pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-bottom: 2.5pt">Exercisable at June 30, 2023</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left"> </td><td id="xdx_988_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityExercisable_iE_c20230101__20230630__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zf8NNrvAG8Ha" style="border-bottom: Black 2.5pt double; text-align: right" title="Shares Exercisable, Ending Balance"><span style="-sec-ix-hidden: xdx2ixbrl1343">-</span></td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="padding-bottom: 2.5pt; text-align: left">$</td><td id="xdx_984_ecustom--ShareBasedCompensationArrangementByShareBasedPaymetAwardNonOptionWeightedAverageExercisable_iE_c20230101__20230630__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zpJyk6Fm8887" style="padding-bottom: 2.5pt; text-align: right" title="Weighted Average Exercise Price Per Share, Exercisable Ending Balance"><span style="-sec-ix-hidden: xdx2ixbrl1345">-</span></td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt; text-align: right">-</td><td style="padding-bottom: 2.5pt; text-align: left"> </td></tr> </table> <p id="xdx_8A0_zDYDYuq8d988" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b> </b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b> </b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Endonovo Therapeutics, Inc.</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Notes to Condensed Consolidated Financial Statements (continued)</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p id="xdx_89E_ecustom--ScheduleOfPreferredStockTableTextBlock_zH2GqsA9Yr9" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The Company has authorized <span class="xdx_phnt_RGlzY2xvc3VyZSAtIFNoYXJlaG9sZGVyc5IgRGVmaWNpdCAoRGV0YWlscyBOYXJyYXRpdmUpAA__" id="xdx_905_eus-gaap--PreferredStockSharesAuthorized_iI_pid_c20230630__us-gaap--StatementEquityComponentsAxis__custom--PreferredStockDesignatedMember_zOPL3nWiYbcg" title="Preferred stock, shares authorized">5,000,000</span> shares of preferred stock which have been designated as follows:</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0pt; margin-bottom: 0pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span><span id="xdx_8B4_ztcspczIZUwc" style="display: none">Schedule of Preferred Stock</span></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"> <tr style="vertical-align: bottom"> <td> </td><td style="padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center">Number of Shares <br/>Authorized</td><td style="padding-bottom: 1.5pt"> </td><td style="padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center">Number of Shares <br/>Outstanding at <br/>June 30, 2023</td><td style="padding-bottom: 1.5pt"> </td><td style="padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center">Par Value</td><td style="padding-bottom: 1.5pt"> </td><td style="padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center"><p style="margin-top: 0; margin-bottom: 0">Liquidation</p> <p style="margin-top: 0; margin-bottom: 0">Value</p></td><td style="padding-bottom: 1.5pt"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 40%; text-align: left">Series AA</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left"> </td><td id="xdx_98A_eus-gaap--PreferredStockSharesAuthorized_iI_pid_c20230630__us-gaap--StatementEquityComponentsAxis__custom--SeriesAAMember_z0YniJvTn68c" style="width: 11%; text-align: right" title="Number of Shares Authorized">1,000,000</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left"> </td><td id="xdx_982_eus-gaap--PreferredStockSharesOutstanding_iI_pid_c20230630__us-gaap--StatementEquityComponentsAxis__custom--SeriesAAMember_ziWp0zUN46ef" style="width: 11%; text-align: right" title="Number of Shares Outstanding">25,000</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td id="xdx_985_eus-gaap--PreferredStockParOrStatedValuePerShare_iI_pid_c20230630__us-gaap--StatementEquityComponentsAxis__custom--SeriesAAMember_zPKTy5re23Da" style="width: 11%; text-align: right" title="Par Value">0.0010</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td id="xdx_98A_eus-gaap--PreferredStockLiquidationPreferenceValue_iI_pp0p0_c20230630__us-gaap--StatementEquityComponentsAxis__custom--SeriesAAMember_zJuGfOsEIshg" style="width: 11%; text-align: right" title="Liquidation Value"><span style="-sec-ix-hidden: xdx2ixbrl1133">-</span></td><td style="width: 1%; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left">Preferred Series B</td><td> </td> <td style="text-align: left"> </td><td id="xdx_985_eus-gaap--PreferredStockSharesAuthorized_iI_pid_c20230630__us-gaap--StatementEquityComponentsAxis__custom--PreferredSeriesBMember_zwATapP1sd5d" style="text-align: right" title="Number of Shares Authorized">50,000</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_986_eus-gaap--PreferredStockSharesOutstanding_iI_pid_c20230630__us-gaap--StatementEquityComponentsAxis__custom--PreferredSeriesBMember_zJ8ZgHgOqHrh" style="text-align: right" title="Number of Shares Outstanding">600</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left">$</td><td id="xdx_98B_eus-gaap--PreferredStockParOrStatedValuePerShare_iI_pid_c20230630__us-gaap--StatementEquityComponentsAxis__custom--PreferredSeriesBMember_z5vyALhnBFBj" style="text-align: right" title="Par Value">0.0001</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left">$</td><td id="xdx_989_eus-gaap--PreferredStockLiquidationPreferenceValue_iI_pp0p0_c20230630__us-gaap--StatementEquityComponentsAxis__custom--PreferredSeriesBMember_zXfq6ZaOjPGd" style="text-align: right" title="Liquidation Value">100</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left">Preferred Series C</td><td> </td> <td style="text-align: left"> </td><td id="xdx_987_eus-gaap--PreferredStockSharesAuthorized_iI_pid_c20230630__us-gaap--StatementEquityComponentsAxis__custom--PreferredSeriesCMember_ziV0LxB9BSRj" style="text-align: right" title="Number of Shares Authorized">8,000</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_989_eus-gaap--PreferredStockSharesOutstanding_iI_pid_c20230630__us-gaap--StatementEquityComponentsAxis__custom--PreferredSeriesCMember_z1CKKJQh2004" style="text-align: right" title="Number of Shares Outstanding">738</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left">$</td><td id="xdx_985_eus-gaap--PreferredStockParOrStatedValuePerShare_iI_pid_c20230630__us-gaap--StatementEquityComponentsAxis__custom--PreferredSeriesCMember_zYJW59e06BP" style="text-align: right" title="Par Value">0.0001</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left">$</td><td id="xdx_98E_eus-gaap--PreferredStockLiquidationPreferenceValue_iI_pp0p0_c20230630__us-gaap--StatementEquityComponentsAxis__custom--PreferredSeriesCMember_zaphCbljEJgl" style="text-align: right" title="Liquidation Value">1,000</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left">Preferred Series D</td><td> </td> <td style="text-align: left"> </td><td id="xdx_986_eus-gaap--PreferredStockSharesAuthorized_iI_pid_c20230630__us-gaap--StatementEquityComponentsAxis__custom--PreferredSeriesDMember_zrTXBENnbjnl" style="text-align: right" title="Number of Shares Authorized">20,000</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_989_eus-gaap--PreferredStockSharesOutstanding_iI_pid_c20230630__us-gaap--StatementEquityComponentsAxis__custom--PreferredSeriesDMember_ztwcgFRaCwEa" style="text-align: right" title="Number of Shares Outstanding"><span style="-sec-ix-hidden: xdx2ixbrl1153">-</span></td><td style="text-align: left"> </td><td> </td> <td style="text-align: left">$</td><td id="xdx_982_eus-gaap--PreferredStockParOrStatedValuePerShare_iI_pid_c20230630__us-gaap--StatementEquityComponentsAxis__custom--PreferredSeriesDMember_z0POSIHRNKFd" style="text-align: right" title="Par Value">0.0001</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left">$</td><td id="xdx_988_eus-gaap--PreferredStockLiquidationPreferenceValue_iI_pp0p0_c20230630__us-gaap--StatementEquityComponentsAxis__custom--PreferredSeriesDMember_zVVF2AbZ26fi" style="text-align: right" title="Liquidation Value">1,000</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td>Undesignated</td><td> </td> <td style="text-align: left"> </td><td id="xdx_985_eus-gaap--PreferredStockSharesAuthorized_iI_pid_c20230630__us-gaap--StatementEquityComponentsAxis__custom--UndesignatedMember_ztJ1Lcw9mjob" style="text-align: right" title="Number of Shares Authorized">3,922,000</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_98E_eus-gaap--PreferredStockSharesOutstanding_iI_c20230630__us-gaap--StatementEquityComponentsAxis__custom--UndesignatedMember_zja5RKJV8Bq" style="text-align: right" title="Number of Shares Outstanding"><span style="-sec-ix-hidden: xdx2ixbrl1161">-</span></td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_98C_eus-gaap--PreferredStockParOrStatedValuePerShare_iI_c20230630__us-gaap--StatementEquityComponentsAxis__custom--UndesignatedMember_zPWh94fQhDIc" style="text-align: right" title="Par Value"><span style="-sec-ix-hidden: xdx2ixbrl1163">-</span></td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_980_eus-gaap--PreferredStockLiquidationPreferenceValue_iI_pp0p0_c20230630__us-gaap--StatementEquityComponentsAxis__custom--UndesignatedMember_zqW4ghILwRBi" style="text-align: right" title="Liquidation Value"><span style="-sec-ix-hidden: xdx2ixbrl1165">-</span></td><td style="text-align: left"> </td></tr> </table> 5000000 1000000 25000 0.0010 50000 600 0.0001 100 8000 738 0.0001 1000 20000 0.0001 1000 3922000 1000000 0.001 Each holder of outstanding shares of Series AA Super Voting Preferred Stock shall be entitled to one hundred thousand (100,000) votes for each share of Series AA Super Voting Preferred Stock held on the record date for the determination of stockholders entitled to vote at each meeting of stockholders of the Company 25000 25000 50000 0.75 three-year 1.50 100 600 600 8000 20 1000 the Company filed the amended and restated certificate of designation fort its Series C Secured Redeemable Preferred Stock. The amendment changed the rights of the Series C by (a) removing the requirement to redeem the Series C, (b) removing the obligation to pay dividends on the Series C, (c) Allowing the holders of shares of Series C to convert the stated value of their shares into common stock of the Company at 75% of the closing price of such common stock on the day prior to the conversion. The C Preferred does not have any rights to vote with the common stock 1000 738 738 20000 0.0001 1000 5000000 50 The Company is also committed to providing additional shares of common stock if the holders of Series D do not realize a 15% profit on the resale of the conversion shares 0 50 10900000 109000 1507277 24870 4300590 113650 77000 1667000 24338 5967590 13850000 188950 5000000 50 39398 27500000 253000 850000 11125 10200000 93796 110204 2428777 1050000 62250000 1281900 <p id="xdx_89F_eus-gaap--ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_ze1T2iORuKpc" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The balance of all stock options outstanding as of June 30, 2023, is as follows:</span></p> <p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-right: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span><span id="xdx_8BC_zDc6QnIuD5I7" style="display: none">Schedule of Stock Options Outstanding</span></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"> <tr style="vertical-align: bottom"> <td> </td><td> </td> <td colspan="2"> </td><td> </td><td> </td> <td colspan="2" style="text-align: center">Weighted <br/>Average</td><td> </td><td> </td> <td colspan="2" style="text-align: center">Weighted <br/>Average <br/>Remaining</td><td> </td><td> </td> <td colspan="2" style="text-align: center">Aggregate</td><td> </td></tr> <tr style="vertical-align: bottom"> <td> </td><td> </td> <td colspan="2"> </td><td> </td><td> </td> <td colspan="2" style="text-align: center">Exercise Price</td><td> </td><td> </td> <td colspan="2" style="text-align: center">Contractual</td><td> </td><td> </td> <td colspan="2" style="text-align: center">Intrinsic</td><td> </td></tr> <tr style="vertical-align: bottom"> <td> </td><td style="padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center">Options</td><td style="padding-bottom: 1.5pt"> </td><td style="padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center">Per Share</td><td style="padding-bottom: 1.5pt"> </td><td style="padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center">Term (years)</td><td style="padding-bottom: 1.5pt"> </td><td style="padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center">Value</td><td style="padding-bottom: 1.5pt"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 40%">Outstanding at December 31, 2022</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left"> </td><td id="xdx_986_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iS_c20230101__20230630__us-gaap--FinancialInstrumentAxis__custom--StockOptionsMember_zsOiyCT5vbk6" style="width: 11%; text-align: right" title="Stock Options Outstanding, Beginning Balance">3,012,410</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td id="xdx_989_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_iS_c20230101__20230630__us-gaap--FinancialInstrumentAxis__custom--StockOptionsMember_z00EkPecMAbl" style="width: 11%; text-align: right" title="Weighted Average Exercise Price Per Share, Beginning Balance">0.22</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left"> </td><td style="width: 11%; text-align: right"><span id="xdx_901_ecustom--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm1_dtY_c20230101__20230630__us-gaap--FinancialInstrumentAxis__custom--StockOptionsMember_zHJHlLT6kSXk" title="Weighted Average Remaining Contractual Term (years), Outstanding Beginning">3.40</span></td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left"> </td><td id="xdx_98D_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue_iS_c20230101__20230630__us-gaap--FinancialInstrumentAxis__custom--StockOptionsMember_ztOIJEhr6sv7" style="width: 11%; text-align: right" title="Aggregated Intrinsic Value, Outstanding Beginning Balance">31,200</td><td style="width: 1%; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="padding-left: 10pt">Granted</td><td> </td> <td style="text-align: left"> </td><td id="xdx_987_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_c20230101__20230630__us-gaap--FinancialInstrumentAxis__custom--StockOptionsMember_zBjfcWNHToM7" style="text-align: right" title="Stock Options Outstanding, Granted">3,000,000</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left">$</td><td id="xdx_981_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_c20230101__20230630__us-gaap--FinancialInstrumentAxis__custom--StockOptionsMember_zKD3Tc0ARdoh" style="text-align: right" title="Weighted Average Exercise Price Per Share, Granted">0.01</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">-</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-left: 10pt">Cancelled</td><td> </td> <td style="text-align: left"> </td><td id="xdx_98E_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_iN_di_c20230101__20230630__us-gaap--FinancialInstrumentAxis__custom--StockOptionsMember_zEfJsew9TY37" style="text-align: right" title="Stock Options Outstanding, Cancelled">(660</td><td style="text-align: left">)</td><td> </td> <td style="text-align: left">$</td><td id="xdx_988_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_c20230101__20230630__us-gaap--FinancialInstrumentAxis__custom--StockOptionsMember_zu6jGThdPm3a" style="text-align: right" title="Weighted Average Exercise Price Per Share, Cancelled">11.60</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">-</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="padding-left: 10pt; padding-bottom: 1.5pt">Exercised</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td id="xdx_98F_eus-gaap--StockIssuedDuringPeriodSharesStockOptionsExercised_c20230101__20230630__us-gaap--FinancialInstrumentAxis__custom--StockOptionsMember_zpROFQovvs8b" style="border-bottom: Black 1.5pt solid; text-align: right" title="Stock Options Outstanding, Exercised"><span style="-sec-ix-hidden: xdx2ixbrl1291">-</span></td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="padding-bottom: 1.5pt; text-align: left">$</td><td id="xdx_98F_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_c20230101__20230630__us-gaap--FinancialInstrumentAxis__custom--StockOptionsMember_z3K3yyoyWshk" style="padding-bottom: 1.5pt; text-align: right" title="Weighted Average Exercise Price Per Share, Exercised"><span style="-sec-ix-hidden: xdx2ixbrl1293">-</span></td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt; text-align: right">-</td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt; text-align: right"> </td><td style="padding-bottom: 1.5pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-bottom: 2.5pt">Outstanding at June 30, 2023</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left"> </td><td id="xdx_985_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iE_c20230101__20230630__us-gaap--FinancialInstrumentAxis__custom--StockOptionsMember_zwfMd6MBjOb5" style="border-bottom: Black 2.5pt double; text-align: right" title="Stock Options Outstanding, Ending Balance">6,011,750</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="padding-bottom: 2.5pt; text-align: left">$</td><td id="xdx_987_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_iE_c20230101__20230630__us-gaap--FinancialInstrumentAxis__custom--StockOptionsMember_zBZzskFLFcBg" style="padding-bottom: 2.5pt; text-align: right" title="Weighted Average Exercise Price Per Share, Ending Balance">0.12</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt; text-align: right"><span id="xdx_905_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_dtY_c20230101__20230630__us-gaap--FinancialInstrumentAxis__custom--StockOptionsMember_z8lQ8a35FRG2" title="Weighted Average Remaining Contractual Term (years), Ending">3.06</span></td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="padding-bottom: 2.5pt; text-align: left">$</td><td id="xdx_983_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue_iE_c20230101__20230630__us-gaap--FinancialInstrumentAxis__custom--StockOptionsMember_zQtwEqkvKbl3" style="padding-bottom: 2.5pt; text-align: right" title="Aggregated Intrinsic Value, Ending"><span style="-sec-ix-hidden: xdx2ixbrl1301">-</span></td><td style="padding-bottom: 2.5pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-bottom: 2.5pt">Exercisable at June 30, 2023</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left"> </td><td id="xdx_988_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_iE_c20230101__20230630__us-gaap--FinancialInstrumentAxis__custom--StockOptionsMember_z806iY9kPj62" style="border-bottom: Black 2.5pt double; text-align: right" title="Stock Options Outstanding, Exercisable Ending Balance">1,011,750</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="padding-bottom: 2.5pt; text-align: left">$</td><td id="xdx_982_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_iE_c20230101__20230630__us-gaap--FinancialInstrumentAxis__custom--StockOptionsMember_zNz8Argm2sUl" style="padding-bottom: 2.5pt; text-align: right" title="Weighted Average Exercise Price Per Share, Exercisable Ending Balance">0.64</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt; text-align: right"><span id="xdx_905_ecustom--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualExercisableTerm2_dtY_c20230101__20230630__us-gaap--FinancialInstrumentAxis__custom--StockOptionsMember_zQsdG8tS0vmi" title="Weighted Average Remaining Contractual Term (years), Exercisable">1.83</span></td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="padding-bottom: 2.5pt; text-align: left">$</td><td id="xdx_98E_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_iE_c20230101__20230630__us-gaap--FinancialInstrumentAxis__custom--StockOptionsMember_zfnl7DjGnl3j" style="padding-bottom: 2.5pt; text-align: right" title="Aggregated Intrinsic Value, Exercisable Ending"><span style="-sec-ix-hidden: xdx2ixbrl1309">-</span></td><td style="padding-bottom: 2.5pt; text-align: left"> </td></tr> </table> 3012410 0.22 P3Y4M24D 31200 3000000 0.01 660 11.60 6011750 0.12 P3Y21D 1011750 0.64 P1Y9M29D 6000 0 36000 P2Y6M <p id="xdx_896_eus-gaap--ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock_zLN38eiL6Mda" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The balance of all warrants outstanding as of June 30, 2023, is as follows:</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span><span id="xdx_8BC_zm4hQ9Yj1xbj" style="display: none">Schedule of Warrants Outstanding</span></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-left: auto; border-collapse: collapse; width: 90%; margin-right: auto"> <tr style="vertical-align: bottom"> <td style="text-align: center"> </td><td style="padding-bottom: 1.5pt"> </td> <td colspan="6" style="border-bottom: Black 1.5pt solid; text-align: center">Outstanding Warrants</td><td style="padding-bottom: 1.5pt"> </td><td style="padding-bottom: 1.5pt"> </td> <td colspan="2" style="text-align: center"> </td><td style="padding-bottom: 1.5pt"> </td></tr> <tr style="vertical-align: bottom"> <td style="text-align: center"> </td><td> </td> <td colspan="2" style="text-align: center"> </td><td> </td><td> </td> <td colspan="2" style="text-align: center">Weighted <br/>Average</td><td> </td><td> </td> <td colspan="2" style="text-align: center">Weighted Average Remaining</td><td> </td></tr> <tr style="vertical-align: bottom"> <td style="text-align: center"> </td><td> </td> <td colspan="2" style="text-align: center"> </td><td> </td><td> </td> <td colspan="2" style="text-align: center">Exercise Price</td><td> </td><td> </td> <td colspan="2" style="text-align: center">Contractual</td><td> </td></tr> <tr style="vertical-align: bottom"> <td style="text-align: center"> </td><td style="padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center">Shares</td><td style="padding-bottom: 1.5pt"> </td><td style="padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center">Per Share</td><td style="padding-bottom: 1.5pt"> </td><td style="padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center">Term (years)</td><td style="padding-bottom: 1.5pt"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 46%">Outstanding at December 31, 2022</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left"> </td><td id="xdx_983_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber_iS_c20230101__20230630__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zrJyiUiyoCwl" style="width: 14%; text-align: right" title="Shares Outstanding, Beginning Balance">2,000</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td id="xdx_98E_ecustom--ShareBasedCompensationArrangementByShareBasedPaymetAwardNonOptionOutstandingWeightedAverageExercisePrice_iS_c20230101__20230630__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_z2NasDGsedM2" style="width: 14%; text-align: right" title="Weighted Average Exercise Price Per Share, Outstanding Beginning Balance">50.0</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left"> </td><td style="width: 14%; text-align: right"><span id="xdx_903_ecustom--SharebasedCompensationArrangementBySharebasedPaymentAwardNonOptionsOutstandingWeightedAverageRemainingContractualTerm1_dtY_c20230101__20230630__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zigaLo9ixDIi" title="Weighted Average Remaining Contractual Term (years), Outstanding Beginning">0.22</span></td><td style="width: 1%; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="padding-left: 10pt">Granted</td><td> </td> <td style="text-align: left"> </td><td id="xdx_98B_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted_c20230101__20230630__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zfN8n6JJlxA" style="text-align: right" title="Shares, Granted"><span style="-sec-ix-hidden: xdx2ixbrl1327">-</span></td><td style="text-align: left"> </td><td> </td> <td style="text-align: left">$</td><td id="xdx_986_ecustom--ShareBasedCompensationArrangementByShareBasedPaymetAwardNonOptionGrandInPeriodWeightedAverageExercisePrice_c20230101__20230630__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zPrkc6YTjJYa" style="text-align: right" title="Weighted Average Exercise Price Per Share, Granted"><span style="-sec-ix-hidden: xdx2ixbrl1329">-</span></td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">-</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-left: 10pt">Cancelled</td><td> </td> <td style="text-align: left"> </td><td id="xdx_985_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsForfeitures_iN_di_c20230101__20230630__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_z965mKva35B1" style="text-align: right" title="Shares, Cancelled">(2,000</td><td style="text-align: left">)</td><td> </td> <td style="text-align: left">$</td><td id="xdx_983_ecustom--ShareBasedCompensationArrangementByShareBasedPaymetAwardNonOptionForfeitedOrExpiredInPeriodWeightedAverageExercisePrice_c20230101__20230630__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zapq05LR8qq1" style="text-align: right" title="Weighted Average Exercise Price Per Share, Cancelled">50.0</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">-</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="padding-left: 10pt; padding-bottom: 1.5pt">Exercised</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td id="xdx_989_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised_c20230101__20230630__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zlxHQwh5za09" style="border-bottom: Black 1.5pt solid; text-align: right" title="Shares, Exercised"><span style="-sec-ix-hidden: xdx2ixbrl1335">-</span></td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="padding-bottom: 1.5pt; text-align: left">$</td><td id="xdx_984_ecustom--ShareBasedCompensationArrangementByShareBasedPaymetAwardNonOptionExercisedInPeriodWeightedAverageExercisePrice_c20230101__20230630__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zhqqdFo0Yzlj" style="padding-bottom: 1.5pt; text-align: right" title="Weighted Average Exercise Price Per Share, Exercised"><span style="-sec-ix-hidden: xdx2ixbrl1337">-</span></td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt; text-align: right"> </td><td style="padding-bottom: 1.5pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-bottom: 2.5pt">Outstanding at June 30, 2023</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left"> </td><td id="xdx_98E_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber_iE_c20230101__20230630__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zIAX3g9154W5" style="border-bottom: Black 2.5pt double; text-align: right" title="Shares Outstanding, Ending Balance"><span style="-sec-ix-hidden: xdx2ixbrl1339">-</span></td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="padding-bottom: 2.5pt; text-align: left">$</td><td id="xdx_988_ecustom--ShareBasedCompensationArrangementByShareBasedPaymetAwardNonOptionOutstandingWeightedAverageExercisePrice_iE_c20230101__20230630__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_z39UOseD77H2" style="padding-bottom: 2.5pt; text-align: right" title="Weighted Average Exercise Price Per Share, Outstanding Ending Balance"><span style="-sec-ix-hidden: xdx2ixbrl1341">-</span></td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt; text-align: right">-</td><td style="padding-bottom: 2.5pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-bottom: 2.5pt">Exercisable at June 30, 2023</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left"> </td><td id="xdx_988_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityExercisable_iE_c20230101__20230630__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zf8NNrvAG8Ha" style="border-bottom: Black 2.5pt double; text-align: right" title="Shares Exercisable, Ending Balance"><span style="-sec-ix-hidden: xdx2ixbrl1343">-</span></td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="padding-bottom: 2.5pt; text-align: left">$</td><td id="xdx_984_ecustom--ShareBasedCompensationArrangementByShareBasedPaymetAwardNonOptionWeightedAverageExercisable_iE_c20230101__20230630__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zpJyk6Fm8887" style="padding-bottom: 2.5pt; text-align: right" title="Weighted Average Exercise Price Per Share, Exercisable Ending Balance"><span style="-sec-ix-hidden: xdx2ixbrl1345">-</span></td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt; text-align: right">-</td><td style="padding-bottom: 2.5pt; text-align: left"> </td></tr> </table> 2000 50.0 P0Y2M19D 2000 50.0 <p id="xdx_805_eus-gaap--RelatedPartyTransactionsDisclosureTextBlock_zDF9CbV8mFOl" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Note 7 – <span><span id="xdx_82D_zNo59e21Glx5">Related Party and former related parties Transactions</span>.</span></b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">One executive officer of the Company has agreed to defer a portion of his compensation until cash flow improves. As of June 30, 2023, the balance of the deferred compensation was $<span id="xdx_90D_eus-gaap--DeferredCompensationEquity_iI_c20230630__srt--TitleOfIndividualAxis__srt--ExecutiveOfficerMember_ziIUMG6dUQt8" title="Deferred compensation">570,068</span>, which reflects $<span id="xdx_905_ecustom--AccrualOfDeferredCompensation_iI_c20230630__srt--TitleOfIndividualAxis__srt--ExecutiveOfficerMember_zeAA3pZcK2i2" title="Accrual deferred compensation">150,000</span> accrual of deferred compensation and $<span id="xdx_904_ecustom--RepaymentsOfDeferredCompensation_c20230101__20230630__srt--TitleOfIndividualAxis__srt--ExecutiveOfficerMember_zVBKOuoabrge" title="Cash repayments of deferred compensation">103,750</span> of cash repayment of deferred compensation during the six months ended June 30, 2023.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">As of June 30, 2023, the Company accrued for the issuance of <span id="xdx_90B_eus-gaap--StockIssuedDuringPeriodSharesOther_c20230101__20230630__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zeQzkBVYhFSh" title="Number of shares issued">20,000,000</span> shares of the Company’s common stock with a fair value of $<span id="xdx_903_eus-gaap--StockIssuedDuringPeriodValueOther_c20230101__20230630__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zlkVQt22i232" title="Number of shares issued, value">282,000</span>. Such balance is reported under accounts payable and accrued liabilities related party in the condensed consolidated balance sheet as of June 30, 2022.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">One former executive of the Company has agreed to defer a portion of his compensation until cash flow improves. As of June 30, 2023, the balance of his deferred compensation was $<span id="xdx_903_eus-gaap--DeferredCompensationEquity_iI_c20230630__srt--TitleOfIndividualAxis__custom--OneFormerExecutiveOfficerMember_zMzhgKZ1Dpok" title="Deferred compensation">632,257</span>. No activity occurred during the six months ended June 30, 2023.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">From time-to-time officer of the Company advance monies to the Company to cover costs. The balance of short-term advances due to one officer of the Company at June 30, 2023, was $<span id="xdx_906_eus-gaap--OtherLiabilities_iI_c20230630__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__srt--OfficerMember_zwhQCYGN11h" title="Due to officer">375</span> and is included in the Company’s accounts payable and accrued liabilities balance as of June 30, 2023. During the six months ended June 30, 2023, the Company’s executive officer advanced an aggregate amount of $<span id="xdx_90D_eus-gaap--OtherReceivables_iI_c20230630__srt--TitleOfIndividualAxis__srt--ExecutiveOfficerMember_znSOKbP0jHJ" title="Advance from officer">250</span> for corporate expenses, and $<span id="xdx_90F_eus-gaap--RepaymentsOfRelatedPartyDebt_c20230101__20230630__srt--TitleOfIndividualAxis__srt--ExecutiveOfficerMember_zOcjmBGVdI3k" title="Repayment of debt">2,500</span> was repaid back as of June 30, 2023.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">As of June 30, 2023, notes payable remained outstanding to the former President of the Company, in the amount of $<span id="xdx_903_eus-gaap--NotesPayableCurrent_iI_c20230630__srt--TitleOfIndividualAxis__custom--FormerPresidentMember_zaMmveBz6qyb" title="Notes payable, related parties">104,600</span>. As of June 30, 2023, accrued interests on these notes payable totaled approximately $<span id="xdx_90C_eus-gaap--InterestPayableCurrent_iI_c20230630__srt--TitleOfIndividualAxis__custom--FormerPresidentMember_za34LPaPUjod" title="Interest payable">85,445</span>, and are included in accrued expenses on the condensed consolidated balance sheets.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> 570068 150000 103750 20000000 282000 632257 375 250 2500 104600 85445 <p id="xdx_800_eus-gaap--FairValueDisclosuresTextBlock_z6rWccZda2td" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Note 8 – <span id="xdx_825_zs2bCZXBFyWi">Fair Value Measurements</span></b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The Company issued Variable Debentures, which contained variable conversion rates based on unknown future prices of the Company’s common stock. This results in a conversion feature. The Company measures the conversion feature using the Black Scholes option pricing model using the following assumptions:</span></p> <p id="xdx_89A_eus-gaap--FairValueAssetsMeasuredOnNonrecurringBasisValuationTechniquesTextBlock_z3CuJKxXQj7f" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span><span id="xdx_8BE_zPUxsFr29PCa" style="display: none">Schedule of Conversion Feature Using Black Scholes Option Pricing Model</span></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-left: auto; border-collapse: collapse; width: 80%; margin-right: auto"> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: center; padding-bottom: 1.5pt"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td colspan="5" style="border-bottom: Black 1.5pt solid; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Six months ended June 30,</span></td><td style="padding-bottom: 1.5pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: center; padding-bottom: 1.5pt"> </td><td style="text-align: center; padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: center"> </td><td style="border-bottom: Black 1.5pt solid; text-align: center">2023</td><td style="padding-bottom: 1.5pt; text-align: center"> </td><td style="text-align: center; padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: center"> </td><td style="border-bottom: Black 1.5pt solid; text-align: center">2022</td><td style="padding-bottom: 1.5pt; text-align: center"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: center"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 60%; text-align: left">Expected term</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left"> </td><td style="width: 16%; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_90A_ecustom--FairValueAssumptionsMeasurementInputTerm_dc_c20230101__20230630__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputExpectedTermMember_zOMAer0sdbT9" title="Fair value assumptions, measurement input, term">1 month</span></span></td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left"> </td><td style="width: 16%; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_906_ecustom--FairValueAssumptionsMeasurementInputTerm_dc_c20220101__20220630__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputExpectedTermMember_z5oxd7HNSkQj" title="Fair value assumptions, measurement input, term">1 month</span></span></td><td style="width: 1%; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td>Exercise price</td><td> </td> <td style="text-align: left">$</td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_906_eus-gaap--DerivativeAssetLiabilityNetMeasurementInput_iI_uUSDPShares_c20230630__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputExercisePriceMember__srt--RangeAxis__srt--MinimumMember_zVdcFPVf2xug" title="Fair value assumptions, measurement input, exercise price">0.0066</span>-$<span id="xdx_903_eus-gaap--DerivativeAssetLiabilityNetMeasurementInput_iI_pid_uUSDPShares_c20230630__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputExercisePriceMember__srt--RangeAxis__srt--MaximumMember_zik0MN2u6dC6" title="Fair value assumptions, measurement input, exercise price">0.0151</span></span></td><td style="text-align: left"> </td><td> </td> <td style="text-align: left">$</td><td style="text-align: right"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_901_eus-gaap--DerivativeAssetLiabilityNetMeasurementInput_iI_uUSDPShares_c20220630__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputExercisePriceMember__srt--RangeAxis__srt--MinimumMember_z5sbaKri8941" title="Fair value assumptions, measurement input, exercise price">0.004</span> – $<span id="xdx_901_eus-gaap--DerivativeAssetLiabilityNetMeasurementInput_iI_pid_uUSDPShares_c20220630__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputExercisePriceMember__srt--RangeAxis__srt--MaximumMember_z5oCBaxljd7b" title="Fair value assumptions, measurement input, exercise price">0.015</span></span></p></td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left">Expected volatility</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_908_eus-gaap--DerivativeAssetLiabilityNetMeasurementInput_iI_pid_uPure_c20230630__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputPriceVolatilityMember__srt--RangeAxis__srt--MinimumMember_zxR4svLHaUl2" title="Fair value assumptions, measurement input, percentage">154</span>%-<span id="xdx_90A_eus-gaap--DerivativeAssetLiabilityNetMeasurementInput_iI_pid_uPure_c20230630__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputPriceVolatilityMember__srt--RangeAxis__srt--MaximumMember_zAn5C4vmUEr4" title="Fair value assumptions, measurement input, percentage">158</span></span></td><td style="text-align: left">%</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_902_eus-gaap--DerivativeAssetLiabilityNetMeasurementInput_iI_pid_uPure_c20220630__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputPriceVolatilityMember__srt--RangeAxis__srt--MinimumMember_zzsLhUEfMdM7" title="Fair value assumptions, measurement input, percentage">152</span>%-<span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_900_eus-gaap--DerivativeAssetLiabilityNetMeasurementInput_iI_pid_uPure_c20220630__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputPriceVolatilityMember__srt--RangeAxis__srt--MaximumMember_zl0ZjFe3Eolg" title="Fair value assumptions, measurement input, percentage">169</span></span></span></td><td style="text-align: left">%</td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left">Expected dividends</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_90A_eus-gaap--DerivativeAssetLiabilityNetMeasurementInput_iI_pid_dpn_uPure_c20230630__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputExpectedDividendRateMember_z0ASr2g7LXp2" title="Fair value assumptions, measurement input, percentage">None</span></span></td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_908_eus-gaap--DerivativeAssetLiabilityNetMeasurementInput_iI_pid_dpn_uPure_c20220630__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputExpectedDividendRateMember_zyehvZslId23" title="Fair value assumptions, measurement input, percentage">None</span></span></td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left">Risk-free interest rate</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_905_eus-gaap--DerivativeAssetLiabilityNetMeasurementInput_iI_pid_uPure_c20230630__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputRiskFreeInterestRateMember__srt--RangeAxis__srt--MinimumMember_zJi10KPYjzy1" title="Fair value assumptions, measurement input, percentage">4.64</span>%-<span id="xdx_901_eus-gaap--DerivativeAssetLiabilityNetMeasurementInput_iI_pid_uPure_c20230630__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputRiskFreeInterestRateMember__srt--RangeAxis__srt--MaximumMember_zfLSPsqPqhWa">5.40</span></span></td><td style="text-align: left">%</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_900_eus-gaap--DerivativeAssetLiabilityNetMeasurementInput_iI_pid_uPure_c20220630__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputRiskFreeInterestRateMember__srt--RangeAxis__srt--MinimumMember_zYbQ6Wdpe6Ld" title="Fair value assumptions, measurement input, percentage">1.63</span>% to <span id="xdx_901_eus-gaap--DerivativeAssetLiabilityNetMeasurementInput_iI_pid_uPure_c20220630__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputRiskFreeInterestRateMember__srt--RangeAxis__srt--MaximumMember_zXlc89oShkq7">2.80</span></span></td><td style="text-align: left">%</td></tr> <tr style="vertical-align: bottom; background-color: White"> <td>Forfeitures</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_90A_eus-gaap--DerivativeAssetLiabilityNetMeasurementInput_iI_pid_dpn_uPure_c20230630__us-gaap--MeasurementInputTypeAxis__custom--ForfeituresMember_zM7R9HoDD3Oh" title="Fair value assumptions, measurement input, percentage">None</span></span></td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_90F_eus-gaap--DerivativeAssetLiabilityNetMeasurementInput_iI_pid_dpn_uPure_c20220630__us-gaap--MeasurementInputTypeAxis__custom--ForfeituresMember_zD964hQGG9ej" title="Fair value assumptions, measurement input, percentage">None</span></span></td><td style="text-align: left"> </td></tr> </table> <p id="xdx_8A5_zxgYRNT0s2ij" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The assumptions used in determining fair value represent management’s best estimates, but these estimates involve inherent uncertainties and the application of management’s judgment. As a result, if factors change, including changes in the market value of the Company’s common stock, managements’ assessment, or significant fluctuations in the volatility of the trading market for the Company’s common stock, the Company’s fair value estimates could be materially different in the future.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The Company computes the fair value of the derivative liability at each reporting period and the change in the fair value is recorded as non-cash expense or income. The key component in the value of the derivative liability is the Company’s stock price, which is subject to significant fluctuation and is not under its control. The resulting effect on net income (loss) is therefore subject to significant fluctuation and will continue to be so until the Company’s variable debentures, which the convertible feature is associated with, are converted into common stock or paid in full in cash. Assuming all other fair value inputs remain constant, the Company will record non-cash expense when its stock price increases and non-cash income when its stock price decreases.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Endonovo Therapeutics, Inc.</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Notes to Condensed Consolidated Financial Statements (continued)</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0pt; margin-bottom: 0pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p id="xdx_898_eus-gaap--FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock_zJnjJAZo1398" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The following table presents changes in the liabilities with significant unobservable inputs (level 3) for the three months ended June 30, 2023:</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: left; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span><span id="xdx_8B7_zswKX07Iw77k" style="display: none">Schedule of Fair Value of Derivative Liability</span></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-left: auto; border-collapse: collapse; width: 80%; margin-right: auto"> <tr style="vertical-align: bottom"> <td> </td><td> </td> <td colspan="2" style="text-align: center">Derivative</td><td> </td></tr> <tr style="vertical-align: bottom"> <td> </td><td style="padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center">Liability</td><td style="padding-bottom: 1.5pt"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 80%">Balance December 31, 2022</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td id="xdx_987_eus-gaap--FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisWithUnobservableInputs_iS_c20230101__20230630__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member_z9cdsI352E7f" style="width: 16%; text-align: right" title="Derivative Liability, beginning balance">17,359,064</td><td style="width: 1%; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-left: 10pt; text-align: left">Settlement debt</td><td> </td> <td style="text-align: left"> </td><td id="xdx_986_eus-gaap--FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisUnobservableInputsReconciliationSettlements_c20230101__20230630__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member_zxykwIstxCs8" style="text-align: right" title="Settlement debt">(10,769</td><td style="text-align: left">)</td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="padding-left: 10pt; text-align: left; padding-bottom: 1.5pt">Change in estimated fair value</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td id="xdx_989_eus-gaap--FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisUnobservableInputsReconciliationPeriodIncreaseDecrease_c20230101__20230630__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member_zCC1NkJwSyc" style="border-bottom: Black 1.5pt solid; text-align: right" title="Change in estimated fair value">(11,445,466</td><td style="padding-bottom: 1.5pt; text-align: left">)</td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="padding-bottom: 2.5pt">Balance June 30, 2023</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_984_eus-gaap--FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisWithUnobservableInputs_iE_c20230101__20230630__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member_zwTCzgw7d4rj" style="border-bottom: Black 2.5pt double; text-align: right" title="Derivative Liability, ending balance">5,902,829</td><td style="padding-bottom: 2.5pt; text-align: left"> </td></tr> </table> <p id="xdx_8A9_zFMQ4GgRlFme" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Accounting guidance on fair value measurements and disclosures defines fair value, establishes a framework for measuring the fair value of assets and liabilities using a hierarchy system, and defines required disclosures. It clarifies that fair value is the price that would be received to sell an asset or paid to transfer a liability in an orderly transaction between market participants in the market in which the reporting entity transacts business.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 27pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The Company’s balance sheet contains derivative liabilities that are recorded at fair value on a recurring basis. The three-level valuation hierarchy for disclosure of fair value is as follows:</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 27pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Level 1: uses quoted market prices in active markets for identical assets or liabilities.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 27pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Level 2: uses observable market-based inputs or unobservable inputs that are corroborated by market data.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 27pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Level 3: uses unobservable inputs that are not corroborated by market data.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 27pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The fair value of the Company’s recorded derivative liability is determined based on unobservable inputs that are not corroborated by market data, which require a Level 3 classification. A Black Scholes option pricing model was used to determine the fair value. The Company records derivative liability on the condensed consolidated balance sheets at fair value with changes in fair value recorded in the condensed consolidated statements of operation.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 27pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p id="xdx_890_eus-gaap--ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock_z3zNgPfAyEY8" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The following table presents balances in the liabilities with significant unobservable inputs (Level 3) as of June 30, 2023:</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 27pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span><span id="xdx_8BD_zfHOEZNJkaf1" style="display: none">Schedule of Liabilities Significant Unobservable Inputs</span></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"> <tr style="vertical-align: bottom"> <td> </td><td style="padding-bottom: 1.5pt"> </td> <td colspan="14" style="border-bottom: Black 1.5pt solid; text-align: center">Fair Value Measurements Using</td><td style="padding-bottom: 1.5pt"> </td></tr> <tr style="vertical-align: bottom"> <td style="text-align: center"> </td><td> </td> <td colspan="2" style="text-align: center">Quoted <br/>Prices in</td><td> </td><td> </td> <td colspan="2"> </td><td> </td><td> </td> <td colspan="2"> </td><td> </td><td> </td> <td colspan="2" style="text-align: center"> </td><td> </td></tr> <tr style="vertical-align: bottom"> <td style="text-align: center"> </td><td> </td> <td colspan="2" style="text-align: center">Active <br/>Markets for</td><td> </td><td> </td> <td colspan="2" style="text-align: center">Significant Other</td><td> </td><td> </td> <td colspan="2" style="text-align: center">Significant</td><td> </td><td> </td> <td colspan="2" style="text-align: center"> </td><td> </td></tr> <tr style="vertical-align: bottom"> <td style="text-align: center"> </td><td> </td> <td colspan="2" style="text-align: center">Identical <br/>Assets</td><td> </td><td> </td> <td colspan="2" style="text-align: center">Observable <br/>Inputs</td><td> </td><td> </td> <td colspan="2" style="text-align: center">Unobservable <br/>Inputs</td><td> </td><td> </td> <td colspan="2" style="text-align: center"> </td><td> </td></tr> <tr style="vertical-align: bottom"> <td style="text-align: center"> </td><td style="padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center">(Level 1)</td><td style="padding-bottom: 1.5pt"> </td><td style="padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center">(Level 2)</td><td style="padding-bottom: 1.5pt"> </td><td style="padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center">(Level 3)</td><td style="padding-bottom: 1.5pt"> </td><td style="padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center">Total</td><td style="padding-bottom: 1.5pt"> </td></tr> <tr style="vertical-align: bottom"> <td> </td><td> </td> <td colspan="2" style="text-align: right"> </td><td> </td><td> </td> <td colspan="2" style="text-align: right"> </td><td> </td><td> </td> <td colspan="2" style="text-align: right"> </td><td> </td><td> </td> <td colspan="2" style="text-align: right"> </td><td> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td>As of June 30, 2023</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="padding-left: 10pt; width: 40%; text-align: left; padding-bottom: 1.5pt">Derivative liability</td><td style="width: 2%; padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; width: 1%; text-align: left">$</td><td id="xdx_98F_eus-gaap--DerivativeLiabilities_iI_c20230630__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel1Member_zxPQOathi5vk" style="border-bottom: Black 1.5pt solid; width: 11%; text-align: right" title="Derivative liability">    <span style="-sec-ix-hidden: xdx2ixbrl1421">-</span></td><td style="width: 1%; padding-bottom: 1.5pt; text-align: left"> </td><td style="width: 2%; padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; width: 1%; text-align: left">$</td><td id="xdx_98D_eus-gaap--DerivativeLiabilities_iI_c20230630__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel2Member_z0putGh7eNu3" style="border-bottom: Black 1.5pt solid; width: 11%; text-align: right" title="Derivative liability">    <span style="-sec-ix-hidden: xdx2ixbrl1423">-</span></td><td style="width: 1%; padding-bottom: 1.5pt; text-align: left"> </td><td style="width: 2%; padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; width: 1%; text-align: left">$</td><td id="xdx_98B_eus-gaap--DerivativeLiabilities_iI_c20230630__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member_zp4YfabIWHAe" style="border-bottom: Black 1.5pt solid; width: 11%; text-align: right" title="Derivative liability">5,902,829</td><td style="width: 1%; padding-bottom: 1.5pt; text-align: left"> </td><td style="width: 2%; padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; width: 1%; text-align: left">$</td><td id="xdx_98C_eus-gaap--DerivativeLiabilities_iI_c20230630_zVD4ppDvAZy2" style="border-bottom: Black 1.5pt solid; width: 11%; text-align: right" title="Derivative liability">5,902,829</td><td style="width: 1%; padding-bottom: 1.5pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-bottom: 2.5pt">Total</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_98C_eus-gaap--FinancialLiabilitiesFairValueDisclosure_iI_c20230630__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel1Member_zaBErfmEvC8b" style="border-bottom: Black 2.5pt double; text-align: right" title="Total"><span style="-sec-ix-hidden: xdx2ixbrl1429">-</span></td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_980_eus-gaap--FinancialLiabilitiesFairValueDisclosure_iI_c20230630__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel2Member_zgYTmqtFDM44" style="border-bottom: Black 2.5pt double; text-align: right" title="Total"><span style="-sec-ix-hidden: xdx2ixbrl1431">-</span></td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_989_eus-gaap--FinancialLiabilitiesFairValueDisclosure_iI_c20230630__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member_zRxnLe8p6Lc7" style="border-bottom: Black 2.5pt double; text-align: right" title="Total">5,902,829</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_989_eus-gaap--FinancialLiabilitiesFairValueDisclosure_iI_c20230630_zpaGAgPcbIN6" style="border-bottom: Black 2.5pt double; text-align: right" title="Total">5,902,829</td><td style="padding-bottom: 2.5pt; text-align: left"> </td></tr> </table> <p id="xdx_8A9_zJ2wUMbNzLya" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b> </b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b> </b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Endonovo Therapeutics, Inc.</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Notes to Condensed Consolidated Financial Statements (continued)</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p id="xdx_89A_eus-gaap--FairValueAssetsMeasuredOnNonrecurringBasisValuationTechniquesTextBlock_z3CuJKxXQj7f" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span><span id="xdx_8BE_zPUxsFr29PCa" style="display: none">Schedule of Conversion Feature Using Black Scholes Option Pricing Model</span></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-left: auto; border-collapse: collapse; width: 80%; margin-right: auto"> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: center; padding-bottom: 1.5pt"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td colspan="5" style="border-bottom: Black 1.5pt solid; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Six months ended June 30,</span></td><td style="padding-bottom: 1.5pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: center; padding-bottom: 1.5pt"> </td><td style="text-align: center; padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: center"> </td><td style="border-bottom: Black 1.5pt solid; text-align: center">2023</td><td style="padding-bottom: 1.5pt; text-align: center"> </td><td style="text-align: center; padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: center"> </td><td style="border-bottom: Black 1.5pt solid; text-align: center">2022</td><td style="padding-bottom: 1.5pt; text-align: center"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: center"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 60%; text-align: left">Expected term</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left"> </td><td style="width: 16%; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_90A_ecustom--FairValueAssumptionsMeasurementInputTerm_dc_c20230101__20230630__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputExpectedTermMember_zOMAer0sdbT9" title="Fair value assumptions, measurement input, term">1 month</span></span></td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left"> </td><td style="width: 16%; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_906_ecustom--FairValueAssumptionsMeasurementInputTerm_dc_c20220101__20220630__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputExpectedTermMember_z5oxd7HNSkQj" title="Fair value assumptions, measurement input, term">1 month</span></span></td><td style="width: 1%; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td>Exercise price</td><td> </td> <td style="text-align: left">$</td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_906_eus-gaap--DerivativeAssetLiabilityNetMeasurementInput_iI_uUSDPShares_c20230630__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputExercisePriceMember__srt--RangeAxis__srt--MinimumMember_zVdcFPVf2xug" title="Fair value assumptions, measurement input, exercise price">0.0066</span>-$<span id="xdx_903_eus-gaap--DerivativeAssetLiabilityNetMeasurementInput_iI_pid_uUSDPShares_c20230630__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputExercisePriceMember__srt--RangeAxis__srt--MaximumMember_zik0MN2u6dC6" title="Fair value assumptions, measurement input, exercise price">0.0151</span></span></td><td style="text-align: left"> </td><td> </td> <td style="text-align: left">$</td><td style="text-align: right"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_901_eus-gaap--DerivativeAssetLiabilityNetMeasurementInput_iI_uUSDPShares_c20220630__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputExercisePriceMember__srt--RangeAxis__srt--MinimumMember_z5sbaKri8941" title="Fair value assumptions, measurement input, exercise price">0.004</span> – $<span id="xdx_901_eus-gaap--DerivativeAssetLiabilityNetMeasurementInput_iI_pid_uUSDPShares_c20220630__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputExercisePriceMember__srt--RangeAxis__srt--MaximumMember_z5oCBaxljd7b" title="Fair value assumptions, measurement input, exercise price">0.015</span></span></p></td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left">Expected volatility</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_908_eus-gaap--DerivativeAssetLiabilityNetMeasurementInput_iI_pid_uPure_c20230630__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputPriceVolatilityMember__srt--RangeAxis__srt--MinimumMember_zxR4svLHaUl2" title="Fair value assumptions, measurement input, percentage">154</span>%-<span id="xdx_90A_eus-gaap--DerivativeAssetLiabilityNetMeasurementInput_iI_pid_uPure_c20230630__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputPriceVolatilityMember__srt--RangeAxis__srt--MaximumMember_zAn5C4vmUEr4" title="Fair value assumptions, measurement input, percentage">158</span></span></td><td style="text-align: left">%</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_902_eus-gaap--DerivativeAssetLiabilityNetMeasurementInput_iI_pid_uPure_c20220630__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputPriceVolatilityMember__srt--RangeAxis__srt--MinimumMember_zzsLhUEfMdM7" title="Fair value assumptions, measurement input, percentage">152</span>%-<span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_900_eus-gaap--DerivativeAssetLiabilityNetMeasurementInput_iI_pid_uPure_c20220630__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputPriceVolatilityMember__srt--RangeAxis__srt--MaximumMember_zl0ZjFe3Eolg" title="Fair value assumptions, measurement input, percentage">169</span></span></span></td><td style="text-align: left">%</td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left">Expected dividends</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_90A_eus-gaap--DerivativeAssetLiabilityNetMeasurementInput_iI_pid_dpn_uPure_c20230630__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputExpectedDividendRateMember_z0ASr2g7LXp2" title="Fair value assumptions, measurement input, percentage">None</span></span></td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_908_eus-gaap--DerivativeAssetLiabilityNetMeasurementInput_iI_pid_dpn_uPure_c20220630__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputExpectedDividendRateMember_zyehvZslId23" title="Fair value assumptions, measurement input, percentage">None</span></span></td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left">Risk-free interest rate</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_905_eus-gaap--DerivativeAssetLiabilityNetMeasurementInput_iI_pid_uPure_c20230630__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputRiskFreeInterestRateMember__srt--RangeAxis__srt--MinimumMember_zJi10KPYjzy1" title="Fair value assumptions, measurement input, percentage">4.64</span>%-<span id="xdx_901_eus-gaap--DerivativeAssetLiabilityNetMeasurementInput_iI_pid_uPure_c20230630__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputRiskFreeInterestRateMember__srt--RangeAxis__srt--MaximumMember_zfLSPsqPqhWa">5.40</span></span></td><td style="text-align: left">%</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_900_eus-gaap--DerivativeAssetLiabilityNetMeasurementInput_iI_pid_uPure_c20220630__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputRiskFreeInterestRateMember__srt--RangeAxis__srt--MinimumMember_zYbQ6Wdpe6Ld" title="Fair value assumptions, measurement input, percentage">1.63</span>% to <span id="xdx_901_eus-gaap--DerivativeAssetLiabilityNetMeasurementInput_iI_pid_uPure_c20220630__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputRiskFreeInterestRateMember__srt--RangeAxis__srt--MaximumMember_zXlc89oShkq7">2.80</span></span></td><td style="text-align: left">%</td></tr> <tr style="vertical-align: bottom; background-color: White"> <td>Forfeitures</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_90A_eus-gaap--DerivativeAssetLiabilityNetMeasurementInput_iI_pid_dpn_uPure_c20230630__us-gaap--MeasurementInputTypeAxis__custom--ForfeituresMember_zM7R9HoDD3Oh" title="Fair value assumptions, measurement input, percentage">None</span></span></td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_90F_eus-gaap--DerivativeAssetLiabilityNetMeasurementInput_iI_pid_dpn_uPure_c20220630__us-gaap--MeasurementInputTypeAxis__custom--ForfeituresMember_zD964hQGG9ej" title="Fair value assumptions, measurement input, percentage">None</span></span></td><td style="text-align: left"> </td></tr> </table> P1M P1M 0.0066 0.0151 0.004 0.015 154 158 152 169 0 0 4.64 5.40 1.63 2.80 0 0 <p id="xdx_898_eus-gaap--FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock_zJnjJAZo1398" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The following table presents changes in the liabilities with significant unobservable inputs (level 3) for the three months ended June 30, 2023:</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: left; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span><span id="xdx_8B7_zswKX07Iw77k" style="display: none">Schedule of Fair Value of Derivative Liability</span></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-left: auto; border-collapse: collapse; width: 80%; margin-right: auto"> <tr style="vertical-align: bottom"> <td> </td><td> </td> <td colspan="2" style="text-align: center">Derivative</td><td> </td></tr> <tr style="vertical-align: bottom"> <td> </td><td style="padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center">Liability</td><td style="padding-bottom: 1.5pt"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 80%">Balance December 31, 2022</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td id="xdx_987_eus-gaap--FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisWithUnobservableInputs_iS_c20230101__20230630__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member_z9cdsI352E7f" style="width: 16%; text-align: right" title="Derivative Liability, beginning balance">17,359,064</td><td style="width: 1%; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-left: 10pt; text-align: left">Settlement debt</td><td> </td> <td style="text-align: left"> </td><td id="xdx_986_eus-gaap--FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisUnobservableInputsReconciliationSettlements_c20230101__20230630__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member_zxykwIstxCs8" style="text-align: right" title="Settlement debt">(10,769</td><td style="text-align: left">)</td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="padding-left: 10pt; text-align: left; padding-bottom: 1.5pt">Change in estimated fair value</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td id="xdx_989_eus-gaap--FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisUnobservableInputsReconciliationPeriodIncreaseDecrease_c20230101__20230630__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member_zCC1NkJwSyc" style="border-bottom: Black 1.5pt solid; text-align: right" title="Change in estimated fair value">(11,445,466</td><td style="padding-bottom: 1.5pt; text-align: left">)</td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="padding-bottom: 2.5pt">Balance June 30, 2023</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_984_eus-gaap--FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisWithUnobservableInputs_iE_c20230101__20230630__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member_zwTCzgw7d4rj" style="border-bottom: Black 2.5pt double; text-align: right" title="Derivative Liability, ending balance">5,902,829</td><td style="padding-bottom: 2.5pt; text-align: left"> </td></tr> </table> 17359064 -10769 -11445466 5902829 <p id="xdx_890_eus-gaap--ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock_z3zNgPfAyEY8" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The following table presents balances in the liabilities with significant unobservable inputs (Level 3) as of June 30, 2023:</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 27pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span><span id="xdx_8BD_zfHOEZNJkaf1" style="display: none">Schedule of Liabilities Significant Unobservable Inputs</span></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"> <tr style="vertical-align: bottom"> <td> </td><td style="padding-bottom: 1.5pt"> </td> <td colspan="14" style="border-bottom: Black 1.5pt solid; text-align: center">Fair Value Measurements Using</td><td style="padding-bottom: 1.5pt"> </td></tr> <tr style="vertical-align: bottom"> <td style="text-align: center"> </td><td> </td> <td colspan="2" style="text-align: center">Quoted <br/>Prices in</td><td> </td><td> </td> <td colspan="2"> </td><td> </td><td> </td> <td colspan="2"> </td><td> </td><td> </td> <td colspan="2" style="text-align: center"> </td><td> </td></tr> <tr style="vertical-align: bottom"> <td style="text-align: center"> </td><td> </td> <td colspan="2" style="text-align: center">Active <br/>Markets for</td><td> </td><td> </td> <td colspan="2" style="text-align: center">Significant Other</td><td> </td><td> </td> <td colspan="2" style="text-align: center">Significant</td><td> </td><td> </td> <td colspan="2" style="text-align: center"> </td><td> </td></tr> <tr style="vertical-align: bottom"> <td style="text-align: center"> </td><td> </td> <td colspan="2" style="text-align: center">Identical <br/>Assets</td><td> </td><td> </td> <td colspan="2" style="text-align: center">Observable <br/>Inputs</td><td> </td><td> </td> <td colspan="2" style="text-align: center">Unobservable <br/>Inputs</td><td> </td><td> </td> <td colspan="2" style="text-align: center"> </td><td> </td></tr> <tr style="vertical-align: bottom"> <td style="text-align: center"> </td><td style="padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center">(Level 1)</td><td style="padding-bottom: 1.5pt"> </td><td style="padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center">(Level 2)</td><td style="padding-bottom: 1.5pt"> </td><td style="padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center">(Level 3)</td><td style="padding-bottom: 1.5pt"> </td><td style="padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center">Total</td><td style="padding-bottom: 1.5pt"> </td></tr> <tr style="vertical-align: bottom"> <td> </td><td> </td> <td colspan="2" style="text-align: right"> </td><td> </td><td> </td> <td colspan="2" style="text-align: right"> </td><td> </td><td> </td> <td colspan="2" style="text-align: right"> </td><td> </td><td> </td> <td colspan="2" style="text-align: right"> </td><td> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td>As of June 30, 2023</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="padding-left: 10pt; width: 40%; text-align: left; padding-bottom: 1.5pt">Derivative liability</td><td style="width: 2%; padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; width: 1%; text-align: left">$</td><td id="xdx_98F_eus-gaap--DerivativeLiabilities_iI_c20230630__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel1Member_zxPQOathi5vk" style="border-bottom: Black 1.5pt solid; width: 11%; text-align: right" title="Derivative liability">    <span style="-sec-ix-hidden: xdx2ixbrl1421">-</span></td><td style="width: 1%; padding-bottom: 1.5pt; text-align: left"> </td><td style="width: 2%; padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; width: 1%; text-align: left">$</td><td id="xdx_98D_eus-gaap--DerivativeLiabilities_iI_c20230630__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel2Member_z0putGh7eNu3" style="border-bottom: Black 1.5pt solid; width: 11%; text-align: right" title="Derivative liability">    <span style="-sec-ix-hidden: xdx2ixbrl1423">-</span></td><td style="width: 1%; padding-bottom: 1.5pt; text-align: left"> </td><td style="width: 2%; padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; width: 1%; text-align: left">$</td><td id="xdx_98B_eus-gaap--DerivativeLiabilities_iI_c20230630__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member_zp4YfabIWHAe" style="border-bottom: Black 1.5pt solid; width: 11%; text-align: right" title="Derivative liability">5,902,829</td><td style="width: 1%; padding-bottom: 1.5pt; text-align: left"> </td><td style="width: 2%; padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; width: 1%; text-align: left">$</td><td id="xdx_98C_eus-gaap--DerivativeLiabilities_iI_c20230630_zVD4ppDvAZy2" style="border-bottom: Black 1.5pt solid; width: 11%; text-align: right" title="Derivative liability">5,902,829</td><td style="width: 1%; padding-bottom: 1.5pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-bottom: 2.5pt">Total</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_98C_eus-gaap--FinancialLiabilitiesFairValueDisclosure_iI_c20230630__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel1Member_zaBErfmEvC8b" style="border-bottom: Black 2.5pt double; text-align: right" title="Total"><span style="-sec-ix-hidden: xdx2ixbrl1429">-</span></td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_980_eus-gaap--FinancialLiabilitiesFairValueDisclosure_iI_c20230630__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel2Member_zgYTmqtFDM44" style="border-bottom: Black 2.5pt double; text-align: right" title="Total"><span style="-sec-ix-hidden: xdx2ixbrl1431">-</span></td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_989_eus-gaap--FinancialLiabilitiesFairValueDisclosure_iI_c20230630__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member_zRxnLe8p6Lc7" style="border-bottom: Black 2.5pt double; text-align: right" title="Total">5,902,829</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_989_eus-gaap--FinancialLiabilitiesFairValueDisclosure_iI_c20230630_zpaGAgPcbIN6" style="border-bottom: Black 2.5pt double; text-align: right" title="Total">5,902,829</td><td style="padding-bottom: 2.5pt; text-align: left"> </td></tr> </table> 5902829 5902829 5902829 5902829 <p id="xdx_807_eus-gaap--CommitmentsAndContingenciesDisclosureTextBlock_z4LMWKOuG9H9" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Note 9 – <span id="xdx_824_zJwRiPQ4dM0l">Commitments and Contingencies</span></b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Legal Matters</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The Company is subject to certain legal proceedings, which it considers routine to its business activities. As of June 30, 2023, the Company believes, after consultation with legal counsel, that the ultimate outcome of such legal proceedings, whether individually or in the aggregate, is not likely to have a material adverse effect on the Company’s financial position, results of operations or liquidity.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p id="xdx_80D_eus-gaap--ConcentrationRiskDisclosureTextBlock_zCCutbva7qt9" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Note 10 – <span><span id="xdx_821_zzm5AzXDT5Af">Concentrations</span>.</span></b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Sales</i></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">During the six months ended June 30, 2023, we had one significant customer, which accounted for approximately <span id="xdx_90F_eus-gaap--ConcentrationRiskPercentage1_pid_dp_uPure_c20230101__20230630__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--SalesRevenueNetMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember__srt--MajorCustomersAxis__custom--OneSignificantCustomerMember_zx7Ef0gRLiNa" title="Concentration risk, percentage">100</span>% of sales. In addition, the Company generated all of its royalty/licensing revenue from one former related party.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Supplier</i></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We also have a single source for our bioelectric medical devices, which account for <span id="xdx_90D_eus-gaap--ConcentrationRiskPercentage1_pid_dp_uPure_c20230101__20230630__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--SalesRevenueNetMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--SupplierConcentrationRiskMember__srt--MajorCustomersAxis__custom--SupplierMember_z65Twtee9Wk5" title="Concentration risk, percentage">100</span>% of our sales. The interruption of products provided by this supplier would adversely affect our business and financial condition unless an alternative source of products could be found.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> 1 1 <p id="xdx_805_eus-gaap--SubsequentEventsTextBlock_zZtsCjbJAhm2" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Note 11 – <span id="xdx_82E_zgt9dhs2b1Jd">Subsequent Events</span></b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Management has evaluated events that have occurred subsequent to the date of these consolidated condensed financial statements and has determined that, other than those listed below, no such reportable subsequent events exist through the date the financial statements were issued in accordance with FASB ASC Topic 855, “Subsequent Events.”</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Subsequent to June 30, 2023, </span>the Company issued <span id="xdx_901_eus-gaap--StockIssuedDuringPeriodSharesNewIssues_c20230701__20230814__us-gaap--TypeOfArrangementAxis__custom--TwoNotesExtensionAgreementsMember__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember_z7e8OGDEVOQ2" title="Number of shares issued">500,000</span> shares of common stock pursuant to two notes extension agreements.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Subsequent to June 30, 2023, the Company issued <span id="xdx_90F_eus-gaap--StockIssuedDuringPeriodSharesNewIssues_c20230701__20230814__us-gaap--TypeOfArrangementAxis__custom--SecuriyPurchaseAgreementMember__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember__srt--TitleOfIndividualAxis__custom--OneInvestorMember_zmgQ0pIzuVk1" title="Number of shares issued">1,000,000</span> shares of common stock pursuant to a securities purchase agreement with one investor. Such a liability was accrued for and reported under <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">accounts payable and accrued liabilities in the consolidated balance sheet as of June 30, 2023.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Subsequent to June 30, 2023, the Company issued <span id="xdx_90E_eus-gaap--StockIssuedDuringPeriodSharesNewIssues_c20230701__20230814__us-gaap--TypeOfArrangementAxis__custom--ProductionAgreementMember__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember_zEL9t7qdmcbj" title="Number of shares issued">8,000,000</span> shares of common stock pursuant to a production agreement.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Subsequent to June 30, 2023, the Company issued a convertible note in the principal amount of $<span id="xdx_904_eus-gaap--DebtInstrumentFaceAmount_iI_c20230814__us-gaap--ShortTermDebtTypeAxis__us-gaap--ConvertibleDebtMember__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember_zZ33HcpJZUhk" title="Principal amount">20,000</span> carrying a coupon of <span id="xdx_908_ecustom--DebtInstrumentCouponRate_iI_pid_uPure_c20230814__us-gaap--ShortTermDebtTypeAxis__us-gaap--ConvertibleDebtMember__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember_zOYId6LWUFnb" title="Coupon rate">10%</span> and a <span id="xdx_907_eus-gaap--DebtInstrumentMaturityDateDescription_dxL_c20230701__20230814__us-gaap--ShortTermDebtTypeAxis__us-gaap--ConvertibleDebtMember__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember_z1nnCgSDuSfi" title="Maturity period::XDX::P3Y"><span style="-sec-ix-hidden: xdx2ixbrl1457">three</span></span>-month maturity date.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0">Subsequent to June 30, 2023, the Company issued an aggregate of <span id="xdx_90C_eus-gaap--StockIssuedDuringPeriodSharesNewIssues_c20230701__20230814__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember__srt--TitleOfIndividualAxis__custom--ConsultantAndChiefExecutiveOfficerMember_zjGTiDgpP2Qa" title="Number of shares issued">29,600,000</span> shares of common stock for additional consideration to consultants and to the Company’s Chief Executive Officer, previously granted in the first fiscal quarter. Such a liability was accrued for and reported under <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">accounts payable and accrued liabilities in the consolidated balance sheet as of June 30, 2023.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"></p> 500000 1000000 8000000 20000 0.10 29600000 EXCEL 54 Financial_Report.xlsx IDEA: XBRL DOCUMENT begin 644 Financial_Report.xlsx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end XML 55 Show.js IDEA: XBRL DOCUMENT // Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission. Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105. var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0); e.removeAttribute('id');a.parentNode.appendChild(e)}} if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'} e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}} XML 56 report.css IDEA: XBRL DOCUMENT /* Updated 2009-11-04 */ /* v2.2.0.24 */ /* DefRef Styles */ ..report table.authRefData{ background-color: #def; border: 2px solid #2F4497; font-size: 1em; position: absolute; } ..report table.authRefData a { display: block; font-weight: bold; } ..report table.authRefData p { margin-top: 0px; } ..report table.authRefData .hide { background-color: #2F4497; padding: 1px 3px 0px 0px; text-align: right; } ..report table.authRefData .hide a:hover { background-color: #2F4497; } ..report table.authRefData .body { height: 150px; overflow: auto; width: 400px; } ..report table.authRefData table{ font-size: 1em; } /* Report Styles */ ..pl a, .pl a:visited { color: black; text-decoration: none; } /* table */ ..report { background-color: white; border: 2px solid #acf; clear: both; color: black; font: normal 8pt Helvetica, Arial, san-serif; margin-bottom: 2em; } ..report hr { border: 1px solid #acf; } /* Top labels */ ..report th { background-color: #acf; color: black; font-weight: bold; text-align: center; } ..report th.void { background-color: transparent; color: #000000; font: bold 10pt Helvetica, Arial, san-serif; text-align: left; } ..report .pl { text-align: left; vertical-align: top; white-space: normal; width: 200px; white-space: normal; /* word-wrap: break-word; */ } ..report td.pl a.a { cursor: pointer; display: block; width: 200px; overflow: hidden; } ..report td.pl div.a { width: 200px; } ..report td.pl a:hover { background-color: #ffc; } /* Header rows... */ ..report tr.rh { background-color: #acf; color: black; font-weight: bold; } /* Calendars... */ ..report .rc { background-color: #f0f0f0; } /* Even rows... */ ..report .re, .report .reu { background-color: #def; } ..report .reu td { border-bottom: 1px solid black; } /* Odd rows... */ ..report .ro, .report .rou { background-color: white; } ..report .rou td { border-bottom: 1px solid black; } ..report .rou table td, .report .reu table td { border-bottom: 0px solid black; } /* styles for footnote marker */ ..report .fn { white-space: nowrap; } /* styles for numeric types */ ..report .num, .report .nump { text-align: right; white-space: nowrap; } ..report .nump { padding-left: 2em; } ..report .nump { padding: 0px 0.4em 0px 2em; } /* styles for text types */ ..report .text { text-align: left; white-space: normal; } ..report .text .big { margin-bottom: 1em; width: 17em; } ..report .text .more { display: none; } ..report .text .note { font-style: italic; font-weight: bold; } ..report .text .small { width: 10em; } ..report sup { font-style: italic; } ..report .outerFootnotes { font-size: 1em; } XML 57 FilingSummary.xml IDEA: XBRL DOCUMENT 3.23.2 html 214 250 1 false 67 0 false 5 false false R1.htm 00000001 - Document - Cover Sheet http://endonovo.com/role/Cover Cover Cover 1 false false R2.htm 00000002 - Statement - Condensed Consolidated Balance Sheets Sheet http://endonovo.com/role/BalanceSheets Condensed Consolidated Balance Sheets Statements 2 false false R3.htm 00000003 - Statement - Condensed Consolidated Balance Sheets (Parenthetical) Sheet http://endonovo.com/role/BalanceSheetsParenthetical Condensed Consolidated Balance Sheets (Parenthetical) Statements 3 false false R4.htm 00000004 - Statement - Condensed Consolidated Statements of Operations (Unaudited) Sheet http://endonovo.com/role/StatementsOfOperations Condensed Consolidated Statements of Operations (Unaudited) Statements 4 false false R5.htm 00000005 - Statement - Condensed Consolidated Statements of Cash Flows (Unaudited) Sheet http://endonovo.com/role/StatementsOfCashFlows Condensed Consolidated Statements of Cash Flows (Unaudited) Statements 5 false false R6.htm 00000006 - Statement - Condensed Consolidated Statement of Shareholders' Deficit (Unaudited) Sheet http://endonovo.com/role/StatementOfShareholdersDeficit Condensed Consolidated Statement of Shareholders' Deficit (Unaudited) Statements 6 false false R7.htm 00000007 - Disclosure - Organization and Nature of Business Sheet http://endonovo.com/role/OrganizationAndNatureOfBusiness Organization and Nature of Business Notes 7 false false R8.htm 00000008 - Disclosure - Summary of significant accounting policies Sheet http://endonovo.com/role/SummaryOfSignificantAccountingPolicies Summary of significant accounting policies Notes 8 false false R9.htm 00000009 - Disclosure - Revenue Recognition Sheet http://endonovo.com/role/RevenueRecognition Revenue Recognition Notes 9 false false R10.htm 00000010 - Disclosure - Patents Sheet http://endonovo.com/role/Patents Patents Notes 10 false false R11.htm 00000011 - Disclosure - Notes Payable Notes http://endonovo.com/role/NotesPayable Notes Payable Notes 11 false false R12.htm 00000012 - Disclosure - Shareholders??? Deficit Sheet http://endonovo.com/role/ShareholdersDeficit Shareholders??? Deficit Notes 12 false false R13.htm 00000013 - Disclosure - Related Party and former related parties Transactions Sheet http://endonovo.com/role/RelatedPartyAndFormerRelatedPartiesTransactions Related Party and former related parties Transactions Notes 13 false false R14.htm 00000014 - Disclosure - Fair Value Measurements Sheet http://endonovo.com/role/FairValueMeasurements Fair Value Measurements Notes 14 false false R15.htm 00000015 - Disclosure - Commitments and Contingencies Sheet http://endonovo.com/role/CommitmentsAndContingencies Commitments and Contingencies Notes 15 false false R16.htm 00000016 - Disclosure - Concentrations Sheet http://endonovo.com/role/Concentrations Concentrations Notes 16 false false R17.htm 00000017 - Disclosure - Subsequent Events Sheet http://endonovo.com/role/SubsequentEvents Subsequent Events Notes 17 false false R18.htm 00000018 - Disclosure - Summary of significant accounting policies (Policies) Sheet http://endonovo.com/role/SummaryOfSignificantAccountingPoliciesPolicies Summary of significant accounting policies (Policies) Policies 18 false false R19.htm 00000019 - Disclosure - Summary of significant accounting policies (Tables) Sheet http://endonovo.com/role/SummaryOfSignificantAccountingPoliciesTables Summary of significant accounting policies (Tables) Tables http://endonovo.com/role/SummaryOfSignificantAccountingPolicies 19 false false R20.htm 00000020 - Disclosure - Revenue Recognition (Tables) Sheet http://endonovo.com/role/RevenueRecognitionTables Revenue Recognition (Tables) Tables http://endonovo.com/role/RevenueRecognition 20 false false R21.htm 00000021 - Disclosure - Patents (Tables) Sheet http://endonovo.com/role/PatentsTables Patents (Tables) Tables http://endonovo.com/role/Patents 21 false false R22.htm 00000022 - Disclosure - Notes Payable (Tables) Notes http://endonovo.com/role/NotesPayableTables Notes Payable (Tables) Tables http://endonovo.com/role/NotesPayable 22 false false R23.htm 00000023 - Disclosure - Shareholders??? Deficit (Tables) Sheet http://endonovo.com/role/ShareholdersDeficitTables Shareholders??? Deficit (Tables) Tables http://endonovo.com/role/ShareholdersDeficit 23 false false R24.htm 00000024 - Disclosure - Fair Value Measurements (Tables) Sheet http://endonovo.com/role/FairValueMeasurementsTables Fair Value Measurements (Tables) Tables http://endonovo.com/role/FairValueMeasurements 24 false false R25.htm 00000025 - Disclosure - Schedule of Earnings Per Share Basic and Diluted (Details) Sheet http://endonovo.com/role/ScheduleOfEarningsPerShareBasicAndDilutedDetails Schedule of Earnings Per Share Basic and Diluted (Details) Details 25 false false R26.htm 00000026 - Disclosure - Summary of significant accounting policies (Details Narrative) Sheet http://endonovo.com/role/SummaryOfSignificantAccountingPoliciesDetailsNarrative Summary of significant accounting policies (Details Narrative) Details http://endonovo.com/role/SummaryOfSignificantAccountingPoliciesTables 26 false false R27.htm 00000027 - Disclosure - Schedule of Source of Revenue (Details) Sheet http://endonovo.com/role/ScheduleOfSourceOfRevenueDetails Schedule of Source of Revenue (Details) Details 27 false false R28.htm 00000028 - Disclosure - Revenue Recognition (Details Narrative) Sheet http://endonovo.com/role/RevenueRecognitionDetailsNarrative Revenue Recognition (Details Narrative) Details http://endonovo.com/role/RevenueRecognitionTables 28 false false R29.htm 00000029 - Disclosure - Schedule of Patents (Details) Sheet http://endonovo.com/role/ScheduleOfPatentsDetails Schedule of Patents (Details) Details 29 false false R30.htm 00000030 - Disclosure - Schedule of Estimated Future Amortization Expense (Details) Sheet http://endonovo.com/role/ScheduleOfEstimatedFutureAmortizationExpenseDetails Schedule of Estimated Future Amortization Expense (Details) Details 30 false false R31.htm 00000031 - Disclosure - Patents (Details Narrative) Sheet http://endonovo.com/role/PatentsDetailsNarrative Patents (Details Narrative) Details http://endonovo.com/role/PatentsTables 31 false false R32.htm 00000032 - Disclosure - Schedule of Notes Payable (Details) Notes http://endonovo.com/role/ScheduleOfNotesPayableDetails Schedule of Notes Payable (Details) Details 32 false false R33.htm 00000033 - Disclosure - Schedule of Maturity Dates of Notes Payable (Details) Notes http://endonovo.com/role/ScheduleOfMaturityDatesOfNotesPayableDetails Schedule of Maturity Dates of Notes Payable (Details) Details 33 false false R34.htm 00000034 - Disclosure - Notes Payable (Details Narrative) Notes http://endonovo.com/role/NotesPayableDetailsNarrative Notes Payable (Details Narrative) Details http://endonovo.com/role/NotesPayableTables 34 false false R35.htm 00000035 - Disclosure - Schedule of Preferred Stock (Details) Sheet http://endonovo.com/role/ScheduleOfPreferredStockDetails Schedule of Preferred Stock (Details) Details 35 false false R36.htm 00000036 - Disclosure - Schedule of Stock Options Outstanding (Details) Sheet http://endonovo.com/role/ScheduleOfStockOptionsOutstandingDetails Schedule of Stock Options Outstanding (Details) Details 36 false false R37.htm 00000037 - Disclosure - Schedule of Warrants Outstanding (Details) Sheet http://endonovo.com/role/ScheduleOfWarrantsOutstandingDetails Schedule of Warrants Outstanding (Details) Details 37 false false R38.htm 00000038 - Disclosure - Shareholders??? Deficit (Details Narrative) Sheet http://endonovo.com/role/ShareholdersDeficitDetailsNarrative Shareholders??? Deficit (Details Narrative) Details http://endonovo.com/role/ShareholdersDeficitTables 38 false false R39.htm 00000039 - Disclosure - Related Party and former related parties Transactions (Details Narrative) Sheet http://endonovo.com/role/RelatedPartyAndFormerRelatedPartiesTransactionsDetailsNarrative Related Party and former related parties Transactions (Details Narrative) Details http://endonovo.com/role/RelatedPartyAndFormerRelatedPartiesTransactions 39 false false R40.htm 00000040 - Disclosure - Schedule of Conversion Feature Using Black Scholes Option Pricing Model (Details) Sheet http://endonovo.com/role/ScheduleOfConversionFeatureUsingBlackScholesOptionPricingModelDetails Schedule of Conversion Feature Using Black Scholes Option Pricing Model (Details) Details 40 false false R41.htm 00000041 - Disclosure - Schedule of Fair Value of Derivative Liability (Details) Sheet http://endonovo.com/role/ScheduleOfFairValueOfDerivativeLiabilityDetails Schedule of Fair Value of Derivative Liability (Details) Details 41 false false R42.htm 00000042 - Disclosure - Schedule of Liabilities Significant Unobservable Inputs (Details) Sheet http://endonovo.com/role/ScheduleOfLiabilitiesSignificantUnobservableInputsDetails Schedule of Liabilities Significant Unobservable Inputs (Details) Details 42 false false R43.htm 00000043 - Disclosure - Concentrations (Details Narrative) Sheet http://endonovo.com/role/ConcentrationsDetailsNarrative Concentrations (Details Narrative) Details http://endonovo.com/role/Concentrations 43 false false R44.htm 00000044 - Disclosure - Subsequent Events (Details Narrative) Sheet http://endonovo.com/role/SubsequentEventsDetailsNarrative Subsequent Events (Details Narrative) Details http://endonovo.com/role/SubsequentEvents 44 false false All Reports Book All Reports form10-q.htm endv-20230630.xsd endv-20230630_cal.xml endv-20230630_def.xml endv-20230630_lab.xml endv-20230630_pre.xml ex31-1.htm ex32-1.htm http://fasb.org/us-gaap/2023 http://xbrl.sec.gov/dei/2023 true true JSON 60 MetaLinks.json IDEA: XBRL DOCUMENT { "instance": { "form10-q.htm": { "axisCustom": 0, "axisStandard": 20, "baseTaxonomies": { "http://fasb.org/us-gaap/2023": 773, "http://xbrl.sec.gov/dei/2023": 27 }, "contextCount": 214, "dts": { "calculationLink": { "local": [ "endv-20230630_cal.xml" ] }, "definitionLink": { "local": [ "endv-20230630_def.xml" ] }, "inline": { "local": [ "form10-q.htm" ] }, "labelLink": { "local": [ "endv-20230630_lab.xml" ] }, "presentationLink": { "local": [ "endv-20230630_pre.xml" ] }, "schema": { "local": [ "endv-20230630.xsd" ], "remote": [ "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd", "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd", "http://www.xbrl.org/2003/xl-2003-12-31.xsd", "http://www.xbrl.org/2003/xlink-2003-12-31.xsd", "http://www.xbrl.org/2005/xbrldt-2005.xsd", "http://www.xbrl.org/2006/ref-2006-02-27.xsd", "http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd", "http://www.xbrl.org/lrr/role/net-2009-12-16.xsd", "http://www.xbrl.org/lrr/role/reference-2009-12-16.xsd", "https://www.xbrl.org/2020/extensible-enumerations-2.0.xsd", "https://www.xbrl.org/dtr/type/2020-01-21/types.xsd", "https://www.xbrl.org/dtr/type/2022-03-31/types.xsd", "https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd", "https://xbrl.fasb.org/srt/2023/elts/srt-roles-2023.xsd", "https://xbrl.fasb.org/srt/2023/elts/srt-types-2023.xsd", "https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd", "https://xbrl.fasb.org/us-gaap/2023/elts/us-roles-2023.xsd", "https://xbrl.fasb.org/us-gaap/2023/elts/us-types-2023.xsd", "https://xbrl.sec.gov/country/2023/country-2023.xsd", "https://xbrl.sec.gov/dei/2023/dei-2023.xsd" ] } }, "elementCount": 440, "entityCount": 1, "hidden": { "http://endonovo.com/20230630": 32, "http://fasb.org/us-gaap/2023": 175, "http://xbrl.sec.gov/dei/2023": 4, "total": 211 }, "keyCustom": 43, "keyStandard": 207, "memberCustom": 38, "memberStandard": 28, "nsprefix": "ENDV", "nsuri": "http://endonovo.com/20230630", "report": { "R1": { "firstAnchor": { "ancestors": [ "span", "b", "span", "p", "body", "html" ], "baseRef": "form10-q.htm", "contextRef": "From2023-01-01to2023-06-30", "decimals": null, "first": true, "lang": "en-US", "name": "dei:DocumentType", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "document", "isDefault": "true", "longName": "00000001 - Document - Cover", "menuCat": "Cover", "order": "1", "role": "http://endonovo.com/role/Cover", "shortName": "Cover", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "b", "span", "p", "body", "html" ], "baseRef": "form10-q.htm", "contextRef": "From2023-01-01to2023-06-30", "decimals": null, "first": true, "lang": "en-US", "name": "dei:DocumentType", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R10": { "firstAnchor": { "ancestors": [ "body", "html" ], "baseRef": "form10-q.htm", "contextRef": "From2023-01-01to2023-06-30", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:IntangibleAssetsDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "00000010 - Disclosure - Patents", "menuCat": "Notes", "order": "10", "role": "http://endonovo.com/role/Patents", "shortName": "Patents", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "body", "html" ], "baseRef": "form10-q.htm", "contextRef": "From2023-01-01to2023-06-30", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:IntangibleAssetsDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R11": { "firstAnchor": { "ancestors": [ "body", "html" ], "baseRef": "form10-q.htm", "contextRef": "From2023-01-01to2023-06-30", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:DebtDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "00000011 - Disclosure - Notes Payable", "menuCat": "Notes", "order": "11", "role": "http://endonovo.com/role/NotesPayable", "shortName": "Notes Payable", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "body", "html" ], "baseRef": "form10-q.htm", "contextRef": "From2023-01-01to2023-06-30", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:DebtDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R12": { "firstAnchor": { "ancestors": [ "body", "html" ], "baseRef": "form10-q.htm", "contextRef": "From2023-01-01to2023-06-30", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:StockholdersEquityNoteDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "00000012 - Disclosure - Shareholders\u2019 Deficit", "menuCat": "Notes", "order": "12", "role": "http://endonovo.com/role/ShareholdersDeficit", "shortName": "Shareholders\u2019 Deficit", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "body", "html" ], "baseRef": "form10-q.htm", "contextRef": "From2023-01-01to2023-06-30", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:StockholdersEquityNoteDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R13": { "firstAnchor": { "ancestors": [ "body", "html" ], "baseRef": "form10-q.htm", "contextRef": "From2023-01-01to2023-06-30", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:RelatedPartyTransactionsDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "00000013 - Disclosure - Related Party and former related parties Transactions", "menuCat": "Notes", "order": "13", "role": "http://endonovo.com/role/RelatedPartyAndFormerRelatedPartiesTransactions", "shortName": "Related Party and former related parties Transactions", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "body", "html" ], "baseRef": "form10-q.htm", "contextRef": "From2023-01-01to2023-06-30", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:RelatedPartyTransactionsDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R14": { "firstAnchor": { "ancestors": [ "body", "html" ], "baseRef": "form10-q.htm", "contextRef": "From2023-01-01to2023-06-30", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:FairValueDisclosuresTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "00000014 - Disclosure - Fair Value Measurements", "menuCat": "Notes", "order": "14", "role": "http://endonovo.com/role/FairValueMeasurements", "shortName": "Fair Value Measurements", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "body", "html" ], "baseRef": "form10-q.htm", "contextRef": "From2023-01-01to2023-06-30", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:FairValueDisclosuresTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R15": { "firstAnchor": { "ancestors": [ "body", "html" ], "baseRef": "form10-q.htm", "contextRef": "From2023-01-01to2023-06-30", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "00000015 - Disclosure - Commitments and Contingencies", "menuCat": "Notes", "order": "15", "role": "http://endonovo.com/role/CommitmentsAndContingencies", "shortName": "Commitments and Contingencies", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "body", "html" ], "baseRef": "form10-q.htm", "contextRef": "From2023-01-01to2023-06-30", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R16": { "firstAnchor": { "ancestors": [ "body", "html" ], "baseRef": "form10-q.htm", "contextRef": "From2023-01-01to2023-06-30", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ConcentrationRiskDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "00000016 - Disclosure - Concentrations", "menuCat": "Notes", "order": "16", "role": "http://endonovo.com/role/Concentrations", "shortName": "Concentrations", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "body", "html" ], "baseRef": "form10-q.htm", "contextRef": "From2023-01-01to2023-06-30", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ConcentrationRiskDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R17": { "firstAnchor": { "ancestors": [ "body", "html" ], "baseRef": "form10-q.htm", "contextRef": "From2023-01-01to2023-06-30", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:SubsequentEventsTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "00000017 - Disclosure - Subsequent Events", "menuCat": "Notes", "order": "17", "role": "http://endonovo.com/role/SubsequentEvents", "shortName": "Subsequent Events", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "body", "html" ], "baseRef": "form10-q.htm", "contextRef": "From2023-01-01to2023-06-30", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:SubsequentEventsTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R18": { "firstAnchor": { "ancestors": [ "us-gaap:SignificantAccountingPoliciesTextBlock", "body", "html" ], "baseRef": "form10-q.htm", "contextRef": "From2023-01-01to2023-06-30", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:BasisOfAccountingPolicyPolicyTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "00000018 - Disclosure - Summary of significant accounting policies (Policies)", "menuCat": "Policies", "order": "18", "role": "http://endonovo.com/role/SummaryOfSignificantAccountingPoliciesPolicies", "shortName": "Summary of significant accounting policies (Policies)", "subGroupType": "policies", "uniqueAnchor": { "ancestors": [ "us-gaap:SignificantAccountingPoliciesTextBlock", "body", "html" ], "baseRef": "form10-q.htm", "contextRef": "From2023-01-01to2023-06-30", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:BasisOfAccountingPolicyPolicyTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R19": { "firstAnchor": { "ancestors": [ "us-gaap:EarningsPerSharePolicyTextBlock", "us-gaap:SignificantAccountingPoliciesTextBlock", "body", "html" ], "baseRef": "form10-q.htm", "contextRef": "From2023-01-01to2023-06-30", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "00000019 - Disclosure - Summary of significant accounting policies (Tables)", "menuCat": "Tables", "order": "19", "role": "http://endonovo.com/role/SummaryOfSignificantAccountingPoliciesTables", "shortName": "Summary of significant accounting policies (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "us-gaap:EarningsPerSharePolicyTextBlock", "us-gaap:SignificantAccountingPoliciesTextBlock", "body", "html" ], "baseRef": "form10-q.htm", "contextRef": "From2023-01-01to2023-06-30", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R2": { "firstAnchor": { "ancestors": [ "td", "tr", "table", "body", "html" ], "baseRef": "form10-q.htm", "contextRef": "AsOf2023-06-30", "decimals": "0", "first": true, "lang": null, "name": "us-gaap:CashAndCashEquivalentsAtCarryingValue", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" }, "groupType": "statement", "isDefault": "false", "longName": "00000002 - Statement - Condensed Consolidated Balance Sheets", "menuCat": "Statements", "order": "2", "role": "http://endonovo.com/role/BalanceSheets", "shortName": "Condensed Consolidated Balance Sheets", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "td", "tr", "table", "body", "html" ], "baseRef": "form10-q.htm", "contextRef": "AsOf2023-06-30", "decimals": "0", "first": true, "lang": null, "name": "us-gaap:CashAndCashEquivalentsAtCarryingValue", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" } }, "R20": { "firstAnchor": { "ancestors": [ "us-gaap:RevenueFromContractWithCustomerTextBlock", "body", "html" ], "baseRef": "form10-q.htm", "contextRef": "From2023-01-01to2023-06-30", "decimals": null, "first": true, "lang": "en-US", "name": "ENDV:ScheduleOfSourceOfRevenueTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "00000020 - Disclosure - Revenue Recognition (Tables)", "menuCat": "Tables", "order": "20", "role": "http://endonovo.com/role/RevenueRecognitionTables", "shortName": "Revenue Recognition (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "us-gaap:RevenueFromContractWithCustomerTextBlock", "body", "html" ], "baseRef": "form10-q.htm", "contextRef": "From2023-01-01to2023-06-30", "decimals": null, "first": true, "lang": "en-US", "name": "ENDV:ScheduleOfSourceOfRevenueTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R21": { "firstAnchor": { "ancestors": [ "us-gaap:IntangibleAssetsDisclosureTextBlock", "body", "html" ], "baseRef": "form10-q.htm", "contextRef": "From2023-01-01to2023-06-30", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "00000021 - Disclosure - Patents (Tables)", "menuCat": "Tables", "order": "21", "role": "http://endonovo.com/role/PatentsTables", "shortName": "Patents (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "us-gaap:IntangibleAssetsDisclosureTextBlock", "body", "html" ], "baseRef": "form10-q.htm", "contextRef": "From2023-01-01to2023-06-30", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R22": { "firstAnchor": { "ancestors": [ "us-gaap:DebtDisclosureTextBlock", "body", "html" ], "baseRef": "form10-q.htm", "contextRef": "From2023-01-01to2023-06-30", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfDebtTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "00000022 - Disclosure - Notes Payable (Tables)", "menuCat": "Tables", "order": "22", "role": "http://endonovo.com/role/NotesPayableTables", "shortName": "Notes Payable (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "us-gaap:DebtDisclosureTextBlock", "body", "html" ], "baseRef": "form10-q.htm", "contextRef": "From2023-01-01to2023-06-30", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfDebtTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R23": { "firstAnchor": { "ancestors": [ "us-gaap:StockholdersEquityNoteDisclosureTextBlock", "body", "html" ], "baseRef": "form10-q.htm", "contextRef": "From2023-01-01to2023-06-30", "decimals": null, "first": true, "lang": "en-US", "name": "ENDV:ScheduleOfPreferredStockTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "00000023 - Disclosure - Shareholders\u2019 Deficit (Tables)", "menuCat": "Tables", "order": "23", "role": "http://endonovo.com/role/ShareholdersDeficitTables", "shortName": "Shareholders\u2019 Deficit (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "us-gaap:StockholdersEquityNoteDisclosureTextBlock", "body", "html" ], "baseRef": "form10-q.htm", "contextRef": "From2023-01-01to2023-06-30", "decimals": null, "first": true, "lang": "en-US", "name": "ENDV:ScheduleOfPreferredStockTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R24": { "firstAnchor": { "ancestors": [ "us-gaap:FairValueDisclosuresTextBlock", "body", "html" ], "baseRef": "form10-q.htm", "contextRef": "From2023-01-01to2023-06-30", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:FairValueAssetsMeasuredOnNonrecurringBasisValuationTechniquesTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "00000024 - Disclosure - Fair Value Measurements (Tables)", "menuCat": "Tables", "order": "24", "role": "http://endonovo.com/role/FairValueMeasurementsTables", "shortName": "Fair Value Measurements (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "us-gaap:FairValueDisclosuresTextBlock", "body", "html" ], "baseRef": "form10-q.htm", "contextRef": "From2023-01-01to2023-06-30", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:FairValueAssetsMeasuredOnNonrecurringBasisValuationTechniquesTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R25": { "firstAnchor": { "ancestors": [ "td", "tr", "table", "us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock", "us-gaap:EarningsPerSharePolicyTextBlock", "us-gaap:SignificantAccountingPoliciesTextBlock", "body", "html" ], "baseRef": "form10-q.htm", "contextRef": "From2023-04-012023-06-30", "decimals": "0", "first": true, "lang": null, "name": "us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "00000025 - Disclosure - Schedule of Earnings Per Share Basic and Diluted (Details)", "menuCat": "Details", "order": "25", "role": "http://endonovo.com/role/ScheduleOfEarningsPerShareBasicAndDilutedDetails", "shortName": "Schedule of Earnings Per Share Basic and Diluted (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "td", "tr", "table", "us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock", "us-gaap:EarningsPerSharePolicyTextBlock", "us-gaap:SignificantAccountingPoliciesTextBlock", "body", "html" ], "baseRef": "form10-q.htm", "contextRef": "From2023-04-012023-06-30", "decimals": "0", "first": true, "lang": null, "name": "us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" } }, "R26": { "firstAnchor": { "ancestors": [ "span", "span", "p", "ENDV:LiquidityAndGoingConcernPolicyTextTextBlock", "us-gaap:SignificantAccountingPoliciesTextBlock", "body", "html" ], "baseRef": "form10-q.htm", "contextRef": "AsOf2023-06-30", "decimals": "0", "first": true, "lang": null, "name": "us-gaap:Cash", "reportCount": 1, "unitRef": "USD", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "00000026 - Disclosure - Summary of significant accounting policies (Details Narrative)", "menuCat": "Details", "order": "26", "role": "http://endonovo.com/role/SummaryOfSignificantAccountingPoliciesDetailsNarrative", "shortName": "Summary of significant accounting policies (Details Narrative)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "span", "p", "ENDV:LiquidityAndGoingConcernPolicyTextTextBlock", "us-gaap:SignificantAccountingPoliciesTextBlock", "body", "html" ], "baseRef": "form10-q.htm", "contextRef": "From2023-01-01to2023-06-30", "decimals": "-5", "lang": null, "name": "us-gaap:ProceedsFromIssuanceOrSaleOfEquity", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" } }, "R27": { "firstAnchor": { "ancestors": [ "td", "tr", "table", "body", "html" ], "baseRef": "form10-q.htm", "contextRef": "From2023-04-012023-06-30", "decimals": "0", "first": true, "lang": null, "name": "us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax", "reportCount": 1, "unitRef": "USD", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "00000027 - Disclosure - Schedule of Source of Revenue (Details)", "menuCat": "Details", "order": "27", "role": "http://endonovo.com/role/ScheduleOfSourceOfRevenueDetails", "shortName": "Schedule of Source of Revenue (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "td", "tr", "table", "ENDV:ScheduleOfSourceOfRevenueTableTextBlock", "us-gaap:RevenueFromContractWithCustomerTextBlock", "body", "html" ], "baseRef": "form10-q.htm", "contextRef": "From2023-04-012023-06-30_custom_RoyaltyAndLicensingNetMember", "decimals": "0", "lang": null, "name": "us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" } }, "R28": { "firstAnchor": { "ancestors": [ "span", "p", "us-gaap:RevenueFromContractWithCustomerTextBlock", "body", "html" ], "baseRef": "form10-q.htm", "contextRef": "AsOf2023-01-25_custom_SalesSupportServiceAgreementMember_custom_PulseTherapeuticTechnologyMember", "decimals": "0", "first": true, "lang": null, "name": "us-gaap:DeferredCompensationLiabilityCurrent", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "00000028 - Disclosure - Revenue Recognition (Details Narrative)", "menuCat": "Details", "order": "28", "role": "http://endonovo.com/role/RevenueRecognitionDetailsNarrative", "shortName": "Revenue Recognition (Details Narrative)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "p", "us-gaap:RevenueFromContractWithCustomerTextBlock", "body", "html" ], "baseRef": "form10-q.htm", "contextRef": "AsOf2023-01-25_custom_SalesSupportServiceAgreementMember_custom_PulseTherapeuticTechnologyMember", "decimals": "0", "first": true, "lang": null, "name": "us-gaap:DeferredCompensationLiabilityCurrent", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" } }, "R29": { "firstAnchor": { "ancestors": [ "td", "tr", "table", "us-gaap:ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock", "us-gaap:IntangibleAssetsDisclosureTextBlock", "body", "html" ], "baseRef": "form10-q.htm", "contextRef": "AsOf2023-06-30", "decimals": "0", "first": true, "lang": null, "name": "us-gaap:FiniteLivedPatentsGross", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "00000029 - Disclosure - Schedule of Patents (Details)", "menuCat": "Details", "order": "29", "role": "http://endonovo.com/role/ScheduleOfPatentsDetails", "shortName": "Schedule of Patents (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "td", "tr", "table", "us-gaap:ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock", "us-gaap:IntangibleAssetsDisclosureTextBlock", "body", "html" ], "baseRef": "form10-q.htm", "contextRef": "AsOf2023-06-30", "decimals": "0", "first": true, "lang": null, "name": "us-gaap:FiniteLivedPatentsGross", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" } }, "R3": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "body", "html" ], "baseRef": "form10-q.htm", "contextRef": "AsOf2023-06-30", "decimals": "0", "first": true, "lang": null, "name": "us-gaap:DebtInstrumentUnamortizedDiscountCurrent", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" }, "groupType": "statement", "isDefault": "false", "longName": "00000003 - Statement - Condensed Consolidated Balance Sheets (Parenthetical)", "menuCat": "Statements", "order": "3", "role": "http://endonovo.com/role/BalanceSheetsParenthetical", "shortName": "Condensed Consolidated Balance Sheets (Parenthetical)", "subGroupType": "parenthetical", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "body", "html" ], "baseRef": "form10-q.htm", "contextRef": "AsOf2023-06-30", "decimals": "0", "first": true, "lang": null, "name": "us-gaap:DebtInstrumentUnamortizedDiscountCurrent", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" } }, "R30": { "firstAnchor": { "ancestors": [ "td", "tr", "table", "us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseTableTextBlock", "us-gaap:IntangibleAssetsDisclosureTextBlock", "body", "html" ], "baseRef": "form10-q.htm", "contextRef": "AsOf2023-06-30", "decimals": "0", "first": true, "lang": null, "name": "us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "00000030 - Disclosure - Schedule of Estimated Future Amortization Expense (Details)", "menuCat": "Details", "order": "30", "role": "http://endonovo.com/role/ScheduleOfEstimatedFutureAmortizationExpenseDetails", "shortName": "Schedule of Estimated Future Amortization Expense (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "td", "tr", "table", "us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseTableTextBlock", "us-gaap:IntangibleAssetsDisclosureTextBlock", "body", "html" ], "baseRef": "form10-q.htm", "contextRef": "AsOf2023-06-30", "decimals": "0", "first": true, "lang": null, "name": "us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" } }, "R31": { "firstAnchor": { "ancestors": [ "span", "span", "span", "p", "us-gaap:IntangibleAssetsDisclosureTextBlock", "body", "html" ], "baseRef": "form10-q.htm", "contextRef": "From2023-01-01to2023-06-30", "decimals": "0", "first": true, "lang": null, "name": "us-gaap:AmortizationOfIntangibleAssets", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "00000031 - Disclosure - Patents (Details Narrative)", "menuCat": "Details", "order": "31", "role": "http://endonovo.com/role/PatentsDetailsNarrative", "shortName": "Patents (Details Narrative)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "span", "span", "p", "us-gaap:IntangibleAssetsDisclosureTextBlock", "body", "html" ], "baseRef": "form10-q.htm", "contextRef": "From2023-01-01to2023-06-30", "decimals": "0", "first": true, "lang": null, "name": "us-gaap:AmortizationOfIntangibleAssets", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" } }, "R32": { "firstAnchor": { "ancestors": [ "td", "tr", "table", "us-gaap:ScheduleOfDebtTableTextBlock", "us-gaap:DebtDisclosureTextBlock", "body", "html" ], "baseRef": "form10-q.htm", "contextRef": "AsOf2022-12-31", "decimals": "0", "first": true, "lang": null, "name": "us-gaap:NotesPayable", "reportCount": 1, "unitRef": "USD", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "00000032 - Disclosure - Schedule of Notes Payable (Details)", "menuCat": "Details", "order": "32", "role": "http://endonovo.com/role/ScheduleOfNotesPayableDetails", "shortName": "Schedule of Notes Payable (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "td", "tr", "table", "us-gaap:ScheduleOfDebtTableTextBlock", "us-gaap:DebtDisclosureTextBlock", "body", "html" ], "baseRef": "form10-q.htm", "contextRef": "From2023-01-01to2023-06-30", "decimals": "0", "lang": null, "name": "us-gaap:RepaymentsOfNotesPayable", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" } }, "R33": { "firstAnchor": { "ancestors": [ "td", "tr", "table", "us-gaap:ScheduleOfMaturitiesOfLongTermDebtTableTextBlock", "us-gaap:DebtDisclosureTextBlock", "body", "html" ], "baseRef": "form10-q.htm", "contextRef": "AsOf2023-06-30", "decimals": "0", "first": true, "lang": null, "name": "ENDV:LongTermDebtPastMaturity", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "00000033 - Disclosure - Schedule of Maturity Dates of Notes Payable (Details)", "menuCat": "Details", "order": "33", "role": "http://endonovo.com/role/ScheduleOfMaturityDatesOfNotesPayableDetails", "shortName": "Schedule of Maturity Dates of Notes Payable (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "td", "tr", "table", "us-gaap:ScheduleOfMaturitiesOfLongTermDebtTableTextBlock", "us-gaap:DebtDisclosureTextBlock", "body", "html" ], "baseRef": "form10-q.htm", "contextRef": "AsOf2023-06-30", "decimals": "0", "first": true, "lang": null, "name": "ENDV:LongTermDebtPastMaturity", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" } }, "R34": { "firstAnchor": { "ancestors": [ "span", "span", "p", "us-gaap:DebtDisclosureTextBlock", "body", "html" ], "baseRef": "form10-q.htm", "contextRef": "From2023-01-01to2023-06-30", "decimals": "0", "first": true, "lang": null, "name": "us-gaap:DebtConversionOriginalDebtAmount1", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "00000034 - Disclosure - Notes Payable (Details Narrative)", "menuCat": "Details", "order": "34", "role": "http://endonovo.com/role/NotesPayableDetailsNarrative", "shortName": "Notes Payable (Details Narrative)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "span", "p", "us-gaap:DebtDisclosureTextBlock", "body", "html" ], "baseRef": "form10-q.htm", "contextRef": "From2023-01-01to2023-06-30", "decimals": "0", "first": true, "lang": null, "name": "us-gaap:DebtConversionOriginalDebtAmount1", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" } }, "R35": { "firstAnchor": { "ancestors": [ "td", "tr", "table", "ENDV:ScheduleOfPreferredStockTableTextBlock", "us-gaap:StockholdersEquityNoteDisclosureTextBlock", "body", "html" ], "baseRef": "form10-q.htm", "contextRef": "AsOf2023-06-30_custom_SeriesAAMember", "decimals": "INF", "first": true, "lang": null, "name": "us-gaap:PreferredStockSharesAuthorized", "reportCount": 1, "unique": true, "unitRef": "Shares", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "00000035 - Disclosure - Schedule of Preferred Stock (Details)", "menuCat": "Details", "order": "35", "role": "http://endonovo.com/role/ScheduleOfPreferredStockDetails", "shortName": "Schedule of Preferred Stock (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "td", "tr", "table", "ENDV:ScheduleOfPreferredStockTableTextBlock", "us-gaap:StockholdersEquityNoteDisclosureTextBlock", "body", "html" ], "baseRef": "form10-q.htm", "contextRef": "AsOf2023-06-30_custom_SeriesAAMember", "decimals": "INF", "first": true, "lang": null, "name": "us-gaap:PreferredStockSharesAuthorized", "reportCount": 1, "unique": true, "unitRef": "Shares", "xsiNil": "false" } }, "R36": { "firstAnchor": { "ancestors": [ "td", "tr", "table", "us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock", "us-gaap:StockholdersEquityNoteDisclosureTextBlock", "body", "html" ], "baseRef": "form10-q.htm", "contextRef": "AsOf2022-12-31_custom_StockOptionsMember", "decimals": "INF", "first": true, "lang": null, "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber", "reportCount": 1, "unique": true, "unitRef": "Shares", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "00000036 - Disclosure - Schedule of Stock Options Outstanding (Details)", "menuCat": "Details", "order": "36", "role": "http://endonovo.com/role/ScheduleOfStockOptionsOutstandingDetails", "shortName": "Schedule of Stock Options Outstanding (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "td", "tr", "table", "us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock", "us-gaap:StockholdersEquityNoteDisclosureTextBlock", "body", "html" ], "baseRef": "form10-q.htm", "contextRef": "AsOf2022-12-31_custom_StockOptionsMember", "decimals": "INF", "first": true, "lang": null, "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber", "reportCount": 1, "unique": true, "unitRef": "Shares", "xsiNil": "false" } }, "R37": { "firstAnchor": { "ancestors": [ "td", "tr", "table", "us-gaap:ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock", "us-gaap:StockholdersEquityNoteDisclosureTextBlock", "body", "html" ], "baseRef": "form10-q.htm", "contextRef": "AsOf2022-12-31_us-gaap_WarrantMember", "decimals": "INF", "first": true, "lang": null, "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber", "reportCount": 1, "unique": true, "unitRef": "Shares", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "00000037 - Disclosure - Schedule of Warrants Outstanding (Details)", "menuCat": "Details", "order": "37", "role": "http://endonovo.com/role/ScheduleOfWarrantsOutstandingDetails", "shortName": "Schedule of Warrants Outstanding (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "td", "tr", "table", "us-gaap:ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock", "us-gaap:StockholdersEquityNoteDisclosureTextBlock", "body", "html" ], "baseRef": "form10-q.htm", "contextRef": "AsOf2022-12-31_us-gaap_WarrantMember", "decimals": "INF", "first": true, "lang": null, "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber", "reportCount": 1, "unique": true, "unitRef": "Shares", "xsiNil": "false" } }, "R38": { "firstAnchor": { "ancestors": [ "td", "tr", "table", "body", "html" ], "baseRef": "form10-q.htm", "contextRef": "From2023-04-012023-06-30", "decimals": "0", "first": true, "lang": null, "name": "us-gaap:GainsLossesOnExtinguishmentOfDebt", "reportCount": 1, "unitRef": "USD", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "00000038 - Disclosure - Shareholders\u2019 Deficit (Details Narrative)", "menuCat": "Details", "order": "38", "role": "http://endonovo.com/role/ShareholdersDeficitDetailsNarrative", "shortName": "Shareholders\u2019 Deficit (Details Narrative)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "span", "p", "us-gaap:StockholdersEquityNoteDisclosureTextBlock", "body", "html" ], "baseRef": "form10-q.htm", "contextRef": "From2023-01-01to2023-06-30", "decimals": "0", "lang": null, "name": "us-gaap:ShareBasedCompensation", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" } }, "R39": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "body", "html" ], "baseRef": "form10-q.htm", "contextRef": "From2023-01-012023-03-31", "decimals": "0", "first": true, "lang": null, "name": "us-gaap:StockIssuedDuringPeriodValueOther", "reportCount": 1, "unitRef": "USD", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "00000039 - Disclosure - Related Party and former related parties Transactions (Details Narrative)", "menuCat": "Details", "order": "39", "role": "http://endonovo.com/role/RelatedPartyAndFormerRelatedPartiesTransactionsDetailsNarrative", "shortName": "Related Party and former related parties Transactions (Details Narrative)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "span", "p", "us-gaap:RelatedPartyTransactionsDisclosureTextBlock", "body", "html" ], "baseRef": "form10-q.htm", "contextRef": "AsOf2023-06-30_srt_OfficerMember", "decimals": "0", "lang": null, "name": "us-gaap:OtherLiabilities", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" } }, "R4": { "firstAnchor": { "ancestors": [ "td", "tr", "table", "body", "html" ], "baseRef": "form10-q.htm", "contextRef": "From2023-04-012023-06-30", "decimals": "0", "first": true, "lang": null, "name": "us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax", "reportCount": 1, "unitRef": "USD", "xsiNil": "false" }, "groupType": "statement", "isDefault": "false", "longName": "00000004 - Statement - Condensed Consolidated Statements of Operations (Unaudited)", "menuCat": "Statements", "order": "4", "role": "http://endonovo.com/role/StatementsOfOperations", "shortName": "Condensed Consolidated Statements of Operations (Unaudited)", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "td", "tr", "table", "body", "html" ], "baseRef": "form10-q.htm", "contextRef": "From2022-04-012022-06-30", "decimals": "0", "lang": null, "name": "us-gaap:CostOfRevenue", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" } }, "R40": { "firstAnchor": { "ancestors": [ "span", "span", "td", "tr", "table", "us-gaap:FairValueAssetsMeasuredOnNonrecurringBasisValuationTechniquesTextBlock", "us-gaap:FairValueDisclosuresTextBlock", "body", "html" ], "baseRef": "form10-q.htm", "contextRef": "From2023-01-012023-06-30_us-gaap_MeasurementInputExpectedTermMember", "decimals": null, "first": true, "lang": "en-US", "name": "ENDV:FairValueAssumptionsMeasurementInputTerm", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "00000040 - Disclosure - Schedule of Conversion Feature Using Black Scholes Option Pricing Model (Details)", "menuCat": "Details", "order": "40", "role": "http://endonovo.com/role/ScheduleOfConversionFeatureUsingBlackScholesOptionPricingModelDetails", "shortName": "Schedule of Conversion Feature Using Black Scholes Option Pricing Model (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "span", "td", "tr", "table", "us-gaap:FairValueAssetsMeasuredOnNonrecurringBasisValuationTechniquesTextBlock", "us-gaap:FairValueDisclosuresTextBlock", "body", "html" ], "baseRef": "form10-q.htm", "contextRef": "From2023-01-012023-06-30_us-gaap_MeasurementInputExpectedTermMember", "decimals": null, "first": true, "lang": "en-US", "name": "ENDV:FairValueAssumptionsMeasurementInputTerm", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R41": { "firstAnchor": { "ancestors": [ "td", "tr", "table", "us-gaap:FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock", "us-gaap:FairValueDisclosuresTextBlock", "body", "html" ], "baseRef": "form10-q.htm", "contextRef": "AsOf2022-12-31_us-gaap_FairValueInputsLevel3Member", "decimals": "0", "first": true, "lang": null, "name": "us-gaap:FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisWithUnobservableInputs", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "00000041 - Disclosure - Schedule of Fair Value of Derivative Liability (Details)", "menuCat": "Details", "order": "41", "role": "http://endonovo.com/role/ScheduleOfFairValueOfDerivativeLiabilityDetails", "shortName": "Schedule of Fair Value of Derivative Liability (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "td", "tr", "table", "us-gaap:FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock", "us-gaap:FairValueDisclosuresTextBlock", "body", "html" ], "baseRef": "form10-q.htm", "contextRef": "AsOf2022-12-31_us-gaap_FairValueInputsLevel3Member", "decimals": "0", "first": true, "lang": null, "name": "us-gaap:FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisWithUnobservableInputs", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" } }, "R42": { "firstAnchor": { "ancestors": [ "td", "tr", "table", "us-gaap:ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock", "us-gaap:FairValueDisclosuresTextBlock", "body", "html" ], "baseRef": "form10-q.htm", "contextRef": "AsOf2023-06-30", "decimals": "0", "first": true, "lang": null, "name": "us-gaap:DerivativeLiabilities", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "00000042 - Disclosure - Schedule of Liabilities Significant Unobservable Inputs (Details)", "menuCat": "Details", "order": "42", "role": "http://endonovo.com/role/ScheduleOfLiabilitiesSignificantUnobservableInputsDetails", "shortName": "Schedule of Liabilities Significant Unobservable Inputs (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "td", "tr", "table", "us-gaap:ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock", "us-gaap:FairValueDisclosuresTextBlock", "body", "html" ], "baseRef": "form10-q.htm", "contextRef": "AsOf2023-06-30", "decimals": "0", "first": true, "lang": null, "name": "us-gaap:DerivativeLiabilities", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" } }, "R43": { "firstAnchor": { "ancestors": [ "span", "span", "p", "us-gaap:ConcentrationRiskDisclosureTextBlock", "body", "html" ], "baseRef": "form10-q.htm", "contextRef": "From2023-01-012023-06-30_us-gaap_SalesRevenueNetMember_us-gaap_CustomerConcentrationRiskMember_custom_OneSignificantCustomerMember", "decimals": "INF", "first": true, "lang": null, "name": "us-gaap:ConcentrationRiskPercentage1", "reportCount": 1, "unique": true, "unitRef": "Pure", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "00000043 - Disclosure - Concentrations (Details Narrative)", "menuCat": "Details", "order": "43", "role": "http://endonovo.com/role/ConcentrationsDetailsNarrative", "shortName": "Concentrations (Details Narrative)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "span", "p", "us-gaap:ConcentrationRiskDisclosureTextBlock", "body", "html" ], "baseRef": "form10-q.htm", "contextRef": "From2023-01-012023-06-30_us-gaap_SalesRevenueNetMember_us-gaap_CustomerConcentrationRiskMember_custom_OneSignificantCustomerMember", "decimals": "INF", "first": true, "lang": null, "name": "us-gaap:ConcentrationRiskPercentage1", "reportCount": 1, "unique": true, "unitRef": "Pure", "xsiNil": "false" } }, "R44": { "firstAnchor": { "ancestors": [ "span", "span", "p", "us-gaap:DebtDisclosureTextBlock", "body", "html" ], "baseRef": "form10-q.htm", "contextRef": "AsOf2023-06-30", "decimals": "0", "first": true, "lang": null, "name": "us-gaap:DebtInstrumentFaceAmount", "reportCount": 1, "unitRef": "USD", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "00000044 - Disclosure - Subsequent Events (Details Narrative)", "menuCat": "Details", "order": "44", "role": "http://endonovo.com/role/SubsequentEventsDetailsNarrative", "shortName": "Subsequent Events (Details Narrative)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "p", "us-gaap:SubsequentEventsTextBlock", "body", "html" ], "baseRef": "form10-q.htm", "contextRef": "AsOf2023-08-14_us-gaap_ConvertibleDebtMember_us-gaap_SubsequentEventMember", "decimals": "0", "lang": null, "name": "us-gaap:DebtInstrumentFaceAmount", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" } }, "R5": { "firstAnchor": { "ancestors": [ "td", "tr", "table", "body", "html" ], "baseRef": "form10-q.htm", "contextRef": "From2023-01-01to2023-06-30", "decimals": "0", "first": true, "lang": null, "name": "us-gaap:NetIncomeLoss", "reportCount": 1, "unitRef": "USD", "xsiNil": "false" }, "groupType": "statement", "isDefault": "false", "longName": "00000005 - Statement - Condensed Consolidated Statements of Cash Flows (Unaudited)", "menuCat": "Statements", "order": "5", "role": "http://endonovo.com/role/StatementsOfCashFlows", "shortName": "Condensed Consolidated Statements of Cash Flows (Unaudited)", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "td", "tr", "table", "body", "html" ], "baseRef": "form10-q.htm", "contextRef": "From2023-01-01to2023-06-30", "decimals": "0", "lang": null, "name": "us-gaap:DepreciationDepletionAndAmortization", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" } }, "R6": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "body", "html" ], "baseRef": "form10-q.htm", "contextRef": "AsOf2021-12-31_us-gaap_PreferredStockMember_custom_SeriesAAPreferredStockMember", "decimals": "0", "first": true, "lang": null, "name": "us-gaap:StockholdersEquity", "reportCount": 1, "unitRef": "USD", "xsiNil": "false" }, "groupType": "statement", "isDefault": "false", "longName": "00000006 - Statement - Condensed Consolidated Statement of Shareholders' Deficit (Unaudited)", "menuCat": "Statements", "order": "6", "role": "http://endonovo.com/role/StatementOfShareholdersDeficit", "shortName": "Condensed Consolidated Statement of Shareholders' Deficit (Unaudited)", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "body", "html" ], "baseRef": "form10-q.htm", "contextRef": "From2022-01-012022-03-31_us-gaap_CommonStockMember", "decimals": "0", "lang": null, "name": "us-gaap:DebtConversionConvertedInstrumentAmount1", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" } }, "R7": { "firstAnchor": { "ancestors": [ "body", "html" ], "baseRef": "form10-q.htm", "contextRef": "From2023-01-01to2023-06-30", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "00000007 - Disclosure - Organization and Nature of Business", "menuCat": "Notes", "order": "7", "role": "http://endonovo.com/role/OrganizationAndNatureOfBusiness", "shortName": "Organization and Nature of Business", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "body", "html" ], "baseRef": "form10-q.htm", "contextRef": "From2023-01-01to2023-06-30", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R8": { "firstAnchor": { "ancestors": [ "body", "html" ], "baseRef": "form10-q.htm", "contextRef": "From2023-01-01to2023-06-30", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:SignificantAccountingPoliciesTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "00000008 - Disclosure - Summary of significant accounting policies", "menuCat": "Notes", "order": "8", "role": "http://endonovo.com/role/SummaryOfSignificantAccountingPolicies", "shortName": "Summary of significant accounting policies", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "body", "html" ], "baseRef": "form10-q.htm", "contextRef": "From2023-01-01to2023-06-30", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:SignificantAccountingPoliciesTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R9": { "firstAnchor": { "ancestors": [ "body", "html" ], "baseRef": "form10-q.htm", "contextRef": "From2023-01-01to2023-06-30", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:RevenueFromContractWithCustomerTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "00000009 - Disclosure - Revenue Recognition", "menuCat": "Notes", "order": "9", "role": "http://endonovo.com/role/RevenueRecognition", "shortName": "Revenue Recognition", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "body", "html" ], "baseRef": "form10-q.htm", "contextRef": "From2023-01-01to2023-06-30", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:RevenueFromContractWithCustomerTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } } }, "segmentCount": 67, "tag": { "ENDV_AccrualOfDeferredCompensation": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Accrual of deferred compensation.", "label": "Accrual deferred compensation" } } }, "localname": "AccrualOfDeferredCompensation", "nsuri": "http://endonovo.com/20230630", "presentation": [ "http://endonovo.com/role/RelatedPartyAndFormerRelatedPartiesTransactionsDetailsNarrative" ], "xbrltype": "monetaryItemType" }, "ENDV_AccruedInterestRelatedToNotesPayable": { "auth_ref": [], "calculation": { "http://endonovo.com/role/BalanceSheets": { "order": 2.0, "parentTag": "us-gaap_LiabilitiesCurrent", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Accrued interest related to notes payable.", "label": "Accrued interest related to notes payable" } } }, "localname": "AccruedInterestRelatedToNotesPayable", "nsuri": "http://endonovo.com/20230630", "presentation": [ "http://endonovo.com/role/BalanceSheets" ], "xbrltype": "monetaryItemType" }, "ENDV_AmortizationOfNoteDiscountAndOriginalIssueDiscount": { "auth_ref": [], "calculation": { "http://endonovo.com/role/StatementsOfCashFlows": { "order": 6.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amortization of note discount and original issue discount.", "label": "Amortization of note discount and original issue discount" } } }, "localname": "AmortizationOfNoteDiscountAndOriginalIssueDiscount", "nsuri": "http://endonovo.com/20230630", "presentation": [ "http://endonovo.com/role/StatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "ENDV_AssetsPurchaseAgreementMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Assets Purchase Agreement [Member]", "label": "Assets Purchase Agreement [Member]" } } }, "localname": "AssetsPurchaseAgreementMember", "nsuri": "http://endonovo.com/20230630", "presentation": [ "http://endonovo.com/role/SummaryOfSignificantAccountingPoliciesDetailsNarrative" ], "xbrltype": "domainItemType" }, "ENDV_CertainFixedPercentageOfCashPremium": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Certain fixed percentage of cash premium", "label": "Description of percentage of cash premium" } } }, "localname": "CertainFixedPercentageOfCashPremium", "nsuri": "http://endonovo.com/20230630", "presentation": [ "http://endonovo.com/role/NotesPayableDetailsNarrative" ], "xbrltype": "stringItemType" }, "ENDV_ChangeInRightsDueToAmendmendAndRestatedCertificateDescription": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Change in rights due to amendmend and restated certificate, description.", "label": "Change in rights due to amendment and restated certificate, description" } } }, "localname": "ChangeInRightsDueToAmendmendAndRestatedCertificateDescription", "nsuri": "http://endonovo.com/20230630", "presentation": [ "http://endonovo.com/role/ShareholdersDeficitDetailsNarrative" ], "xbrltype": "stringItemType" }, "ENDV_CommonStockAndCommonStockEquivalentsUsedForDilutedIncomePerShare": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Common stock and common stock equivalents used for diluted income per share.", "label": "Common stock and common stock equivalents used for diluted loss per share" } } }, "localname": "CommonStockAndCommonStockEquivalentsUsedForDilutedIncomePerShare", "nsuri": "http://endonovo.com/20230630", "presentation": [ "http://endonovo.com/role/ScheduleOfEarningsPerShareBasicAndDilutedDetails" ], "xbrltype": "sharesItemType" }, "ENDV_ConsultantAndChiefExecutiveOfficerMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Consultant and Chief Executive Officer [Member]", "label": "Consultant and Chief Executive Officer [Member]" } } }, "localname": "ConsultantAndChiefExecutiveOfficerMember", "nsuri": "http://endonovo.com/20230630", "presentation": [ "http://endonovo.com/role/SubsequentEventsDetailsNarrative" ], "xbrltype": "domainItemType" }, "ENDV_ConversionOfNotesToCommonStockPursuantToSettlementAgreement": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "label": "Conversion of notes to common stock pursuant to settlement agreement" } } }, "localname": "ConversionOfNotesToCommonStockPursuantToSettlementAgreement", "nsuri": "http://endonovo.com/20230630", "presentation": [ "http://endonovo.com/role/StatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "ENDV_ConversionOfPreferredCStockToCommonStock": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Conversion Of Preferred C Stock To Common Stock", "label": "Conversion of Preferred C Stock to common stock" } } }, "localname": "ConversionOfPreferredCStockToCommonStock", "nsuri": "http://endonovo.com/20230630", "presentation": [ "http://endonovo.com/role/StatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "ENDV_ConversionPricePercentage": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Conversion price percentage.", "label": "Conversion price" } } }, "localname": "ConversionPricePercentage", "nsuri": "http://endonovo.com/20230630", "presentation": [ "http://endonovo.com/role/ShareholdersDeficitDetailsNarrative" ], "xbrltype": "percentItemType" }, "ENDV_DebtDiscountFromIssuanceOfDebt": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Debt discount from issuance of debt.", "label": "Debt discount from issuance of debt" } } }, "localname": "DebtDiscountFromIssuanceOfDebt", "nsuri": "http://endonovo.com/20230630", "presentation": [ "http://endonovo.com/role/StatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "ENDV_DebtInstrumentCouponRate": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Debt instrument coupon rate.", "label": "Coupon rate" } } }, "localname": "DebtInstrumentCouponRate", "nsuri": "http://endonovo.com/20230630", "presentation": [ "http://endonovo.com/role/SubsequentEventsDetailsNarrative" ], "xbrltype": "percentItemType" }, "ENDV_DirectSalesMedicalCareProvidersGrossMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Direct Sales Medical Care Providers Gross [Member]", "label": "Direct Sales Medical Care Providers Gross [Member]" } } }, "localname": "DirectSalesMedicalCareProvidersGrossMember", "nsuri": "http://endonovo.com/20230630", "presentation": [ "http://endonovo.com/role/ScheduleOfSourceOfRevenueDetails" ], "xbrltype": "domainItemType" }, "ENDV_ExtensionFeePayable": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Extension fee payable.", "label": "Extension fee payable" } } }, "localname": "ExtensionFeePayable", "nsuri": "http://endonovo.com/20230630", "presentation": [ "http://endonovo.com/role/NotesPayableDetailsNarrative" ], "xbrltype": "monetaryItemType" }, "ENDV_FairValueAssumptionsMeasurementInputTerm": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Fair value assumptions, measurement input, term.", "label": "Fair value assumptions, measurement input, term" } } }, "localname": "FairValueAssumptionsMeasurementInputTerm", "nsuri": "http://endonovo.com/20230630", "presentation": [ "http://endonovo.com/role/ScheduleOfConversionFeatureUsingBlackScholesOptionPricingModelDetails" ], "xbrltype": "durationItemType" }, "ENDV_FixedRateNotesMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Fixed Rate Notes [Member]", "label": "Fixed Rate Notes [Member]" } } }, "localname": "FixedRateNotesMember", "nsuri": "http://endonovo.com/20230630", "presentation": [ "http://endonovo.com/role/NotesPayableDetailsNarrative" ], "xbrltype": "domainItemType" }, "ENDV_ForfeituresMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Forfeitures [Member]", "label": "Forfeitures [Member]" } } }, "localname": "ForfeituresMember", "nsuri": "http://endonovo.com/20230630", "presentation": [ "http://endonovo.com/role/ScheduleOfConversionFeatureUsingBlackScholesOptionPricingModelDetails" ], "xbrltype": "domainItemType" }, "ENDV_FormerPresidentMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Former President [Member]", "label": "Former President [Member]" } } }, "localname": "FormerPresidentMember", "nsuri": "http://endonovo.com/20230630", "presentation": [ "http://endonovo.com/role/RelatedPartyAndFormerRelatedPartiesTransactionsDetailsNarrative" ], "xbrltype": "domainItemType" }, "ENDV_FormerRelatedPartyMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Former Related Party [Member]", "label": "Former Related Party [Member]" } } }, "localname": "FormerRelatedPartyMember", "nsuri": "http://endonovo.com/20230630", "presentation": [ "http://endonovo.com/role/NotesPayableDetailsNarrative", "http://endonovo.com/role/ScheduleOfMaturityDatesOfNotesPayableDetails", "http://endonovo.com/role/ScheduleOfNotesPayableDetails" ], "xbrltype": "domainItemType" }, "ENDV_GoodProvisionValue": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Good provision value.", "label": "Value of good provision" } } }, "localname": "GoodProvisionValue", "nsuri": "http://endonovo.com/20230630", "presentation": [ "http://endonovo.com/role/NotesPayableDetailsNarrative" ], "xbrltype": "monetaryItemType" }, "ENDV_GrossSaleValueOfOngoingContract": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Gross sales value of ongoing contract.", "label": "[custom:GrossSaleValueOfOngoingContract]" } } }, "localname": "GrossSaleValueOfOngoingContract", "nsuri": "http://endonovo.com/20230630", "presentation": [ "http://endonovo.com/role/RevenueRecognitionDetailsNarrative" ], "xbrltype": "monetaryItemType" }, "ENDV_InducementLossRelatedToConversionOfPreferredStock": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Inducement loss related to conversion of preferred stock.", "label": "Inducement loss" } } }, "localname": "InducementLossRelatedToConversionOfPreferredStock", "nsuri": "http://endonovo.com/20230630", "presentation": [ "http://endonovo.com/role/ShareholdersDeficitDetailsNarrative" ], "xbrltype": "monetaryItemType" }, "ENDV_IssuanceOfCommonStockToSettleDebt": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Issuance of common stock to settle debt", "label": "Issuance of common stock to settle debt" } } }, "localname": "IssuanceOfCommonStockToSettleDebt", "nsuri": "http://endonovo.com/20230630", "presentation": [ "http://endonovo.com/role/StatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "ENDV_LiquidityAndGoingConcernPolicyTextTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy for liquidity and going concern.", "label": "Liquidity and Going Concern" } } }, "localname": "LiquidityAndGoingConcernPolicyTextTextBlock", "nsuri": "http://endonovo.com/20230630", "presentation": [ "http://endonovo.com/role/SummaryOfSignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "ENDV_LongTermDebtPastMaturity": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Long term debt past maturity.", "label": "Past due" } } }, "localname": "LongTermDebtPastMaturity", "nsuri": "http://endonovo.com/20230630", "presentation": [ "http://endonovo.com/role/ScheduleOfMaturityDatesOfNotesPayableDetails" ], "xbrltype": "monetaryItemType" }, "ENDV_NotesPayableIssued": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Notes payable issued to non-related parties.", "label": "Notes payable issued", "verboseLabel": "Note payable issued" } } }, "localname": "NotesPayableIssued", "nsuri": "http://endonovo.com/20230630", "presentation": [ "http://endonovo.com/role/NotesPayableDetailsNarrative", "http://endonovo.com/role/ScheduleOfNotesPayableDetails" ], "xbrltype": "monetaryItemType" }, "ENDV_OneFormerExecutiveOfficerMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "One Former Executive Officer [Member]", "label": "One Former Executive Officer [Member]" } } }, "localname": "OneFormerExecutiveOfficerMember", "nsuri": "http://endonovo.com/20230630", "presentation": [ "http://endonovo.com/role/RelatedPartyAndFormerRelatedPartiesTransactionsDetailsNarrative" ], "xbrltype": "domainItemType" }, "ENDV_OneInvestorMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "One Investor [Member]", "label": "One Investor [Member]" } } }, "localname": "OneInvestorMember", "nsuri": "http://endonovo.com/20230630", "presentation": [ "http://endonovo.com/role/ShareholdersDeficitDetailsNarrative", "http://endonovo.com/role/SubsequentEventsDetailsNarrative" ], "xbrltype": "domainItemType" }, "ENDV_OneSignificantCustomerMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "One Significant Customer [Member]", "label": "One Significant Customer [Member]" } } }, "localname": "OneSignificantCustomerMember", "nsuri": "http://endonovo.com/20230630", "presentation": [ "http://endonovo.com/role/ConcentrationsDetailsNarrative" ], "xbrltype": "domainItemType" }, "ENDV_PastMaturityMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Past Maturity [Member]", "label": "Past Maturity [Member]" } } }, "localname": "PastMaturityMember", "nsuri": "http://endonovo.com/20230630", "presentation": [ "http://endonovo.com/role/NotesPayableDetailsNarrative" ], "xbrltype": "domainItemType" }, "ENDV_PatentsExpirationPeriod": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Patents expiration period.", "label": "Patents expiration period" } } }, "localname": "PatentsExpirationPeriod", "nsuri": "http://endonovo.com/20230630", "presentation": [ "http://endonovo.com/role/PatentsDetailsNarrative" ], "xbrltype": "gYearItemType" }, "ENDV_PreferredSeriesBMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Preferred Series B [Member]", "label": "Preferred Series B [Member]" } } }, "localname": "PreferredSeriesBMember", "nsuri": "http://endonovo.com/20230630", "presentation": [ "http://endonovo.com/role/ScheduleOfPreferredStockDetails" ], "xbrltype": "domainItemType" }, "ENDV_PreferredSeriesCMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Preferred Series C [Member]", "label": "Preferred Series C [Member]" } } }, "localname": "PreferredSeriesCMember", "nsuri": "http://endonovo.com/20230630", "presentation": [ "http://endonovo.com/role/ScheduleOfPreferredStockDetails" ], "xbrltype": "domainItemType" }, "ENDV_PreferredSeriesDMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Preferred Series D [Member]", "label": "Preferred Series D [Member]" } } }, "localname": "PreferredSeriesDMember", "nsuri": "http://endonovo.com/20230630", "presentation": [ "http://endonovo.com/role/ScheduleOfPreferredStockDetails" ], "xbrltype": "domainItemType" }, "ENDV_PreferredStockDesignatedMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Preferred Stock Designated [Member]", "label": "Preferred Stock Designated [Member]" } } }, "localname": "PreferredStockDesignatedMember", "nsuri": "http://endonovo.com/20230630", "presentation": [ "http://endonovo.com/role/ShareholdersDeficitDetailsNarrative" ], "xbrltype": "domainItemType" }, "ENDV_PrepaymentPenalty": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Prepayment Penalty", "label": "Prepayment penalty" } } }, "localname": "PrepaymentPenalty", "nsuri": "http://endonovo.com/20230630", "presentation": [ "http://endonovo.com/role/NotesPayableDetailsNarrative" ], "xbrltype": "monetaryItemType" }, "ENDV_ProductionAgreementMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Production Agreement [Member]", "label": "Production Agreement [Member]" } } }, "localname": "ProductionAgreementMember", "nsuri": "http://endonovo.com/20230630", "presentation": [ "http://endonovo.com/role/SubsequentEventsDetailsNarrative" ], "xbrltype": "domainItemType" }, "ENDV_PulseTherapeuticTechnologyMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Pulse Therapeutic Technology [Member]", "label": "Pulse Therapeutic Technology [Member]" } } }, "localname": "PulseTherapeuticTechnologyMember", "nsuri": "http://endonovo.com/20230630", "presentation": [ "http://endonovo.com/role/RevenueRecognitionDetailsNarrative" ], "xbrltype": "domainItemType" }, "ENDV_PurchaseAgreementMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Purchase Agreement [Member]", "label": "Purchase Agreement [Member]" } } }, "localname": "PurchaseAgreementMember", "nsuri": "http://endonovo.com/20230630", "presentation": [ "http://endonovo.com/role/ShareholdersDeficitDetailsNarrative" ], "xbrltype": "domainItemType" }, "ENDV_RepaymentsOfDeferredCompensation": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Repayments of deferred compensation.", "label": "Cash repayments of deferred compensation" } } }, "localname": "RepaymentsOfDeferredCompensation", "nsuri": "http://endonovo.com/20230630", "presentation": [ "http://endonovo.com/role/RelatedPartyAndFormerRelatedPartiesTransactionsDetailsNarrative" ], "xbrltype": "monetaryItemType" }, "ENDV_RioGrandeNeurosciencesIncMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Rio Grande Neurosciences, Inc. [Member]", "label": "Rio Grande Neurosciences, Inc. [Member]" } } }, "localname": "RioGrandeNeurosciencesIncMember", "nsuri": "http://endonovo.com/20230630", "presentation": [ "http://endonovo.com/role/PatentsDetailsNarrative" ], "xbrltype": "domainItemType" }, "ENDV_RoyaltyAndLicensingNetMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Royalty/Licensing, Net [Member]", "label": "Royalty/Licensing, Net [Member]" } } }, "localname": "RoyaltyAndLicensingNetMember", "nsuri": "http://endonovo.com/20230630", "presentation": [ "http://endonovo.com/role/RevenueRecognitionDetailsNarrative", "http://endonovo.com/role/ScheduleOfSourceOfRevenueDetails" ], "xbrltype": "domainItemType" }, "ENDV_SalesSupportServiceAgreementMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Sales Support Service Agreement [Member]", "label": "Sales Support Service Agreement [Member]" } } }, "localname": "SalesSupportServiceAgreementMember", "nsuri": "http://endonovo.com/20230630", "presentation": [ "http://endonovo.com/role/RevenueRecognitionDetailsNarrative" ], "xbrltype": "domainItemType" }, "ENDV_ScheduleOfPreferredStockTableTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Schedule of preferred stock [Table text block].", "label": "Schedule of Preferred Stock" } } }, "localname": "ScheduleOfPreferredStockTableTextBlock", "nsuri": "http://endonovo.com/20230630", "presentation": [ "http://endonovo.com/role/ShareholdersDeficitTables" ], "xbrltype": "textBlockItemType" }, "ENDV_ScheduleOfSourceOfRevenueTableTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Schedule of Source of Revenue [Table Text Block]", "label": "Schedule of Source of Revenue" } } }, "localname": "ScheduleOfSourceOfRevenueTableTextBlock", "nsuri": "http://endonovo.com/20230630", "presentation": [ "http://endonovo.com/role/RevenueRecognitionTables" ], "xbrltype": "textBlockItemType" }, "ENDV_SecuritiesPurchaseAgreementsMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Securities Purchase Agreements [Member]", "label": "Securities Purchase Agreements [Member]" } } }, "localname": "SecuritiesPurchaseAgreementsMember", "nsuri": "http://endonovo.com/20230630", "presentation": [ "http://endonovo.com/role/ShareholdersDeficitDetailsNarrative" ], "xbrltype": "domainItemType" }, "ENDV_SecuriyPurchaseAgreementMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Securiy Purchase Agreement [Member]", "label": "Securiy Purchase Agreement [Member]" } } }, "localname": "SecuriyPurchaseAgreementMember", "nsuri": "http://endonovo.com/20230630", "presentation": [ "http://endonovo.com/role/SubsequentEventsDetailsNarrative" ], "xbrltype": "domainItemType" }, "ENDV_SeriesAAMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Series AA [Member]", "label": "Series AA [Member]" } } }, "localname": "SeriesAAMember", "nsuri": "http://endonovo.com/20230630", "presentation": [ "http://endonovo.com/role/ScheduleOfPreferredStockDetails" ], "xbrltype": "domainItemType" }, "ENDV_SeriesAAPreferredStockMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Series AA Preferred Stock [Member]", "label": "Series AA Preferred Stock [Member]" } } }, "localname": "SeriesAAPreferredStockMember", "nsuri": "http://endonovo.com/20230630", "presentation": [ "http://endonovo.com/role/ShareholdersDeficitDetailsNarrative", "http://endonovo.com/role/StatementOfShareholdersDeficit" ], "xbrltype": "domainItemType" }, "ENDV_SeriesBConvertiblePreferredStockMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Series B Convertible Preferred Stock [Member]", "label": "Series B Convertible Preferred Stock [Member]" } } }, "localname": "SeriesBConvertiblePreferredStockMember", "nsuri": "http://endonovo.com/20230630", "presentation": [ "http://endonovo.com/role/BalanceSheets", "http://endonovo.com/role/BalanceSheetsParenthetical", "http://endonovo.com/role/StatementOfShareholdersDeficit" ], "xbrltype": "domainItemType" }, "ENDV_SeriesCConvertiblePreferredStockMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Series C Convertible Preferred Stock [Member]", "label": "Series C Convertible Preferred Stock [Member]" } } }, "localname": "SeriesCConvertiblePreferredStockMember", "nsuri": "http://endonovo.com/20230630", "presentation": [ "http://endonovo.com/role/BalanceSheets", "http://endonovo.com/role/BalanceSheetsParenthetical", "http://endonovo.com/role/StatementOfShareholdersDeficit" ], "xbrltype": "domainItemType" }, "ENDV_SeriesCConvertibleRedeemablePreferredStockMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Series C Convertible Redeemable Preferred Stock [Member]", "label": "Series C Convertible Redeemable Preferred Stock [Member]" } } }, "localname": "SeriesCConvertibleRedeemablePreferredStockMember", "nsuri": "http://endonovo.com/20230630", "presentation": [ "http://endonovo.com/role/ShareholdersDeficitDetailsNarrative" ], "xbrltype": "domainItemType" }, "ENDV_SeriesDConvertiblePreferredStockMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Series D Convertible Preferred Stock [Member]", "label": "Series D Convertible Preferred Stock [Member]" } } }, "localname": "SeriesDConvertiblePreferredStockMember", "nsuri": "http://endonovo.com/20230630", "presentation": [ "http://endonovo.com/role/BalanceSheets", "http://endonovo.com/role/BalanceSheetsParenthetical", "http://endonovo.com/role/ShareholdersDeficitDetailsNarrative", "http://endonovo.com/role/StatementOfShareholdersDeficit" ], "xbrltype": "domainItemType" }, "ENDV_SettlementsOnNotePayable": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Settlements on note payable.", "label": "Settlement on note payable" } } }, "localname": "SettlementsOnNotePayable", "nsuri": "http://endonovo.com/20230630", "presentation": [ "http://endonovo.com/role/ScheduleOfNotesPayableDetails" ], "xbrltype": "monetaryItemType" }, "ENDV_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityExercisable": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Share based compensation arrangement by share based payment award non option equity exercisable.", "label": "Series B preferred stock dividend payable in common stock", "periodEndLabel": "Shares Exercisable, Ending Balance" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityExercisable", "nsuri": "http://endonovo.com/20230630", "presentation": [ "http://endonovo.com/role/ScheduleOfWarrantsOutstandingDetails" ], "xbrltype": "sharesItemType" }, "ENDV_ShareBasedCompensationArrangementByShareBasedPaymetAwardNonOptionExercisedInPeriodWeightedAverageExercisePrice": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Share based compensation arrangement by share based paymet award non option exercised in period weighted average exercise price.", "label": "ShareBasedCompensationArrangementByShareBasedPaymetAwardNonOptionExercisedInPeriodWeightedAverageExercisePrice", "verboseLabel": "Weighted Average Exercise Price Per Share, Exercised" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymetAwardNonOptionExercisedInPeriodWeightedAverageExercisePrice", "nsuri": "http://endonovo.com/20230630", "presentation": [ "http://endonovo.com/role/ScheduleOfWarrantsOutstandingDetails" ], "xbrltype": "perShareItemType" }, "ENDV_ShareBasedCompensationArrangementByShareBasedPaymetAwardNonOptionForfeitedOrExpiredInPeriodWeightedAverageExercisePrice": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Share based compensation arrangement by share based paymet award non option forfeited or expired in period weighted average exercise price.", "label": "ShareBasedCompensationArrangementByShareBasedPaymetAwardNonOptionForfeitedOrExpiredInPeriodWeightedAverageExercisePrice", "verboseLabel": "Weighted Average Exercise Price Per Share, Cancelled" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymetAwardNonOptionForfeitedOrExpiredInPeriodWeightedAverageExercisePrice", "nsuri": "http://endonovo.com/20230630", "presentation": [ "http://endonovo.com/role/ScheduleOfWarrantsOutstandingDetails" ], "xbrltype": "perShareItemType" }, "ENDV_ShareBasedCompensationArrangementByShareBasedPaymetAwardNonOptionGrandInPeriodWeightedAverageExercisePrice": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Share based compensation arrangement by share based paymet award non option grand in period weighted average exercise price.", "label": "Term loan", "verboseLabel": "Weighted Average Exercise Price Per Share, Granted" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymetAwardNonOptionGrandInPeriodWeightedAverageExercisePrice", "nsuri": "http://endonovo.com/20230630", "presentation": [ "http://endonovo.com/role/ScheduleOfWarrantsOutstandingDetails" ], "xbrltype": "perShareItemType" }, "ENDV_ShareBasedCompensationArrangementByShareBasedPaymetAwardNonOptionOutstandingWeightedAverageExercisePrice": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Share based compensation for outstanding weighted average exercise price.", "label": "ShareBasedCompensationArrangementByShareBasedPaymetAwardNonOptionOutstandingWeightedAverageExercisePrice", "periodEndLabel": "Weighted Average Exercise Price Per Share, Outstanding Ending Balance", "periodStartLabel": "Weighted Average Exercise Price Per Share, Outstanding Beginning Balance" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymetAwardNonOptionOutstandingWeightedAverageExercisePrice", "nsuri": "http://endonovo.com/20230630", "presentation": [ "http://endonovo.com/role/ScheduleOfWarrantsOutstandingDetails" ], "xbrltype": "perShareItemType" }, "ENDV_ShareBasedCompensationArrangementByShareBasedPaymetAwardNonOptionWeightedAverageExercisable": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Share based compensation arrangement by share based paymet award non option weighted average exercisable.", "label": "ShareBasedCompensationArrangementByShareBasedPaymetAwardNonOptionWeightedAverageExercisable", "periodEndLabel": "Weighted Average Exercise Price Per Share, Exercisable Ending Balance" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymetAwardNonOptionWeightedAverageExercisable", "nsuri": "http://endonovo.com/20230630", "presentation": [ "http://endonovo.com/role/ScheduleOfWarrantsOutstandingDetails" ], "xbrltype": "perShareItemType" }, "ENDV_ShareExercisePercentage": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Share exercise percentage.", "label": "Share exercise price" } } }, "localname": "ShareExercisePercentage", "nsuri": "http://endonovo.com/20230630", "presentation": [ "http://endonovo.com/role/ShareholdersDeficitDetailsNarrative" ], "xbrltype": "percentItemType" }, "ENDV_SharebasedCompensationArrangementBySharebasedPaymentAwardNonOptionsOutstandingWeightedAverageRemainingContractualTerm1": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Weighted average remaining contractual term (years), beginning outstanding.", "label": "SharebasedCompensationArrangementBySharebasedPaymentAwardNonOptionsOutstandingWeightedAverageRemainingContractualTerm1", "verboseLabel": "Weighted Average Remaining Contractual Term (years), Outstanding Beginning" } } }, "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardNonOptionsOutstandingWeightedAverageRemainingContractualTerm1", "nsuri": "http://endonovo.com/20230630", "presentation": [ "http://endonovo.com/role/ScheduleOfWarrantsOutstandingDetails" ], "xbrltype": "durationItemType" }, "ENDV_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualExercisableTerm2": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Exercisable Term 2.", "label": "Weighted Average Remaining Contractual Term (years), Exercisable" } } }, "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualExercisableTerm2", "nsuri": "http://endonovo.com/20230630", "presentation": [ "http://endonovo.com/role/ScheduleOfStockOptionsOutstandingDetails" ], "xbrltype": "durationItemType" }, "ENDV_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm1": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Weighted average remaining contractual term (years), beginning outstanding.", "label": "Weighted Average Remaining Contractual Term (years), Outstanding Beginning" } } }, "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm1", "nsuri": "http://endonovo.com/20230630", "presentation": [ "http://endonovo.com/role/ScheduleOfStockOptionsOutstandingDetails" ], "xbrltype": "durationItemType" }, "ENDV_SharesIssuedForConversionOfDeferredCompensationShares": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Shares issued for conversion of deferred compensation shares.", "label": "Shares issued for conversion of deferred compensation, shares", "verboseLabel": "Number of shares issued, share" } } }, "localname": "SharesIssuedForConversionOfDeferredCompensationShares", "nsuri": "http://endonovo.com/20230630", "presentation": [ "http://endonovo.com/role/ShareholdersDeficitDetailsNarrative", "http://endonovo.com/role/StatementOfShareholdersDeficit" ], "xbrltype": "sharesItemType" }, "ENDV_SharesIssuedForConversionOfDeferredCompensationValue": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Shares issued for conversion of deferred compensation value.", "label": "Shares issued for conversion of deferred compensation", "verboseLabel": "Fair value of defered compensation" } } }, "localname": "SharesIssuedForConversionOfDeferredCompensationValue", "nsuri": "http://endonovo.com/20230630", "presentation": [ "http://endonovo.com/role/ShareholdersDeficitDetailsNarrative", "http://endonovo.com/role/StatementOfShareholdersDeficit" ], "xbrltype": "monetaryItemType" }, "ENDV_SixteenFixedRatedNotesMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Sixteen Fixed Rated Notes [Member]", "label": "16 Fixed Rated Notes [Member]" } } }, "localname": "SixteenFixedRatedNotesMember", "nsuri": "http://endonovo.com/20230630", "presentation": [ "http://endonovo.com/role/NotesPayableDetailsNarrative" ], "xbrltype": "domainItemType" }, "ENDV_StockIssuedDuringPeriodSharesConnectionWithPromissoryNotes": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Stock issued during period shares connection with promissory notes.", "label": "Issuance of commitment shares in connection with promissory notes, shares" } } }, "localname": "StockIssuedDuringPeriodSharesConnectionWithPromissoryNotes", "nsuri": "http://endonovo.com/20230630", "presentation": [ "http://endonovo.com/role/StatementOfShareholdersDeficit" ], "xbrltype": "sharesItemType" }, "ENDV_StockIssuedDuringPeriodValueConnectionWithPromissoryNotes": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Stock issued during period value connection with promissory notes.", "label": "Issuance of commitment shares in connection with promissory note" } } }, "localname": "StockIssuedDuringPeriodValueConnectionWithPromissoryNotes", "nsuri": "http://endonovo.com/20230630", "presentation": [ "http://endonovo.com/role/StatementOfShareholdersDeficit" ], "xbrltype": "monetaryItemType" }, "ENDV_StockOptionsMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Stock Options [Member]", "label": "Stock Options [Member]" } } }, "localname": "StockOptionsMember", "nsuri": "http://endonovo.com/20230630", "presentation": [ "http://endonovo.com/role/ScheduleOfStockOptionsOutstandingDetails" ], "xbrltype": "domainItemType" }, "ENDV_SubscriptionReceivableMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Subscription Receivable [Member]", "label": "Subscription Receivable [Member]" } } }, "localname": "SubscriptionReceivableMember", "nsuri": "http://endonovo.com/20230630", "presentation": [ "http://endonovo.com/role/StatementOfShareholdersDeficit" ], "xbrltype": "domainItemType" }, "ENDV_SuperAASuperVotingPreferredStockMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Super AA Super Voting Preferred Stock [Member]", "label": "Super AA Super Voting Preferred Stock [Member]" } } }, "localname": "SuperAASuperVotingPreferredStockMember", "nsuri": "http://endonovo.com/20230630", "presentation": [ "http://endonovo.com/role/BalanceSheets", "http://endonovo.com/role/BalanceSheetsParenthetical" ], "xbrltype": "domainItemType" }, "ENDV_SupplierMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Supplier [Member]", "label": "Supplier [Member]" } } }, "localname": "SupplierMember", "nsuri": "http://endonovo.com/20230630", "presentation": [ "http://endonovo.com/role/ConcentrationsDetailsNarrative" ], "xbrltype": "domainItemType" }, "ENDV_ThreeFixedRatedNotesMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Three Fixed Rated Notes [Member]", "label": "3 Fixed Rated Notes [Member]" } } }, "localname": "ThreeFixedRatedNotesMember", "nsuri": "http://endonovo.com/20230630", "presentation": [ "http://endonovo.com/role/NotesPayableDetailsNarrative" ], "xbrltype": "domainItemType" }, "ENDV_TwoNotesExtensionAgreementsMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Two Notes Extension Agreements [Member]", "label": "Two Notes Extension Agreements [Member]" } } }, "localname": "TwoNotesExtensionAgreementsMember", "nsuri": "http://endonovo.com/20230630", "presentation": [ "http://endonovo.com/role/SubsequentEventsDetailsNarrative" ], "xbrltype": "domainItemType" }, "ENDV_UndesignatedMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Undesignated [Member]", "label": "Undesignated [Member]" } } }, "localname": "UndesignatedMember", "nsuri": "http://endonovo.com/20230630", "presentation": [ "http://endonovo.com/role/ScheduleOfPreferredStockDetails" ], "xbrltype": "domainItemType" }, "ENDV_VariableRateNotesMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Variable Rate Notes [Member]", "label": "Variable Rate Notes [Member]" } } }, "localname": "VariableRateNotesMember", "nsuri": "http://endonovo.com/20230630", "presentation": [ "http://endonovo.com/role/NotesPayableDetailsNarrative" ], "xbrltype": "domainItemType" }, "ENDV_WarrantTerm": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Warrant term.", "label": "Warrants term" } } }, "localname": "WarrantTerm", "nsuri": "http://endonovo.com/20230630", "presentation": [ "http://endonovo.com/role/ShareholdersDeficitDetailsNarrative" ], "xbrltype": "stringItemType" }, "ENDV_WeightedAverageNumberOfDilutedSharesOutstandingGross": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "The average number of shares or units issued and outstanding gross that are used in calculating diluted EPS or earnings per unit (EPU), determined based on the timing of issuance of shares or units in the period.", "label": "Weighted-average number of common shares outstanding during the period" } } }, "localname": "WeightedAverageNumberOfDilutedSharesOutstandingGross", "nsuri": "http://endonovo.com/20230630", "presentation": [ "http://endonovo.com/role/ScheduleOfEarningsPerShareBasicAndDilutedDetails" ], "xbrltype": "sharesItemType" }, "ENDV_WorkingCapitalDeficiency": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Working capital deficiency.", "label": "Working capital" } } }, "localname": "WorkingCapitalDeficiency", "nsuri": "http://endonovo.com/20230630", "presentation": [ "http://endonovo.com/role/SummaryOfSignificantAccountingPoliciesDetailsNarrative" ], "xbrltype": "monetaryItemType" }, "dei_AmendmentDescription": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Description of changes contained within amended document.", "label": "Amendment Description" } } }, "localname": "AmendmentDescription", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://endonovo.com/role/Cover" ], "xbrltype": "stringItemType" }, "dei_AmendmentFlag": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.", "label": "Amendment Flag" } } }, "localname": "AmendmentFlag", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://endonovo.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_AnnualInformationForm": { "auth_ref": [ "r660" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag with value true on a form if it is an annual report containing an annual information form.", "label": "Annual Information Form" } } }, "localname": "AnnualInformationForm", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://endonovo.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_AuditedAnnualFinancialStatements": { "auth_ref": [ "r660" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag with value true on a form if it is an annual report containing audited financial statements.", "label": "Audited Annual Financial Statements" } } }, "localname": "AuditedAnnualFinancialStatements", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://endonovo.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_CityAreaCode": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Area code of city", "label": "City Area Code" } } }, "localname": "CityAreaCode", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://endonovo.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_CountryRegion": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Region code of country", "label": "Country Region" } } }, "localname": "CountryRegion", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://endonovo.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_CoverAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Cover page.", "label": "Cover [Abstract]" } } }, "localname": "CoverAbstract", "nsuri": "http://xbrl.sec.gov/dei/2023", "xbrltype": "stringItemType" }, "dei_CurrentFiscalYearEndDate": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "End date of current fiscal year in the format --MM-DD.", "label": "Current Fiscal Year End Date" } } }, "localname": "CurrentFiscalYearEndDate", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://endonovo.com/role/Cover" ], "xbrltype": "gMonthDayItemType" }, "dei_DocumentAccountingStandard": { "auth_ref": [ "r659" ], "lang": { "en-us": { "role": { "documentation": "The basis of accounting the registrant has used to prepare the financial statements included in this filing This can either be 'U.S. GAAP', 'International Financial Reporting Standards', or 'Other'.", "label": "Document Accounting Standard" } } }, "localname": "DocumentAccountingStandard", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://endonovo.com/role/Cover" ], "xbrltype": "accountingStandardItemType" }, "dei_DocumentAnnualReport": { "auth_ref": [ "r657", "r659", "r660" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true only for a form used as an annual report.", "label": "Document Annual Report" } } }, "localname": "DocumentAnnualReport", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://endonovo.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_DocumentFiscalPeriodFocus": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Fiscal period values are FY, Q1, Q2, and Q3. 1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY.", "label": "Document Fiscal Period Focus" } } }, "localname": "DocumentFiscalPeriodFocus", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://endonovo.com/role/Cover" ], "xbrltype": "fiscalPeriodItemType" }, "dei_DocumentFiscalYearFocus": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006.", "label": "Document Fiscal Year Focus" } } }, "localname": "DocumentFiscalYearFocus", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://endonovo.com/role/Cover" ], "xbrltype": "gYearItemType" }, "dei_DocumentPeriodEndDate": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD.", "label": "Document Period End Date" } } }, "localname": "DocumentPeriodEndDate", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://endonovo.com/role/Cover" ], "xbrltype": "dateItemType" }, "dei_DocumentPeriodStartDate": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "The start date of the period covered in the document, in YYYY-MM-DD format.", "label": "Document Period Start Date" } } }, "localname": "DocumentPeriodStartDate", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://endonovo.com/role/Cover" ], "xbrltype": "dateItemType" }, "dei_DocumentQuarterlyReport": { "auth_ref": [ "r658" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true only for a form used as an quarterly report.", "label": "Document Quarterly Report" } } }, "localname": "DocumentQuarterlyReport", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://endonovo.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_DocumentRegistrationStatement": { "auth_ref": [ "r646" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true only for a form used as a registration statement.", "label": "Document Registration Statement" } } }, "localname": "DocumentRegistrationStatement", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://endonovo.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_DocumentShellCompanyEventDate": { "auth_ref": [ "r659" ], "lang": { "en-us": { "role": { "documentation": "Date of event requiring a shell company report.", "label": "Document Shell Company Event Date" } } }, "localname": "DocumentShellCompanyEventDate", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://endonovo.com/role/Cover" ], "xbrltype": "dateItemType" }, "dei_DocumentShellCompanyReport": { "auth_ref": [ "r659" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true for a Shell Company Report pursuant to section 13 or 15(d) of the Exchange Act.", "label": "Document Shell Company Report" } } }, "localname": "DocumentShellCompanyReport", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://endonovo.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_DocumentTransitionReport": { "auth_ref": [ "r661" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true only for a form used as a transition report.", "label": "Document Transition Report" } } }, "localname": "DocumentTransitionReport", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://endonovo.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_DocumentType": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.", "label": "Document Type" } } }, "localname": "DocumentType", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://endonovo.com/role/Cover" ], "xbrltype": "submissionTypeItemType" }, "dei_DocumentsIncorporatedByReferenceTextBlock": { "auth_ref": [ "r649" ], "lang": { "en-us": { "role": { "documentation": "Documents incorporated by reference.", "label": "Documents Incorporated by Reference [Text Block]" } } }, "localname": "DocumentsIncorporatedByReferenceTextBlock", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://endonovo.com/role/Cover" ], "xbrltype": "textBlockItemType" }, "dei_EntityAddressAddressLine1": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Address Line 1 such as Attn, Building Name, Street Name", "label": "Entity Address, Address Line One" } } }, "localname": "EntityAddressAddressLine1", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://endonovo.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressAddressLine2": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Address Line 2 such as Street or Suite number", "label": "Entity Address, Address Line Two" } } }, "localname": "EntityAddressAddressLine2", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://endonovo.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressAddressLine3": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Address Line 3 such as an Office Park", "label": "Entity Address, Address Line Three" } } }, "localname": "EntityAddressAddressLine3", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://endonovo.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressCityOrTown": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Name of the City or Town", "label": "Entity Address, City or Town" } } }, "localname": "EntityAddressCityOrTown", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://endonovo.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressCountry": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "ISO 3166-1 alpha-2 country code.", "label": "Entity Address, Country" } } }, "localname": "EntityAddressCountry", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://endonovo.com/role/Cover" ], "xbrltype": "countryCodeItemType" }, "dei_EntityAddressPostalZipCode": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Code for the postal or zip code", "label": "Entity Address, Postal Zip Code" } } }, "localname": "EntityAddressPostalZipCode", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://endonovo.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressStateOrProvince": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Name of the state or province.", "label": "Entity Address, State or Province" } } }, "localname": "EntityAddressStateOrProvince", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://endonovo.com/role/Cover" ], "xbrltype": "stateOrProvinceItemType" }, "dei_EntityBankruptcyProceedingsReportingCurrent": { "auth_ref": [ "r652" ], "lang": { "en-us": { "role": { "documentation": "For registrants involved in bankruptcy proceedings during the preceding five years, the value Yes indicates that the registrant has filed all documents and reports required to be filed by Section 12, 13 or 15(d) of the Securities Exchange Act of 1934 subsequent to the distribution of securities under a plan confirmed by a court; the value No indicates the registrant has not. Registrants not involved in bankruptcy proceedings during the preceding five years should not report this element.", "label": "Entity Bankruptcy Proceedings, Reporting Current" } } }, "localname": "EntityBankruptcyProceedingsReportingCurrent", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://endonovo.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_EntityCentralIndexKey": { "auth_ref": [ "r648" ], "lang": { "en-us": { "role": { "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.", "label": "Entity Central Index Key" } } }, "localname": "EntityCentralIndexKey", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://endonovo.com/role/Cover" ], "xbrltype": "centralIndexKeyItemType" }, "dei_EntityCommonStockSharesOutstanding": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument.", "label": "Entity Common Stock, Shares Outstanding" } } }, "localname": "EntityCommonStockSharesOutstanding", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://endonovo.com/role/Cover" ], "xbrltype": "sharesItemType" }, "dei_EntityCurrentReportingStatus": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure.", "label": "Entity Current Reporting Status" } } }, "localname": "EntityCurrentReportingStatus", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://endonovo.com/role/Cover" ], "xbrltype": "yesNoItemType" }, "dei_EntityDomain": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "All the names of the entities being reported upon in a document. Any legal structure used to conduct activities or to hold assets. Some examples of such structures are corporations, partnerships, limited liability companies, grantor trusts, and other trusts. This item does not include business and geographical segments which are included in the geographical or business segments domains." } } }, "localname": "EntityDomain", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://endonovo.com/role/PatentsDetailsNarrative" ], "xbrltype": "domainItemType" }, "dei_EntityEmergingGrowthCompany": { "auth_ref": [ "r648" ], "lang": { "en-us": { "role": { "documentation": "Indicate if registrant meets the emerging growth company criteria.", "label": "Entity Emerging Growth Company" } } }, "localname": "EntityEmergingGrowthCompany", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://endonovo.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_EntityExTransitionPeriod": { "auth_ref": [ "r665" ], "lang": { "en-us": { "role": { "documentation": "Indicate if an emerging growth company has elected not to use the extended transition period for complying with any new or revised financial accounting standards.", "label": "Elected Not To Use the Extended Transition Period" } } }, "localname": "EntityExTransitionPeriod", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://endonovo.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_EntityFileNumber": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.", "label": "Entity File Number" } } }, "localname": "EntityFileNumber", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://endonovo.com/role/Cover" ], "xbrltype": "fileNumberItemType" }, "dei_EntityFilerCategory": { "auth_ref": [ "r648" ], "lang": { "en-us": { "role": { "documentation": "Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure.", "label": "Entity Filer Category" } } }, "localname": "EntityFilerCategory", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://endonovo.com/role/Cover" ], "xbrltype": "filerCategoryItemType" }, "dei_EntityIncorporationStateCountryCode": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Two-character EDGAR code representing the state or country of incorporation.", "label": "Entity Incorporation, State or Country Code" } } }, "localname": "EntityIncorporationStateCountryCode", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://endonovo.com/role/Cover" ], "xbrltype": "edgarStateCountryItemType" }, "dei_EntityInteractiveDataCurrent": { "auth_ref": [ "r662" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).", "label": "Entity Interactive Data Current" } } }, "localname": "EntityInteractiveDataCurrent", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://endonovo.com/role/Cover" ], "xbrltype": "yesNoItemType" }, "dei_EntityPrimarySicNumber": { "auth_ref": [ "r660" ], "lang": { "en-us": { "role": { "documentation": "Primary Standard Industrial Classification (SIC) Number for the Entity.", "label": "Entity Primary SIC Number" } } }, "localname": "EntityPrimarySicNumber", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://endonovo.com/role/Cover" ], "xbrltype": "sicNumberItemType" }, "dei_EntityPublicFloat": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The aggregate market value of the voting and non-voting common equity held by non-affiliates computed by reference to the price at which the common equity was last sold, or the average bid and asked price of such common equity, as of the last business day of the registrant's most recently completed second fiscal quarter.", "label": "Entity Public Float" } } }, "localname": "EntityPublicFloat", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://endonovo.com/role/Cover" ], "xbrltype": "monetaryItemType" }, "dei_EntityRegistrantName": { "auth_ref": [ "r648" ], "lang": { "en-us": { "role": { "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.", "label": "Entity Registrant Name" } } }, "localname": "EntityRegistrantName", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://endonovo.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityShellCompany": { "auth_ref": [ "r648" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act.", "label": "Entity Shell Company" } } }, "localname": "EntityShellCompany", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://endonovo.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_EntitySmallBusiness": { "auth_ref": [ "r648" ], "lang": { "en-us": { "role": { "documentation": "Indicates that the company is a Smaller Reporting Company (SRC).", "label": "Entity Small Business" } } }, "localname": "EntitySmallBusiness", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://endonovo.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_EntityTaxIdentificationNumber": { "auth_ref": [ "r648" ], "lang": { "en-us": { "role": { "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.", "label": "Entity Tax Identification Number" } } }, "localname": "EntityTaxIdentificationNumber", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://endonovo.com/role/Cover" ], "xbrltype": "employerIdItemType" }, "dei_EntityVoluntaryFilers": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Indicate 'Yes' or 'No' if the registrant is not required to file reports pursuant to Section 13 or Section 15(d) of the Act.", "label": "Entity Voluntary Filers" } } }, "localname": "EntityVoluntaryFilers", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://endonovo.com/role/Cover" ], "xbrltype": "yesNoItemType" }, "dei_EntityWellKnownSeasonedIssuer": { "auth_ref": [ "r663" ], "lang": { "en-us": { "role": { "documentation": "Indicate 'Yes' or 'No' if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act. Is used on Form Type: 10-K, 10-Q, 8-K, 20-F, 6-K, 10-K/A, 10-Q/A, 20-F/A, 6-K/A, N-CSR, N-Q, N-1A.", "label": "Entity Well-known Seasoned Issuer" } } }, "localname": "EntityWellKnownSeasonedIssuer", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://endonovo.com/role/Cover" ], "xbrltype": "yesNoItemType" }, "dei_Extension": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Extension number for local phone number.", "label": "Extension" } } }, "localname": "Extension", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://endonovo.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_LegalEntityAxis": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "The set of legal entities associated with a report.", "label": "Legal Entity [Axis]" } } }, "localname": "LegalEntityAxis", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://endonovo.com/role/PatentsDetailsNarrative" ], "xbrltype": "stringItemType" }, "dei_LocalPhoneNumber": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Local phone number for entity.", "label": "Local Phone Number" } } }, "localname": "LocalPhoneNumber", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://endonovo.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_NoTradingSymbolFlag": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true only for a security having no trading symbol.", "label": "No Trading Symbol Flag" } } }, "localname": "NoTradingSymbolFlag", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://endonovo.com/role/Cover" ], "xbrltype": "trueItemType" }, "dei_OtherReportingStandardItemNumber": { "auth_ref": [ "r659" ], "lang": { "en-us": { "role": { "documentation": "\"Item 17\" or \"Item 18\" specified when the basis of accounting is neither US GAAP nor IFRS.", "label": "Other Reporting Standard Item Number" } } }, "localname": "OtherReportingStandardItemNumber", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://endonovo.com/role/Cover" ], "xbrltype": "otherReportingStandardItemNumberItemType" }, "dei_PreCommencementIssuerTenderOffer": { "auth_ref": [ "r653" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act.", "label": "Pre-commencement Issuer Tender Offer" } } }, "localname": "PreCommencementIssuerTenderOffer", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://endonovo.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_PreCommencementTenderOffer": { "auth_ref": [ "r654" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act.", "label": "Pre-commencement Tender Offer" } } }, "localname": "PreCommencementTenderOffer", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://endonovo.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_Security12bTitle": { "auth_ref": [ "r647" ], "lang": { "en-us": { "role": { "documentation": "Title of a 12(b) registered security.", "label": "Title of 12(b) Security" } } }, "localname": "Security12bTitle", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://endonovo.com/role/Cover" ], "xbrltype": "securityTitleItemType" }, "dei_Security12gTitle": { "auth_ref": [ "r651" ], "lang": { "en-us": { "role": { "documentation": "Title of a 12(g) registered security.", "label": "Title of 12(g) Security" } } }, "localname": "Security12gTitle", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://endonovo.com/role/Cover" ], "xbrltype": "securityTitleItemType" }, "dei_SecurityExchangeName": { "auth_ref": [ "r650" ], "lang": { "en-us": { "role": { "documentation": "Name of the Exchange on which a security is registered.", "label": "Security Exchange Name" } } }, "localname": "SecurityExchangeName", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://endonovo.com/role/Cover" ], "xbrltype": "edgarExchangeCodeItemType" }, "dei_SecurityReportingObligation": { "auth_ref": [ "r655" ], "lang": { "en-us": { "role": { "documentation": "15(d), indicating whether the security has a reporting obligation under that section of the Exchange Act.", "label": "Security Reporting Obligation" } } }, "localname": "SecurityReportingObligation", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://endonovo.com/role/Cover" ], "xbrltype": "securityReportingObligationItemType" }, "dei_SolicitingMaterial": { "auth_ref": [ "r656" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act.", "label": "Soliciting Material" } } }, "localname": "SolicitingMaterial", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://endonovo.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_TradingSymbol": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Trading symbol of an instrument as listed on an exchange.", "label": "Trading Symbol" } } }, "localname": "TradingSymbol", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://endonovo.com/role/Cover" ], "xbrltype": "tradingSymbolItemType" }, "dei_WrittenCommunications": { "auth_ref": [ "r664" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act.", "label": "Written Communications" } } }, "localname": "WrittenCommunications", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://endonovo.com/role/Cover" ], "xbrltype": "booleanItemType" }, "srt_ExecutiveOfficerMember": { "auth_ref": [ "r695" ], "lang": { "en-us": { "role": { "label": "Executive Officer [Member]" } } }, "localname": "ExecutiveOfficerMember", "nsuri": "http://fasb.org/srt/2023", "presentation": [ "http://endonovo.com/role/RelatedPartyAndFormerRelatedPartiesTransactionsDetailsNarrative" ], "xbrltype": "domainItemType" }, "srt_MajorCustomersAxis": { "auth_ref": [ "r222", "r622", "r712", "r729", "r730" ], "lang": { "en-us": { "role": { "label": "Customer [Axis]" } } }, "localname": "MajorCustomersAxis", "nsuri": "http://fasb.org/srt/2023", "presentation": [ "http://endonovo.com/role/ConcentrationsDetailsNarrative" ], "xbrltype": "stringItemType" }, "srt_MaximumMember": { "auth_ref": [ "r274", "r275", "r276", "r277", "r351", "r448", "r484", "r520", "r521", "r584", "r585", "r586", "r587", "r595", "r604", "r605", "r612", "r619", "r630", "r634", "r708", "r721", "r722", "r723", "r724", "r725", "r726" ], "lang": { "en-us": { "role": { "label": "Maximum [Member]" } } }, "localname": "MaximumMember", "nsuri": "http://fasb.org/srt/2023", "presentation": [ "http://endonovo.com/role/NotesPayableDetailsNarrative", "http://endonovo.com/role/ScheduleOfConversionFeatureUsingBlackScholesOptionPricingModelDetails" ], "xbrltype": "domainItemType" }, "srt_MinimumMember": { "auth_ref": [ "r274", "r275", "r276", "r277", "r351", "r448", "r484", "r520", "r521", "r584", "r585", "r586", "r587", "r595", "r604", "r605", "r612", "r619", "r630", "r634", "r708", "r721", "r722", "r723", "r724", "r725", "r726" ], "lang": { "en-us": { "role": { "label": "Minimum [Member]" } } }, "localname": "MinimumMember", "nsuri": "http://fasb.org/srt/2023", "presentation": [ "http://endonovo.com/role/NotesPayableDetailsNarrative", "http://endonovo.com/role/ScheduleOfConversionFeatureUsingBlackScholesOptionPricingModelDetails" ], "xbrltype": "domainItemType" }, "srt_NameOfMajorCustomerDomain": { "auth_ref": [ "r222", "r622", "r712", "r729", "r730" ], "localname": "NameOfMajorCustomerDomain", "nsuri": "http://fasb.org/srt/2023", "presentation": [ "http://endonovo.com/role/ConcentrationsDetailsNarrative" ], "xbrltype": "domainItemType" }, "srt_OfficerMember": { "auth_ref": [ "r223", "r733" ], "lang": { "en-us": { "role": { "label": "Officer [Member]" } } }, "localname": "OfficerMember", "nsuri": "http://fasb.org/srt/2023", "presentation": [ "http://endonovo.com/role/RelatedPartyAndFormerRelatedPartiesTransactionsDetailsNarrative" ], "xbrltype": "domainItemType" }, "srt_ProductOrServiceAxis": { "auth_ref": [ "r220", "r449", "r478", "r479", "r480", "r481", "r482", "r483", "r606", "r620", "r633", "r671", "r704", "r705", "r712", "r729" ], "lang": { "en-us": { "role": { "label": "Product and Service [Axis]" } } }, "localname": "ProductOrServiceAxis", "nsuri": "http://fasb.org/srt/2023", "presentation": [ "http://endonovo.com/role/RevenueRecognitionDetailsNarrative", "http://endonovo.com/role/ScheduleOfSourceOfRevenueDetails" ], "xbrltype": "stringItemType" }, "srt_ProductsAndServicesDomain": { "auth_ref": [ "r220", "r449", "r478", "r479", "r480", "r481", "r482", "r483", "r606", "r620", "r633", "r671", "r704", "r705", "r712", "r729" ], "localname": "ProductsAndServicesDomain", "nsuri": "http://fasb.org/srt/2023", "presentation": [ "http://endonovo.com/role/RevenueRecognitionDetailsNarrative", "http://endonovo.com/role/ScheduleOfSourceOfRevenueDetails" ], "xbrltype": "domainItemType" }, "srt_RangeAxis": { "auth_ref": [ "r274", "r275", "r276", "r277", "r343", "r351", "r361", "r362", "r363", "r424", "r448", "r484", "r520", "r521", "r584", "r585", "r586", "r587", "r595", "r604", "r605", "r612", "r619", "r630", "r634", "r637", "r702", "r708", "r722", "r723", "r724", "r725", "r726" ], "lang": { "en-us": { "role": { "label": "Statistical Measurement [Axis]" } } }, "localname": "RangeAxis", "nsuri": "http://fasb.org/srt/2023", "presentation": [ "http://endonovo.com/role/NotesPayableDetailsNarrative", "http://endonovo.com/role/ScheduleOfConversionFeatureUsingBlackScholesOptionPricingModelDetails" ], "xbrltype": "stringItemType" }, "srt_RangeMember": { "auth_ref": [ "r274", "r275", "r276", "r277", "r343", "r351", "r361", "r362", "r363", "r424", "r448", "r484", "r520", "r521", "r584", "r585", "r586", "r587", "r595", "r604", "r605", "r612", "r619", "r630", "r634", "r637", "r702", "r708", "r722", "r723", "r724", "r725", "r726" ], "localname": "RangeMember", "nsuri": "http://fasb.org/srt/2023", "presentation": [ "http://endonovo.com/role/NotesPayableDetailsNarrative", "http://endonovo.com/role/ScheduleOfConversionFeatureUsingBlackScholesOptionPricingModelDetails" ], "xbrltype": "domainItemType" }, "srt_ScenarioUnspecifiedDomain": { "auth_ref": [ "r191", "r352", "r667", "r692" ], "localname": "ScenarioUnspecifiedDomain", "nsuri": "http://fasb.org/srt/2023", "presentation": [ "http://endonovo.com/role/NotesPayableDetailsNarrative" ], "xbrltype": "domainItemType" }, "srt_StatementScenarioAxis": { "auth_ref": [ "r191", "r352", "r667", "r668", "r692" ], "lang": { "en-us": { "role": { "label": "Scenario [Axis]" } } }, "localname": "StatementScenarioAxis", "nsuri": "http://fasb.org/srt/2023", "presentation": [ "http://endonovo.com/role/NotesPayableDetailsNarrative" ], "xbrltype": "stringItemType" }, "srt_TitleOfIndividualAxis": { "auth_ref": [ "r695", "r717" ], "lang": { "en-us": { "role": { "label": "Title of Individual [Axis]" } } }, "localname": "TitleOfIndividualAxis", "nsuri": "http://fasb.org/srt/2023", "presentation": [ "http://endonovo.com/role/RelatedPartyAndFormerRelatedPartiesTransactionsDetailsNarrative", "http://endonovo.com/role/ShareholdersDeficitDetailsNarrative", "http://endonovo.com/role/SubsequentEventsDetailsNarrative" ], "xbrltype": "stringItemType" }, "srt_TitleOfIndividualWithRelationshipToEntityDomain": { "auth_ref": [], "localname": "TitleOfIndividualWithRelationshipToEntityDomain", "nsuri": "http://fasb.org/srt/2023", "presentation": [ "http://endonovo.com/role/RelatedPartyAndFormerRelatedPartiesTransactionsDetailsNarrative", "http://endonovo.com/role/ShareholdersDeficitDetailsNarrative", "http://endonovo.com/role/SubsequentEventsDetailsNarrative" ], "xbrltype": "domainItemType" }, "us-gaap_AccountingPoliciesAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Accounting Policies [Abstract]" } } }, "localname": "AccountingPoliciesAbstract", "nsuri": "http://fasb.org/us-gaap/2023", "xbrltype": "stringItemType" }, "us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent": { "auth_ref": [ "r22" ], "calculation": { "http://endonovo.com/role/BalanceSheets": { "order": 1.0, "parentTag": "us-gaap_LiabilitiesCurrent", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Sum of the carrying values as of the balance sheet date of obligations incurred through that date and due within one year (or the operating cycle, if longer), including liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received, taxes, interest, rent and utilities, accrued salaries and bonuses, payroll taxes and fringe benefits.", "label": "Accounts payable and accrued liabilities" } } }, "localname": "AccountsPayableAndAccruedLiabilitiesCurrent", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://endonovo.com/role/BalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems": { "auth_ref": [ "r160", "r161", "r398", "r399", "r400", "r401", "r402", "r403" ], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Accumulated Other Comprehensive Income (Loss) [Line Items]" } } }, "localname": "AccumulatedOtherComprehensiveIncomeLossLineItems", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://endonovo.com/role/ScheduleOfPreferredStockDetails", "http://endonovo.com/role/ScheduleOfWarrantsOutstandingDetails", "http://endonovo.com/role/ShareholdersDeficitDetailsNarrative" ], "xbrltype": "stringItemType" }, "us-gaap_AccumulatedOtherComprehensiveIncomeLossTable": { "auth_ref": [ "r160", "r161", "r398", "r399", "r400", "r401", "r402", "r403" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of information about components of accumulated other comprehensive income (loss).", "label": "Accumulated Other Comprehensive Income (Loss) [Table]" } } }, "localname": "AccumulatedOtherComprehensiveIncomeLossTable", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://endonovo.com/role/ScheduleOfPreferredStockDetails", "http://endonovo.com/role/ScheduleOfWarrantsOutstandingDetails", "http://endonovo.com/role/ShareholdersDeficitDetailsNarrative" ], "xbrltype": "stringItemType" }, "us-gaap_AdditionalPaidInCapital": { "auth_ref": [ "r93", "r632", "r734" ], "calculation": { "http://endonovo.com/role/BalanceSheets": { "order": 3.0, "parentTag": "us-gaap_StockholdersEquity", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of excess of issue price over par or stated value of stock and from other transaction involving stock or stockholder. Includes, but is not limited to, additional paid-in capital (APIC) for common and preferred stock.", "label": "Additional paid-in capital" } } }, "localname": "AdditionalPaidInCapital", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://endonovo.com/role/BalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_AdditionalPaidInCapitalMember": { "auth_ref": [ "r366", "r367", "r368", "r500", "r689", "r690", "r691", "r714", "r735" ], "lang": { "en-us": { "role": { "documentation": "Excess of issue price over par or stated value of the entity's capital stock and amounts received from other transactions involving the entity's stock or stockholders.", "label": "Additional Paid-in Capital [Member]" } } }, "localname": "AdditionalPaidInCapitalMember", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://endonovo.com/role/StatementOfShareholdersDeficit" ], "xbrltype": "domainItemType" }, "us-gaap_AdjustmentsToAdditionalPaidInCapitalOther": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of other increase (decrease) in additional paid in capital (APIC).", "label": "Inducement loss related to conversion of preferred stock" } } }, "localname": "AdjustmentsToAdditionalPaidInCapitalOther", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://endonovo.com/role/StatementOfShareholdersDeficit" ], "xbrltype": "monetaryItemType" }, "us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue": { "auth_ref": [ "r70", "r71", "r353" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of increase to additional paid-in capital (APIC) for recognition of cost for award under share-based payment arrangement.", "label": "Stock-based compensation" } } }, "localname": "AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://endonovo.com/role/StatementOfShareholdersDeficit" ], "xbrltype": "monetaryItemType" }, "us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Adjustments to reconcile net income (loss) to cash used in operating activities:" } } }, "localname": "AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://endonovo.com/role/StatementsOfCashFlows" ], "xbrltype": "stringItemType" }, "us-gaap_AllocatedShareBasedCompensationExpense": { "auth_ref": [ "r364", "r369" ], "calculation": { "http://endonovo.com/role/StatementsOfCashFlows": { "order": 3.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of expense for award under share-based payment arrangement. Excludes amount capitalized.", "label": "Stock compensation expense" } } }, "localname": "AllocatedShareBasedCompensationExpense", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://endonovo.com/role/StatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_AllowanceForDoubtfulAccountsReceivableCurrent": { "auth_ref": [ "r154", "r226", "r261" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of allowance for credit loss on accounts receivable, classified as current.", "label": "Accounts receivable allowance for credit loss, current" } } }, "localname": "AllowanceForDoubtfulAccountsReceivableCurrent", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://endonovo.com/role/SummaryOfSignificantAccountingPoliciesDetailsNarrative" ], "xbrltype": "monetaryItemType" }, "us-gaap_AmortizationOfIntangibleAssets": { "auth_ref": [ "r5", "r51", "r54" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The aggregate expense charged against earnings to allocate the cost of intangible assets (nonphysical assets not used in production) in a systematic and rational manner to the periods expected to benefit from such assets. As a noncash expense, this element is added back to net income when calculating cash provided by or used in operations using the indirect method.", "label": "Amortization of Intangible Assets", "verboseLabel": "Amortization expense" } } }, "localname": "AmortizationOfIntangibleAssets", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://endonovo.com/role/PatentsDetailsNarrative" ], "xbrltype": "monetaryItemType" }, "us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount": { "auth_ref": [ "r202" ], "lang": { "en-us": { "role": { "documentation": "Securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) or earnings per unit (EPU) in the future that were not included in the computation of diluted EPS or EPU because to do so would increase EPS or EPU amounts or decrease loss per share or unit amounts for the period presented.", "label": "Dilutive effect of convertible notes payable", "verboseLabel": "Anti dilutive shares" } } }, "localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://endonovo.com/role/ScheduleOfEarningsPerShareBasicAndDilutedDetails", "http://endonovo.com/role/SummaryOfSignificantAccountingPoliciesDetailsNarrative" ], "xbrltype": "sharesItemType" }, "us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis": { "auth_ref": [ "r41" ], "lang": { "en-us": { "role": { "documentation": "Information by type of antidilutive security.", "label": "Antidilutive Securities [Axis]" } } }, "localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://endonovo.com/role/SummaryOfSignificantAccountingPoliciesDetailsNarrative" ], "xbrltype": "stringItemType" }, "us-gaap_AntidilutiveSecuritiesNameDomain": { "auth_ref": [ "r41" ], "lang": { "en-us": { "role": { "documentation": "Incremental common shares attributable to securities that were not included in diluted earnings per share (EPS) because to do so would increase EPS amounts or decrease loss per share amounts for the period presented." } } }, "localname": "AntidilutiveSecuritiesNameDomain", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://endonovo.com/role/SummaryOfSignificantAccountingPoliciesDetailsNarrative" ], "xbrltype": "domainItemType" }, "us-gaap_ArrangementsAndNonarrangementTransactionsMember": { "auth_ref": [ "r374" ], "lang": { "en-us": { "role": { "documentation": "Collaborative arrangement and arrangement other than collaborative applicable to revenue-generating activity or operations." } } }, "localname": "ArrangementsAndNonarrangementTransactionsMember", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://endonovo.com/role/RevenueRecognitionDetailsNarrative", "http://endonovo.com/role/ShareholdersDeficitDetailsNarrative", "http://endonovo.com/role/SubsequentEventsDetailsNarrative", "http://endonovo.com/role/SummaryOfSignificantAccountingPoliciesDetailsNarrative" ], "xbrltype": "domainItemType" }, "us-gaap_Assets": { "auth_ref": [ "r124", "r149", "r174", "r207", "r214", "r218", "r258", "r278", "r279", "r280", "r281", "r282", "r283", "r284", "r285", "r286", "r375", "r377", "r397", "r466", "r544", "r632", "r645", "r706", "r707", "r719" ], "calculation": { "http://endonovo.com/role/BalanceSheets": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Sum of the carrying amounts as of the balance sheet date of all assets that are recognized. Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.", "label": "Assets", "totalLabel": "Total assets" } } }, "localname": "Assets", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://endonovo.com/role/BalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_AssetsAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "ASSETS" } } }, "localname": "AssetsAbstract", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://endonovo.com/role/BalanceSheets" ], "xbrltype": "stringItemType" }, "us-gaap_AssetsCurrent": { "auth_ref": [ "r145", "r155", "r174", "r258", "r278", "r279", "r280", "r281", "r282", "r283", "r284", "r285", "r286", "r375", "r377", "r397", "r632", "r706", "r707", "r719" ], "calculation": { "http://endonovo.com/role/BalanceSheets": { "order": 1.0, "parentTag": "us-gaap_Assets", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Sum of the carrying amounts as of the balance sheet date of all assets that are expected to be realized in cash, sold, or consumed within one year (or the normal operating cycle, if longer). Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.", "label": "Assets, Current", "totalLabel": "Total current assets" } } }, "localname": "AssetsCurrent", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://endonovo.com/role/BalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_AssetsCurrentAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Current assets:" } } }, "localname": "AssetsCurrentAbstract", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://endonovo.com/role/BalanceSheets" ], "xbrltype": "stringItemType" }, "us-gaap_BasisOfAccountingPolicyPolicyTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy for basis of accounting, or basis of presentation, used to prepare the financial statements (for example, US Generally Accepted Accounting Principles, Other Comprehensive Basis of Accounting, IFRS).", "label": "Basis of Presentation and Principles of Consolidation" } } }, "localname": "BasisOfAccountingPolicyPolicyTextBlock", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://endonovo.com/role/SummaryOfSignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_BusinessCombinationContingentConsiderationLiabilityNoncurrent": { "auth_ref": [ "r1", "r72" ], "calculation": { "http://endonovo.com/role/BalanceSheets": { "order": 2.0, "parentTag": "us-gaap_Liabilities", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of liability recognized arising from contingent consideration in a business combination, expected to be settled beyond one year or the normal operating cycle, if longer.", "label": "Acquisition payable" } } }, "localname": "BusinessCombinationContingentConsiderationLiabilityNoncurrent", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://endonovo.com/role/BalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_Cash": { "auth_ref": [ "r135", "r468", "r511", "r538", "r632", "r645", "r679" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Excludes cash and cash equivalents within disposal group and discontinued operation.", "label": "Cash [Default Label]", "verboseLabel": "Cash" } } }, "localname": "Cash", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://endonovo.com/role/SummaryOfSignificantAccountingPoliciesDetailsNarrative" ], "xbrltype": "monetaryItemType" }, "us-gaap_CashAndCashEquivalentsAtCarryingValue": { "auth_ref": [ "r36", "r147", "r607" ], "calculation": { "http://endonovo.com/role/BalanceSheets": { "order": 1.0, "parentTag": "us-gaap_AssetsCurrent", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.", "label": "Cash" } } }, "localname": "CashAndCashEquivalentsAtCarryingValue", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://endonovo.com/role/BalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations": { "auth_ref": [ "r36", "r105", "r169" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; including, but not limited to, disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.", "label": "Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents, Including Disposal Group and Discontinued Operations", "periodEndLabel": "Cash, end of period", "periodStartLabel": "Cash, beginning of year" } } }, "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://endonovo.com/role/StatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect": { "auth_ref": [ "r2", "r105" ], "calculation": { "http://endonovo.com/role/StatementsOfCashFlows": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of increase (decrease) in cash, cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; including effect from exchange rate change. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.", "label": "Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect", "totalLabel": "Net increase (decrease) in cash" } } }, "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://endonovo.com/role/StatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_ClassOfStockDomain": { "auth_ref": [ "r142", "r150", "r151", "r152", "r174", "r195", "r196", "r199", "r201", "r205", "r206", "r258", "r278", "r280", "r281", "r282", "r285", "r286", "r316", "r317", "r319", "r322", "r329", "r397", "r492", "r493", "r494", "r495", "r500", "r501", "r502", "r503", "r504", "r505", "r506", "r507", "r508", "r509", "r510", "r512", "r530", "r553", "r575", "r596", "r597", "r598", "r599", "r600", "r666", "r684", "r693" ], "lang": { "en-us": { "role": { "documentation": "Share of stock differentiated by the voting rights the holder receives. Examples include, but are not limited to, common stock, redeemable preferred stock, nonredeemable preferred stock, and convertible stock." } } }, "localname": "ClassOfStockDomain", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://endonovo.com/role/BalanceSheets", "http://endonovo.com/role/BalanceSheetsParenthetical", "http://endonovo.com/role/ShareholdersDeficitDetailsNarrative", "http://endonovo.com/role/StatementOfShareholdersDeficit" ], "xbrltype": "domainItemType" }, "us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems": { "auth_ref": [ "r374" ], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]" } } }, "localname": "CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://endonovo.com/role/SummaryOfSignificantAccountingPoliciesDetailsNarrative" ], "xbrltype": "stringItemType" }, "us-gaap_CommitmentsAndContingencies": { "auth_ref": [ "r29", "r85", "r467", "r529" ], "calculation": { "http://endonovo.com/role/BalanceSheets": { "order": 2.0, "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Represents the caption on the face of the balance sheet to indicate that the entity has entered into (1) purchase or supply arrangements that will require expending a portion of its resources to meet the terms thereof, and (2) is exposed to potential losses or, less frequently, gains, arising from (a) possible claims against a company's resources due to future performance under contract terms, and (b) possible losses or likely gains from uncertainties that will ultimately be resolved when one or more future events that are deemed likely to occur do occur or fail to occur.", "label": "COMMITMENTS AND CONTINGENCIES, note 9" } } }, "localname": "CommitmentsAndContingencies", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://endonovo.com/role/BalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_CommitmentsAndContingenciesDisclosureAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Commitments and Contingencies Disclosure [Abstract]" } } }, "localname": "CommitmentsAndContingenciesDisclosureAbstract", "nsuri": "http://fasb.org/us-gaap/2023", "xbrltype": "stringItemType" }, "us-gaap_CommitmentsAndContingenciesDisclosureTextBlock": { "auth_ref": [ "r113", "r272", "r273", "r603", "r703" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for commitments and contingencies.", "label": "Commitments and Contingencies" } } }, "localname": "CommitmentsAndContingenciesDisclosureTextBlock", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://endonovo.com/role/CommitmentsAndContingencies" ], "xbrltype": "textBlockItemType" }, "us-gaap_CommonStockMember": { "auth_ref": [ "r635", "r636", "r637", "r639", "r640", "r641", "r642", "r689", "r690", "r714", "r731", "r735" ], "lang": { "en-us": { "role": { "documentation": "Stock that is subordinate to all other stock of the issuer.", "label": "Common Stock [Member]" } } }, "localname": "CommonStockMember", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://endonovo.com/role/RelatedPartyAndFormerRelatedPartiesTransactionsDetailsNarrative", "http://endonovo.com/role/ShareholdersDeficitDetailsNarrative", "http://endonovo.com/role/StatementOfShareholdersDeficit" ], "xbrltype": "domainItemType" }, "us-gaap_CommonStockParOrStatedValuePerShare": { "auth_ref": [ "r92" ], "lang": { "en-us": { "role": { "documentation": "Face amount or stated value per share of common stock.", "label": "Common stock, par value" } } }, "localname": "CommonStockParOrStatedValuePerShare", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://endonovo.com/role/BalanceSheetsParenthetical" ], "xbrltype": "perShareItemType" }, "us-gaap_CommonStockSharesAuthorized": { "auth_ref": [ "r92", "r530" ], "lang": { "en-us": { "role": { "documentation": "The maximum number of common shares permitted to be issued by an entity's charter and bylaws.", "label": "Common stock, shares authorized" } } }, "localname": "CommonStockSharesAuthorized", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://endonovo.com/role/BalanceSheetsParenthetical" ], "xbrltype": "sharesItemType" }, "us-gaap_CommonStockSharesIssued": { "auth_ref": [ "r92" ], "lang": { "en-us": { "role": { "documentation": "Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury.", "label": "Common stock, shares issued" } } }, "localname": "CommonStockSharesIssued", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://endonovo.com/role/BalanceSheetsParenthetical" ], "xbrltype": "sharesItemType" }, "us-gaap_CommonStockSharesOutstanding": { "auth_ref": [ "r8", "r92", "r530", "r550", "r735", "r736" ], "lang": { "en-us": { "role": { "documentation": "Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation.", "label": "Common stock, shares outstanding" } } }, "localname": "CommonStockSharesOutstanding", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://endonovo.com/role/BalanceSheetsParenthetical" ], "xbrltype": "sharesItemType" }, "us-gaap_CommonStockValue": { "auth_ref": [ "r92", "r470", "r632" ], "calculation": { "http://endonovo.com/role/BalanceSheets": { "order": 2.0, "parentTag": "us-gaap_StockholdersEquity", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Aggregate par or stated value of issued nonredeemable common stock (or common stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable common shares, par value and other disclosure concepts are in another section within stockholders' equity.", "label": "Common stock, $0.0001 par value; 2,500,000,000 shares authorized; 278,802,405 and 213,227,538 shares issued and outstanding as of June 30, 2023 and December 31, 2022" } } }, "localname": "CommonStockValue", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://endonovo.com/role/BalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_ConcentrationRiskBenchmarkDomain": { "auth_ref": [ "r44", "r46", "r76", "r77", "r222", "r602" ], "lang": { "en-us": { "role": { "documentation": "The denominator in a calculation of a disclosed concentration risk percentage." } } }, "localname": "ConcentrationRiskBenchmarkDomain", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://endonovo.com/role/ConcentrationsDetailsNarrative" ], "xbrltype": "domainItemType" }, "us-gaap_ConcentrationRiskByBenchmarkAxis": { "auth_ref": [ "r44", "r46", "r76", "r77", "r222", "r490", "r602" ], "lang": { "en-us": { "role": { "documentation": "Information by benchmark of concentration risk.", "label": "Concentration Risk Benchmark [Axis]" } } }, "localname": "ConcentrationRiskByBenchmarkAxis", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://endonovo.com/role/ConcentrationsDetailsNarrative" ], "xbrltype": "stringItemType" }, "us-gaap_ConcentrationRiskByTypeAxis": { "auth_ref": [ "r44", "r46", "r76", "r77", "r222", "r602", "r670" ], "lang": { "en-us": { "role": { "documentation": "Information by type of concentration risk, for example, but not limited to, asset, liability, net assets, geographic, customer, employees, supplier, lender.", "label": "Concentration Risk Type [Axis]" } } }, "localname": "ConcentrationRiskByTypeAxis", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://endonovo.com/role/ConcentrationsDetailsNarrative" ], "xbrltype": "stringItemType" }, "us-gaap_ConcentrationRiskDisclosureTextBlock": { "auth_ref": [ "r109" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for any concentrations existing at the date of the financial statements that make an entity vulnerable to a reasonably possible, near-term, severe impact. This disclosure informs financial statement users about the general nature of the risk associated with the concentration, and may indicate the percentage of concentration risk as of the balance sheet date.", "label": "Concentrations" } } }, "localname": "ConcentrationRiskDisclosureTextBlock", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://endonovo.com/role/Concentrations" ], "xbrltype": "textBlockItemType" }, "us-gaap_ConcentrationRiskLineItems": { "auth_ref": [ "r602" ], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Concentration Risk [Line Items]" } } }, "localname": "ConcentrationRiskLineItems", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://endonovo.com/role/ConcentrationsDetailsNarrative" ], "xbrltype": "stringItemType" }, "us-gaap_ConcentrationRiskPercentage1": { "auth_ref": [ "r44", "r46", "r76", "r77", "r222" ], "lang": { "en-us": { "role": { "documentation": "For an entity that discloses a concentration risk in relation to quantitative amount, which serves as the \"benchmark\" (or denominator) in the equation, this concept represents the concentration percentage derived from the division.", "label": "Concentration risk, percentage" } } }, "localname": "ConcentrationRiskPercentage1", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://endonovo.com/role/ConcentrationsDetailsNarrative" ], "xbrltype": "percentItemType" }, "us-gaap_ConcentrationRiskTable": { "auth_ref": [ "r43", "r44", "r46", "r47", "r76", "r123", "r602" ], "lang": { "en-us": { "role": { "documentation": "Describes the nature of a concentration, a benchmark to which it is compared, and the percentage that the risk is to the benchmark.", "label": "Concentration Risk [Table]" } } }, "localname": "ConcentrationRiskTable", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://endonovo.com/role/ConcentrationsDetailsNarrative" ], "xbrltype": "stringItemType" }, "us-gaap_ConcentrationRiskTypeDomain": { "auth_ref": [ "r44", "r46", "r76", "r77", "r222", "r602" ], "lang": { "en-us": { "role": { "documentation": "For an entity that discloses a concentration risk as a percentage of some financial balance or benchmark, identifies the type (for example, asset, liability, net assets, geographic, customer, employees, supplier, lender) of the concentration." } } }, "localname": "ConcentrationRiskTypeDomain", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://endonovo.com/role/ConcentrationsDetailsNarrative" ], "xbrltype": "domainItemType" }, "us-gaap_ContractWithCustomerLiabilityRevenueRecognized": { "auth_ref": [ "r341" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of revenue recognized that was previously included in balance of obligation to transfer good or service to customer for which consideration from customer has been received or is due.", "label": "Contract with Customer, Liability, Revenue Recognized" } } }, "localname": "ContractWithCustomerLiabilityRevenueRecognized", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://endonovo.com/role/RevenueRecognitionDetailsNarrative" ], "xbrltype": "monetaryItemType" }, "us-gaap_ConversionOfStockAmountConverted1": { "auth_ref": [ "r38", "r39", "r40" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The value of the stock converted in a noncash (or part noncash) transaction. Noncash is defined as transactions during a period that do not result in cash receipts or cash payments in the period. \"Part noncash\" refers to that portion of the transaction not resulting in cash receipts or cash payments in the period.", "label": "Conversion of Stock, Amount Converted", "negatedLabel": "Less amounts converted to stock" } } }, "localname": "ConversionOfStockAmountConverted1", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://endonovo.com/role/ScheduleOfNotesPayableDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_ConversionOfStockAmountIssued1": { "auth_ref": [ "r38", "r39", "r40" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The value of the financial instrument issued [noncash or part noncash] in the conversion of stock. Noncash is defined as transactions during a period that do not result in cash receipts or cash payments in the period. \"Part noncash\" refers to that portion of the transaction not resulting in cash receipts or cash payments in the period.", "label": "Shares issued for conversion of notes payable" } } }, "localname": "ConversionOfStockAmountIssued1", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://endonovo.com/role/ShareholdersDeficitDetailsNarrative" ], "xbrltype": "monetaryItemType" }, "us-gaap_ConversionOfStockDescription": { "auth_ref": [ "r38", "r39", "r40" ], "lang": { "en-us": { "role": { "documentation": "A unique description of a noncash or part noncash stock conversion. The description would be expected to include sufficient information to provide an understanding of the nature and purpose of the conversion. Noncash is defined as transactions during a period that do not result in cash receipts or cash payments in the period. \"Part noncash\" refers to that portion of the transaction not resulting in cash receipts or cash payments in the period.", "label": "Conversion of stock description" } } }, "localname": "ConversionOfStockDescription", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://endonovo.com/role/ShareholdersDeficitDetailsNarrative" ], "xbrltype": "stringItemType" }, "us-gaap_ConversionOfStockSharesIssued1": { "auth_ref": [ "r38", "r39", "r40" ], "lang": { "en-us": { "role": { "documentation": "The number of new shares issued in the conversion of stock in a noncash (or part noncash) transaction. Noncash is defined as transactions during a period that do not result in cash receipts or cash payments in the period. \"Part noncash\" refers to that portion of the transaction not resulting in cash receipts or cash payments in the period.", "label": "Shares issued for conversion of notes payable, shares" } } }, "localname": "ConversionOfStockSharesIssued1", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://endonovo.com/role/ShareholdersDeficitDetailsNarrative" ], "xbrltype": "sharesItemType" }, "us-gaap_ConvertibleDebt": { "auth_ref": [ "r19", "r126", "r728" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Including the current and noncurrent portions, carrying amount of debt identified as being convertible into another form of financial instrument (typically the entity's common stock) as of the balance sheet date, which originally required full repayment more than twelve months after issuance or greater than the normal operating cycle of the company.", "label": "Convertible Debt", "verboseLabel": "Convertible notes" } } }, "localname": "ConvertibleDebt", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://endonovo.com/role/NotesPayableDetailsNarrative" ], "xbrltype": "monetaryItemType" }, "us-gaap_ConvertibleDebtMember": { "auth_ref": [ "r115", "r288", "r289", "r299", "r300", "r301", "r305", "r306", "r307", "r308", "r309", "r614", "r615", "r616", "r617", "r618" ], "lang": { "en-us": { "role": { "documentation": "Borrowing which can be exchanged for a specified number of another security at the option of the issuer or the holder, for example, but not limited to, the entity's common stock.", "label": "Convertible Debt [Member]" } } }, "localname": "ConvertibleDebtMember", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://endonovo.com/role/SubsequentEventsDetailsNarrative" ], "xbrltype": "domainItemType" }, "us-gaap_CostOfRevenue": { "auth_ref": [ "r101", "r174", "r258", "r278", "r279", "r280", "r281", "r282", "r283", "r284", "r285", "r286", "r397", "r706" ], "calculation": { "http://endonovo.com/role/StatementsOfOperations": { "order": 2.0, "parentTag": "us-gaap_GrossProfit", "weight": -1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The aggregate cost of goods produced and sold and services rendered during the reporting period.", "label": "Cost of revenue" } } }, "localname": "CostOfRevenue", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://endonovo.com/role/StatementsOfOperations" ], "xbrltype": "monetaryItemType" }, "us-gaap_CustomerConcentrationRiskMember": { "auth_ref": [ "r45", "r222" ], "lang": { "en-us": { "role": { "documentation": "Reflects the percentage that revenues in the period from one or more significant customers is to net revenues, as defined by the entity, such as total net revenues, product line revenues, segment revenues. The risk is the materially adverse effects of loss of a significant customer.", "label": "Customer Concentration Risk [Member]" } } }, "localname": "CustomerConcentrationRiskMember", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://endonovo.com/role/ConcentrationsDetailsNarrative" ], "xbrltype": "domainItemType" }, "us-gaap_DebtConversionConvertedInstrumentAmount1": { "auth_ref": [ "r38", "r40" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The value of the financial instrument(s) that the original debt is being converted into in a noncash (or part noncash) transaction. \"Part noncash\" refers to that portion of the transaction not resulting in cash receipts or cash payments in the period.", "label": "Shares issued for conversion of notes payable and accrued interest" } } }, "localname": "DebtConversionConvertedInstrumentAmount1", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://endonovo.com/role/StatementOfShareholdersDeficit" ], "xbrltype": "monetaryItemType" }, "us-gaap_DebtConversionConvertedInstrumentSharesIssued1": { "auth_ref": [ "r38", "r40" ], "lang": { "en-us": { "role": { "documentation": "The number of shares issued in exchange for the original debt being converted in a noncash (or part noncash) transaction. \"Part noncash\" refers to that portion of the transaction not resulting in cash receipts or payments in the period.", "label": "Shares issued for conversion of notes payable and accrued interest, shares", "verboseLabel": "Debt conversion, stock issued shares" } } }, "localname": "DebtConversionConvertedInstrumentSharesIssued1", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://endonovo.com/role/NotesPayableDetailsNarrative", "http://endonovo.com/role/ShareholdersDeficitDetailsNarrative", "http://endonovo.com/role/StatementOfShareholdersDeficit" ], "xbrltype": "sharesItemType" }, "us-gaap_DebtConversionOriginalDebtAmount1": { "auth_ref": [ "r38", "r40" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The amount of the original debt being converted in a noncash (or part noncash) transaction. \"Part noncash\" refers to that portion of the transaction not resulting in cash receipts or cash payments in the period.", "label": "Debt conversion, stock issued value" } } }, "localname": "DebtConversionOriginalDebtAmount1", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://endonovo.com/role/NotesPayableDetailsNarrative" ], "xbrltype": "monetaryItemType" }, "us-gaap_DebtDisclosureAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Debt Disclosure [Abstract]" } } }, "localname": "DebtDisclosureAbstract", "nsuri": "http://fasb.org/us-gaap/2023", "xbrltype": "stringItemType" }, "us-gaap_DebtDisclosureTextBlock": { "auth_ref": [ "r114", "r171", "r287", "r293", "r294", "r295", "r296", "r297", "r298", "r303", "r310", "r311", "r313" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for information about short-term and long-term debt arrangements, which includes amounts of borrowings under each line of credit, note payable, commercial paper issue, bonds indenture, debenture issue, own-share lending arrangements and any other contractual agreement to repay funds, and about the underlying arrangements, rationale for a classification as long-term, including repayment terms, interest rates, collateral provided, restrictions on use of assets and activities, whether or not in compliance with debt covenants, and other matters important to users of the financial statements, such as the effects of refinancing and noncompliance with debt covenants.", "label": "Notes Payable" } } }, "localname": "DebtDisclosureTextBlock", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://endonovo.com/role/NotesPayable" ], "xbrltype": "textBlockItemType" }, "us-gaap_DebtInstrumentAxis": { "auth_ref": [ "r19", "r89", "r90", "r125", "r126", "r177", "r288", "r289", "r290", "r291", "r292", "r294", "r299", "r300", "r301", "r302", "r304", "r305", "r306", "r307", "r308", "r309", "r405", "r614", "r615", "r616", "r617", "r618", "r685" ], "lang": { "en-us": { "role": { "documentation": "Information by type of debt instrument, including, but not limited to, draws against credit facilities.", "label": "Debt Instrument [Axis]" } } }, "localname": "DebtInstrumentAxis", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://endonovo.com/role/NotesPayableDetailsNarrative" ], "xbrltype": "stringItemType" }, "us-gaap_DebtInstrumentDescription": { "auth_ref": [ "r19", "r58", "r87", "r89", "r125", "r126" ], "lang": { "en-us": { "role": { "documentation": "Identification of the lender and information about a contractual promise to repay a short-term or long-term obligation, which includes borrowings under lines of credit, notes payable, commercial paper, bonds payable, debentures, and other contractual obligations for payment. This may include rationale for entering into the arrangement, significant terms of the arrangement, which may include amount, repayment terms, priority, collateral required, debt covenants, borrowing capacity, call features, participation rights, conversion provisions, sinking-fund requirements, voting rights, basis for conversion if convertible and remarketing provisions. The description may be provided for individual debt instruments, rational groupings of debt instruments, or by debt in total.", "label": "Debt instrument description" } } }, "localname": "DebtInstrumentDescription", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://endonovo.com/role/NotesPayableDetailsNarrative" ], "xbrltype": "stringItemType" }, "us-gaap_DebtInstrumentFaceAmount": { "auth_ref": [ "r79", "r80", "r288", "r405", "r615", "r616" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Face (par) amount of debt instrument at time of issuance.", "label": "Principal amount" } } }, "localname": "DebtInstrumentFaceAmount", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://endonovo.com/role/NotesPayableDetailsNarrative", "http://endonovo.com/role/ShareholdersDeficitDetailsNarrative", "http://endonovo.com/role/SubsequentEventsDetailsNarrative" ], "xbrltype": "monetaryItemType" }, "us-gaap_DebtInstrumentIncreaseAccruedInterest": { "auth_ref": [ "r685" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Increase for accrued, but unpaid interest on the debt instrument for the period.", "label": "Debt instrument, accrued interest" } } }, "localname": "DebtInstrumentIncreaseAccruedInterest", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://endonovo.com/role/NotesPayableDetailsNarrative" ], "xbrltype": "monetaryItemType" }, "us-gaap_DebtInstrumentInterestRateStatedPercentage": { "auth_ref": [ "r26", "r289" ], "lang": { "en-us": { "role": { "documentation": "Contractual interest rate for funds borrowed, under the debt agreement.", "label": "Debt instrument, interest rate" } } }, "localname": "DebtInstrumentInterestRateStatedPercentage", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://endonovo.com/role/NotesPayableDetailsNarrative" ], "xbrltype": "percentItemType" }, "us-gaap_DebtInstrumentInterestRateTerms": { "auth_ref": [ "r26" ], "lang": { "en-us": { "role": { "documentation": "Description of the interest rate as being fixed or variable, and, if variable, identification of the index or rate on which the interest rate is based and the number of points or percentage added to that index or rate to set the rate, and other pertinent information, such as frequency of rate resets.", "label": "Debt Instrument, Interest Rate Terms", "verboseLabel": "Debt instrument description" } } }, "localname": "DebtInstrumentInterestRateTerms", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://endonovo.com/role/NotesPayableDetailsNarrative" ], "xbrltype": "stringItemType" }, "us-gaap_DebtInstrumentLineItems": { "auth_ref": [ "r177", "r288", "r289", "r290", "r291", "r292", "r294", "r299", "r300", "r301", "r302", "r304", "r305", "r306", "r307", "r308", "r309", "r312", "r405", "r614", "r615", "r616", "r617", "r618", "r685" ], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Debt Instrument [Line Items]" } } }, "localname": "DebtInstrumentLineItems", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://endonovo.com/role/NotesPayableDetailsNarrative" ], "xbrltype": "stringItemType" }, "us-gaap_DebtInstrumentMaturityDateDescription": { "auth_ref": [ "r27" ], "lang": { "en-us": { "role": { "documentation": "Description of the maturity date of the debt instrument including whether the debt matures serially and, if so, a brief description of the serial maturities.", "label": "Maturity period" } } }, "localname": "DebtInstrumentMaturityDateDescription", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://endonovo.com/role/SubsequentEventsDetailsNarrative" ], "xbrltype": "stringItemType" }, "us-gaap_DebtInstrumentNameDomain": { "auth_ref": [ "r28", "r177", "r288", "r289", "r290", "r291", "r292", "r294", "r299", "r300", "r301", "r302", "r304", "r305", "r306", "r307", "r308", "r309", "r405", "r614", "r615", "r616", "r617", "r618", "r685" ], "lang": { "en-us": { "role": { "documentation": "The name for the particular debt instrument or borrowing that distinguishes it from other debt instruments or borrowings, including draws against credit facilities." } } }, "localname": "DebtInstrumentNameDomain", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://endonovo.com/role/NotesPayableDetailsNarrative" ], "xbrltype": "domainItemType" }, "us-gaap_DebtInstrumentTable": { "auth_ref": [ "r28", "r58", "r60", "r78", "r79", "r80", "r86", "r117", "r118", "r177", "r288", "r289", "r290", "r291", "r292", "r294", "r299", "r300", "r301", "r302", "r304", "r305", "r306", "r307", "r308", "r309", "r312", "r405", "r614", "r615", "r616", "r617", "r618", "r685" ], "lang": { "en-us": { "role": { "documentation": "A table or schedule providing information pertaining to long-term debt instruments or arrangements, including identification, terms, features, collateral requirements and other information necessary to a fair presentation. These are debt arrangements that originally required repayment more than twelve months after issuance or greater than the normal operating cycle of the company, if longer.", "label": "Schedule of Long-Term Debt Instruments [Table]" } } }, "localname": "DebtInstrumentTable", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://endonovo.com/role/NotesPayableDetailsNarrative" ], "xbrltype": "stringItemType" }, "us-gaap_DebtInstrumentTerm": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Period of time between issuance and maturity of debt instrument, in PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.", "label": "Maturity term" } } }, "localname": "DebtInstrumentTerm", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://endonovo.com/role/NotesPayableDetailsNarrative" ], "xbrltype": "durationItemType" }, "us-gaap_DebtInstrumentUnamortizedDiscount": { "auth_ref": [ "r78", "r80", "r709" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount, after accumulated amortization, of debt discount.", "label": "Debt Instrument, Unamortized Discount", "negatedPeriodEndLabel": "Less debt discount" } } }, "localname": "DebtInstrumentUnamortizedDiscount", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://endonovo.com/role/ScheduleOfNotesPayableDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DebtInstrumentUnamortizedDiscountCurrent": { "auth_ref": [ "r78", "r80" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of debt discount to be amortized within one year or within the normal operating cycle, if longer.", "label": "Discounts on notes payable current" } } }, "localname": "DebtInstrumentUnamortizedDiscountCurrent", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://endonovo.com/role/BalanceSheetsParenthetical" ], "xbrltype": "monetaryItemType" }, "us-gaap_DebtSecuritiesHeldToMaturityAllowanceForCreditLossTable": { "auth_ref": [ "r701" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of information about allowance for credit loss on investment in debt security measured at amortized cost (held-to-maturity).", "label": "Debt Securities, Held-to-Maturity, Allowance for Credit Loss [Table]" } } }, "localname": "DebtSecuritiesHeldToMaturityAllowanceForCreditLossTable", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://endonovo.com/role/ScheduleOfStockOptionsOutstandingDetails" ], "xbrltype": "stringItemType" }, "us-gaap_DebtSecuritiesHeldtomaturityAllowanceForCreditLossLineItems": { "auth_ref": [ "r701" ], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Debt Securities, Held-to-Maturity, Allowance for Credit Loss [Line Items]" } } }, "localname": "DebtSecuritiesHeldtomaturityAllowanceForCreditLossLineItems", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://endonovo.com/role/ScheduleOfStockOptionsOutstandingDetails" ], "xbrltype": "stringItemType" }, "us-gaap_DeferredCompensationEquity": { "auth_ref": [ "r32", "r66" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Value of stock issued under share-based plans to employees or officers which is the unearned portion, accounted for under the fair value method.", "label": "Deferred Compensation Equity", "verboseLabel": "Deferred compensation" } } }, "localname": "DeferredCompensationEquity", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://endonovo.com/role/RelatedPartyAndFormerRelatedPartiesTransactionsDetailsNarrative" ], "xbrltype": "monetaryItemType" }, "us-gaap_DeferredCompensationLiabilityCurrent": { "auth_ref": [ "r61", "r120" ], "calculation": { "http://endonovo.com/role/BalanceSheets": { "order": 3.0, "parentTag": "us-gaap_LiabilitiesCurrent", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Aggregate carrying value as of the balance sheet date of the liabilities for all deferred compensation arrangements payable within one year (or the operating cycle, if longer). Represents currently earned compensation under compensation arrangements that is not actually paid until a later date.", "label": "Deferred compensation" } } }, "localname": "DeferredCompensationLiabilityCurrent", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://endonovo.com/role/BalanceSheets", "http://endonovo.com/role/RevenueRecognitionDetailsNarrative" ], "xbrltype": "monetaryItemType" }, "us-gaap_DefinedBenefitPlanDisclosureLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Defined Benefit Plan Disclosure [Line Items]" } } }, "localname": "DefinedBenefitPlanDisclosureLineItems", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://endonovo.com/role/ScheduleOfMaturityDatesOfNotesPayableDetails", "http://endonovo.com/role/ScheduleOfNotesPayableDetails" ], "xbrltype": "stringItemType" }, "us-gaap_DepreciationDepletionAndAmortization": { "auth_ref": [ "r5", "r210" ], "calculation": { "http://endonovo.com/role/StatementsOfCashFlows": { "order": 2.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The aggregate expense recognized in the current period that allocates the cost of tangible assets, intangible assets, or depleting assets to periods that benefit from use of the assets.", "label": "Amortization expense" } } }, "localname": "DepreciationDepletionAndAmortization", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://endonovo.com/role/StatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_DerivativeAssetLiabilityNetMeasurementInput": { "auth_ref": [ "r394" ], "lang": { "en-us": { "role": { "documentation": "Value of input used to measure net derivative asset (liability).", "label": "Fair value assumptions, measurement input, percentage" } } }, "localname": "DerivativeAssetLiabilityNetMeasurementInput", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://endonovo.com/role/ScheduleOfConversionFeatureUsingBlackScholesOptionPricingModelDetails" ], "xbrltype": "decimalItemType" }, "us-gaap_DerivativeGainLossOnDerivativeNet": { "auth_ref": [ "r713" ], "calculation": { "http://endonovo.com/role/StatementsOfCashFlows": { "order": 7.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": -1.0 }, "http://endonovo.com/role/StatementsOfOperations": { "order": 1.0, "parentTag": "us-gaap_NonoperatingIncomeExpense", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of increase (decrease) in the fair value of derivatives recognized in the income statement.", "label": "Change in fair value of derivative liability", "negatedLabel": "Change in fair value of derivative liability" } } }, "localname": "DerivativeGainLossOnDerivativeNet", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://endonovo.com/role/StatementsOfCashFlows", "http://endonovo.com/role/StatementsOfOperations" ], "xbrltype": "monetaryItemType" }, "us-gaap_DerivativeLiabilities": { "auth_ref": [ "r156", "r157", "r396", "r513", "r514", "r515", "r516", "r517", "r518", "r519", "r520", "r521", "r545", "r547", "r548", "r588", "r589", "r590", "r591", "r592", "r593", "r594", "r608", "r732" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Fair value, after the effects of master netting arrangements, of a financial liability or contract with one or more underlyings, notional amount or payment provision or both, and the contract can be net settled by means outside the contract or delivery of an asset. Includes liabilities not subject to a master netting arrangement and not elected to be offset.", "label": "Derivative Liability", "verboseLabel": "Derivative liability" } } }, "localname": "DerivativeLiabilities", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://endonovo.com/role/ScheduleOfLiabilitiesSignificantUnobservableInputsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DerivativeLiabilitiesCurrent": { "auth_ref": [ "r156" ], "calculation": { "http://endonovo.com/role/BalanceSheets": { "order": 5.0, "parentTag": "us-gaap_LiabilitiesCurrent", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Fair value, after the effects of master netting arrangements, of a financial liability or contract with one or more underlyings, notional amount or payment provision or both, and the contract can be net settled by means outside the contract or delivery of an asset, expected to be settled within one year or normal operating cycle, if longer. Includes assets not subject to a master netting arrangement and not elected to be offset.", "label": "Derivative liability" } } }, "localname": "DerivativeLiabilitiesCurrent", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://endonovo.com/role/BalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_DilutiveSecuritiesEffectOnBasicEarningsPerShareOther": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of increase (decrease) to net income used for calculating diluted earnings per share (EPS), resulting from the assumed exercise of dilutive convertible securities excluding adjustments related to ESOP convertible preferred stock, stock options, and restrictive stock units.", "label": "Convertible notes" } } }, "localname": "DilutiveSecuritiesEffectOnBasicEarningsPerShareOther", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://endonovo.com/role/ScheduleOfEarningsPerShareBasicAndDilutedDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DisaggregationOfRevenueLineItems": { "auth_ref": [ "r340", "r620", "r621", "r622", "r623", "r624", "r625", "r626" ], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Disaggregation of Revenue [Line Items]" } } }, "localname": "DisaggregationOfRevenueLineItems", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://endonovo.com/role/RevenueRecognitionDetailsNarrative", "http://endonovo.com/role/ScheduleOfSourceOfRevenueDetails" ], "xbrltype": "stringItemType" }, "us-gaap_DisaggregationOfRevenueTable": { "auth_ref": [ "r340", "r620", "r621", "r622", "r623", "r624", "r625", "r626" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of information about disaggregation of revenue into categories depicting how nature, amount, timing, and uncertainty of revenue and cash flows are affected by economic factor.", "label": "Disaggregation of Revenue [Table]" } } }, "localname": "DisaggregationOfRevenueTable", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://endonovo.com/role/RevenueRecognitionDetailsNarrative", "http://endonovo.com/role/ScheduleOfSourceOfRevenueDetails" ], "xbrltype": "stringItemType" }, "us-gaap_EarningsPerShareBasic": { "auth_ref": [ "r163", "r183", "r184", "r185", "r186", "r187", "r192", "r195", "r199", "r200", "r201", "r203", "r388", "r389", "r463", "r476", "r609" ], "lang": { "en-us": { "role": { "documentation": "The amount of net income (loss) for the period per each share of common stock or unit outstanding during the reporting period.", "label": "Basic Income (Loss) per share" } } }, "localname": "EarningsPerShareBasic", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://endonovo.com/role/StatementsOfOperations" ], "xbrltype": "perShareItemType" }, "us-gaap_EarningsPerShareDiluted": { "auth_ref": [ "r163", "r183", "r184", "r185", "r186", "r187", "r195", "r199", "r200", "r201", "r203", "r388", "r389", "r463", "r476", "r609" ], "lang": { "en-us": { "role": { "documentation": "The amount of net income (loss) for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period.", "label": "Diluted Loss per share" } } }, "localname": "EarningsPerShareDiluted", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://endonovo.com/role/StatementsOfOperations" ], "xbrltype": "perShareItemType" }, "us-gaap_EarningsPerSharePolicyTextBlock": { "auth_ref": [ "r41", "r42" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy for computing basic and diluted earnings or loss per share for each class of common stock and participating security. Addresses all significant policy factors, including any antidilutive items that have been excluded from the computation and takes into account stock dividends, splits and reverse splits that occur after the balance sheet date of the latest reporting period but before the issuance of the financial statements.", "label": "Earnings (Loss) Per Share" } } }, "localname": "EarningsPerSharePolicyTextBlock", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://endonovo.com/role/SummaryOfSignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized": { "auth_ref": [ "r365" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of cost not yet recognized for nonvested award under share-based payment arrangement.", "label": "Unrecognized stock-based compensation expense" } } }, "localname": "EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://endonovo.com/role/ShareholdersDeficitDetailsNarrative" ], "xbrltype": "monetaryItemType" }, "us-gaap_EmployeeStockOptionMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Share-based payment arrangement granting right, subject to vesting and other restrictions, to purchase or sell certain number of shares at predetermined price for specified period of time.", "label": "Share-Based Payment Arrangement, Option [Member]" } } }, "localname": "EmployeeStockOptionMember", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://endonovo.com/role/SummaryOfSignificantAccountingPoliciesDetailsNarrative" ], "xbrltype": "domainItemType" }, "us-gaap_EquityAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Equity [Abstract]" } } }, "localname": "EquityAbstract", "nsuri": "http://fasb.org/us-gaap/2023", "xbrltype": "stringItemType" }, "us-gaap_EquityComponentDomain": { "auth_ref": [ "r8", "r143", "r160", "r161", "r162", "r178", "r179", "r180", "r182", "r188", "r190", "r204", "r259", "r260", "r330", "r366", "r367", "r368", "r371", "r372", "r379", "r380", "r381", "r382", "r383", "r384", "r387", "r398", "r399", "r400", "r401", "r402", "r403", "r406", "r485", "r486", "r487", "r500", "r575" ], "lang": { "en-us": { "role": { "documentation": "Components of equity are the parts of the total Equity balance including that which is allocated to common, preferred, treasury stock, retained earnings, etc." } } }, "localname": "EquityComponentDomain", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://endonovo.com/role/RelatedPartyAndFormerRelatedPartiesTransactionsDetailsNarrative", "http://endonovo.com/role/ScheduleOfPreferredStockDetails", "http://endonovo.com/role/ScheduleOfWarrantsOutstandingDetails", "http://endonovo.com/role/ShareholdersDeficitDetailsNarrative", "http://endonovo.com/role/StatementOfShareholdersDeficit" ], "xbrltype": "domainItemType" }, "us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems": { "auth_ref": [ "r391", "r392", "r395" ], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]" } } }, "localname": "FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://endonovo.com/role/ScheduleOfFairValueOfDerivativeLiabilityDetails", "http://endonovo.com/role/ScheduleOfLiabilitiesSignificantUnobservableInputsDetails" ], "xbrltype": "stringItemType" }, "us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable": { "auth_ref": [ "r391", "r392", "r395" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of information about asset and liability measured at fair value on recurring and nonrecurring basis.", "label": "Fair Value, Recurring and Nonrecurring [Table]" } } }, "localname": "FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://endonovo.com/role/ScheduleOfFairValueOfDerivativeLiabilityDetails", "http://endonovo.com/role/ScheduleOfLiabilitiesSignificantUnobservableInputsDetails" ], "xbrltype": "stringItemType" }, "us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Fair Value Measurement Inputs and Valuation Techniques [Line Items]" } } }, "localname": "FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://endonovo.com/role/ScheduleOfConversionFeatureUsingBlackScholesOptionPricingModelDetails" ], "xbrltype": "stringItemType" }, "us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable": { "auth_ref": [ "r9" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of information about input and valuation technique used to measure fair value and change in valuation approach and technique for each separate class of asset and liability measured on recurring and nonrecurring basis.", "label": "Fair Value Measurement Inputs and Valuation Techniques [Table]" } } }, "localname": "FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://endonovo.com/role/ScheduleOfConversionFeatureUsingBlackScholesOptionPricingModelDetails" ], "xbrltype": "stringItemType" }, "us-gaap_FairValueAssetsMeasuredOnNonrecurringBasisValuationTechniquesTextBlock": { "auth_ref": [ "r9" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of input and valuation technique used to measure fair value and change in valuation approach and technique used to measure similar asset in prior period by class of asset or liability on non-recurring basis.", "label": "Schedule of Conversion Feature Using Black Scholes Option Pricing Model" } } }, "localname": "FairValueAssetsMeasuredOnNonrecurringBasisValuationTechniquesTextBlock", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://endonovo.com/role/FairValueMeasurementsTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock": { "auth_ref": [ "r10", "r75" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of the fair value measurement of assets using significant unobservable inputs (Level 3), a reconciliation of the beginning and ending balances, separately presenting changes during the period attributable to the following: (1) total gains or losses for the period (realized and unrealized), segregating those gains or losses included in earnings (or changes in net assets) and gains or losses recognized in other comprehensive income (loss), and a description of where those gains or losses included in earnings (or changes in net assets) are reported in the statement of income (or activities); (2) purchases, sales, issues, and settlements (each type disclosed separately); and (3) transfers in and transfers out of Level 3 (for example, transfers due to changes in the observability of significant inputs), by class of asset.", "label": "Schedule of Fair Value of Derivative Liability" } } }, "localname": "FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://endonovo.com/role/FairValueMeasurementsTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_FairValueByFairValueHierarchyLevelAxis": { "auth_ref": [ "r301", "r344", "r345", "r346", "r347", "r348", "r349", "r392", "r421", "r422", "r423", "r615", "r616", "r627", "r628", "r629" ], "lang": { "en-us": { "role": { "documentation": "Information by level within fair value hierarchy and fair value measured at net asset value per share as practical expedient.", "label": "Fair Value Hierarchy and NAV [Axis]" } } }, "localname": "FairValueByFairValueHierarchyLevelAxis", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://endonovo.com/role/ScheduleOfFairValueOfDerivativeLiabilityDetails", "http://endonovo.com/role/ScheduleOfLiabilitiesSignificantUnobservableInputsDetails" ], "xbrltype": "stringItemType" }, "us-gaap_FairValueDisclosuresAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Fair Value Disclosures [Abstract]" } } }, "localname": "FairValueDisclosuresAbstract", "nsuri": "http://fasb.org/us-gaap/2023", "xbrltype": "stringItemType" }, "us-gaap_FairValueDisclosuresTextBlock": { "auth_ref": [ "r390" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for the fair value of financial instruments (as defined), including financial assets and financial liabilities (collectively, as defined), and the measurements of those instruments as well as disclosures related to the fair value of non-financial assets and liabilities. Such disclosures about the financial instruments, assets, and liabilities would include: (1) the fair value of the required items together with their carrying amounts (as appropriate); (2) for items for which it is not practicable to estimate fair value, disclosure would include: (a) information pertinent to estimating fair value (including, carrying amount, effective interest rate, and maturity, and (b) the reasons why it is not practicable to estimate fair value; (3) significant concentrations of credit risk including: (a) information about the activity, region, or economic characteristics identifying a concentration, (b) the maximum amount of loss the entity is exposed to based on the gross fair value of the related item, (c) policy for requiring collateral or other security and information as to accessing such collateral or security, and (d) the nature and brief description of such collateral or security; (4) quantitative information about market risks and how such risks are managed; (5) for items measured on both a recurring and nonrecurring basis information regarding the inputs used to develop the fair value measurement; and (6) for items presented in the financial statement for which fair value measurement is elected: (a) information necessary to understand the reasons for the election, (b) discussion of the effect of fair value changes on earnings, (c) a description of [similar groups] items for which the election is made and the relation thereof to the balance sheet, the aggregate carrying value of items included in the balance sheet that are not eligible for the election; (7) all other required (as defined) and desired information.", "label": "Fair Value Measurements" } } }, "localname": "FairValueDisclosuresTextBlock", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://endonovo.com/role/FairValueMeasurements" ], "xbrltype": "textBlockItemType" }, "us-gaap_FairValueInputsLevel1Member": { "auth_ref": [ "r301", "r344", "r349", "r392", "r421", "r627", "r628", "r629" ], "lang": { "en-us": { "role": { "documentation": "Quoted prices in active markets for identical assets or liabilities that the reporting entity can access at the measurement date.", "label": "Fair Value, Inputs, Level 1 [Member]" } } }, "localname": "FairValueInputsLevel1Member", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://endonovo.com/role/ScheduleOfLiabilitiesSignificantUnobservableInputsDetails" ], "xbrltype": "domainItemType" }, "us-gaap_FairValueInputsLevel2Member": { "auth_ref": [ "r301", "r344", "r349", "r392", "r422", "r615", "r616", "r627", "r628", "r629" ], "lang": { "en-us": { "role": { "documentation": "Inputs other than quoted prices included within level 1 that are observable for an asset or liability, either directly or indirectly, including, but not limited to, quoted prices for similar assets or liabilities in active markets, or quoted prices for identical or similar assets or liabilities in inactive markets.", "label": "Fair Value, Inputs, Level 2 [Member]" } } }, "localname": "FairValueInputsLevel2Member", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://endonovo.com/role/ScheduleOfLiabilitiesSignificantUnobservableInputsDetails" ], "xbrltype": "domainItemType" }, "us-gaap_FairValueInputsLevel3Member": { "auth_ref": [ "r301", "r344", "r345", "r346", "r347", "r348", "r349", "r392", "r423", "r615", "r616", "r627", "r628", "r629" ], "lang": { "en-us": { "role": { "documentation": "Unobservable inputs that reflect the entity's own assumption about the assumptions market participants would use in pricing.", "label": "Fair Value, Inputs, Level 3 [Member]" } } }, "localname": "FairValueInputsLevel3Member", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://endonovo.com/role/ScheduleOfFairValueOfDerivativeLiabilityDetails", "http://endonovo.com/role/ScheduleOfLiabilitiesSignificantUnobservableInputsDetails" ], "xbrltype": "domainItemType" }, "us-gaap_FairValueMeasurementsFairValueHierarchyDomain": { "auth_ref": [ "r301", "r344", "r345", "r346", "r347", "r348", "r349", "r421", "r422", "r423", "r615", "r616", "r627", "r628", "r629" ], "lang": { "en-us": { "role": { "documentation": "Categories used to prioritize the inputs to valuation techniques to measure fair value." } } }, "localname": "FairValueMeasurementsFairValueHierarchyDomain", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://endonovo.com/role/ScheduleOfFairValueOfDerivativeLiabilityDetails", "http://endonovo.com/role/ScheduleOfLiabilitiesSignificantUnobservableInputsDetails" ], "xbrltype": "domainItemType" }, "us-gaap_FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisUnobservableInputsReconciliationPeriodIncreaseDecrease": { "auth_ref": [ "r10", "r18" ], "lang": { "en-us": { "role": { "documentation": "Amount of increase (decrease) of financial instrument classified as a derivative asset (liability) after deduction of derivative liability (asset), measured using unobservable inputs that reflect the entity's own assumption about the assumptions market participants would use in pricing.", "label": "Change in estimated fair value" } } }, "localname": "FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisUnobservableInputsReconciliationPeriodIncreaseDecrease", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://endonovo.com/role/ScheduleOfFairValueOfDerivativeLiabilityDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisUnobservableInputsReconciliationSettlements": { "auth_ref": [ "r18", "r74" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of settlements of financial instrument classified as a derivative asset (liability) after deduction of derivative liability, measured using unobservable inputs that reflect the entity's own assumption about the assumptions market participants would use in pricing.", "label": "Settlement debt" } } }, "localname": "FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisUnobservableInputsReconciliationSettlements", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://endonovo.com/role/ScheduleOfFairValueOfDerivativeLiabilityDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisWithUnobservableInputs": { "auth_ref": [ "r18", "r73" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Fair value of financial instrument classified as derivative asset (liability) after deduction of derivative liability (asset), measured using unobservable inputs that reflect the entity's own assumption about the assumptions market participants would use in pricing.", "label": "Fair Value, Net Derivative Asset (Liability) Measured on Recurring Basis with Unobservable Inputs", "periodEndLabel": "Derivative Liability, ending balance", "periodStartLabel": "Derivative Liability, beginning balance" } } }, "localname": "FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisWithUnobservableInputs", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://endonovo.com/role/ScheduleOfFairValueOfDerivativeLiabilityDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_FinancialInstrumentAxis": { "auth_ref": [ "r228", "r229", "r230", "r231", "r232", "r233", "r234", "r235", "r236", "r237", "r238", "r239", "r240", "r241", "r242", "r243", "r244", "r245", "r246", "r247", "r248", "r249", "r250", "r251", "r252", "r253", "r254", "r255", "r256", "r257", "r262", "r263", "r264", "r265", "r266", "r267", "r268", "r269", "r312", "r327", "r385", "r418", "r419", "r420", "r421", "r422", "r423", "r424", "r425", "r426", "r427", "r428", "r429", "r430", "r431", "r432", "r433", "r434", "r435", "r436", "r437", "r438", "r439", "r440", "r441", "r442", "r443", "r444", "r445", "r446", "r447", "r475", "r613", "r672", "r673", "r674", "r675", "r676", "r677", "r678", "r696", "r697", "r698", "r699" ], "lang": { "en-us": { "role": { "documentation": "Information by type of financial instrument.", "label": "Financial Instrument [Axis]" } } }, "localname": "FinancialInstrumentAxis", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://endonovo.com/role/ScheduleOfStockOptionsOutstandingDetails" ], "xbrltype": "stringItemType" }, "us-gaap_FinancialLiabilitiesFairValueDisclosure": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Fair value of financial obligations, including, but not limited to, debt instruments, derivative liabilities, federal funds purchased and sold under agreements to repurchase, securities loaned or sold under agreements to repurchase, financial instruments sold not yet purchased, guarantees, line of credit, loans and notes payable, servicing liability, and trading liabilities.", "label": "Financial Liabilities Fair Value Disclosure", "verboseLabel": "Total" } } }, "localname": "FinancialLiabilitiesFairValueDisclosure", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://endonovo.com/role/ScheduleOfLiabilitiesSignificantUnobservableInputsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization": { "auth_ref": [ "r148", "r271" ], "calculation": { "http://endonovo.com/role/ScheduleOfPatentsDetails": { "order": 2.0, "parentTag": "us-gaap_FiniteLivedIntangibleAssetsNet", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Accumulated amount of amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life.", "label": "Less accumulated amortization" } } }, "localname": "FiniteLivedIntangibleAssetsAccumulatedAmortization", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://endonovo.com/role/ScheduleOfPatentsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths": { "auth_ref": [ "r112" ], "calculation": { "http://endonovo.com/role/ScheduleOfEstimatedFutureAmortizationExpenseDetails": { "order": 1.0, "parentTag": "us-gaap_FiniteLivedIntangibleAssetsNet", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).", "label": "2024" } } }, "localname": "FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://endonovo.com/role/ScheduleOfEstimatedFutureAmortizationExpenseDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseTableTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of amortization expense of assets, excluding financial assets, that lack physical substance, having a limited useful life.", "label": "Schedule of Estimated Future Amortization Expense" } } }, "localname": "FiniteLivedIntangibleAssetsAmortizationExpenseTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://endonovo.com/role/PatentsTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo": { "auth_ref": [ "r112" ], "calculation": { "http://endonovo.com/role/ScheduleOfEstimatedFutureAmortizationExpenseDetails": { "order": 2.0, "parentTag": "us-gaap_FiniteLivedIntangibleAssetsNet", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in second fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).", "label": "2025" } } }, "localname": "FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://endonovo.com/role/ScheduleOfEstimatedFutureAmortizationExpenseDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_FiniteLivedIntangibleAssetsNet": { "auth_ref": [ "r111", "r450" ], "calculation": { "http://endonovo.com/role/BalanceSheets": { "order": 2.0, "parentTag": "us-gaap_Assets", "weight": 1.0 }, "http://endonovo.com/role/ScheduleOfEstimatedFutureAmortizationExpenseDetails": { "order": null, "parentTag": null, "root": true, "weight": null }, "http://endonovo.com/role/ScheduleOfPatentsDetails": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount after amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life.", "label": "Patents, net", "totalLabel": "Patents, net" } } }, "localname": "FiniteLivedIntangibleAssetsNet", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://endonovo.com/role/BalanceSheets", "http://endonovo.com/role/ScheduleOfEstimatedFutureAmortizationExpenseDetails", "http://endonovo.com/role/ScheduleOfPatentsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_FiniteLivedPatentsGross": { "auth_ref": [ "r111" ], "calculation": { "http://endonovo.com/role/ScheduleOfPatentsDetails": { "order": 1.0, "parentTag": "us-gaap_FiniteLivedIntangibleAssetsNet", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Gross carrying amount before accumulated amortization as of the balance sheet date of the costs pertaining to the exclusive legal rights granted to the owner of the patent to exploit an invention or a process for a period of time specified by law. Such costs may have been expended to directly apply and receive patent rights, or to acquire such rights.", "label": "Finite-Lived Patents, Gross", "verboseLabel": "Patents" } } }, "localname": "FiniteLivedPatentsGross", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://endonovo.com/role/ScheduleOfPatentsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_GainsLossesOnExtinguishmentOfDebt": { "auth_ref": [ "r5", "r55", "r56" ], "calculation": { "http://endonovo.com/role/StatementsOfCashFlows": { "order": 5.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": -1.0 }, "http://endonovo.com/role/StatementsOfOperations": { "order": 2.0, "parentTag": "us-gaap_NonoperatingIncomeExpense", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Difference between the fair value of payments made and the carrying amount of debt which is extinguished prior to maturity.", "label": "Gain (loss) on settlement of debt", "negatedLabel": "Loss (gain) on extinguishment of debt", "verboseLabel": "Gain on debt extinguishment" } } }, "localname": "GainsLossesOnExtinguishmentOfDebt", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://endonovo.com/role/NotesPayableDetailsNarrative", "http://endonovo.com/role/ShareholdersDeficitDetailsNarrative", "http://endonovo.com/role/StatementsOfCashFlows", "http://endonovo.com/role/StatementsOfOperations" ], "xbrltype": "monetaryItemType" }, "us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Goodwill and Intangible Assets Disclosure [Abstract]" } } }, "localname": "GoodwillAndIntangibleAssetsDisclosureAbstract", "nsuri": "http://fasb.org/us-gaap/2023", "xbrltype": "stringItemType" }, "us-gaap_GrossProfit": { "auth_ref": [ "r100", "r174", "r207", "r213", "r217", "r219", "r258", "r278", "r279", "r280", "r281", "r282", "r283", "r284", "r285", "r286", "r397", "r611", "r706" ], "calculation": { "http://endonovo.com/role/StatementsOfOperations": { "order": 1.0, "parentTag": "us-gaap_OperatingIncomeLoss", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Aggregate revenue less cost of goods and services sold or operating expenses directly attributable to the revenue generation activity.", "label": "Gross Profit", "totalLabel": "Gross profit" } } }, "localname": "GrossProfit", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://endonovo.com/role/StatementsOfOperations" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest": { "auth_ref": [ "r0", "r98", "r128", "r207", "r213", "r217", "r219", "r464", "r473", "r611" ], "calculation": { "http://endonovo.com/role/StatementsOfOperations": { "order": 1.0, "parentTag": "us-gaap_NetIncomeLoss", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of income (loss) from continuing operations, including income (loss) from equity method investments, before deduction of income tax expense (benefit), and income (loss) attributable to noncontrolling interest.", "label": "Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest", "totalLabel": "Income (Loss) before income taxes" } } }, "localname": "IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://endonovo.com/role/StatementsOfOperations" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncomeStatementAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Income Statement [Abstract]" } } }, "localname": "IncomeStatementAbstract", "nsuri": "http://fasb.org/us-gaap/2023", "xbrltype": "stringItemType" }, "us-gaap_IncomeTaxExpenseBenefit": { "auth_ref": [ "r134", "r140", "r189", "r190", "r211", "r370", "r373", "r477" ], "calculation": { "http://endonovo.com/role/StatementsOfOperations": { "order": 2.0, "parentTag": "us-gaap_NetIncomeLoss", "weight": -1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.", "label": "Provision for income taxes" } } }, "localname": "IncomeTaxExpenseBenefit", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://endonovo.com/role/StatementsOfOperations" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncomeTaxesPaid": { "auth_ref": [ "r35", "r37" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The amount of cash paid during the current period to foreign, federal, state, and local authorities as taxes on income.", "label": "Cash paid for income taxes" } } }, "localname": "IncomeTaxesPaid", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://endonovo.com/role/StatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities": { "auth_ref": [ "r4" ], "calculation": { "http://endonovo.com/role/StatementsOfCashFlows": { "order": 9.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The increase (decrease) during the reporting period in the amounts payable to vendors for goods and services received and the amount of obligations and expenses incurred but not paid.", "label": "Account payable and accrued liabilities (related and unrelated parties)" } } }, "localname": "IncreaseDecreaseInAccountsPayableAndAccruedLiabilities", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://endonovo.com/role/StatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncreaseDecreaseInDeferredCompensation": { "auth_ref": [ "r4" ], "calculation": { "http://endonovo.com/role/StatementsOfCashFlows": { "order": 11.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The increase (decrease) during the reporting period in the obligation created by employee agreements whereby earned compensation will be paid in the future.", "label": "Increase (Decrease) in Deferred Compensation", "verboseLabel": "Deferred compensation" } } }, "localname": "IncreaseDecreaseInDeferredCompensation", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://endonovo.com/role/StatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncreaseDecreaseInInterestPayableNet": { "auth_ref": [ "r4" ], "calculation": { "http://endonovo.com/role/StatementsOfCashFlows": { "order": 10.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The increase (decrease) during the reporting period in interest payable, which represents the amount owed to note holders, bond holders, and other parties for interest earned on loans or credit extended to the reporting entity.", "label": "Accrued interest" } } }, "localname": "IncreaseDecreaseInInterestPayableNet", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://endonovo.com/role/StatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncreaseDecreaseInOperatingCapitalAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Changes in assets and liabilities:" } } }, "localname": "IncreaseDecreaseInOperatingCapitalAbstract", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://endonovo.com/role/StatementsOfCashFlows" ], "xbrltype": "stringItemType" }, "us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets": { "auth_ref": [ "r4" ], "calculation": { "http://endonovo.com/role/StatementsOfCashFlows": { "order": 8.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of increase (decrease) in prepaid expenses, and assets classified as other.", "label": "Increase (Decrease) in Prepaid Expense and Other Assets", "negatedLabel": "Prepaid expenses and other current assets" } } }, "localname": "IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://endonovo.com/role/StatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_IntangibleAssetsDisclosureTextBlock": { "auth_ref": [ "r270" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for all or part of the information related to intangible assets.", "label": "Patents" } } }, "localname": "IntangibleAssetsDisclosureTextBlock", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://endonovo.com/role/Patents" ], "xbrltype": "textBlockItemType" }, "us-gaap_InterestIncomeExpenseNet": { "auth_ref": [ "r130" ], "calculation": { "http://endonovo.com/role/StatementsOfOperations": { "order": 4.0, "parentTag": "us-gaap_NonoperatingIncomeExpense", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The net amount of operating interest income (expense).", "label": "Interest expense, net" } } }, "localname": "InterestIncomeExpenseNet", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://endonovo.com/role/StatementsOfOperations" ], "xbrltype": "monetaryItemType" }, "us-gaap_InterestPaidNet": { "auth_ref": [ "r165", "r167", "r168" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of cash paid for interest, excluding capitalized interest, classified as operating activity. Includes, but is not limited to, payment to settle zero-coupon bond for accreted interest of debt discount and debt instrument with insignificant coupon interest rate in relation to effective interest rate of borrowing attributable to accreted interest of debt discount.", "label": "Cash paid for interest" } } }, "localname": "InterestPaidNet", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://endonovo.com/role/StatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_InterestPayableCurrent": { "auth_ref": [ "r24" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Carrying value as of the balance sheet date of [accrued] interest payable on all forms of debt, including trade payables, that has been incurred and is unpaid. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).", "label": "Interest payable", "verboseLabel": "Accrued interest" } } }, "localname": "InterestPayableCurrent", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://endonovo.com/role/NotesPayableDetailsNarrative", "http://endonovo.com/role/RelatedPartyAndFormerRelatedPartiesTransactionsDetailsNarrative" ], "xbrltype": "monetaryItemType" }, "us-gaap_InterestPayableCurrentAndNoncurrent": { "auth_ref": [ "r83", "r727" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of interest payable on debt, including, but not limited to, trade payables.", "label": "Interest Payable", "verboseLabel": "Accrued interest" } } }, "localname": "InterestPayableCurrentAndNoncurrent", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://endonovo.com/role/NotesPayableDetailsNarrative", "http://endonovo.com/role/ShareholdersDeficitDetailsNarrative" ], "xbrltype": "monetaryItemType" }, "us-gaap_IssuanceOfStockAndWarrantsForServicesOrClaims": { "auth_ref": [ "r5" ], "calculation": { "http://endonovo.com/role/StatementsOfCashFlows": { "order": 4.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Fair value of share-based compensation granted to nonemployees as payment for services rendered or acknowledged claims.", "label": "Fair value of equity issued for services" } } }, "localname": "IssuanceOfStockAndWarrantsForServicesOrClaims", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://endonovo.com/role/StatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_Liabilities": { "auth_ref": [ "r23", "r174", "r258", "r278", "r279", "r280", "r281", "r282", "r283", "r284", "r285", "r286", "r376", "r377", "r378", "r397", "r528", "r610", "r645", "r706", "r719", "r720" ], "calculation": { "http://endonovo.com/role/BalanceSheets": { "order": 1.0, "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Sum of the carrying amounts as of the balance sheet date of all liabilities that are recognized. Liabilities are probable future sacrifices of economic benefits arising from present obligations of an entity to transfer assets or provide services to other entities in the future.", "label": "Liabilities", "totalLabel": "Total liabilities" } } }, "localname": "Liabilities", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://endonovo.com/role/BalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_LiabilitiesAndStockholdersEquity": { "auth_ref": [ "r97", "r127", "r472", "r632", "r686", "r700", "r716" ], "calculation": { "http://endonovo.com/role/BalanceSheets": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of liabilities and equity items, including the portion of equity attributable to noncontrolling interests, if any.", "label": "Liabilities and Equity", "totalLabel": "Total liabilities and shareholders\u2019 deficit" } } }, "localname": "LiabilitiesAndStockholdersEquity", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://endonovo.com/role/BalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_LiabilitiesAndStockholdersEquityAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "LIABILITIES AND SHAREHOLDERS\u2019 DEFICIT" } } }, "localname": "LiabilitiesAndStockholdersEquityAbstract", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://endonovo.com/role/BalanceSheets" ], "xbrltype": "stringItemType" }, "us-gaap_LiabilitiesCurrent": { "auth_ref": [ "r25", "r146", "r174", "r258", "r278", "r279", "r280", "r281", "r282", "r283", "r284", "r285", "r286", "r376", "r377", "r378", "r397", "r632", "r706", "r719", "r720" ], "calculation": { "http://endonovo.com/role/BalanceSheets": { "order": 1.0, "parentTag": "us-gaap_Liabilities", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Total obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if longer.", "label": "Liabilities, Current", "totalLabel": "Total current liabilities" } } }, "localname": "LiabilitiesCurrent", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://endonovo.com/role/BalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_LiabilitiesCurrentAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Current liabilities" } } }, "localname": "LiabilitiesCurrentAbstract", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://endonovo.com/role/BalanceSheets" ], "xbrltype": "stringItemType" }, "us-gaap_LongTermDebt": { "auth_ref": [ "r19", "r126", "r300", "r314", "r615", "r616", "r728" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount, after deduction of unamortized premium (discount) and debt issuance cost, of long-term debt. Excludes lease obligation.", "label": "Total" } } }, "localname": "LongTermDebt", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://endonovo.com/role/ScheduleOfMaturityDatesOfNotesPayableDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths": { "auth_ref": [ "r6", "r177", "r305" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of long-term debt payable, sinking fund requirement, and other securities issued that are redeemable by holder at fixed or determinable price and date, maturing in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).", "label": "June 30, 2024" } } }, "localname": "LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://endonovo.com/role/ScheduleOfMaturityDatesOfNotesPayableDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_MeasurementInputExercisePriceMember": { "auth_ref": [ "r715" ], "lang": { "en-us": { "role": { "documentation": "Measurement input using agreed upon price for exchange of underlying asset.", "label": "Measurement Input, Exercise Price [Member]" } } }, "localname": "MeasurementInputExercisePriceMember", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://endonovo.com/role/ScheduleOfConversionFeatureUsingBlackScholesOptionPricingModelDetails" ], "xbrltype": "domainItemType" }, "us-gaap_MeasurementInputExpectedDividendRateMember": { "auth_ref": [ "r715" ], "lang": { "en-us": { "role": { "documentation": "Measurement input using expected dividend rate to be paid to holder of share per year.", "label": "Measurement Input, Expected Dividend Rate [Member]" } } }, "localname": "MeasurementInputExpectedDividendRateMember", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://endonovo.com/role/ScheduleOfConversionFeatureUsingBlackScholesOptionPricingModelDetails" ], "xbrltype": "domainItemType" }, "us-gaap_MeasurementInputExpectedTermMember": { "auth_ref": [ "r715" ], "lang": { "en-us": { "role": { "documentation": "Measurement input using period financial instrument is expected to be outstanding. Excludes maturity date.", "label": "Measurement Input, Expected Term [Member]" } } }, "localname": "MeasurementInputExpectedTermMember", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://endonovo.com/role/ScheduleOfConversionFeatureUsingBlackScholesOptionPricingModelDetails" ], "xbrltype": "domainItemType" }, "us-gaap_MeasurementInputPriceVolatilityMember": { "auth_ref": [ "r715" ], "lang": { "en-us": { "role": { "documentation": "Measurement input using rate at which price of security will increase (decrease) for given set of returns.", "label": "Measurement Input, Price Volatility [Member]" } } }, "localname": "MeasurementInputPriceVolatilityMember", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://endonovo.com/role/ScheduleOfConversionFeatureUsingBlackScholesOptionPricingModelDetails" ], "xbrltype": "domainItemType" }, "us-gaap_MeasurementInputRiskFreeInterestRateMember": { "auth_ref": [ "r715" ], "lang": { "en-us": { "role": { "documentation": "Measurement input using interest rate on instrument with zero risk of financial loss.", "label": "Measurement Input, Risk Free Interest Rate [Member]" } } }, "localname": "MeasurementInputRiskFreeInterestRateMember", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://endonovo.com/role/ScheduleOfConversionFeatureUsingBlackScholesOptionPricingModelDetails" ], "xbrltype": "domainItemType" }, "us-gaap_MeasurementInputTypeAxis": { "auth_ref": [ "r393" ], "lang": { "en-us": { "role": { "documentation": "Information by type of measurement input used to determine value of asset and liability.", "label": "Measurement Input Type [Axis]" } } }, "localname": "MeasurementInputTypeAxis", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://endonovo.com/role/ScheduleOfConversionFeatureUsingBlackScholesOptionPricingModelDetails" ], "xbrltype": "stringItemType" }, "us-gaap_MeasurementInputTypeDomain": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Measurement input used to determine value of asset and liability." } } }, "localname": "MeasurementInputTypeDomain", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://endonovo.com/role/ScheduleOfConversionFeatureUsingBlackScholesOptionPricingModelDetails" ], "xbrltype": "domainItemType" }, "us-gaap_NetCashProvidedByUsedInFinancingActivities": { "auth_ref": [ "r166" ], "calculation": { "http://endonovo.com/role/StatementsOfCashFlows": { "order": 2.0, "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of cash inflow (outflow) from financing activities, including discontinued operations. Financing activity cash flows include obtaining resources from owners and providing them with a return on, and a return of, their investment; borrowing money and repaying amounts borrowed, or settling the obligation; and obtaining and paying for other resources obtained from creditors on long-term credit.", "label": "Net Cash Provided by (Used in) Financing Activities", "totalLabel": "Net cash provided by financing activities" } } }, "localname": "NetCashProvidedByUsedInFinancingActivities", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://endonovo.com/role/StatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Financing activities:" } } }, "localname": "NetCashProvidedByUsedInFinancingActivitiesAbstract", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://endonovo.com/role/StatementsOfCashFlows" ], "xbrltype": "stringItemType" }, "us-gaap_NetCashProvidedByUsedInOperatingActivities": { "auth_ref": [ "r105", "r106", "r107" ], "calculation": { "http://endonovo.com/role/StatementsOfCashFlows": { "order": 1.0, "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect", "weight": 1.0 } }, "lang": { "en-us": { "role": { "documentation": "Amount of cash inflow (outflow) from operating activities, including discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities.", "label": "Net Cash Provided by (Used in) Operating Activities", "negatedLabel": "Net cash provided by (used in) operating activities", "totalLabel": "Net cash used in operating activities" } } }, "localname": "NetCashProvidedByUsedInOperatingActivities", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://endonovo.com/role/StatementsOfCashFlows", "http://endonovo.com/role/SummaryOfSignificantAccountingPoliciesDetailsNarrative" ], "xbrltype": "monetaryItemType" }, "us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Operating activities:" } } }, "localname": "NetCashProvidedByUsedInOperatingActivitiesAbstract", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://endonovo.com/role/StatementsOfCashFlows" ], "xbrltype": "stringItemType" }, "us-gaap_NetIncomeLoss": { "auth_ref": [ "r99", "r107", "r129", "r144", "r158", "r159", "r162", "r174", "r181", "r183", "r184", "r185", "r186", "r189", "r190", "r197", "r207", "r213", "r217", "r219", "r258", "r278", "r279", "r280", "r281", "r282", "r283", "r284", "r285", "r286", "r389", "r397", "r474", "r552", "r573", "r574", "r611", "r643", "r706" ], "calculation": { "http://endonovo.com/role/StatementsOfCashFlows": { "order": 1.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 }, "http://endonovo.com/role/StatementsOfOperations": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.", "label": "Net Income (Loss)", "totalLabel": "Net Income (Loss)", "verboseLabel": "Net Income (loss)" } } }, "localname": "NetIncomeLoss", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://endonovo.com/role/StatementOfShareholdersDeficit", "http://endonovo.com/role/StatementsOfCashFlows", "http://endonovo.com/role/StatementsOfOperations" ], "xbrltype": "monetaryItemType" }, "us-gaap_NetIncomeLossAttributableToParentDiluted": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The portion of profit or loss for the period, net of income taxes, which is attributable to the parent, and includes adjustments resulting from the assumption that dilutive convertible securities were converted, options or warrants were exercised, or that other shares were issued upon the satisfaction of certain conditions.", "label": "Net loss for diluted earnings per share" } } }, "localname": "NetIncomeLossAttributableToParentDiluted", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://endonovo.com/role/ScheduleOfEarningsPerShareBasicAndDilutedDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic": { "auth_ref": [ "r164", "r183", "r184", "r185", "r186", "r192", "r193", "r198", "r201", "r207", "r213", "r217", "r219", "r611" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount, after deduction of tax, noncontrolling interests, dividends on preferred stock and participating securities; of income (loss) available to common shareholders.", "label": "Net income (loss) attributable to common shareholders" } } }, "localname": "NetIncomeLossAvailableToCommonStockholdersBasic", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://endonovo.com/role/ScheduleOfEarningsPerShareBasicAndDilutedDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy pertaining to new accounting pronouncements that may impact the entity's financial reporting. Includes, but is not limited to, quantification of the expected or actual impact.", "label": "Newly Adopted Accounting Principles" } } }, "localname": "NewAccountingPronouncementsPolicyPolicyTextBlock", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://endonovo.com/role/SummaryOfSignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_NoncashInvestingAndFinancingItemsAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Non-Cash Investing and Financing Activities:" } } }, "localname": "NoncashInvestingAndFinancingItemsAbstract", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://endonovo.com/role/StatementsOfCashFlows" ], "xbrltype": "stringItemType" }, "us-gaap_NonoperatingIncomeExpense": { "auth_ref": [ "r102" ], "calculation": { "http://endonovo.com/role/StatementsOfOperations": { "order": 2.0, "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The aggregate amount of income or expense from ancillary business-related activities (that is to say, excluding major activities considered part of the normal operations of the business).", "label": "Nonoperating Income (Expense)", "totalLabel": "Other income (expense)" } } }, "localname": "NonoperatingIncomeExpense", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://endonovo.com/role/StatementsOfOperations" ], "xbrltype": "monetaryItemType" }, "us-gaap_NonoperatingIncomeExpenseAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Other income (expense)" } } }, "localname": "NonoperatingIncomeExpenseAbstract", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://endonovo.com/role/StatementsOfOperations" ], "xbrltype": "stringItemType" }, "us-gaap_NonrelatedPartyMember": { "auth_ref": [ "r687", "r688" ], "lang": { "en-us": { "role": { "documentation": "Party not related to reporting entity.", "label": "Nonrelated Party [Member]" } } }, "localname": "NonrelatedPartyMember", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://endonovo.com/role/BalanceSheets", "http://endonovo.com/role/ScheduleOfMaturityDatesOfNotesPayableDetails", "http://endonovo.com/role/ScheduleOfNotesPayableDetails" ], "xbrltype": "domainItemType" }, "us-gaap_NotesAndLoansPayable": { "auth_ref": [ "r19", "r126", "r728" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Including the current and noncurrent portions, carrying value as of the balance sheet date of all notes and loans payable (with maturities initially due after one year or beyond the operating cycle if longer).", "label": "Notes and Loans Payable", "periodEndLabel": "Note payable, net" } } }, "localname": "NotesAndLoansPayable", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://endonovo.com/role/ScheduleOfNotesPayableDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_NotesIssued1": { "auth_ref": [ "r38", "r39", "r40" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The fair value of notes issued in noncash investing and financing activities.", "label": "Conversion of notes payable and accrued interest to common stock" } } }, "localname": "NotesIssued1", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://endonovo.com/role/StatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_NotesPayable": { "auth_ref": [ "r19", "r126", "r728" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Including the current and noncurrent portions, aggregate carrying amount of all types of notes payable, as of the balance sheet date, with initial maturities beyond one year or beyond the normal operating cycle, if longer.", "label": "Notes Payable [Default Label]", "periodEndLabel": "Notes payable at end of period", "periodStartLabel": "Notes payable at beginning of period", "verboseLabel": "Notes payable" } } }, "localname": "NotesPayable", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://endonovo.com/role/NotesPayableDetailsNarrative", "http://endonovo.com/role/ScheduleOfNotesPayableDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_NotesPayableCurrent": { "auth_ref": [ "r22" ], "calculation": { "http://endonovo.com/role/BalanceSheets": { "order": 4.0, "parentTag": "us-gaap_LiabilitiesCurrent", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Sum of the carrying values as of the balance sheet date of the portions of long-term notes payable due within one year or the operating cycle if longer.", "label": "Notes payable", "terseLabel": "Notes payable, related parties", "verboseLabel": "Note payable outstanding" } } }, "localname": "NotesPayableCurrent", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://endonovo.com/role/BalanceSheets", "http://endonovo.com/role/NotesPayableDetailsNarrative", "http://endonovo.com/role/RelatedPartyAndFormerRelatedPartiesTransactionsDetailsNarrative", "http://endonovo.com/role/ScheduleOfNotesPayableDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_NumberOfReportingUnits": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Number of reporting units tested for impairment of goodwill. A reporting unit is an operating segment or one level below an operating segment.", "label": "Number of Reporting Units" } } }, "localname": "NumberOfReportingUnits", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://endonovo.com/role/RevenueRecognitionDetailsNarrative" ], "xbrltype": "integerItemType" }, "us-gaap_OperatingExpenses": { "auth_ref": [], "calculation": { "http://endonovo.com/role/StatementsOfOperations": { "order": 2.0, "parentTag": "us-gaap_OperatingIncomeLoss", "weight": -1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Generally recurring costs associated with normal operations except for the portion of these expenses which can be clearly related to production and included in cost of sales or services. Includes selling, general and administrative expense.", "label": "Operating expenses" } } }, "localname": "OperatingExpenses", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://endonovo.com/role/StatementsOfOperations" ], "xbrltype": "monetaryItemType" }, "us-gaap_OperatingIncomeLoss": { "auth_ref": [ "r207", "r213", "r217", "r219", "r611" ], "calculation": { "http://endonovo.com/role/StatementsOfOperations": { "order": 1.0, "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The net result for the period of deducting operating expenses from operating revenues.", "label": "Operating Income (Loss)", "totalLabel": "Loss from operations" } } }, "localname": "OperatingIncomeLoss", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://endonovo.com/role/StatementsOfOperations" ], "xbrltype": "monetaryItemType" }, "us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Organization, Consolidation and Presentation of Financial Statements [Abstract]" } } }, "localname": "OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract", "nsuri": "http://fasb.org/us-gaap/2023", "xbrltype": "stringItemType" }, "us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock": { "auth_ref": [ "r88", "r108", "r109", "r122" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for the organization, consolidation and basis of presentation of financial statements disclosure, and significant accounting policies of the reporting entity. May be provided in more than one note to the financial statements, as long as users are provided with an understanding of (1) the significant judgments and assumptions made by an enterprise in determining whether it must consolidate a VIE and/or disclose information about its involvement with a VIE, (2) the nature of restrictions on a consolidated VIE's assets reported by an enterprise in its statement of financial position, including the carrying amounts of such assets, (3) the nature of, and changes in, the risks associated with an enterprise's involvement with the VIE, and (4) how an enterprise's involvement with the VIE affects the enterprise's financial position, financial performance, and cash flows. Describes procedure if disclosures are provided in more than one note to the financial statements.", "label": "Organization and Nature of Business" } } }, "localname": "OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://endonovo.com/role/OrganizationAndNatureOfBusiness" ], "xbrltype": "textBlockItemType" }, "us-gaap_OtherLiabilities": { "auth_ref": [ "r84", "r465", "r524", "r525", "r645", "r733" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of liabilities classified as other.", "label": "Due to officer" } } }, "localname": "OtherLiabilities", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://endonovo.com/role/RelatedPartyAndFormerRelatedPartiesTransactionsDetailsNarrative" ], "xbrltype": "monetaryItemType" }, "us-gaap_OtherNonoperatingIncomeExpense": { "auth_ref": [ "r103" ], "calculation": { "http://endonovo.com/role/StatementsOfOperations": { "order": 3.0, "parentTag": "us-gaap_NonoperatingIncomeExpense", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of income (expense) related to nonoperating activities, classified as other.", "label": "Other expense" } } }, "localname": "OtherNonoperatingIncomeExpense", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://endonovo.com/role/StatementsOfOperations" ], "xbrltype": "monetaryItemType" }, "us-gaap_OtherNotesPayable": { "auth_ref": [ "r19", "r126", "r728" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of long-term notes payable classified as other.", "label": "Promissory notes" } } }, "localname": "OtherNotesPayable", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://endonovo.com/role/NotesPayableDetailsNarrative" ], "xbrltype": "monetaryItemType" }, "us-gaap_OtherReceivables": { "auth_ref": [ "r153", "r539" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount due from parties in nontrade transactions, classified as other.", "label": "Advance from officer" } } }, "localname": "OtherReceivables", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://endonovo.com/role/RelatedPartyAndFormerRelatedPartiesTransactionsDetailsNarrative" ], "xbrltype": "monetaryItemType" }, "us-gaap_PaymentsToAcquireIntangibleAssets": { "auth_ref": [ "r104" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The cash outflow to acquire asset without physical form usually arising from contractual or other legal rights, excluding goodwill.", "label": "Acquisition of patents" } } }, "localname": "PaymentsToAcquireIntangibleAssets", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://endonovo.com/role/PatentsDetailsNarrative" ], "xbrltype": "monetaryItemType" }, "us-gaap_PreferredStockDividendsPerShareCashPaid": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Aggregate dividends paid during the period for each share of preferred stock outstanding.", "label": "Preferred stock, dividend per share" } } }, "localname": "PreferredStockDividendsPerShareCashPaid", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://endonovo.com/role/ShareholdersDeficitDetailsNarrative" ], "xbrltype": "perShareItemType" }, "us-gaap_PreferredStockLiquidationPreference": { "auth_ref": [ "r58", "r59", "r91", "r684", "r710" ], "lang": { "en-us": { "role": { "documentation": "The per share liquidation preference (or restrictions) of nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer) that has a preference in involuntary liquidation considerably in excess of the par or stated value of the shares. The liquidation preference is the difference between the preference in liquidation and the par or stated values of the share.", "label": "Liquidation value of preferred stock, per share" } } }, "localname": "PreferredStockLiquidationPreference", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://endonovo.com/role/ShareholdersDeficitDetailsNarrative" ], "xbrltype": "perShareItemType" }, "us-gaap_PreferredStockLiquidationPreferenceValue": { "auth_ref": [ "r172", "r319" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Value of the difference between preference in liquidation and the par or stated values of the preferred shares.", "label": "Liquidation Value" } } }, "localname": "PreferredStockLiquidationPreferenceValue", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://endonovo.com/role/ScheduleOfPreferredStockDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_PreferredStockMember": { "auth_ref": [ "r635", "r636", "r639", "r640", "r641", "r642", "r731", "r735" ], "lang": { "en-us": { "role": { "documentation": "Preferred shares may provide a preferential dividend to the dividend on common stock and may take precedence over common stock in the event of a liquidation. Preferred shares typically represent an ownership interest in the company.", "label": "Preferred Stock [Member]" } } }, "localname": "PreferredStockMember", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://endonovo.com/role/StatementOfShareholdersDeficit" ], "xbrltype": "domainItemType" }, "us-gaap_PreferredStockParOrStatedValuePerShare": { "auth_ref": [ "r91", "r316" ], "lang": { "en-us": { "role": { "documentation": "Face amount or stated value per share of preferred stock nonredeemable or redeemable solely at the option of the issuer.", "label": "Preferred stock, par value", "verboseLabel": "Par Value" } } }, "localname": "PreferredStockParOrStatedValuePerShare", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://endonovo.com/role/BalanceSheetsParenthetical", "http://endonovo.com/role/ScheduleOfPreferredStockDetails", "http://endonovo.com/role/ShareholdersDeficitDetailsNarrative" ], "xbrltype": "perShareItemType" }, "us-gaap_PreferredStockSharesAuthorized": { "auth_ref": [ "r91", "r530" ], "lang": { "en-us": { "role": { "documentation": "The maximum number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) permitted to be issued by an entity's charter and bylaws.", "label": "Preferred stock, shares authorized", "terseLabel": "Number of shares authorized", "verboseLabel": "Number of Shares Authorized" } } }, "localname": "PreferredStockSharesAuthorized", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://endonovo.com/role/BalanceSheetsParenthetical", "http://endonovo.com/role/ScheduleOfPreferredStockDetails", "http://endonovo.com/role/ShareholdersDeficitDetailsNarrative" ], "xbrltype": "sharesItemType" }, "us-gaap_PreferredStockSharesIssued": { "auth_ref": [ "r91", "r316" ], "lang": { "en-us": { "role": { "documentation": "Total number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) issued to shareholders (includes related preferred shares that were issued, repurchased, and remain in the treasury). May be all or portion of the number of preferred shares authorized. Excludes preferred shares that are classified as debt.", "label": "Preferred stock, shares issued" } } }, "localname": "PreferredStockSharesIssued", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://endonovo.com/role/BalanceSheetsParenthetical" ], "xbrltype": "sharesItemType" }, "us-gaap_PreferredStockSharesOutstanding": { "auth_ref": [ "r91", "r530", "r550", "r735", "r736" ], "lang": { "en-us": { "role": { "documentation": "Aggregate share number for all nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer) held by stockholders. Does not include preferred shares that have been repurchased.", "label": "Preferred stock, shares outstanding", "verboseLabel": "Number of Shares Outstanding" } } }, "localname": "PreferredStockSharesOutstanding", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://endonovo.com/role/BalanceSheetsParenthetical", "http://endonovo.com/role/ScheduleOfPreferredStockDetails", "http://endonovo.com/role/ShareholdersDeficitDetailsNarrative" ], "xbrltype": "sharesItemType" }, "us-gaap_PreferredStockValue": { "auth_ref": [ "r91", "r469", "r632" ], "calculation": { "http://endonovo.com/role/BalanceSheets": { "order": 1.0, "parentTag": "us-gaap_StockholdersEquity", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Aggregate par or stated value of issued nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable preferred shares, par value and other disclosure concepts are in another section within stockholders' equity.", "label": "Preferred stock value" } } }, "localname": "PreferredStockValue", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://endonovo.com/role/BalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_PreferredStockVotingRights": { "auth_ref": [ "r58", "r91" ], "lang": { "en-us": { "role": { "documentation": "Description of voting rights of nonredeemable preferred stock. Includes eligibility to vote and votes per share owned. Include also, if any, unusual voting rights.", "label": "Preferred stock voting rights" } } }, "localname": "PreferredStockVotingRights", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://endonovo.com/role/ShareholdersDeficitDetailsNarrative" ], "xbrltype": "stringItemType" }, "us-gaap_PrepaidExpenseAndOtherAssetsCurrent": { "auth_ref": [ "r682" ], "calculation": { "http://endonovo.com/role/BalanceSheets": { "order": 2.0, "parentTag": "us-gaap_AssetsCurrent", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of asset related to consideration paid in advance for costs that provide economic benefits in future periods, and amount of other assets that are expected to be realized or consumed within one year or the normal operating cycle, if longer.", "label": "Prepaid expenses and other current assets" } } }, "localname": "PrepaidExpenseAndOtherAssetsCurrent", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://endonovo.com/role/BalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_PrivatePlacementMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "A private placement is a direct offering of securities to a limited number of sophisticated investors such as insurance companies, pension funds, mezzanine funds, stock funds and trusts.", "label": "Private Placement [Member]" } } }, "localname": "PrivatePlacementMember", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://endonovo.com/role/NotesPayableDetailsNarrative", "http://endonovo.com/role/ShareholdersDeficitDetailsNarrative" ], "xbrltype": "domainItemType" }, "us-gaap_ProceedsFromIssuanceOfCommonStock": { "auth_ref": [ "r3" ], "calculation": { "http://endonovo.com/role/StatementsOfCashFlows": { "order": 4.0, "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The cash inflow from the additional capital contribution to the entity.", "label": "Proceeds from issuance of common stock and units, net" } } }, "localname": "ProceedsFromIssuanceOfCommonStock", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://endonovo.com/role/StatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_ProceedsFromIssuanceOrSaleOfEquity": { "auth_ref": [ "r3", "r492" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The cash inflow from the issuance of common stock, preferred stock, treasury stock, stock options, and other types of equity.", "label": "Proceeds from equity financing" } } }, "localname": "ProceedsFromIssuanceOrSaleOfEquity", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://endonovo.com/role/SummaryOfSignificantAccountingPoliciesDetailsNarrative" ], "xbrltype": "monetaryItemType" }, "us-gaap_ProceedsFromNotesPayable": { "auth_ref": [ "r33" ], "calculation": { "http://endonovo.com/role/StatementsOfCashFlows": { "order": 1.0, "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The cash inflow from a borrowing supported by a written promise to pay an obligation.", "label": "Proceeds from the issuance of notes payable not of costs", "verboseLabel": "Proceeds from issuance of note payable" } } }, "localname": "ProceedsFromNotesPayable", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://endonovo.com/role/NotesPayableDetailsNarrative", "http://endonovo.com/role/StatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_RelatedPartyDomain": { "auth_ref": [ "r350", "r410", "r411", "r523", "r524", "r525", "r526", "r527", "r549", "r551", "r583" ], "lang": { "en-us": { "role": { "documentation": "Related parties include affiliates; other entities for which investments are accounted for by the equity method by the entity; trusts for benefit of employees; and principal owners, management, and members of immediate families. It also may include other parties with which the entity may control or can significantly influence the management or operating policies of the other to an extent that one of the transacting parties might be prevented from fully pursuing its own separate interests." } } }, "localname": "RelatedPartyDomain", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://endonovo.com/role/BalanceSheets", "http://endonovo.com/role/NotesPayableDetailsNarrative", "http://endonovo.com/role/RelatedPartyAndFormerRelatedPartiesTransactionsDetailsNarrative", "http://endonovo.com/role/RevenueRecognitionDetailsNarrative", "http://endonovo.com/role/ScheduleOfMaturityDatesOfNotesPayableDetails", "http://endonovo.com/role/ScheduleOfNotesPayableDetails" ], "xbrltype": "domainItemType" }, "us-gaap_RelatedPartyMember": { "auth_ref": [ "r175", "r176", "r410", "r411", "r412", "r413", "r523", "r524", "r525", "r526", "r527", "r549", "r551", "r583" ], "lang": { "en-us": { "role": { "documentation": "Party related to reporting entity. Includes, but is not limited to, affiliate, entity for which investment is accounted for by equity method, trust for benefit of employees, and principal owner, management, and members of immediate family.", "label": "Related Party [Member]" } } }, "localname": "RelatedPartyMember", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://endonovo.com/role/BalanceSheets" ], "xbrltype": "domainItemType" }, "us-gaap_RelatedPartyTransactionLineItems": { "auth_ref": [ "r556", "r557", "r560" ], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Related Party Transaction [Line Items]" } } }, "localname": "RelatedPartyTransactionLineItems", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://endonovo.com/role/RelatedPartyAndFormerRelatedPartiesTransactionsDetailsNarrative" ], "xbrltype": "stringItemType" }, "us-gaap_RelatedPartyTransactionsAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Related Party Transactions [Abstract]" } } }, "localname": "RelatedPartyTransactionsAbstract", "nsuri": "http://fasb.org/us-gaap/2023", "xbrltype": "stringItemType" }, "us-gaap_RelatedPartyTransactionsByRelatedPartyAxis": { "auth_ref": [ "r350", "r410", "r411", "r451", "r452", "r453", "r454", "r455", "r456", "r457", "r458", "r459", "r460", "r461", "r462", "r523", "r524", "r525", "r526", "r527", "r549", "r551", "r583", "r718" ], "lang": { "en-us": { "role": { "documentation": "Information by type of related party. Related parties include, but not limited to, affiliates; other entities for which investments are accounted for by the equity method by the entity; trusts for benefit of employees; and principal owners, management, and members of immediate families. It also may include other parties with which the entity may control or can significantly influence the management or operating policies of the other to an extent that one of the transacting parties might be prevented from fully pursuing its own separate interests.", "label": "Related Party, Type [Axis]" } } }, "localname": "RelatedPartyTransactionsByRelatedPartyAxis", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://endonovo.com/role/BalanceSheets", "http://endonovo.com/role/NotesPayableDetailsNarrative", "http://endonovo.com/role/RelatedPartyAndFormerRelatedPartiesTransactionsDetailsNarrative", "http://endonovo.com/role/RevenueRecognitionDetailsNarrative", "http://endonovo.com/role/ScheduleOfMaturityDatesOfNotesPayableDetails", "http://endonovo.com/role/ScheduleOfNotesPayableDetails" ], "xbrltype": "stringItemType" }, "us-gaap_RelatedPartyTransactionsDisclosureTextBlock": { "auth_ref": [ "r407", "r408", "r409", "r411", "r414", "r497", "r498", "r499", "r558", "r559", "r560", "r579", "r581" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for related party transactions. Examples of related party transactions include transactions between (a) a parent company and its subsidiary; (b) subsidiaries of a common parent; (c) and entity and its principal owners; and (d) affiliates.", "label": "Related Party and former related parties Transactions" } } }, "localname": "RelatedPartyTransactionsDisclosureTextBlock", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://endonovo.com/role/RelatedPartyAndFormerRelatedPartiesTransactions" ], "xbrltype": "textBlockItemType" }, "us-gaap_RepaymentsOfConvertibleDebt": { "auth_ref": [ "r34" ], "calculation": { "http://endonovo.com/role/StatementsOfCashFlows": { "order": 3.0, "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The cash outflow from the repayment of a long-term debt instrument which can be exchanged for a specified amount of another security, typically the entity's common stock, at the option of the issuer or the holder.", "label": "Repayments of convertible debt in cash", "negatedLabel": "Repayments of convertible debt in cash" } } }, "localname": "RepaymentsOfConvertibleDebt", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://endonovo.com/role/NotesPayableDetailsNarrative", "http://endonovo.com/role/StatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_RepaymentsOfDebt": { "auth_ref": [ "r683" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of cash outflow for short-term and long-term debt. Excludes payment of lease obligation.", "label": "Principal payment of debt" } } }, "localname": "RepaymentsOfDebt", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://endonovo.com/role/NotesPayableDetailsNarrative" ], "xbrltype": "monetaryItemType" }, "us-gaap_RepaymentsOfNotesPayable": { "auth_ref": [ "r34" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The cash outflow for a borrowing supported by a written promise to pay an obligation.", "label": "Repayments of Notes Payable", "negatedLabel": "Repayments of notes payable in cash" } } }, "localname": "RepaymentsOfNotesPayable", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://endonovo.com/role/ScheduleOfNotesPayableDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_RepaymentsOfRelatedPartyDebt": { "auth_ref": [ "r34" ], "calculation": { "http://endonovo.com/role/StatementsOfCashFlows": { "order": 2.0, "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The cash outflow for the payment of a long-term borrowing made from a related party where one party can exercise control or significant influence over another party; including affiliates, owners or officers and their immediate families, pension trusts, and so forth. Alternate caption: Payments for Advances from Affiliates.", "label": "Repayment of debt", "negatedLabel": "Repayments on former related party of notes payable" } } }, "localname": "RepaymentsOfRelatedPartyDebt", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://endonovo.com/role/RelatedPartyAndFormerRelatedPartiesTransactionsDetailsNarrative", "http://endonovo.com/role/StatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_RetainedEarningsAccumulatedDeficit": { "auth_ref": [ "r94", "r119", "r471", "r488", "r489", "r496", "r531", "r632" ], "calculation": { "http://endonovo.com/role/BalanceSheets": { "order": 5.0, "parentTag": "us-gaap_StockholdersEquity", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of accumulated undistributed earnings (deficit).", "label": "Accumulated deficit", "negatedLabel": "Accumulated deficit" } } }, "localname": "RetainedEarningsAccumulatedDeficit", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://endonovo.com/role/BalanceSheets", "http://endonovo.com/role/SummaryOfSignificantAccountingPoliciesDetailsNarrative" ], "xbrltype": "monetaryItemType" }, "us-gaap_RetainedEarningsMember": { "auth_ref": [ "r143", "r178", "r179", "r180", "r182", "r188", "r190", "r259", "r260", "r366", "r367", "r368", "r371", "r372", "r379", "r381", "r382", "r384", "r387", "r485", "r487", "r500", "r735" ], "lang": { "en-us": { "role": { "documentation": "Accumulated undistributed earnings (deficit).", "label": "Retained Earnings [Member]" } } }, "localname": "RetainedEarningsMember", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://endonovo.com/role/StatementOfShareholdersDeficit" ], "xbrltype": "domainItemType" }, "us-gaap_RevenueFromContractWithCustomerAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Revenue from Contract with Customer [Abstract]" } } }, "localname": "RevenueFromContractWithCustomerAbstract", "nsuri": "http://fasb.org/us-gaap/2023", "xbrltype": "stringItemType" }, "us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax": { "auth_ref": [ "r208", "r209", "r212", "r215", "r216", "r220", "r221", "r222", "r339", "r340", "r449" ], "calculation": { "http://endonovo.com/role/StatementsOfOperations": { "order": 1.0, "parentTag": "us-gaap_GrossProfit", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount, excluding tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value added and excise.", "label": "Revenue", "verboseLabel": "Total sources of revenue" } } }, "localname": "RevenueFromContractWithCustomerExcludingAssessedTax", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://endonovo.com/role/ScheduleOfSourceOfRevenueDetails", "http://endonovo.com/role/StatementsOfOperations" ], "xbrltype": "monetaryItemType" }, "us-gaap_RevenueFromContractWithCustomerTextBlock": { "auth_ref": [ "r141", "r331", "r332", "r333", "r334", "r335", "r336", "r337", "r338", "r342" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure of revenue from contract with customer to transfer good or service and to transfer nonfinancial asset. Includes, but is not limited to, disaggregation of revenue, credit loss recognized from contract with customer, judgment and change in judgment related to contract with customer, and asset recognized from cost incurred to obtain or fulfill contract with customer. Excludes insurance and lease contracts.", "label": "Revenue Recognition" } } }, "localname": "RevenueFromContractWithCustomerTextBlock", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://endonovo.com/role/RevenueRecognition" ], "xbrltype": "textBlockItemType" }, "us-gaap_RisksAndUncertaintiesAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Risks and Uncertainties [Abstract]" } } }, "localname": "RisksAndUncertaintiesAbstract", "nsuri": "http://fasb.org/us-gaap/2023", "xbrltype": "stringItemType" }, "us-gaap_SaleOfStockNameOfTransactionDomain": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Sale of the entity's stock, including, but not limited to, initial public offering (IPO) and private placement." } } }, "localname": "SaleOfStockNameOfTransactionDomain", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://endonovo.com/role/NotesPayableDetailsNarrative", "http://endonovo.com/role/ShareholdersDeficitDetailsNarrative" ], "xbrltype": "domainItemType" }, "us-gaap_SalesRevenueNetMember": { "auth_ref": [ "r222", "r669" ], "lang": { "en-us": { "role": { "documentation": "Revenue from sale of product and rendering of service and other sources of income, when it serves as benchmark in concentration of risk calculation.", "label": "Revenue Benchmark [Member]" } } }, "localname": "SalesRevenueNetMember", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://endonovo.com/role/ConcentrationsDetailsNarrative" ], "xbrltype": "domainItemType" }, "us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable": { "auth_ref": [ "r374" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of information about collaborative arrangement and arrangement other than collaborative applicable to revenue-generating activity or operations.", "label": "Collaborative Arrangement and Arrangement Other than Collaborative [Table]" } } }, "localname": "ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://endonovo.com/role/SummaryOfSignificantAccountingPoliciesDetailsNarrative" ], "xbrltype": "stringItemType" }, "us-gaap_ScheduleOfDebtTableTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of information pertaining to short-term and long-debt instruments or arrangements, including but not limited to identification of terms, features, collateral requirements and other information necessary to a fair presentation.", "label": "Schedule of Notes Payable" } } }, "localname": "ScheduleOfDebtTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://endonovo.com/role/NotesPayableTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTable": { "auth_ref": [ "r7", "r62", "r63", "r64", "r65" ], "lang": { "en-us": { "role": { "documentation": "Disclosures about an individual defined benefit pension plan or an other postretirement defined benefit plan. It may be appropriate to group certain similar plans. Also includes schedule for fair value of plan assets by major categories of plan assets by the level within the fair value hierarchy in which the fair value measurements in their entirety fall, segregating fair value measurements using quoted prices in active markets for identical assets or liabilities (Level 1), Significant other observable inputs (Level 2), and significant unobservable inputs (Level 3).", "label": "Schedule of Defined Benefit Plans Disclosures [Table]" } } }, "localname": "ScheduleOfDefinedBenefitPlansDisclosuresTable", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://endonovo.com/role/ScheduleOfMaturityDatesOfNotesPayableDetails", "http://endonovo.com/role/ScheduleOfNotesPayableDetails" ], "xbrltype": "stringItemType" }, "us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock": { "auth_ref": [ "r694" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of an entity's basic and diluted earnings per share calculations, including a reconciliation of numerators and denominators of the basic and diluted per-share computations for income from continuing operations.", "label": "Schedule of Earnings Per Share Basic and Diluted" } } }, "localname": "ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://endonovo.com/role/SummaryOfSignificantAccountingPoliciesTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock": { "auth_ref": [ "r391", "r392" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of assets and liabilities, including [financial] instruments measured at fair value that are classified in stockholders' equity, if any, that are measured at fair value on a recurring basis. The disclosures contemplated herein include the fair value measurements at the reporting date by the level within the fair value hierarchy in which the fair value measurements in their entirety fall, segregating fair value measurements using quoted prices in active markets for identical assets (Level 1), significant other observable inputs (Level 2), and significant unobservable inputs (Level 3).", "label": "Schedule of Liabilities Significant Unobservable Inputs" } } }, "localname": "ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://endonovo.com/role/FairValueMeasurementsTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock": { "auth_ref": [ "r52", "r53" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of assets, excluding financial assets and goodwill, lacking physical substance with a finite life, by either major class or business segment.", "label": "Schedule of Patents" } } }, "localname": "ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://endonovo.com/role/PatentsTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfMaturitiesOfLongTermDebtTableTextBlock": { "auth_ref": [ "r6" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of maturity and sinking fund requirement for long-term debt.", "label": "Schedule of Maturity Dates of Notes Payable" } } }, "localname": "ScheduleOfMaturitiesOfLongTermDebtTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://endonovo.com/role/NotesPayableTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable": { "auth_ref": [ "r81", "r82", "r556", "r557", "r560" ], "lang": { "en-us": { "role": { "documentation": "Schedule of quantitative and qualitative information pertaining to related party transactions. Examples of related party transactions include transactions between (a) a parent company and its subsidiary; (b) subsidiaries of a common parent; (c) and entity and its principal owners; and (d) affiliates.", "label": "Schedule of Related Party Transactions, by Related Party [Table]" } } }, "localname": "ScheduleOfRelatedPartyTransactionsByRelatedPartyTable", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://endonovo.com/role/RelatedPartyAndFormerRelatedPartiesTransactionsDetailsNarrative" ], "xbrltype": "stringItemType" }, "us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock": { "auth_ref": [ "r16", "r17", "r69" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure for stock option plans. Includes, but is not limited to, outstanding awards at beginning and end of year, grants, exercises, forfeitures, and weighted-average grant date fair value.", "label": "Schedule of Stock Options Outstanding" } } }, "localname": "ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://endonovo.com/role/ShareholdersDeficitTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock": { "auth_ref": [ "r67" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of warrants or rights issued. Warrants and rights outstanding are derivative securities that give the holder the right to purchase securities (usually equity) from the issuer at a specific price within a certain time frame. Warrants are often included in a new debt issue to entice investors by a higher return potential. The main difference between warrants and call options is that warrants are issued and guaranteed by the company, whereas options are exchange instruments and are not issued by the company. Also, the lifetime of a warrant is often measured in years, while the lifetime of a typical option is measured in months. Disclose the title of issue of securities called for by warrants and rights outstanding, the aggregate amount of securities called for by warrants and rights outstanding, the date from which the warrants or rights are exercisable, and the price at which the warrant or right is exercisable.", "label": "Schedule of Warrants Outstanding" } } }, "localname": "ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://endonovo.com/role/ShareholdersDeficitTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_SeriesBPreferredStockMember": { "auth_ref": [ "r680", "r681", "r711" ], "lang": { "en-us": { "role": { "documentation": "Series B preferred stock.", "label": "Series B Preferred Stock [Member]" } } }, "localname": "SeriesBPreferredStockMember", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://endonovo.com/role/ShareholdersDeficitDetailsNarrative" ], "xbrltype": "domainItemType" }, "us-gaap_SeriesDPreferredStockMember": { "auth_ref": [ "r680", "r681", "r711" ], "lang": { "en-us": { "role": { "documentation": "Series D preferred stock.", "label": "Series D Preferred Stock [Member]" } } }, "localname": "SeriesDPreferredStockMember", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://endonovo.com/role/ShareholdersDeficitDetailsNarrative" ], "xbrltype": "domainItemType" }, "us-gaap_ShareBasedCompensation": { "auth_ref": [ "r4" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of noncash expense for share-based payment arrangement.", "label": "Share-based compensation expenses" } } }, "localname": "ShareBasedCompensation", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://endonovo.com/role/ShareholdersDeficitDetailsNarrative" ], "xbrltype": "monetaryItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1": { "auth_ref": [ "r631" ], "lang": { "en-us": { "role": { "documentation": "Period over which grantee's right to exercise award under share-based payment arrangement is no longer contingent on satisfaction of service or performance condition, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days. Includes, but is not limited to, combination of market, performance or service condition.", "label": "Remaining vesting period" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://endonovo.com/role/ShareholdersDeficitDetailsNarrative" ], "xbrltype": "durationItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate": { "auth_ref": [ "r362" ], "lang": { "en-us": { "role": { "documentation": "The estimated dividend rate (a percentage of the share price) to be paid (expected dividends) to holders of the underlying shares over the option's term.", "label": "Stated value dividend" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://endonovo.com/role/ShareholdersDeficitDetailsNarrative" ], "xbrltype": "percentItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised": { "auth_ref": [ "r14" ], "lang": { "en-us": { "role": { "documentation": "Number of non-option equity instruments exercised by participants.", "label": "Shares, Exercised" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://endonovo.com/role/ScheduleOfWarrantsOutstandingDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsForfeitures": { "auth_ref": [ "r15" ], "lang": { "en-us": { "role": { "documentation": "Number of shares under non-option equity instrument agreements that were cancelled as a result of occurrence of a terminating event.", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Non-Option Equity Instruments, Forfeitures", "negatedLabel": "Shares, Cancelled" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsForfeitures", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://endonovo.com/role/ScheduleOfWarrantsOutstandingDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted": { "auth_ref": [ "r13" ], "lang": { "en-us": { "role": { "documentation": "Net number of non-option equity instruments granted to participants.", "label": "Shares, Granted" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://endonovo.com/role/ScheduleOfWarrantsOutstandingDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber": { "auth_ref": [ "r11", "r12" ], "lang": { "en-us": { "role": { "documentation": "Number of equity instruments other than options outstanding, including both vested and non-vested instruments.", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Non-Option Equity Instruments, Outstanding, Number", "periodEndLabel": "Shares Outstanding, Ending Balance", "periodStartLabel": "Shares Outstanding, Beginning Balance" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://endonovo.com/role/ScheduleOfWarrantsOutstandingDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber": { "auth_ref": [ "r356" ], "lang": { "en-us": { "role": { "documentation": "The number of shares into which fully or partially vested stock options outstanding as of the balance sheet date can be currently converted under the option plan.", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Number", "periodEndLabel": "Stock Options Outstanding, Exercisable Ending Balance" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://endonovo.com/role/ScheduleOfStockOptionsOutstandingDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice": { "auth_ref": [ "r356" ], "lang": { "en-us": { "role": { "documentation": "The weighted-average price as of the balance sheet date at which grantees can acquire the shares reserved for issuance on vested portions of options outstanding and currently exercisable under the stock option plan.", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Weighted Average Exercise Price", "periodEndLabel": "Weighted Average Exercise Price Per Share, Exercisable Ending Balance" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://endonovo.com/role/ScheduleOfStockOptionsOutstandingDetails" ], "xbrltype": "perShareItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod": { "auth_ref": [ "r359" ], "lang": { "en-us": { "role": { "documentation": "The number of shares under options that were cancelled during the reporting period as a result of occurrence of a terminating event specified in contractual agreements pertaining to the stock option plan.", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Forfeitures in Period", "negatedLabel": "Stock Options Outstanding, Cancelled" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://endonovo.com/role/ScheduleOfStockOptionsOutstandingDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross": { "auth_ref": [ "r357" ], "lang": { "en-us": { "role": { "documentation": "Gross number of share options (or share units) granted during the period.", "label": "Stock Options Outstanding, Granted" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://endonovo.com/role/ScheduleOfStockOptionsOutstandingDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber": { "auth_ref": [ "r354", "r355" ], "lang": { "en-us": { "role": { "documentation": "Number of options outstanding, including both vested and non-vested options.", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Number", "periodEndLabel": "Stock Options Outstanding, Ending Balance", "periodStartLabel": "Stock Options Outstanding, Beginning Balance" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://endonovo.com/role/ScheduleOfStockOptionsOutstandingDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice": { "auth_ref": [ "r354", "r355" ], "lang": { "en-us": { "role": { "documentation": "Weighted average price at which grantees can acquire the shares reserved for issuance under the stock option plan.", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Weighted Average Exercise Price", "periodEndLabel": "Weighted Average Exercise Price Per Share, Ending Balance", "periodStartLabel": "Weighted Average Exercise Price Per Share, Beginning Balance" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://endonovo.com/role/ScheduleOfStockOptionsOutstandingDetails" ], "xbrltype": "perShareItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue": { "auth_ref": [ "r360" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount by which current fair value of underlying stock exceeds exercise price of fully vested and expected to vest options outstanding. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested and Expected to Vest, Outstanding, Aggregate Intrinsic Value", "periodEndLabel": "Aggregated Intrinsic Value, Ending", "periodStartLabel": "Aggregated Intrinsic Value, Outstanding Beginning Balance" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://endonovo.com/role/ScheduleOfStockOptionsOutstandingDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice": { "auth_ref": [ "r358" ], "lang": { "en-us": { "role": { "documentation": "Weighted average price at which option holders acquired shares when converting their stock options into shares.", "label": "Weighted Average Exercise Price Per Share, Exercised" } } }, "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://endonovo.com/role/ScheduleOfStockOptionsOutstandingDetails" ], "xbrltype": "perShareItemType" }, "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice": { "auth_ref": [ "r359" ], "lang": { "en-us": { "role": { "documentation": "Weighted average price at which grantees could have acquired the underlying shares with respect to stock options that were terminated.", "label": "Weighted Average Exercise Price Per Share, Cancelled" } } }, "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://endonovo.com/role/ScheduleOfStockOptionsOutstandingDetails" ], "xbrltype": "perShareItemType" }, "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice": { "auth_ref": [ "r357" ], "lang": { "en-us": { "role": { "documentation": "Weighted average per share amount at which grantees can acquire shares of common stock by exercise of options.", "label": "Weighted Average Exercise Price Per Share, Granted" } } }, "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://endonovo.com/role/ScheduleOfStockOptionsOutstandingDetails" ], "xbrltype": "perShareItemType" }, "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1": { "auth_ref": [ "r68" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of difference between fair value of the underlying shares reserved for issuance and exercise price of vested portions of options outstanding and currently exercisable.", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Intrinsic Value", "periodEndLabel": "Aggregated Intrinsic Value, Exercisable Ending" } } }, "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://endonovo.com/role/ScheduleOfStockOptionsOutstandingDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2": { "auth_ref": [ "r121" ], "lang": { "en-us": { "role": { "documentation": "Weighted average remaining contractual term for option awards outstanding, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.", "label": "Weighted Average Remaining Contractual Term (years), Ending" } } }, "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://endonovo.com/role/ScheduleOfStockOptionsOutstandingDetails" ], "xbrltype": "durationItemType" }, "us-gaap_SharesIssued": { "auth_ref": [ "r8" ], "lang": { "en-us": { "role": { "documentation": "Number of shares of stock issued as of the balance sheet date, including shares that had been issued and were previously outstanding but which are now held in the treasury.", "label": "Number of shares issued" } } }, "localname": "SharesIssued", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://endonovo.com/role/ShareholdersDeficitDetailsNarrative" ], "xbrltype": "sharesItemType" }, "us-gaap_SharesOutstanding": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Number of shares issued which are neither cancelled nor held in the treasury.", "label": "Shares, Outstanding", "periodEndLabel": "Balance, shares", "periodStartLabel": "Balance, shares" } } }, "localname": "SharesOutstanding", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://endonovo.com/role/StatementOfShareholdersDeficit" ], "xbrltype": "sharesItemType" }, "us-gaap_ShortTermDebtTypeAxis": { "auth_ref": [ "r21" ], "lang": { "en-us": { "role": { "documentation": "Information by type of short-term debt arrangement.", "label": "Short-Term Debt, Type [Axis]" } } }, "localname": "ShortTermDebtTypeAxis", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://endonovo.com/role/SubsequentEventsDetailsNarrative" ], "xbrltype": "stringItemType" }, "us-gaap_ShortTermDebtTypeDomain": { "auth_ref": [ "r20" ], "lang": { "en-us": { "role": { "documentation": "Type of short-term debt arrangement, such as notes, line of credit, commercial paper, asset-based financing, project financing, letter of credit financing." } } }, "localname": "ShortTermDebtTypeDomain", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://endonovo.com/role/SubsequentEventsDetailsNarrative" ], "xbrltype": "domainItemType" }, "us-gaap_SignificantAccountingPoliciesTextBlock": { "auth_ref": [ "r108", "r170" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for all significant accounting policies of the reporting entity.", "label": "Summary of significant accounting policies" } } }, "localname": "SignificantAccountingPoliciesTextBlock", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://endonovo.com/role/SummaryOfSignificantAccountingPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_StatementClassOfStockAxis": { "auth_ref": [ "r142", "r150", "r151", "r152", "r174", "r195", "r196", "r199", "r201", "r205", "r206", "r258", "r278", "r280", "r281", "r282", "r285", "r286", "r316", "r317", "r319", "r322", "r329", "r397", "r492", "r493", "r494", "r495", "r500", "r501", "r502", "r503", "r504", "r505", "r506", "r507", "r508", "r509", "r510", "r512", "r530", "r553", "r575", "r596", "r597", "r598", "r599", "r600", "r666", "r684", "r693" ], "lang": { "en-us": { "role": { "documentation": "Information by the different classes of stock of the entity.", "label": "Class of Stock [Axis]" } } }, "localname": "StatementClassOfStockAxis", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://endonovo.com/role/BalanceSheets", "http://endonovo.com/role/BalanceSheetsParenthetical", "http://endonovo.com/role/ShareholdersDeficitDetailsNarrative", "http://endonovo.com/role/StatementOfShareholdersDeficit" ], "xbrltype": "stringItemType" }, "us-gaap_StatementEquityComponentsAxis": { "auth_ref": [ "r8", "r31", "r143", "r160", "r161", "r162", "r178", "r179", "r180", "r182", "r188", "r190", "r204", "r259", "r260", "r330", "r366", "r367", "r368", "r371", "r372", "r379", "r380", "r381", "r382", "r383", "r384", "r387", "r398", "r399", "r400", "r401", "r402", "r403", "r406", "r485", "r486", "r487", "r500", "r575" ], "lang": { "en-us": { "role": { "documentation": "Information by component of equity.", "label": "Equity Components [Axis]" } } }, "localname": "StatementEquityComponentsAxis", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://endonovo.com/role/RelatedPartyAndFormerRelatedPartiesTransactionsDetailsNarrative", "http://endonovo.com/role/ScheduleOfPreferredStockDetails", "http://endonovo.com/role/ScheduleOfWarrantsOutstandingDetails", "http://endonovo.com/role/ShareholdersDeficitDetailsNarrative", "http://endonovo.com/role/StatementOfShareholdersDeficit" ], "xbrltype": "stringItemType" }, "us-gaap_StatementLineItems": { "auth_ref": [ "r178", "r179", "r180", "r204", "r449", "r491", "r512", "r522", "r523", "r524", "r525", "r526", "r527", "r530", "r533", "r534", "r535", "r536", "r537", "r540", "r541", "r542", "r543", "r545", "r546", "r547", "r548", "r549", "r551", "r554", "r555", "r561", "r562", "r563", "r564", "r565", "r566", "r567", "r568", "r569", "r570", "r571", "r572", "r575", "r638" ], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Statement [Line Items]" } } }, "localname": "StatementLineItems", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://endonovo.com/role/BalanceSheets", "http://endonovo.com/role/BalanceSheetsParenthetical", "http://endonovo.com/role/PatentsDetailsNarrative", "http://endonovo.com/role/StatementOfShareholdersDeficit" ], "xbrltype": "stringItemType" }, "us-gaap_StatementOfCashFlowsAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Statement of Cash Flows [Abstract]" } } }, "localname": "StatementOfCashFlowsAbstract", "nsuri": "http://fasb.org/us-gaap/2023", "xbrltype": "stringItemType" }, "us-gaap_StatementOfFinancialPositionAbstract": { "auth_ref": [], "localname": "StatementOfFinancialPositionAbstract", "nsuri": "http://fasb.org/us-gaap/2023", "xbrltype": "stringItemType" }, "us-gaap_StatementOfStockholdersEquityAbstract": { "auth_ref": [], "localname": "StatementOfStockholdersEquityAbstract", "nsuri": "http://fasb.org/us-gaap/2023", "xbrltype": "stringItemType" }, "us-gaap_StatementTable": { "auth_ref": [ "r178", "r179", "r180", "r204", "r449", "r491", "r512", "r522", "r523", "r524", "r525", "r526", "r527", "r530", "r533", "r534", "r535", "r536", "r537", "r540", "r541", "r542", "r543", "r545", "r546", "r547", "r548", "r549", "r551", "r554", "r555", "r561", "r562", "r563", "r564", "r565", "r566", "r567", "r568", "r569", "r570", "r571", "r572", "r575", "r638" ], "lang": { "en-us": { "role": { "documentation": "Schedule reflecting a Statement of Income, Statement of Cash Flows, Statement of Financial Position, Statement of Shareholders' Equity and Other Comprehensive Income, or other statement as needed.", "label": "Statement [Table]" } } }, "localname": "StatementTable", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://endonovo.com/role/BalanceSheets", "http://endonovo.com/role/BalanceSheetsParenthetical", "http://endonovo.com/role/PatentsDetailsNarrative", "http://endonovo.com/role/StatementOfShareholdersDeficit" ], "xbrltype": "stringItemType" }, "us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities": { "auth_ref": [ "r8", "r30", "r58", "r119", "r304" ], "lang": { "en-us": { "role": { "documentation": "Number of shares issued during the period as a result of the conversion of convertible securities.", "label": "Shares issued for conversion of Preferred Series D to common shares, shares" } } }, "localname": "StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://endonovo.com/role/StatementOfShareholdersDeficit" ], "xbrltype": "sharesItemType" }, "us-gaap_StockIssuedDuringPeriodSharesConversionOfUnits": { "auth_ref": [ "r8", "r58", "r91", "r92", "r119" ], "lang": { "en-us": { "role": { "documentation": "The number of shares issued during the period upon the conversion of units. An example of a convertible unit is an umbrella partnership real estate investment trust unit (UPREIT unit).", "label": "Common stock issued for settlement of debt, shares" } } }, "localname": "StockIssuedDuringPeriodSharesConversionOfUnits", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://endonovo.com/role/StatementOfShareholdersDeficit" ], "xbrltype": "sharesItemType" }, "us-gaap_StockIssuedDuringPeriodSharesIssuedForServices": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Number of shares issued in lieu of cash for services contributed to the entity. Number of shares includes, but is not limited to, shares issued for services contributed by vendors and founders.", "label": "Common Shares issued for services, shares", "verboseLabel": "Shares issued for common stock for services, shares" } } }, "localname": "StockIssuedDuringPeriodSharesIssuedForServices", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://endonovo.com/role/ShareholdersDeficitDetailsNarrative", "http://endonovo.com/role/StatementOfShareholdersDeficit" ], "xbrltype": "sharesItemType" }, "us-gaap_StockIssuedDuringPeriodSharesNewIssues": { "auth_ref": [ "r8", "r91", "r92", "r119", "r492", "r575", "r597" ], "lang": { "en-us": { "role": { "documentation": "Number of new stock issued during the period.", "label": "Common stock issued for cash, net of fees, shares", "terseLabel": "Number of shares issued", "verboseLabel": "Issuance of common stock" } } }, "localname": "StockIssuedDuringPeriodSharesNewIssues", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://endonovo.com/role/ShareholdersDeficitDetailsNarrative", "http://endonovo.com/role/StatementOfShareholdersDeficit", "http://endonovo.com/role/SubsequentEventsDetailsNarrative" ], "xbrltype": "sharesItemType" }, "us-gaap_StockIssuedDuringPeriodSharesOther": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Number of shares of stock issued attributable to transactions classified as other.", "label": "Shares issued pursuant to make good provision, shares", "verboseLabel": "Number of shares issued" } } }, "localname": "StockIssuedDuringPeriodSharesOther", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://endonovo.com/role/RelatedPartyAndFormerRelatedPartiesTransactionsDetailsNarrative", "http://endonovo.com/role/StatementOfShareholdersDeficit" ], "xbrltype": "sharesItemType" }, "us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised": { "auth_ref": [ "r8", "r91", "r92", "r119", "r358" ], "lang": { "en-us": { "role": { "documentation": "Number of share options (or share units) exercised during the current period.", "label": "Stock Options Outstanding, Exercised" } } }, "localname": "StockIssuedDuringPeriodSharesStockOptionsExercised", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://endonovo.com/role/ScheduleOfStockOptionsOutstandingDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities": { "auth_ref": [ "r8", "r31", "r119" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The gross value of stock issued during the period upon the conversion of convertible securities.", "label": "Shares issued for conversion of Preferred Series D to common shares" } } }, "localname": "StockIssuedDuringPeriodValueConversionOfConvertibleSecurities", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://endonovo.com/role/StatementOfShareholdersDeficit" ], "xbrltype": "monetaryItemType" }, "us-gaap_StockIssuedDuringPeriodValueConversionOfUnits": { "auth_ref": [ "r8", "r31", "r119" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Value of stock issued during the period upon the conversion of units. An example of a convertible unit is an umbrella partnership real estate investment trust unit (UPREIT unit).", "label": "Common stock issued for settlement of debt" } } }, "localname": "StockIssuedDuringPeriodValueConversionOfUnits", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://endonovo.com/role/StatementOfShareholdersDeficit" ], "xbrltype": "monetaryItemType" }, "us-gaap_StockIssuedDuringPeriodValueIssuedForServices": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Value of stock issued in lieu of cash for services contributed to the entity. Value of the stock issued includes, but is not limited to, services contributed by vendors and founders.", "label": "Common Shares issued for services", "verboseLabel": "Shares issued for common stock for services, value" } } }, "localname": "StockIssuedDuringPeriodValueIssuedForServices", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://endonovo.com/role/ShareholdersDeficitDetailsNarrative", "http://endonovo.com/role/StatementOfShareholdersDeficit" ], "xbrltype": "monetaryItemType" }, "us-gaap_StockIssuedDuringPeriodValueNewIssues": { "auth_ref": [ "r8", "r91", "r92", "r119", "r500", "r575", "r597", "r644" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Equity impact of the value of new stock issued during the period. Includes shares issued in an initial public offering or a secondary public offering.", "label": "Common stock issued for cash, net of fees", "verboseLabel": "Common stock new issuance, value" } } }, "localname": "StockIssuedDuringPeriodValueNewIssues", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://endonovo.com/role/ShareholdersDeficitDetailsNarrative", "http://endonovo.com/role/StatementOfShareholdersDeficit" ], "xbrltype": "monetaryItemType" }, "us-gaap_StockIssuedDuringPeriodValueOther": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Value of shares of stock issued attributable to transactions classified as other.", "label": "Shares issued pursuant to make good provision", "verboseLabel": "Number of shares issued, value" } } }, "localname": "StockIssuedDuringPeriodValueOther", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://endonovo.com/role/RelatedPartyAndFormerRelatedPartiesTransactionsDetailsNarrative", "http://endonovo.com/role/StatementOfShareholdersDeficit" ], "xbrltype": "monetaryItemType" }, "us-gaap_StockIssuedDuringPeriodValuePurchaseOfAssets": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Value of shares of stock issued during the period as part of a transaction to acquire assets that do not qualify as a business combination.", "label": "Purchase of assets and Liabilities" } } }, "localname": "StockIssuedDuringPeriodValuePurchaseOfAssets", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://endonovo.com/role/SummaryOfSignificantAccountingPoliciesDetailsNarrative" ], "xbrltype": "monetaryItemType" }, "us-gaap_StockholdersEquity": { "auth_ref": [ "r92", "r95", "r96", "r110", "r532", "r550", "r576", "r577", "r632", "r645", "r686", "r700", "r716", "r735" ], "calculation": { "http://endonovo.com/role/BalanceSheets": { "order": 3.0, "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of equity (deficit) attributable to parent. Excludes temporary equity and equity attributable to noncontrolling interest.", "label": "Equity, Attributable to Parent", "periodEndLabel": "Balance", "periodStartLabel": "Balance", "totalLabel": "Total shareholders\u2019 deficit" } } }, "localname": "StockholdersEquity", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://endonovo.com/role/BalanceSheets", "http://endonovo.com/role/StatementOfShareholdersDeficit" ], "xbrltype": "monetaryItemType" }, "us-gaap_StockholdersEquityAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Shareholders\u2019 deficit" } } }, "localname": "StockholdersEquityAbstract", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://endonovo.com/role/BalanceSheets" ], "xbrltype": "stringItemType" }, "us-gaap_StockholdersEquityNoteDisclosureTextBlock": { "auth_ref": [ "r116", "r173", "r315", "r317", "r318", "r319", "r320", "r321", "r322", "r323", "r324", "r325", "r326", "r328", "r330", "r386", "r578", "r580", "r601" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for equity.", "label": "Shareholders\u2019 Deficit" } } }, "localname": "StockholdersEquityNoteDisclosureTextBlock", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://endonovo.com/role/ShareholdersDeficit" ], "xbrltype": "textBlockItemType" }, "us-gaap_StockholdersEquityNoteSubscriptionsReceivable": { "auth_ref": [ "r57", "r91", "r92", "r95", "r582" ], "calculation": { "http://endonovo.com/role/BalanceSheets": { "order": 4.0, "parentTag": "us-gaap_StockholdersEquity", "weight": -1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Note received instead of cash as contribution to equity. The transaction may be a sale of capital stock or a contribution to paid-in capital.", "label": "Stockholders' Equity Note, Subscriptions Receivable", "negatedLabel": "Stock subscriptions receivable" } } }, "localname": "StockholdersEquityNoteSubscriptionsReceivable", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://endonovo.com/role/BalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_SubsequentEventLineItems": { "auth_ref": [ "r404", "r416" ], "lang": { "en-us": { "role": { "documentation": "Detail information of subsequent event by type. User is expected to use existing line items from elsewhere in the taxonomy as the primary line items for this disclosure, which is further associated with dimension and member elements pertaining to a subsequent event.", "label": "Subsequent Event [Line Items]" } } }, "localname": "SubsequentEventLineItems", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://endonovo.com/role/SubsequentEventsDetailsNarrative" ], "xbrltype": "stringItemType" }, "us-gaap_SubsequentEventMember": { "auth_ref": [ "r404", "r416" ], "lang": { "en-us": { "role": { "documentation": "Identifies event that occurred after the balance sheet date but before financial statements are issued or available to be issued.", "label": "Subsequent Event [Member]" } } }, "localname": "SubsequentEventMember", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://endonovo.com/role/SubsequentEventsDetailsNarrative" ], "xbrltype": "domainItemType" }, "us-gaap_SubsequentEventTable": { "auth_ref": [ "r404", "r416" ], "lang": { "en-us": { "role": { "documentation": "Discloses pertinent information about one or more significant events or transactions that occurred after the balance sheet date through the date the financial statements were issued or the date the financial statements were available to be issued.", "label": "Subsequent Event [Table]" } } }, "localname": "SubsequentEventTable", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://endonovo.com/role/SubsequentEventsDetailsNarrative" ], "xbrltype": "stringItemType" }, "us-gaap_SubsequentEventTypeAxis": { "auth_ref": [ "r404", "r416" ], "lang": { "en-us": { "role": { "documentation": "Information by event that occurred after the balance sheet date but before financial statements are issued or available to be issued.", "label": "Subsequent Event Type [Axis]" } } }, "localname": "SubsequentEventTypeAxis", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://endonovo.com/role/SubsequentEventsDetailsNarrative" ], "xbrltype": "stringItemType" }, "us-gaap_SubsequentEventTypeDomain": { "auth_ref": [ "r404", "r416" ], "lang": { "en-us": { "role": { "documentation": "Event that occurred after the balance sheet date but before financial statements are issued or available to be issued." } } }, "localname": "SubsequentEventTypeDomain", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://endonovo.com/role/SubsequentEventsDetailsNarrative" ], "xbrltype": "domainItemType" }, "us-gaap_SubsequentEventsAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Subsequent Events [Abstract]" } } }, "localname": "SubsequentEventsAbstract", "nsuri": "http://fasb.org/us-gaap/2023", "xbrltype": "stringItemType" }, "us-gaap_SubsequentEventsTextBlock": { "auth_ref": [ "r415", "r417" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for significant events or transactions that occurred after the balance sheet date through the date the financial statements were issued or the date the financial statements were available to be issued. Examples include: the sale of a capital stock issue, purchase of a business, settlement of litigation, catastrophic loss, significant foreign exchange rate changes, loans to insiders or affiliates, and transactions not in the ordinary course of business.", "label": "Subsequent Events" } } }, "localname": "SubsequentEventsTextBlock", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://endonovo.com/role/SubsequentEvents" ], "xbrltype": "textBlockItemType" }, "us-gaap_SubsidiarySaleOfStockAxis": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Information by type of sale of the entity's stock.", "label": "Sale of Stock [Axis]" } } }, "localname": "SubsidiarySaleOfStockAxis", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://endonovo.com/role/NotesPayableDetailsNarrative", "http://endonovo.com/role/ShareholdersDeficitDetailsNarrative" ], "xbrltype": "stringItemType" }, "us-gaap_SupplementalCashFlowInformationAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Supplemental disclosure of cash flow information:" } } }, "localname": "SupplementalCashFlowInformationAbstract", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://endonovo.com/role/StatementsOfCashFlows" ], "xbrltype": "stringItemType" }, "us-gaap_SupplierConcentrationRiskMember": { "auth_ref": [ "r45" ], "lang": { "en-us": { "role": { "documentation": "Reflects the percentage that purchases in the period from one or more significant suppliers is to cost of goods or services, as defined by the entity, such as total cost of sales or services, product line cost of sales or services, segment cost of sales or services. Risk is the materially adverse effects of loss of a material supplier or a supplier of critically needed goods or services.", "label": "Supplier Concentration Risk [Member]" } } }, "localname": "SupplierConcentrationRiskMember", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://endonovo.com/role/ConcentrationsDetailsNarrative" ], "xbrltype": "domainItemType" }, "us-gaap_TradeAndOtherAccountsReceivablePolicy": { "auth_ref": [ "r131", "r132", "r133", "r224", "r225", "r227" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy for accounts receivable.", "label": "Accounts Receivable" } } }, "localname": "TradeAndOtherAccountsReceivablePolicy", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://endonovo.com/role/SummaryOfSignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain": { "auth_ref": [ "r228", "r229", "r230", "r231", "r232", "r233", "r234", "r235", "r236", "r237", "r238", "r239", "r240", "r241", "r242", "r243", "r244", "r245", "r246", "r247", "r248", "r249", "r250", "r251", "r252", "r253", "r254", "r255", "r256", "r257", "r312", "r327", "r385", "r418", "r419", "r420", "r421", "r422", "r423", "r424", "r425", "r426", "r427", "r428", "r429", "r430", "r431", "r432", "r433", "r434", "r435", "r436", "r437", "r438", "r439", "r440", "r441", "r442", "r443", "r444", "r445", "r446", "r447", "r475", "r672", "r673", "r674", "r675", "r676", "r677", "r678", "r696", "r697", "r698", "r699" ], "lang": { "en-us": { "role": { "documentation": "Instrument or contract that imposes a contractual obligation to deliver cash or another financial instrument or to exchange other financial instruments on potentially unfavorable terms and conveys a contractual right to receive cash or another financial instrument or to exchange other financial instruments on potentially favorable terms." } } }, "localname": "TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://endonovo.com/role/ScheduleOfStockOptionsOutstandingDetails" ], "xbrltype": "domainItemType" }, "us-gaap_TypeOfArrangementAxis": { "auth_ref": [ "r374" ], "lang": { "en-us": { "role": { "documentation": "Information by collaborative arrangement and arrangement other than collaborative applicable to revenue-generating activity or operations.", "label": "Collaborative Arrangement and Arrangement Other than Collaborative [Axis]" } } }, "localname": "TypeOfArrangementAxis", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://endonovo.com/role/RevenueRecognitionDetailsNarrative", "http://endonovo.com/role/ShareholdersDeficitDetailsNarrative", "http://endonovo.com/role/SubsequentEventsDetailsNarrative", "http://endonovo.com/role/SummaryOfSignificantAccountingPoliciesDetailsNarrative" ], "xbrltype": "stringItemType" }, "us-gaap_UseOfEstimates": { "auth_ref": [ "r48", "r49", "r50", "r136", "r137", "r138", "r139" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy for the use of estimates in the preparation of financial statements in conformity with generally accepted accounting principles.", "label": "Use of Estimates" } } }, "localname": "UseOfEstimates", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://endonovo.com/role/SummaryOfSignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_WarrantMember": { "auth_ref": [ "r635", "r636", "r639", "r640", "r641", "r642" ], "lang": { "en-us": { "role": { "documentation": "Security that gives the holder the right to purchase shares of stock in accordance with the terms of the instrument, usually upon payment of a specified amount.", "label": "Warrant [Member]" } } }, "localname": "WarrantMember", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://endonovo.com/role/ScheduleOfWarrantsOutstandingDetails", "http://endonovo.com/role/SummaryOfSignificantAccountingPoliciesDetailsNarrative" ], "xbrltype": "domainItemType" }, "us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding": { "auth_ref": [ "r194", "r201" ], "lang": { "en-us": { "role": { "documentation": "The average number of shares or units issued and outstanding that are used in calculating diluted EPS or earnings per unit (EPU), determined based on the timing of issuance of shares or units in the period.", "label": "Diluted" } } }, "localname": "WeightedAverageNumberOfDilutedSharesOutstanding", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://endonovo.com/role/StatementsOfOperations" ], "xbrltype": "sharesItemType" }, "us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Weighted average common share outstanding:" } } }, "localname": "WeightedAverageNumberOfSharesOutstandingAbstract", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://endonovo.com/role/StatementsOfOperations" ], "xbrltype": "stringItemType" }, "us-gaap_WeightedAverageNumberOfSharesOutstandingBasic": { "auth_ref": [ "r192", "r201" ], "lang": { "en-us": { "role": { "documentation": "Number of [basic] shares or units, after adjustment for contingently issuable shares or units and other shares or units not deemed outstanding, determined by relating the portion of time within a reporting period that common shares or units have been outstanding to the total time in that period.", "label": "Basic" } } }, "localname": "WeightedAverageNumberOfSharesOutstandingBasic", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://endonovo.com/role/StatementsOfOperations" ], "xbrltype": "sharesItemType" } }, "unitCount": 5 } }, "std_ref": { "r0": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "25", "SubTopic": "20", "Topic": "940", "URI": "https://asc.fasb.org//1943274/2147481913/940-20-25-1", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r1": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "35", "SubTopic": "30", "Subparagraph": "b", "Topic": "805", "URI": "https://asc.fasb.org//1943274/2147479613/805-30-35-1", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r10": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "820", "URI": "https://asc.fasb.org//1943274/2147482106/820-10-50-2", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r100": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03.1,2)", "Topic": "220", "URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-2", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r101": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03.2)", "Topic": "220", "URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-2", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r102": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03.7)", "Topic": "220", "URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-2", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r103": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03.9)", "Topic": "220", "URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-2", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r104": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "230", "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-13", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r105": { "Name": "Accounting Standards Codification", "Paragraph": "24", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "230", "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-24", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r106": { "Name": "Accounting Standards Codification", "Paragraph": "25", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "230", "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-25", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r107": { "Name": "Accounting Standards Codification", "Paragraph": "28", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "230", "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-28", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r108": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "235", "URI": "https://asc.fasb.org//235/tableOfContent", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r109": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "275", "URI": "https://asc.fasb.org//275/tableOfContent", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r11": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1)(i)", "Topic": "718", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r110": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB Topic 4.E)", "Topic": "310", "URI": "https://asc.fasb.org//1943274/2147480418/310-10-S99-2", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r111": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Subparagraph": "(a)(1)", "Topic": "350", "URI": "https://asc.fasb.org//1943274/2147482665/350-30-50-2", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r112": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Subparagraph": "(a)(3)", "Topic": "350", "URI": "https://asc.fasb.org//1943274/2147482665/350-30-50-2", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r113": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "440", "URI": "https://asc.fasb.org//440/tableOfContent", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r114": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "470", "URI": "https://asc.fasb.org//470/tableOfContent", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r115": { "Name": "Accounting Standards Codification", "Paragraph": "10", "Publisher": "FASB", "Section": "25", "SubTopic": "20", "Topic": "470", "URI": "https://asc.fasb.org//1943274/2147481284/470-20-25-10", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r116": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "505", "URI": "https://asc.fasb.org//505/tableOfContent", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r117": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "505", "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-6", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r118": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "505", "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-7", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r119": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.3-04)", "Topic": "505", "URI": "https://asc.fasb.org//1943274/2147480008/505-10-S99-1", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r12": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1)(ii)", "Topic": "718", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r120": { "Name": "Accounting Standards Codification", "Paragraph": "9", "Publisher": "FASB", "Section": "25", "SubTopic": "10", "Topic": "710", "URI": "https://asc.fasb.org//1943274/2147483070/710-10-25-9", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r121": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(e)(1)", "Topic": "718", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r122": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "810", "URI": "https://asc.fasb.org//810/tableOfContent", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r123": { "Name": "Accounting Standards Codification", "Paragraph": "21", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "825", "URI": "https://asc.fasb.org//1943274/2147482907/825-10-50-21", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r124": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.9-03(11))", "Topic": "942", "URI": "https://asc.fasb.org//1943274/2147479853/942-210-S99-1", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r125": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.9-03(13))", "Topic": "942", "URI": "https://asc.fasb.org//1943274/2147479853/942-210-S99-1", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r126": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.9-03(16))", "Topic": "942", "URI": "https://asc.fasb.org//1943274/2147479853/942-210-S99-1", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r127": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.9-03(23))", "Topic": "942", "URI": "https://asc.fasb.org//1943274/2147479853/942-210-S99-1", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r128": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.9-04(15))", "Topic": "942", "URI": "https://asc.fasb.org//1943274/2147483589/942-220-S99-1", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r129": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.9-04(22))", "Topic": "942", "URI": "https://asc.fasb.org//1943274/2147483589/942-220-S99-1", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r13": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1)(iv)(1)", "Topic": "718", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r130": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.9-04.10)", "Topic": "942", "URI": "https://asc.fasb.org//1943274/2147483589/942-220-S99-1", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r131": { "Name": "Accounting Standards Codification", "Paragraph": "11B", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "310", "URI": "https://asc.fasb.org//1943274/2147481962/310-10-50-11B", "role": "http://fasb.org/us-gaap/role/ref/otherTransitionRef" }, "r132": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "310", "URI": "https://asc.fasb.org//1943274/2147481962/310-10-50-15", "role": "http://fasb.org/us-gaap/role/ref/otherTransitionRef" }, "r133": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "310", "URI": "https://asc.fasb.org//1943274/2147481962/310-10-50-6", "role": "http://fasb.org/us-gaap/role/ref/otherTransitionRef" }, "r134": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "45", "SubTopic": "20", "Subparagraph": "(a)", "Topic": "740", "URI": "https://asc.fasb.org//1943274/2147482659/740-20-45-2", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r135": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "45", "SubTopic": "210", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147480555/946-210-45-20", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r136": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "275", "URI": "https://asc.fasb.org//1943274/2147482861/275-10-50-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r137": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "275", "URI": "https://asc.fasb.org//1943274/2147482861/275-10-50-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r138": { "Name": "Accounting Standards Codification", "Paragraph": "11", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "275", "URI": "https://asc.fasb.org//1943274/2147482861/275-10-50-11", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r139": { "Name": "Accounting Standards Codification", "Paragraph": "12", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "275", "URI": "https://asc.fasb.org//1943274/2147482861/275-10-50-12", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r14": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1)(iv)(2)", "Topic": "718", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r140": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.4-08(h))", "Topic": "235", "URI": "https://asc.fasb.org//1943274/2147480678/235-10-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r141": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "606", "URI": "https://asc.fasb.org//606/tableOfContent", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r142": { "Name": "Regulation S-K (SK)", "Number": "229", "Paragraph": "(a)", "Publisher": "SEC", "Section": "1402", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r143": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "105", "URI": "https://asc.fasb.org//1943274/2147479343/105-10-65-6", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r144": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "205", "URI": "https://asc.fasb.org//1943274/2147483499/205-20-50-7", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r145": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "210", "URI": "https://asc.fasb.org//1943274/2147483467/210-10-45-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r146": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "210", "URI": "https://asc.fasb.org//1943274/2147483467/210-10-45-5", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r147": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(1))", "Topic": "210", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r148": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(16))", "Topic": "210", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r149": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(18))", "Topic": "210", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r15": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1)(iv)(3)", "Topic": "718", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r150": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(27)(b))", "Topic": "210", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r151": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(28))", "Topic": "210", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r152": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(29))", "Topic": "210", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r153": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(3)(a)(4))", "Topic": "210", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r154": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(4))", "Topic": "210", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r155": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(9))", "Topic": "210", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r156": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(c)", "Topic": "210", "URI": "https://asc.fasb.org//1943274/2147483466/210-20-50-3", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r157": { "Name": "Accounting Standards Codification", "Paragraph": "10", "Publisher": "FASB", "Section": "55", "SubTopic": "20", "Topic": "210", "URI": "https://asc.fasb.org//1943274/2147483444/210-20-55-10", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r158": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "220", "URI": "https://asc.fasb.org//1943274/2147482790/220-10-45-1A", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r159": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "220", "URI": "https://asc.fasb.org//1943274/2147482790/220-10-45-1B", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r16": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "718", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r160": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "220", "URI": "https://asc.fasb.org//1943274/2147482765/220-10-50-4", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r161": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "220", "URI": "https://asc.fasb.org//1943274/2147482765/220-10-50-5", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r162": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "220", "URI": "https://asc.fasb.org//1943274/2147482765/220-10-50-6", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r163": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03(25))", "Topic": "220", "URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-2", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r164": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB Topic 6.B)", "Topic": "220", "URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-5", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r165": { "Name": "Accounting Standards Codification", "Paragraph": "17", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "230", "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-17", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r166": { "Name": "Accounting Standards Codification", "Paragraph": "24", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "230", "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-24", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r167": { "Name": "Accounting Standards Codification", "Paragraph": "25", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(e)", "Topic": "230", "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-25", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r168": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "230", "URI": "https://asc.fasb.org//1943274/2147482913/230-10-50-2", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r169": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "230", "URI": "https://asc.fasb.org//1943274/2147482913/230-10-50-8", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r17": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(e)", "Topic": "718", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r170": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "235", "URI": "https://asc.fasb.org//1943274/2147483426/235-10-50-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r171": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.4-08(c))", "Topic": "235", "URI": "https://asc.fasb.org//1943274/2147480678/235-10-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r172": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.4-08(d))", "Topic": "235", "URI": "https://asc.fasb.org//1943274/2147480678/235-10-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r173": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.4-08(e)(1))", "Topic": "235", "URI": "https://asc.fasb.org//1943274/2147480678/235-10-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r174": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.4-08(g)(1)(ii))", "Topic": "235", "URI": "https://asc.fasb.org//1943274/2147480678/235-10-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r175": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.4-08(k)(1))", "Topic": "235", "URI": "https://asc.fasb.org//1943274/2147480678/235-10-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r176": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.4-08(k)(2))", "Topic": "235", "URI": "https://asc.fasb.org//1943274/2147480678/235-10-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r177": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.12-04(a))", "Topic": "235", "URI": "https://asc.fasb.org//1943274/2147480678/235-10-S99-3", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r178": { "Name": "Accounting Standards Codification", "Paragraph": "23", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "250", "URI": "https://asc.fasb.org//1943274/2147483421/250-10-45-23", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r179": { "Name": "Accounting Standards Codification", "Paragraph": "24", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "250", "URI": "https://asc.fasb.org//1943274/2147483421/250-10-45-24", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r18": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "820", "URI": "https://asc.fasb.org//1943274/2147482106/820-10-50-3", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r180": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "250", "URI": "https://asc.fasb.org//1943274/2147483421/250-10-45-5", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r181": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)(2)", "Topic": "250", "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r182": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)(3)", "Topic": "250", "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r183": { "Name": "Accounting Standards Codification", "Paragraph": "11", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "250", "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-11", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r184": { "Name": "Accounting Standards Codification", "Paragraph": "11", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "250", "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-11", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r185": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "250", "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-3", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r186": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "250", "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-4", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r187": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "250", "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-7", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r188": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "250", "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-7", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r189": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "250", "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-8", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r19": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(22))", "Topic": "210", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r190": { "Name": "Accounting Standards Codification", "Paragraph": "9", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "250", "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-9", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r191": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB Topic 11.M.Q2)", "Topic": "250", "URI": "https://asc.fasb.org//1943274/2147480530/250-10-S99-5", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r192": { "Name": "Accounting Standards Codification", "Paragraph": "10", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "260", "URI": "https://asc.fasb.org//1943274/2147482689/260-10-45-10", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r193": { "Name": "Accounting Standards Codification", "Paragraph": "11", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "260", "URI": "https://asc.fasb.org//1943274/2147482689/260-10-45-11", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r194": { "Name": "Accounting Standards Codification", "Paragraph": "16", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "260", "URI": "https://asc.fasb.org//1943274/2147482689/260-10-45-16", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r195": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "260", "URI": "https://asc.fasb.org//1943274/2147482689/260-10-45-2", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r196": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "260", "URI": "https://asc.fasb.org//1943274/2147482689/260-10-45-3", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r197": { "Name": "Accounting Standards Codification", "Paragraph": "60B", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "260", "URI": "https://asc.fasb.org//1943274/2147482689/260-10-45-60B", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r198": { "Name": "Accounting Standards Codification", "Paragraph": "60B", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "260", "URI": "https://asc.fasb.org//1943274/2147482689/260-10-45-60B", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r199": { "Name": "Accounting Standards Codification", "Paragraph": "60B", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "260", "URI": "https://asc.fasb.org//1943274/2147482689/260-10-45-60B", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r2": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "230", "Topic": "830", "URI": "https://asc.fasb.org//1943274/2147481877/830-230-45-1", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r20": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.19(a))", "Topic": "210", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r200": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "260", "URI": "https://asc.fasb.org//1943274/2147482689/260-10-45-7", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r201": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "260", "URI": "https://asc.fasb.org//1943274/2147482662/260-10-50-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r202": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "260", "URI": "https://asc.fasb.org//1943274/2147482662/260-10-50-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r203": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "55", "SubTopic": "10", "Topic": "260", "URI": "https://asc.fasb.org//1943274/2147482635/260-10-55-15", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r204": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "272", "URI": "https://asc.fasb.org//1943274/2147483014/272-10-45-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r205": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "272", "URI": "https://asc.fasb.org//1943274/2147482987/272-10-50-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r206": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "272", "URI": "https://asc.fasb.org//1943274/2147482987/272-10-50-3", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r207": { "Name": "Accounting Standards Codification", "Paragraph": "22", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "280", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-22", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r208": { "Name": "Accounting Standards Codification", "Paragraph": "22", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "280", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-22", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r209": { "Name": "Accounting Standards Codification", "Paragraph": "22", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "280", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-22", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r21": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.19)", "Topic": "210", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r210": { "Name": "Accounting Standards Codification", "Paragraph": "22", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(e)", "Topic": "280", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-22", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r211": { "Name": "Accounting Standards Codification", "Paragraph": "22", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(h)", "Topic": "280", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-22", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r212": { "Name": "Accounting Standards Codification", "Paragraph": "30", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "280", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-30", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r213": { "Name": "Accounting Standards Codification", "Paragraph": "30", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "280", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-30", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r214": { "Name": "Accounting Standards Codification", "Paragraph": "30", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "280", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-30", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r215": { "Name": "Accounting Standards Codification", "Paragraph": "32", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "280", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-32", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r216": { "Name": "Accounting Standards Codification", "Paragraph": "32", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "280", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-32", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r217": { "Name": "Accounting Standards Codification", "Paragraph": "32", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "280", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-32", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r218": { "Name": "Accounting Standards Codification", "Paragraph": "32", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "280", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-32", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r219": { "Name": "Accounting Standards Codification", "Paragraph": "32", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(f)", "Topic": "280", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-32", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r22": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.19,20)", "Topic": "210", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r220": { "Name": "Accounting Standards Codification", "Paragraph": "40", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "280", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-40", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r221": { "Name": "Accounting Standards Codification", "Paragraph": "41", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "280", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-41", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r222": { "Name": "Accounting Standards Codification", "Paragraph": "42", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "280", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-42", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r223": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "310", "URI": "https://asc.fasb.org//1943274/2147481990/310-10-45-13", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r224": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "310", "URI": "https://asc.fasb.org//1943274/2147481962/310-10-50-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r225": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "310", "URI": "https://asc.fasb.org//1943274/2147481962/310-10-50-2", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r226": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "310", "URI": "https://asc.fasb.org//1943274/2147481962/310-10-50-4", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r227": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "310", "URI": "https://asc.fasb.org//1943274/2147481569/310-20-50-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r228": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "320", "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-2", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r229": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "320", "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-2", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r23": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.19-26)", "Topic": "210", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r230": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(aa)", "Topic": "320", "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-2", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r231": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(aaa)", "Topic": "320", "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-2", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r232": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "320", "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-2", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r233": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "320", "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-2", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r234": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "320", "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-2", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r235": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "320", "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-3", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r236": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "320", "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-3", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r237": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "320", "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-3", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r238": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "320", "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-3", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r239": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "320", "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-3", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r24": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.20)", "Topic": "210", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r240": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "320", "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-5", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r241": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "320", "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-5", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r242": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(aaa)", "Topic": "320", "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-5", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r243": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "320", "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-5", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r244": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(e)", "Topic": "320", "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-5", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r245": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(f)", "Topic": "320", "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-5", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r246": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(f)(1)", "Topic": "320", "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-5", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r247": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(f)(2)", "Topic": "320", "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-5", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r248": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(f)(3)", "Topic": "320", "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-5", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r249": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(f)(4)", "Topic": "320", "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-5", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r25": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.21)", "Topic": "210", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r250": { "Name": "Accounting Standards Codification", "Paragraph": "5A", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "320", "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-5A", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r251": { "Name": "Accounting Standards Codification", "Paragraph": "5A", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "320", "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-5A", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r252": { "Name": "Accounting Standards Codification", "Paragraph": "5A", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "320", "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-5A", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r253": { "Name": "Accounting Standards Codification", "Paragraph": "5B", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "320", "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-5B", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r254": { "Name": "Accounting Standards Codification", "Paragraph": "5B", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "320", "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-5B", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r255": { "Name": "Accounting Standards Codification", "Paragraph": "5B", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "320", "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-5B", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r256": { "Name": "Accounting Standards Codification", "Paragraph": "5B", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "320", "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-5B", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r257": { "Name": "Accounting Standards Codification", "Paragraph": "5B", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "320", "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-5B", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r258": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "323", "URI": "https://asc.fasb.org//1943274/2147481687/323-10-50-3", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r259": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "326", "URI": "https://asc.fasb.org//1943274/2147479654/326-10-65-4", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r26": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.22(a)(1))", "Topic": "210", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r260": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(c)(2)", "Topic": "326", "URI": "https://asc.fasb.org//1943274/2147479654/326-10-65-5", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r261": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "20", "Topic": "326", "URI": "https://asc.fasb.org//1943274/2147479344/326-20-45-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r262": { "Name": "Accounting Standards Codification", "Paragraph": "11", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "326", "URI": "https://asc.fasb.org//1943274/2147479319/326-20-50-11", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r263": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "326", "URI": "https://asc.fasb.org//1943274/2147479319/326-20-50-13", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r264": { "Name": "Accounting Standards Codification", "Paragraph": "14", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "326", "URI": "https://asc.fasb.org//1943274/2147479319/326-20-50-14", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r265": { "Name": "Accounting Standards Codification", "Paragraph": "16", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "326", "URI": "https://asc.fasb.org//1943274/2147479319/326-20-50-16", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r266": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "326", "URI": "https://asc.fasb.org//1943274/2147479319/326-20-50-5", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r267": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Topic": "326", "URI": "https://asc.fasb.org//1943274/2147479106/326-30-50-4", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r268": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Topic": "326", "URI": "https://asc.fasb.org//1943274/2147479106/326-30-50-7", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r269": { "Name": "Accounting Standards Codification", "Paragraph": "9", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Topic": "326", "URI": "https://asc.fasb.org//1943274/2147479106/326-30-50-9", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r27": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.22(a)(2))", "Topic": "210", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r270": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "SubTopic": "30", "Topic": "350", "URI": "https://asc.fasb.org//350-30/tableOfContent", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r271": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Subparagraph": "(a)(1)", "Topic": "350", "URI": "https://asc.fasb.org//1943274/2147482665/350-30-50-2", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r272": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "440", "URI": "https://asc.fasb.org//1943274/2147482648/440-10-50-4", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r273": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "440", "URI": "https://asc.fasb.org//1943274/2147482648/440-10-50-4", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r274": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)", "Topic": "450", "URI": "https://asc.fasb.org//1943274/2147483076/450-20-50-4", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r275": { "Name": "Accounting Standards Codification", "Paragraph": "9", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)", "Topic": "450", "URI": "https://asc.fasb.org//1943274/2147483076/450-20-50-9", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r276": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "20", "Subparagraph": "(SAB Topic 5.Y.Q2)", "Topic": "450", "URI": "https://asc.fasb.org//1943274/2147480102/450-20-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r277": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "20", "Subparagraph": "(SAB Topic 5.Y.Q4)", "Topic": "450", "URI": "https://asc.fasb.org//1943274/2147480102/450-20-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r278": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-01(a)(4)(i))", "Topic": "470", "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1A", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r279": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-01(a)(4)(iii)(A))", "Topic": "470", "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1A", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r28": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.22)", "Topic": "210", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r280": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-01(a)(4)(iv))", "Topic": "470", "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1A", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r281": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-01(a)(5))", "Topic": "470", "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1A", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r282": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-02(a)(4)(i))", "Topic": "470", "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1B", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r283": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-02(a)(4)(iii)(A))", "Topic": "470", "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1B", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r284": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-02(a)(4)(iii)(B))", "Topic": "470", "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1B", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r285": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-02(a)(4)(iv))", "Topic": "470", "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1B", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r286": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-02(a)(5))", "Topic": "470", "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1B", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r287": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "470", "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1B", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r288": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(a)", "Topic": "470", "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1B", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r289": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)", "Topic": "470", "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1B", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r29": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.25)", "Topic": "210", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r290": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(c)", "Topic": "470", "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1B", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r291": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(e)", "Topic": "470", "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1B", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r292": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(f)", "Topic": "470", "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1B", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r293": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(g)", "Topic": "470", "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1B", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r294": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(h)", "Topic": "470", "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1B", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r295": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(i)", "Topic": "470", "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1B", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r296": { "Name": "Accounting Standards Codification", "Paragraph": "1C", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(a)", "Topic": "470", "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1C", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r297": { "Name": "Accounting Standards Codification", "Paragraph": "1C", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)", "Topic": "470", "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1C", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r298": { "Name": "Accounting Standards Codification", "Paragraph": "1C", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(c)", "Topic": "470", "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1C", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r299": { "Name": "Accounting Standards Codification", "Paragraph": "1D", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(a)", "Topic": "470", "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1D", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r3": { "Name": "Accounting Standards Codification", "Paragraph": "14", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "230", "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-14", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r30": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.29-30)", "Topic": "210", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r300": { "Name": "Accounting Standards Codification", "Paragraph": "1D", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)", "Topic": "470", "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1D", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r301": { "Name": "Accounting Standards Codification", "Paragraph": "1D", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(c)", "Topic": "470", "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1D", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r302": { "Name": "Accounting Standards Codification", "Paragraph": "1E", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(a)", "Topic": "470", "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1E", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r303": { "Name": "Accounting Standards Codification", "Paragraph": "1E", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)", "Topic": "470", "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1E", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r304": { "Name": "Accounting Standards Codification", "Paragraph": "1E", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(c)", "Topic": "470", "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1E", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r305": { "Name": "Accounting Standards Codification", "Paragraph": "1E", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(d)", "Topic": "470", "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1E", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r306": { "Name": "Accounting Standards Codification", "Paragraph": "1F", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(a)", "Topic": "470", "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1F", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r307": { "Name": "Accounting Standards Codification", "Paragraph": "1F", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)", "Topic": "470", "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1F", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r308": { "Name": "Accounting Standards Codification", "Paragraph": "1F", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)(1)", "Topic": "470", "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1F", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r309": { "Name": "Accounting Standards Codification", "Paragraph": "1F", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)(2)", "Topic": "470", "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1F", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r31": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.29-31)", "Topic": "210", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r310": { "Name": "Accounting Standards Codification", "Paragraph": "1I", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(a)", "Topic": "470", "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1I", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r311": { "Name": "Accounting Standards Codification", "Paragraph": "1I", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)", "Topic": "470", "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1I", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r312": { "Name": "Accounting Standards Codification", "Paragraph": "1I", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(c)", "Topic": "470", "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1I", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r313": { "Name": "Accounting Standards Codification", "Paragraph": "1I", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(d)", "Topic": "470", "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1I", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r314": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)(3)", "Topic": "470", "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-4", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r315": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "505", "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-13", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r316": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "505", "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-13", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r317": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "505", "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-13", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r318": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(g)", "Topic": "505", "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-13", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r319": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(h)", "Topic": "505", "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-13", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r32": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.30)", "Topic": "210", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r320": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(i)", "Topic": "505", "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-13", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r321": { "Name": "Accounting Standards Codification", "Paragraph": "14", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "505", "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-14", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r322": { "Name": "Accounting Standards Codification", "Paragraph": "14", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "505", "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-14", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r323": { "Name": "Accounting Standards Codification", "Paragraph": "14", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "505", "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-14", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r324": { "Name": "Accounting Standards Codification", "Paragraph": "16", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "505", "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-16", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r325": { "Name": "Accounting Standards Codification", "Paragraph": "18", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "505", "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-18", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r326": { "Name": "Accounting Standards Codification", "Paragraph": "18", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "505", "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-18", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r327": { "Name": "Accounting Standards Codification", "Paragraph": "18", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "505", "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-18", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r328": { "Name": "Accounting Standards Codification", "Paragraph": "18", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "505", "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-18", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r329": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "505", "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-2", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r33": { "Name": "Accounting Standards Codification", "Paragraph": "14", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "230", "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-14", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r330": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.3-04)", "Topic": "505", "URI": "https://asc.fasb.org//1943274/2147480008/505-10-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r331": { "Name": "Accounting Standards Codification", "Paragraph": "10", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "606", "URI": "https://asc.fasb.org//1943274/2147479806/606-10-50-10", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r332": { "Name": "Accounting Standards Codification", "Paragraph": "12", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "606", "URI": "https://asc.fasb.org//1943274/2147479806/606-10-50-12", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r333": { "Name": "Accounting Standards Codification", "Paragraph": "12", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "606", "URI": "https://asc.fasb.org//1943274/2147479806/606-10-50-12", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r334": { "Name": "Accounting Standards Codification", "Paragraph": "12", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "606", "URI": "https://asc.fasb.org//1943274/2147479806/606-10-50-12", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r335": { "Name": "Accounting Standards Codification", "Paragraph": "12", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "606", "URI": "https://asc.fasb.org//1943274/2147479806/606-10-50-12", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r336": { "Name": "Accounting Standards Codification", "Paragraph": "12", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(e)", "Topic": "606", "URI": "https://asc.fasb.org//1943274/2147479806/606-10-50-12", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r337": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)(2)", "Topic": "606", "URI": "https://asc.fasb.org//1943274/2147479806/606-10-50-13", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r338": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "606", "URI": "https://asc.fasb.org//1943274/2147479806/606-10-50-15", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r339": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "606", "URI": "https://asc.fasb.org//1943274/2147479806/606-10-50-4", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r34": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "230", "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-15", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r340": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "606", "URI": "https://asc.fasb.org//1943274/2147479806/606-10-50-5", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r341": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "606", "URI": "https://asc.fasb.org//1943274/2147479806/606-10-50-8", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r342": { "Name": "Accounting Standards Codification", "Paragraph": "9", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "606", "URI": "https://asc.fasb.org//1943274/2147479806/606-10-50-9", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r343": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(d)(i)", "Topic": "715", "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r344": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(d)(iv)(01)", "Topic": "715", "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r345": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(d)(iv)(02)", "Topic": "715", "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r346": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(d)(iv)(02)(A)", "Topic": "715", "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r347": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(d)(iv)(02)(B)", "Topic": "715", "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r348": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(d)(iv)(02)(C)", "Topic": "715", "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r349": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(d)(iv)(03)", "Topic": "715", "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r35": { "Name": "Accounting Standards Codification", "Paragraph": "25", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(f)", "Topic": "230", "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-25", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r350": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(n)", "Topic": "715", "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r351": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "50", "SubTopic": "80", "Subparagraph": "(d)", "Topic": "715", "URI": "https://asc.fasb.org//1943274/2147480576/715-80-50-5", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r352": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "50", "SubTopic": "80", "Subparagraph": "(f)(3)", "Topic": "715", "URI": "https://asc.fasb.org//1943274/2147480576/715-80-50-5", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r353": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "35", "SubTopic": "10", "Topic": "718", "URI": "https://asc.fasb.org//1943274/2147480483/718-10-35-2", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r354": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1)(i)", "Topic": "718", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r355": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1)(ii)", "Topic": "718", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r356": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1)(iii)", "Topic": "718", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r357": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1)(iv)(01)", "Topic": "718", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r358": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1)(iv)(02)", "Topic": "718", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r359": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1)(iv)(03)", "Topic": "718", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r36": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "230", "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-4", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r360": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(e)(1)", "Topic": "718", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r361": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(f)(2)(ii)", "Topic": "718", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r362": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(f)(2)(iii)", "Topic": "718", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r363": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(f)(2)(iv)", "Topic": "718", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r364": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(h)(1)(i)", "Topic": "718", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r365": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(i)", "Topic": "718", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r366": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(e)", "Topic": "718", "URI": "https://asc.fasb.org//1943274/2147480336/718-10-65-15", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r367": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(f)(1)", "Topic": "718", "URI": "https://asc.fasb.org//1943274/2147480336/718-10-65-15", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r368": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(f)(2)", "Topic": "718", "URI": "https://asc.fasb.org//1943274/2147480336/718-10-65-15", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r369": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB Topic 14.F)", "Topic": "718", "URI": "https://asc.fasb.org//1943274/2147479830/718-10-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r37": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "230", "URI": "https://asc.fasb.org//1943274/2147482913/230-10-50-2", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r370": { "Name": "Accounting Standards Codification", "Paragraph": "10", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "740", "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-10", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r371": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(d)(2)", "Topic": "740", "URI": "https://asc.fasb.org//1943274/2147482615/740-10-65-8", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r372": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(d)(3)", "Topic": "740", "URI": "https://asc.fasb.org//1943274/2147482615/740-10-65-8", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r373": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB TOPIC 6.I.7)", "Topic": "740", "URI": "https://asc.fasb.org//1943274/2147479360/740-10-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r374": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "808", "URI": "https://asc.fasb.org//1943274/2147479402/808-10-50-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r375": { "Name": "Accounting Standards Codification", "Paragraph": "25", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "810", "URI": "https://asc.fasb.org//1943274/2147481231/810-10-45-25", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r376": { "Name": "Accounting Standards Codification", "Paragraph": "25", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "810", "URI": "https://asc.fasb.org//1943274/2147481231/810-10-45-25", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r377": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(bb)", "Topic": "810", "URI": "https://asc.fasb.org//1943274/2147481203/810-10-50-3", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r378": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "810", "URI": "https://asc.fasb.org//1943274/2147481203/810-10-50-3", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r379": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "65", "SubTopic": "20", "Subparagraph": "(e)", "Topic": "815", "URI": "https://asc.fasb.org//1943274/2147480528/815-20-65-6", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r38": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "230", "URI": "https://asc.fasb.org//1943274/2147482913/230-10-50-3", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r380": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "65", "SubTopic": "20", "Subparagraph": "(h)(1)", "Topic": "815", "URI": "https://asc.fasb.org//1943274/2147480528/815-20-65-6", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r381": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "65", "SubTopic": "20", "Subparagraph": "(h)(1)(i)", "Topic": "815", "URI": "https://asc.fasb.org//1943274/2147480528/815-20-65-6", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r382": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "65", "SubTopic": "20", "Subparagraph": "(h)(1)(iii)", "Topic": "815", "URI": "https://asc.fasb.org//1943274/2147480528/815-20-65-6", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r383": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "65", "SubTopic": "20", "Subparagraph": "(h)(1)(iv)", "Topic": "815", "URI": "https://asc.fasb.org//1943274/2147480528/815-20-65-6", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r384": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "65", "SubTopic": "20", "Subparagraph": "(i)(3)", "Topic": "815", "URI": "https://asc.fasb.org//1943274/2147480528/815-20-65-6", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r385": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "50", "SubTopic": "40", "Subparagraph": "(f)", "Topic": "815", "URI": "https://asc.fasb.org//1943274/2147480237/815-40-50-5", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r386": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "50", "SubTopic": "40", "Subparagraph": "(a)", "Topic": "815", "URI": "https://asc.fasb.org//1943274/2147480237/815-40-50-6", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r387": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(e)(3)", "Topic": "815", "URI": "https://asc.fasb.org//1943274/2147480175/815-40-65-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r388": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(e)(4)", "Topic": "815", "URI": "https://asc.fasb.org//1943274/2147480175/815-40-65-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r389": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(f)", "Topic": "815", "URI": "https://asc.fasb.org//1943274/2147480175/815-40-65-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r39": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "230", "URI": "https://asc.fasb.org//1943274/2147482913/230-10-50-4", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r390": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "820", "URI": "https://asc.fasb.org//1943274/2147482106/820-10-50-2", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r391": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "820", "URI": "https://asc.fasb.org//1943274/2147482106/820-10-50-2", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r392": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "820", "URI": "https://asc.fasb.org//1943274/2147482106/820-10-50-2", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r393": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(bbb)", "Topic": "820", "URI": "https://asc.fasb.org//1943274/2147482106/820-10-50-2", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r394": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(bbb)(2)", "Topic": "820", "URI": "https://asc.fasb.org//1943274/2147482106/820-10-50-2", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r395": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "820", "URI": "https://asc.fasb.org//1943274/2147482106/820-10-50-3", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r396": { "Name": "Accounting Standards Codification", "Paragraph": "10", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "825", "URI": "https://asc.fasb.org//1943274/2147482907/825-10-50-10", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r397": { "Name": "Accounting Standards Codification", "Paragraph": "28", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(f)", "Topic": "825", "URI": "https://asc.fasb.org//1943274/2147482907/825-10-50-28", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r398": { "Name": "Accounting Standards Codification", "Paragraph": "17", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Topic": "830", "URI": "https://asc.fasb.org//1943274/2147481694/830-30-45-17", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r399": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Subparagraph": "(a)", "Topic": "830", "URI": "https://asc.fasb.org//1943274/2147481694/830-30-45-20", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r4": { "Name": "Accounting Standards Codification", "Paragraph": "28", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "230", "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-28", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r40": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "230", "URI": "https://asc.fasb.org//1943274/2147482913/230-10-50-5", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r400": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Subparagraph": "(b)", "Topic": "830", "URI": "https://asc.fasb.org//1943274/2147481694/830-30-45-20", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r401": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Subparagraph": "(c)", "Topic": "830", "URI": "https://asc.fasb.org//1943274/2147481694/830-30-45-20", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r402": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Subparagraph": "(d)", "Topic": "830", "URI": "https://asc.fasb.org//1943274/2147481694/830-30-45-20", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r403": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Topic": "830", "URI": "https://asc.fasb.org//1943274/2147481674/830-30-50-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r404": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Topic": "830", "URI": "https://asc.fasb.org//1943274/2147481674/830-30-50-2", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r405": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Topic": "835", "URI": "https://asc.fasb.org//1943274/2147482900/835-30-50-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r406": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(a)(3)(iii)(03)", "Topic": "848", "URI": "https://asc.fasb.org//1943274/2147483550/848-10-65-2", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r407": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "850", "URI": "https://asc.fasb.org//850/tableOfContent", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r408": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "850", "URI": "https://asc.fasb.org//1943274/2147483326/850-10-50-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r409": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "850", "URI": "https://asc.fasb.org//1943274/2147483326/850-10-50-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r41": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "260", "URI": "https://asc.fasb.org//1943274/2147482662/260-10-50-1", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r410": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "850", "URI": "https://asc.fasb.org//1943274/2147483326/850-10-50-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r411": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "850", "URI": "https://asc.fasb.org//1943274/2147483326/850-10-50-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r412": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "850", "URI": "https://asc.fasb.org//1943274/2147483326/850-10-50-2", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r413": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "850", "URI": "https://asc.fasb.org//1943274/2147483326/850-10-50-3", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r414": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "850", "URI": "https://asc.fasb.org//1943274/2147483326/850-10-50-6", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r415": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "855", "URI": "https://asc.fasb.org//855/tableOfContent", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r416": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "855", "URI": "https://asc.fasb.org//1943274/2147483399/855-10-50-2", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r417": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "855", "URI": "https://asc.fasb.org//1943274/2147483399/855-10-50-2", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r418": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)(2)(i)", "Topic": "860", "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-3", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r419": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)(2)(ii)", "Topic": "860", "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-3", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r42": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "260", "URI": "https://asc.fasb.org//1943274/2147482662/260-10-50-2", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r420": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)(3)", "Topic": "860", "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-3", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r421": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(bb)(1)", "Topic": "860", "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-3", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r422": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(bb)(2)", "Topic": "860", "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-3", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r423": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(bb)(3)", "Topic": "860", "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-3", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r424": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(c)(1)", "Topic": "860", "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-3", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r425": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(c)(2)", "Topic": "860", "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-3", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r426": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(c)(3)", "Topic": "860", "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-3", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r427": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)(1)", "Topic": "860", "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-4", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r428": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)(2)", "Topic": "860", "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-4", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r429": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)(3)", "Topic": "860", "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-4", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r43": { "Name": "Accounting Standards Codification", "Paragraph": "16", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "275", "URI": "https://asc.fasb.org//1943274/2147482861/275-10-50-16", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r430": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(c)", "Topic": "860", "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-4", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r431": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Topic": "860", "URI": "https://asc.fasb.org//1943274/2147481444/860-30-45-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r432": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Subparagraph": "(a)", "Topic": "860", "URI": "https://asc.fasb.org//1943274/2147481420/860-30-50-7", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r433": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "50", "Subparagraph": "(a)(1)", "Topic": "860", "URI": "https://asc.fasb.org//1943274/2147481229/860-50-50-3", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r434": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "50", "Subparagraph": "(a)(2)", "Topic": "860", "URI": "https://asc.fasb.org//1943274/2147481229/860-50-50-3", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r435": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "50", "Subparagraph": "(a)(3)", "Topic": "860", "URI": "https://asc.fasb.org//1943274/2147481229/860-50-50-3", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r436": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "50", "Subparagraph": "(a)(4)(i)", "Topic": "860", "URI": "https://asc.fasb.org//1943274/2147481229/860-50-50-3", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r437": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "50", "Subparagraph": "(a)(1)", "Topic": "860", "URI": "https://asc.fasb.org//1943274/2147481229/860-50-50-4", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r438": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "50", "Subparagraph": "(a)(2)", "Topic": "860", "URI": "https://asc.fasb.org//1943274/2147481229/860-50-50-4", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r439": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "50", "Subparagraph": "(a)(3)", "Topic": "860", "URI": "https://asc.fasb.org//1943274/2147481229/860-50-50-4", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r44": { "Name": "Accounting Standards Codification", "Paragraph": "18", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "275", "URI": "https://asc.fasb.org//1943274/2147482861/275-10-50-18", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r440": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "50", "Subparagraph": "(a)(4)", "Topic": "860", "URI": "https://asc.fasb.org//1943274/2147481229/860-50-50-4", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r441": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "50", "Subparagraph": "(a)(5)", "Topic": "860", "URI": "https://asc.fasb.org//1943274/2147481229/860-50-50-4", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r442": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "50", "Subparagraph": "(a)(6)", "Topic": "860", "URI": "https://asc.fasb.org//1943274/2147481229/860-50-50-4", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r443": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "50", "Subparagraph": "(a)(7)", "Topic": "860", "URI": "https://asc.fasb.org//1943274/2147481229/860-50-50-4", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r444": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "50", "Subparagraph": "(b)", "Topic": "860", "URI": "https://asc.fasb.org//1943274/2147481229/860-50-50-4", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r445": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "50", "Subparagraph": "(e)(1)", "Topic": "860", "URI": "https://asc.fasb.org//1943274/2147481229/860-50-50-4", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r446": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "50", "Subparagraph": "(e)(2)", "Topic": "860", "URI": "https://asc.fasb.org//1943274/2147481229/860-50-50-4", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r447": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "50", "Subparagraph": "(e)(3)", "Topic": "860", "URI": "https://asc.fasb.org//1943274/2147481229/860-50-50-4", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r448": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "910", "URI": "https://asc.fasb.org//1943274/2147482546/910-10-50-6", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r449": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB Topic 11.L)", "Topic": "924", "URI": "https://asc.fasb.org//1943274/2147479941/924-10-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r45": { "Name": "Accounting Standards Codification", "Paragraph": "18", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "275", "URI": "https://asc.fasb.org//1943274/2147482861/275-10-50-18", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r450": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "926", "URI": "https://asc.fasb.org//1943274/2147483154/926-20-50-5", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r451": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "50", "SubTopic": "235", "Subparagraph": "(a)", "Topic": "932", "URI": "https://asc.fasb.org//1943274/2147482274/932-235-50-15", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r452": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "50", "SubTopic": "235", "Subparagraph": "(b)", "Topic": "932", "URI": "https://asc.fasb.org//1943274/2147482274/932-235-50-15", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r453": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "50", "SubTopic": "235", "Subparagraph": "(a)", "Topic": "932", "URI": "https://asc.fasb.org//1943274/2147482274/932-235-50-20", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r454": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "50", "SubTopic": "235", "Subparagraph": "(b)", "Topic": "932", "URI": "https://asc.fasb.org//1943274/2147482274/932-235-50-20", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r455": { "Name": "Accounting Standards Codification", "Paragraph": "28", "Publisher": "FASB", "Section": "50", "SubTopic": "235", "Subparagraph": "(a)", "Topic": "932", "URI": "https://asc.fasb.org//1943274/2147482274/932-235-50-28", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r456": { "Name": "Accounting Standards Codification", "Paragraph": "28", "Publisher": "FASB", "Section": "50", "SubTopic": "235", "Subparagraph": "(b)", "Topic": "932", "URI": "https://asc.fasb.org//1943274/2147482274/932-235-50-28", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r457": { "Name": "Accounting Standards Codification", "Paragraph": "33", "Publisher": "FASB", "Section": "50", "SubTopic": "235", "Subparagraph": "(a)", "Topic": "932", "URI": "https://asc.fasb.org//1943274/2147482274/932-235-50-33", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r458": { "Name": "Accounting Standards Codification", "Paragraph": "33", "Publisher": "FASB", "Section": "50", "SubTopic": "235", "Subparagraph": "(b)", "Topic": "932", "URI": "https://asc.fasb.org//1943274/2147482274/932-235-50-33", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r459": { "Name": "Accounting Standards Codification", "Paragraph": "35A", "Publisher": "FASB", "Section": "50", "SubTopic": "235", "Subparagraph": "(a)", "Topic": "932", "URI": "https://asc.fasb.org//1943274/2147482274/932-235-50-35A", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r46": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "275", "URI": "https://asc.fasb.org//1943274/2147482861/275-10-50-20", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r460": { "Name": "Accounting Standards Codification", "Paragraph": "35A", "Publisher": "FASB", "Section": "50", "SubTopic": "235", "Subparagraph": "(b)", "Topic": "932", "URI": "https://asc.fasb.org//1943274/2147482274/932-235-50-35A", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r461": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "50", "SubTopic": "235", "Subparagraph": "(c)(1)", "Topic": "932", "URI": "https://asc.fasb.org//1943274/2147482274/932-235-50-8", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r462": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "50", "SubTopic": "235", "Subparagraph": "(c)(2)", "Topic": "932", "URI": "https://asc.fasb.org//1943274/2147482274/932-235-50-8", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r463": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.9-04(27))", "Topic": "942", "URI": "https://asc.fasb.org//1943274/2147483589/942-220-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r464": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "235", "Subparagraph": "(SX 210.9-05(b)(2))", "Topic": "942", "URI": "https://asc.fasb.org//1943274/2147479557/942-235-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r465": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03(15))", "Topic": "944", "URI": "https://asc.fasb.org//1943274/2147479440/944-210-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r466": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03(a)(12))", "Topic": "944", "URI": "https://asc.fasb.org//1943274/2147479440/944-210-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r467": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03(a)(19))", "Topic": "944", "URI": "https://asc.fasb.org//1943274/2147479440/944-210-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r468": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03(a)(2))", "Topic": "944", "URI": "https://asc.fasb.org//1943274/2147479440/944-210-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r469": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03(a)(21))", "Topic": "944", "URI": "https://asc.fasb.org//1943274/2147479440/944-210-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r47": { "Name": "Accounting Standards Codification", "Paragraph": "21", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "275", "URI": "https://asc.fasb.org//1943274/2147482861/275-10-50-21", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r470": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03(a)(22))", "Topic": "944", "URI": "https://asc.fasb.org//1943274/2147479440/944-210-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r471": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03(a)(23)(a)(4))", "Topic": "944", "URI": "https://asc.fasb.org//1943274/2147479440/944-210-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r472": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03(a)(25))", "Topic": "944", "URI": "https://asc.fasb.org//1943274/2147479440/944-210-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r473": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.7-04(11))", "Topic": "944", "URI": "https://asc.fasb.org//1943274/2147483586/944-220-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r474": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.7-04(18))", "Topic": "944", "URI": "https://asc.fasb.org//1943274/2147483586/944-220-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r475": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.7-04(2)(a))", "Topic": "944", "URI": "https://asc.fasb.org//1943274/2147483586/944-220-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r476": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.7-04(23))", "Topic": "944", "URI": "https://asc.fasb.org//1943274/2147483586/944-220-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r477": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.7-04(9))", "Topic": "944", "URI": "https://asc.fasb.org//1943274/2147483586/944-220-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r478": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "235", "Subparagraph": "(SX 210.12-17(Column A))", "Topic": "944", "URI": "https://asc.fasb.org//1943274/2147480149/944-235-S99-2", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r479": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "235", "Subparagraph": "(SX 210.12-17(Column B))", "Topic": "944", "URI": "https://asc.fasb.org//1943274/2147480149/944-235-S99-2", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r48": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "275", "URI": "https://asc.fasb.org//1943274/2147482861/275-10-50-4", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r480": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "235", "Subparagraph": "(SX 210.12-17(Column C))", "Topic": "944", "URI": "https://asc.fasb.org//1943274/2147480149/944-235-S99-2", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r481": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "235", "Subparagraph": "(SX 210.12-17(Column D))", "Topic": "944", "URI": "https://asc.fasb.org//1943274/2147480149/944-235-S99-2", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r482": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "235", "Subparagraph": "(SX 210.12-17(Column E))", "Topic": "944", "URI": "https://asc.fasb.org//1943274/2147480149/944-235-S99-2", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r483": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "235", "Subparagraph": "(SX 210.12-17(Column F))", "Topic": "944", "URI": "https://asc.fasb.org//1943274/2147480149/944-235-S99-2", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r484": { "Name": "Accounting Standards Codification", "Paragraph": "7A", "Publisher": "FASB", "Section": "50", "SubTopic": "40", "Subparagraph": "(d)", "Topic": "944", "URI": "https://asc.fasb.org//1943274/2147480081/944-40-50-7A", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r485": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(e)", "Topic": "944", "URI": "https://asc.fasb.org//1943274/2147480016/944-40-65-2", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r486": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(f)(1)", "Topic": "944", "URI": "https://asc.fasb.org//1943274/2147480016/944-40-65-2", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r487": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(f)(2)", "Topic": "944", "URI": "https://asc.fasb.org//1943274/2147480016/944-40-65-2", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r488": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(g)(2)(i)", "Topic": "944", "URI": "https://asc.fasb.org//1943274/2147480016/944-40-65-2", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r489": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(h)(2)", "Topic": "944", "URI": "https://asc.fasb.org//1943274/2147480016/944-40-65-2", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r49": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "275", "URI": "https://asc.fasb.org//1943274/2147482861/275-10-50-8", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r490": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "50", "SubTopic": "825", "Topic": "944", "URI": "https://asc.fasb.org//1943274/2147479383/944-825-50-1B", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r491": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.6-03(d))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147479886/946-10-S99-3", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r492": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.6-03(i)(1))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147479886/946-10-S99-3", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r493": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.6-03(i)(2)(i))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147479886/946-10-S99-3", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r494": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.6-03(i)(2)(ii))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147479886/946-10-S99-3", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r495": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.6-03(i)(2))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147479886/946-10-S99-3", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r496": { "Name": "Accounting Standards Codification", "Paragraph": "11", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147480990/946-20-50-11", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r497": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147480990/946-20-50-2", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r498": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147480990/946-20-50-5", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r499": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147480990/946-20-50-6", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r5": { "Name": "Accounting Standards Codification", "Paragraph": "28", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "230", "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-28", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r50": { "Name": "Accounting Standards Codification", "Paragraph": "9", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "275", "URI": "https://asc.fasb.org//1943274/2147482861/275-10-50-9", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r500": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "45", "SubTopic": "205", "Subparagraph": "(a)", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147480767/946-205-45-4", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r501": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "205", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147480737/946-205-50-2", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r502": { "Name": "Accounting Standards Codification", "Paragraph": "27", "Publisher": "FASB", "Section": "50", "SubTopic": "205", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147480737/946-205-50-27", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r503": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "50", "SubTopic": "205", "Subparagraph": "(a)", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147480737/946-205-50-7", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r504": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "50", "SubTopic": "205", "Subparagraph": "(b)", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147480737/946-205-50-7", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r505": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "50", "SubTopic": "205", "Subparagraph": "(c)", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147480737/946-205-50-7", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r506": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "50", "SubTopic": "205", "Subparagraph": "(d)", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147480737/946-205-50-7", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r507": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "50", "SubTopic": "205", "Subparagraph": "(e)", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147480737/946-205-50-7", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r508": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "50", "SubTopic": "205", "Subparagraph": "(f)", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147480737/946-205-50-7", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r509": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "50", "SubTopic": "205", "Subparagraph": "(g)", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147480737/946-205-50-7", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r51": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Topic": "350", "URI": "https://asc.fasb.org//1943274/2147482686/350-30-45-2", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r510": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "50", "SubTopic": "205", "Subparagraph": "(h)", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147480737/946-205-50-7", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r511": { "Name": "Accounting Standards Codification", "Paragraph": "21", "Publisher": "FASB", "Section": "45", "SubTopic": "210", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147480555/946-210-45-21", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r512": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "45", "SubTopic": "210", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147480555/946-210-45-4", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r513": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "210", "Subparagraph": "(a)(1)", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147480524/946-210-50-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r514": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "210", "Subparagraph": "(b)(1)", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147480524/946-210-50-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r515": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "210", "Subparagraph": "(b)(2)", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147480524/946-210-50-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r516": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "210", "Subparagraph": "(c)(2)", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147480524/946-210-50-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r517": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "50", "SubTopic": "210", "Subparagraph": "(a)(1)", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147480524/946-210-50-6", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r518": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "50", "SubTopic": "210", "Subparagraph": "(a)(2)", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147480524/946-210-50-6", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r519": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "50", "SubTopic": "210", "Subparagraph": "(a)(4)", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147480524/946-210-50-6", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r52": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Subparagraph": "(a)", "Topic": "350", "URI": "https://asc.fasb.org//1943274/2147482665/350-30-50-1", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r520": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "50", "SubTopic": "210", "Subparagraph": "(e)", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147480524/946-210-50-6", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r521": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "50", "SubTopic": "210", "Subparagraph": "(f)", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147480524/946-210-50-6", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r522": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.6-04(1))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r523": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.6-04(12)(b)(1))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r524": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.6-04(12)(b)(2))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r525": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.6-04(12)(b)(3))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r526": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.6-04(13)(a)(2))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r527": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.6-04(13)(a)(3))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r528": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.6-04(14))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r529": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.6-04(15))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r53": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Subparagraph": "(a)", "Topic": "350", "URI": "https://asc.fasb.org//1943274/2147482665/350-30-50-2", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r530": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.6-04(16)(a))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r531": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.6-04(17))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r532": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.6-04(19))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r533": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.6-04(2)(a))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r534": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.6-04(2)(b))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r535": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.6-04(3)(a))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r536": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.6-04(3)(b))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r537": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.6-04(3)(c))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r538": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.6-04(4))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r539": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.6-04(5)(a)(5))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r54": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Subparagraph": "(a)(2)", "Topic": "350", "URI": "https://asc.fasb.org//1943274/2147482665/350-30-50-2", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r540": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.6-04(6)(b))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r541": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.6-04(6)(c))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r542": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.6-04(6)(d))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r543": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.6-04(6)(e))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r544": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.6-04(8))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r545": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.6-04(9)(b))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r546": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.6-04(9)(c))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r547": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.6-04(9)(d))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r548": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.6-04(9)(e))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r549": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.6-05(2))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-2", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r55": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "40", "SubTopic": "50", "Topic": "470", "URI": "https://asc.fasb.org//1943274/2147481303/470-50-40-2", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r550": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.6-05(4))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-2", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r551": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "45", "SubTopic": "220", "Subparagraph": "(b)", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147483581/946-220-45-3", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r552": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "45", "SubTopic": "220", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147483581/946-220-45-7", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r553": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "220", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147483580/946-220-50-3", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r554": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.6-07(1))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r555": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.6-07(2)(a))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r556": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.6-07(2)(c)(2)(i))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r557": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.6-07(2)(c)(2)(ii))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r558": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.6-07(2)(c))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r559": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.6-07(2)(e))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r56": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "40", "SubTopic": "50", "Topic": "470", "URI": "https://asc.fasb.org//1943274/2147481303/470-50-40-4", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r560": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.6-07(2)(g)(3))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r561": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.6-07(7)(a)(1))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r562": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.6-07(7)(a)(2))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r563": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.6-07(7)(a)(3))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r564": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.6-07(7)(a)(5))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r565": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.6-07(7)(a)(6))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r566": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.6-07(7)(a)(7))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r567": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.6-07(7)(c)(1))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r568": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.6-07(7)(c)(2))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r569": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.6-07(7)(c)(3))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r57": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "505", "URI": "https://asc.fasb.org//1943274/2147481142/505-10-45-2", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r570": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.6-07(7)(c)(5))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r571": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.6-07(7)(c)(6))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r572": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.6-07(7)(c)(7))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r573": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.6-07(9))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r574": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.6-09(1)(d))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-3", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r575": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.6-09(4)(b))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-3", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r576": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.6-09(6))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-3", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r577": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.6-09(7))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-3", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r578": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "235", "Subparagraph": "(a)", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147481062/946-235-50-2", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r579": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "235", "Subparagraph": "(c)", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147481062/946-235-50-2", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r58": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "505", "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-3", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r580": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "235", "Subparagraph": "(d)", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147481062/946-235-50-2", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r581": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "235", "Subparagraph": "(e)", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147481062/946-235-50-2", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r582": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "310", "Subparagraph": "(c)", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147480833/946-310-45-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r583": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "310", "Subparagraph": "(d)", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147480833/946-310-45-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r584": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "320", "Subparagraph": "(SX 210.12-12(Column A)(Footnote 2))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r585": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "320", "Subparagraph": "(SX 210.12-12A(Column A)(Footnote 2))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-2", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r586": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "S99", "SubTopic": "320", "Subparagraph": "(SX 210.12-12B(Column A)(Footnote 4)(a))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-3", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r587": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "S99", "SubTopic": "320", "Subparagraph": "(SX 210.12-12B(Column A)(Footnote 4)(b))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-3", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r588": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "S99", "SubTopic": "320", "Subparagraph": "(SX 210.12-13(Column G)(Footnote 8))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-5", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r589": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "S99", "SubTopic": "320", "Subparagraph": "(SX 210.12-13(Column G))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-5", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r59": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "505", "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-4", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r590": { "Name": "Accounting Standards Codification", "Paragraph": "5A", "Publisher": "FASB", "Section": "S99", "SubTopic": "320", "Subparagraph": "(SX 210.12-13A(Column E))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-5A", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r591": { "Name": "Accounting Standards Codification", "Paragraph": "5B", "Publisher": "FASB", "Section": "S99", "SubTopic": "320", "Subparagraph": "(SX 210.12-13B(Column E)(Footnote 4))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-5B", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r592": { "Name": "Accounting Standards Codification", "Paragraph": "5B", "Publisher": "FASB", "Section": "S99", "SubTopic": "320", "Subparagraph": "(SX 210.12-13B(Column E))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-5B", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r593": { "Name": "Accounting Standards Codification", "Paragraph": "5C", "Publisher": "FASB", "Section": "S99", "SubTopic": "320", "Subparagraph": "(SX 210.12-13C(Column H)(Footnote 7))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-5C", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r594": { "Name": "Accounting Standards Codification", "Paragraph": "5C", "Publisher": "FASB", "Section": "S99", "SubTopic": "320", "Subparagraph": "(SX 210.12-13C(Column H))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-5C", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r595": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "S99", "SubTopic": "320", "Subparagraph": "(SX 210.12-14(Column A)(Footnote 2))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-6", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r596": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "505", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147481004/946-505-50-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r597": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "505", "Subparagraph": "(a)", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147481004/946-505-50-2", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r598": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "505", "Subparagraph": "(b)", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147481004/946-505-50-2", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r599": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "505", "Subparagraph": "(c)", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147481004/946-505-50-2", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r6": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "470", "URI": "https://asc.fasb.org//1943274/2147481544/470-10-50-1", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r60": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "505", "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-8", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r600": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "505", "Subparagraph": "(d)", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147481004/946-505-50-2", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r601": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "50", "SubTopic": "505", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147481004/946-505-50-6", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r602": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "310", "Topic": "954", "URI": "https://asc.fasb.org//1943274/2147481027/954-310-50-2", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r603": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "440", "Subparagraph": "(a)", "Topic": "954", "URI": "https://asc.fasb.org//1943274/2147480327/954-440-50-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r604": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "310", "Subparagraph": "(c)", "Topic": "976", "URI": "https://asc.fasb.org//1943274/2147482856/976-310-50-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r605": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "310", "Subparagraph": "(b)", "Topic": "978", "URI": "https://asc.fasb.org//1943274/2147482707/978-310-50-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r606": { "Name": "Accounting Standards Codification", "Paragraph": "13H", "Publisher": "FASB", "Section": "55", "SubTopic": "40", "Subparagraph": "(a)", "Topic": "944", "URI": "https://asc.fasb.org//1943274/2147480046/944-40-55-13H", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r607": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "210", "URI": "https://asc.fasb.org//1943274/2147483467/210-10-45-1", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r608": { "Name": "Accounting Standards Codification", "Paragraph": "22", "Publisher": "FASB", "Section": "55", "SubTopic": "20", "Topic": "210", "URI": "https://asc.fasb.org//1943274/2147483444/210-20-55-22", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r609": { "Name": "Accounting Standards Codification", "Paragraph": "52", "Publisher": "FASB", "Section": "55", "SubTopic": "10", "Topic": "260", "URI": "https://asc.fasb.org//1943274/2147482635/260-10-55-52", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r61": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "30", "SubTopic": "10", "Topic": "710", "URI": "https://asc.fasb.org//1943274/2147483043/710-10-30-2", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r610": { "Name": "Accounting Standards Codification", "Paragraph": "30", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "280", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-30", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r611": { "Name": "Accounting Standards Codification", "Paragraph": "31", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "280", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-31", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r612": { "Name": "Accounting Standards Codification", "Paragraph": "12A", "Publisher": "FASB", "Section": "55", "SubTopic": "10", "Topic": "310", "URI": "https://asc.fasb.org//1943274/2147481933/310-10-55-12A", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r613": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "55", "SubTopic": "30", "Topic": "326", "URI": "https://asc.fasb.org//1943274/2147479081/326-30-55-8", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r614": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(d)", "Topic": "470", "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1B", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r615": { "Name": "Accounting Standards Codification", "Paragraph": "69B", "Publisher": "FASB", "Section": "55", "SubTopic": "20", "Topic": "470", "URI": "https://asc.fasb.org//1943274/2147481568/470-20-55-69B", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r616": { "Name": "Accounting Standards Codification", "Paragraph": "69C", "Publisher": "FASB", "Section": "55", "SubTopic": "20", "Topic": "470", "URI": "https://asc.fasb.org//1943274/2147481568/470-20-55-69C", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r617": { "Name": "Accounting Standards Codification", "Paragraph": "69E", "Publisher": "FASB", "Section": "55", "SubTopic": "20", "Topic": "470", "URI": "https://asc.fasb.org//1943274/2147481568/470-20-55-69E", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r618": { "Name": "Accounting Standards Codification", "Paragraph": "69F", "Publisher": "FASB", "Section": "55", "SubTopic": "20", "Topic": "470", "URI": "https://asc.fasb.org//1943274/2147481568/470-20-55-69F", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r619": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "505", "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-13", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r62": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "715", "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-2", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r620": { "Name": "Accounting Standards Codification", "Paragraph": "91", "Publisher": "FASB", "Section": "55", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "606", "URI": "https://asc.fasb.org//1943274/2147479777/606-10-55-91", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r621": { "Name": "Accounting Standards Codification", "Paragraph": "91", "Publisher": "FASB", "Section": "55", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "606", "URI": "https://asc.fasb.org//1943274/2147479777/606-10-55-91", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r622": { "Name": "Accounting Standards Codification", "Paragraph": "91", "Publisher": "FASB", "Section": "55", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "606", "URI": "https://asc.fasb.org//1943274/2147479777/606-10-55-91", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r623": { "Name": "Accounting Standards Codification", "Paragraph": "91", "Publisher": "FASB", "Section": "55", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "606", "URI": "https://asc.fasb.org//1943274/2147479777/606-10-55-91", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r624": { "Name": "Accounting Standards Codification", "Paragraph": "91", "Publisher": "FASB", "Section": "55", "SubTopic": "10", "Subparagraph": "(e)", "Topic": "606", "URI": "https://asc.fasb.org//1943274/2147479777/606-10-55-91", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r625": { "Name": "Accounting Standards Codification", "Paragraph": "91", "Publisher": "FASB", "Section": "55", "SubTopic": "10", "Subparagraph": "(f)", "Topic": "606", "URI": "https://asc.fasb.org//1943274/2147479777/606-10-55-91", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r626": { "Name": "Accounting Standards Codification", "Paragraph": "91", "Publisher": "FASB", "Section": "55", "SubTopic": "10", "Subparagraph": "(g)", "Topic": "606", "URI": "https://asc.fasb.org//1943274/2147479777/606-10-55-91", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r627": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(d)(ii)", "Topic": "715", "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r628": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(d)(iv)(01)", "Topic": "715", "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r629": { "Name": "Accounting Standards Codification", "Paragraph": "17", "Publisher": "FASB", "Section": "55", "SubTopic": "20", "Topic": "715", "URI": "https://asc.fasb.org//1943274/2147480482/715-20-55-17", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r63": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "715", "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-3", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r630": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "55", "SubTopic": "80", "Topic": "715", "URI": "https://asc.fasb.org//1943274/2147480547/715-80-55-8", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r631": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)(1)", "Topic": "718", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r632": { "Name": "Accounting Standards Codification", "Paragraph": "10", "Publisher": "FASB", "Section": "55", "SubTopic": "10", "Topic": "852", "URI": "https://asc.fasb.org//1943274/2147481372/852-10-55-10", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r633": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "55", "SubTopic": "30", "Topic": "944", "URI": "https://asc.fasb.org//1943274/2147479401/944-30-55-2", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r634": { "Name": "Accounting Standards Codification", "Paragraph": "29F", "Publisher": "FASB", "Section": "55", "SubTopic": "40", "Topic": "944", "URI": "https://asc.fasb.org//1943274/2147480046/944-40-55-29F", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r635": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "210", "Subparagraph": "(b)(1)", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147480524/946-210-50-1", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r636": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "50", "SubTopic": "210", "Subparagraph": "(a)(1)", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147480524/946-210-50-6", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r637": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "55", "SubTopic": "210", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147480493/946-210-55-1", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r638": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "310", "Subparagraph": "(d)", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147480833/946-310-45-1", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r639": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "320", "Subparagraph": "(SX 210.12-12(Column A)(Footnote 2)(i))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-1", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r64": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "715", "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-4", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r640": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "320", "Subparagraph": "(SX 210.12-12A(Column A)(Footnote 2))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-2", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r641": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "S99", "SubTopic": "320", "Subparagraph": "(SX 210.12-12B(Column A)(Footnote 1)(a))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-3", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r642": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "S99", "SubTopic": "320", "Subparagraph": "(SX 210.12-14(Column A)(Footnote 2))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-6", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r643": { "Name": "Accounting Standards Codification", "Paragraph": "10", "Publisher": "FASB", "Section": "55", "SubTopic": "830", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147480167/946-830-55-10", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r644": { "Name": "Accounting Standards Codification", "Paragraph": "11", "Publisher": "FASB", "Section": "55", "SubTopic": "830", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147480167/946-830-55-11", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r645": { "Name": "Accounting Standards Codification", "Paragraph": "12", "Publisher": "FASB", "Section": "55", "SubTopic": "830", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147480167/946-830-55-12", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r646": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r647": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "b", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r648": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "b-2", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r649": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "b-23", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r65": { "Name": "Accounting Standards Codification", "Paragraph": "17", "Publisher": "FASB", "Section": "55", "SubTopic": "20", "Topic": "715", "URI": "https://asc.fasb.org//1943274/2147480482/715-20-55-17", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r650": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "d1-1", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r651": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "g", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r652": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12, 13, 15d", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r653": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "13e", "Subsection": "4c", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r654": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "14d", "Subsection": "2b", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r655": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "15", "Subsection": "d", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r656": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "14a", "Subsection": "12", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r657": { "Name": "Form 10-K", "Number": "249", "Publisher": "SEC", "Section": "310", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r658": { "Name": "Form 10-Q", "Number": "240", "Publisher": "SEC", "Section": "308", "Subsection": "a", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r659": { "Name": "Form 20-F", "Number": "249", "Publisher": "SEC", "Section": "220", "Subsection": "f", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r66": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "35", "SubTopic": "10", "Topic": "718", "URI": "https://asc.fasb.org//1943274/2147480483/718-10-35-2", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r660": { "Name": "Form 40-F", "Number": "249", "Publisher": "SEC", "Section": "240", "Subsection": "f", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r661": { "Name": "Forms 10-K, 10-Q, 20-F", "Number": "240", "Publisher": "SEC", "Section": "13", "Subsection": "a-1", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r662": { "Name": "Regulation S-T", "Number": "232", "Publisher": "SEC", "Section": "405", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r663": { "Name": "Securities Act", "Number": "230", "Publisher": "SEC", "Section": "405", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r664": { "Name": "Securities Act", "Number": "230", "Publisher": "SEC", "Section": "425", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r665": { "Name": "Securities Act", "Number": "7A", "Publisher": "SEC", "Section": "B", "Subsection": "2", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r666": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "272", "URI": "https://asc.fasb.org//1943274/2147483014/272-10-45-3", "role": "http://www.xbrl.org/2003/role/recommendedDisclosureRef" }, "r667": { "Name": "Accounting Standards Codification", "Paragraph": "10", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "450", "URI": "https://asc.fasb.org//1943274/2147483076/450-20-50-10", "role": "http://www.xbrl.org/2003/role/recommendedDisclosureRef" }, "r668": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "855", "URI": "https://asc.fasb.org//1943274/2147483399/855-10-50-3", "role": "http://www.xbrl.org/2003/role/recommendedDisclosureRef" }, "r669": { "Name": "Accounting Standards Codification", "Paragraph": "18", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "275", "URI": "https://asc.fasb.org//1943274/2147482861/275-10-50-18", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r67": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "718", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-1", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r670": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "50", "SubTopic": "825", "Topic": "944", "URI": "https://asc.fasb.org//1943274/2147479383/944-825-50-1B", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r671": { "Name": "Accounting Standards Codification", "Paragraph": "4H", "Publisher": "FASB", "Section": "50", "SubTopic": "40", "Topic": "944", "URI": "https://asc.fasb.org//1943274/2147480081/944-40-50-4H", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r672": { "Name": "Regulation S-K (SK)", "Number": "229", "Paragraph": "(a)", "Publisher": "SEC", "Section": "1402", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r673": { "Name": "Regulation S-K (SK)", "Number": "229", "Paragraph": "(b)", "Publisher": "SEC", "Section": "1402", "Subparagraph": "(1)", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r674": { "Name": "Regulation S-K (SK)", "Number": "229", "Paragraph": "(b)", "Publisher": "SEC", "Section": "1402", "Subparagraph": "(2)", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r675": { "Name": "Regulation S-K (SK)", "Number": "229", "Paragraph": "(b)", "Publisher": "SEC", "Section": "1402", "Subparagraph": "(3)", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r676": { "Name": "Regulation S-K (SK)", "Number": "229", "Paragraph": "(c)", "Publisher": "SEC", "Section": "1402", "Subparagraph": "(2)(i)", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r677": { "Name": "Regulation S-K (SK)", "Number": "229", "Paragraph": "(c)", "Publisher": "SEC", "Section": "1402", "Subparagraph": "(2)(ii)", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r678": { "Name": "Regulation S-K (SK)", "Number": "229", "Paragraph": "(c)", "Publisher": "SEC", "Section": "1402", "Subparagraph": "(2)(iii)", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r679": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(1))", "Topic": "210", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r68": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "718", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r680": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(27)(b))", "Topic": "210", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r681": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(28))", "Topic": "210", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r682": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(9))", "Topic": "210", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r683": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "230", "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-15", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r684": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.4-08(d))", "Topic": "235", "URI": "https://asc.fasb.org//1943274/2147480678/235-10-S99-1", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r685": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.4-08(f))", "Topic": "235", "URI": "https://asc.fasb.org//1943274/2147480678/235-10-S99-1", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r686": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.4-08(g)(1)(ii))", "Topic": "235", "URI": "https://asc.fasb.org//1943274/2147480678/235-10-S99-1", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r687": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.4-08(k)(1))", "Topic": "235", "URI": "https://asc.fasb.org//1943274/2147480678/235-10-S99-1", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r688": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.4-08(k)(2))", "Topic": "235", "URI": "https://asc.fasb.org//1943274/2147480678/235-10-S99-1", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r689": { "Name": "Accounting Standards Codification", "Paragraph": "23", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "250", "URI": "https://asc.fasb.org//1943274/2147483421/250-10-45-23", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r69": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1)", "Topic": "718", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r690": { "Name": "Accounting Standards Codification", "Paragraph": "24", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "250", "URI": "https://asc.fasb.org//1943274/2147483421/250-10-45-24", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r691": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "250", "URI": "https://asc.fasb.org//1943274/2147483421/250-10-45-5", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r692": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "250", "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-4", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r693": { "Name": "Accounting Standards Codification", "Paragraph": "55", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "260", "URI": "https://asc.fasb.org//1943274/2147482689/260-10-45-55", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r694": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "260", "URI": "https://asc.fasb.org//1943274/2147482662/260-10-50-1", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r695": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "310", "URI": "https://asc.fasb.org//1943274/2147481990/310-10-45-13", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r696": { "Name": "Accounting Standards Codification", "Paragraph": "9", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "320", "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-9", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r697": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "321", "URI": "https://asc.fasb.org//1943274/2147479536/321-10-50-3", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r698": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "321", "URI": "https://asc.fasb.org//1943274/2147479536/321-10-50-3", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r699": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "321", "URI": "https://asc.fasb.org//1943274/2147479536/321-10-50-3", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r7": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "715", "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r70": { "Name": "Accounting Standards Codification", "Paragraph": "12", "Publisher": "FASB", "Section": "55", "SubTopic": "20", "Topic": "718", "URI": "https://asc.fasb.org//1943274/2147481089/718-20-55-12", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r700": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "323", "URI": "https://asc.fasb.org//1943274/2147481687/323-10-50-3", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r701": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "326", "URI": "https://asc.fasb.org//1943274/2147479319/326-20-50-13", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r702": { "Name": "Accounting Standards Codification", "Paragraph": "10", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Subparagraph": "(c)", "Topic": "410", "URI": "https://asc.fasb.org//1943274/2147481931/410-30-50-10", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r703": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "450", "URI": "https://asc.fasb.org//450/tableOfContent", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r704": { "Name": "Accounting Standards Codification", "Paragraph": "9", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)", "Topic": "450", "URI": "https://asc.fasb.org//1943274/2147483076/450-20-50-9", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r705": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "20", "Subparagraph": "(SAB Topic 5.Y.Q2)", "Topic": "450", "URI": "https://asc.fasb.org//1943274/2147480102/450-20-S99-1", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r706": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-01(a)(4)(ii))", "Topic": "470", "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1A", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r707": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-01(a)(4)(iii))", "Topic": "470", "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1A", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r708": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(d)", "Topic": "470", "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1B", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r709": { "Name": "Accounting Standards Codification", "Paragraph": "1D", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(a)", "Topic": "470", "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1D", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r71": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "55", "SubTopic": "20", "Topic": "718", "URI": "https://asc.fasb.org//1943274/2147481089/718-20-55-13", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r710": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(h)", "Topic": "505", "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-13", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r711": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "505", "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-2", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r712": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "606", "URI": "https://asc.fasb.org//1943274/2147479806/606-10-50-5", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r713": { "Name": "Accounting Standards Codification", "Paragraph": "4A", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)(1)", "Topic": "815", "URI": "https://asc.fasb.org//1943274/2147480434/815-10-50-4A", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r714": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(e)(3)", "Topic": "815", "URI": "https://asc.fasb.org//1943274/2147480175/815-40-65-1", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r715": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(bbb)", "Topic": "820", "URI": "https://asc.fasb.org//1943274/2147482106/820-10-50-2", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r716": { "Name": "Accounting Standards Codification", "Paragraph": "28", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(f)", "Topic": "825", "URI": "https://asc.fasb.org//1943274/2147482907/825-10-50-28", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r717": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "850", "URI": "https://asc.fasb.org//1943274/2147483326/850-10-50-2", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r718": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "850", "URI": "https://asc.fasb.org//1943274/2147483326/850-10-50-3", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r719": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "852", "URI": "https://asc.fasb.org//1943274/2147481404/852-10-50-7", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r72": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "25", "SubTopic": "30", "Topic": "805", "URI": "https://asc.fasb.org//1943274/2147479668/805-30-25-6", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r720": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "852", "URI": "https://asc.fasb.org//1943274/2147481404/852-10-50-7", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r721": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(c)(1)", "Topic": "860", "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-3", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r722": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(c)(2)", "Topic": "860", "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-3", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r723": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(c)(3)", "Topic": "860", "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-3", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r724": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)(1)", "Topic": "860", "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-4", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r725": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)(2)", "Topic": "860", "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-4", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r726": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)(3)", "Topic": "860", "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-4", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r727": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03(a)(15)(a))", "Topic": "944", "URI": "https://asc.fasb.org//1943274/2147479440/944-210-S99-1", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r728": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03(a)(16)(a)(2))", "Topic": "944", "URI": "https://asc.fasb.org//1943274/2147479440/944-210-S99-1", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r729": { "Name": "Accounting Standards Codification", "Paragraph": "2B", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Subparagraph": "(a)", "Topic": "944", "URI": "https://asc.fasb.org//1943274/2147479432/944-30-50-2B", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r73": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "820", "URI": "https://asc.fasb.org//1943274/2147482106/820-10-50-2", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r730": { "Name": "Accounting Standards Codification", "Paragraph": "13H", "Publisher": "FASB", "Section": "55", "SubTopic": "40", "Subparagraph": "(c)", "Topic": "944", "URI": "https://asc.fasb.org//1943274/2147480046/944-40-55-13H", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r731": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "45", "SubTopic": "205", "Subparagraph": "(a)", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147480767/946-205-45-4", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r732": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "50", "SubTopic": "210", "Subparagraph": "(a)(3)", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147480524/946-210-50-6", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r733": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.6-04(12)(b)(1))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r734": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.6-04(18))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r735": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.6-09(4)(b))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-3", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r736": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.6-09(7))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-3", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r74": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(2)", "Topic": "820", "URI": "https://asc.fasb.org//1943274/2147482106/820-10-50-2", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r75": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "820", "URI": "https://asc.fasb.org//1943274/2147482106/820-10-50-3", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r76": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "825", "URI": "https://asc.fasb.org//1943274/2147482907/825-10-50-20", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r77": { "Name": "Accounting Standards Codification", "Paragraph": "21", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "825", "URI": "https://asc.fasb.org//1943274/2147482907/825-10-50-21", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r78": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Topic": "835", "URI": "https://asc.fasb.org//1943274/2147482925/835-30-45-1A", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r79": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Topic": "835", "URI": "https://asc.fasb.org//1943274/2147482925/835-30-45-2", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r8": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "505", "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-2", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r80": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "55", "SubTopic": "30", "Topic": "835", "URI": "https://asc.fasb.org//1943274/2147482949/835-30-55-8", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r81": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "850", "URI": "https://asc.fasb.org//1943274/2147483326/850-10-50-1", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r82": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "850", "URI": "https://asc.fasb.org//1943274/2147483326/850-10-50-3", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r83": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.9-03.15(5))", "Topic": "942", "URI": "https://asc.fasb.org//1943274/2147479853/942-210-S99-1", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r84": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.9-03.15)", "Topic": "942", "URI": "https://asc.fasb.org//1943274/2147479853/942-210-S99-1", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r85": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.9-03.17)", "Topic": "942", "URI": "https://asc.fasb.org//1943274/2147479853/942-210-S99-1", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r86": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "470", "Topic": "942", "URI": "https://asc.fasb.org//1943274/2147480848/942-470-50-3", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r87": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "470", "Subparagraph": "(a)", "Topic": "942", "URI": "https://asc.fasb.org//1943274/2147480848/942-470-50-3", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r88": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "205", "URI": "https://asc.fasb.org//205/tableOfContent", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r89": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(19))", "Topic": "210", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r9": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(bbb)", "Topic": "820", "URI": "https://asc.fasb.org//1943274/2147482106/820-10-50-2", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r90": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(20))", "Topic": "210", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r91": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(28))", "Topic": "210", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r92": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(29))", "Topic": "210", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r93": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(30)(a)(1))", "Topic": "210", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r94": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(30)(a)(3))", "Topic": "210", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r95": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(30))", "Topic": "210", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r96": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(31))", "Topic": "210", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r97": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(32))", "Topic": "210", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r98": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03(10))", "Topic": "220", "URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-2", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r99": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03(20))", "Topic": "220", "URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-2", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" } }, "version": "2.2" } ZIP 61 0001493152-23-029706-xbrl.zip IDEA: XBRL DOCUMENT begin 644 0001493152-23-029706-xbrl.zip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�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�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�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ƕ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end